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SUMMARY 
 
Intravenous lipid emulsions (IVLE’s) form a staple part of parenteral nutrition (PN). 
PN provides life sustaining support where gastrointestinal nutrition is inadequate 
due to disease or prematurity. Whilst the physical stability of IVLE’s is relatively well 
known and quantified, chemical stability is an area where little testing has occurred.  
Lipids are susceptible to breakdown through free radical attack leading to lipid 
peroxidation, a cyclical process resulting in the production of primary and secondary 
toxic lipid peroxidation products. This thesis presents the development and 
validation of a method for measurement of peroxidation and triglyceride (TAG) 
breakdown occurring within two intravenous lipid emulsions.  
The high-performance liquid chromatography (HPLC) method developed uses in-
line ultra-violet (UV) and charged aerosol detection (CAD) to monitor the six main 
TAGs in Intralipid® emulsion and 10 TAGs in SMOFlipid® and detects the toxic 
secondary peroxidation products 4-Hydroxynonenal (HNE) and Hydroxyundecenal 
(HUE). The assay was validated in line and employed to test the chemical stability 
the established lipid emulsion (Intralipid®) and a newer lipid emulsion (SMOFlipid®). 
Both lipids were subject to up to 84 days storage within 50 ml syringes, 250 ml PN 
bags and 50 ml glass vials at room and fridge temperatures. The effect of light 
exposure was tested using light protected and non-light protected samples of each 
lipid. Results within each chapter detail the extensive levels of TAG losses observed 
within each container and the detection of secondary peroxidation products. Fridge 
temperature limited TAG loss and peroxidation in all containers, however secondary 
peroxidation products were detected. Both SMOFlipid® and Intralipid® gave in 
excess of 30 % losses in TAGs over 84 days storage. HNE, HUE and a triglyceride 
remnant were all recorded in SMOFlipid® and Intralipid® syringes (both 
temperatures) and small volume PN bags at room temperature. Light protection 
within this study showed no significant difference vs non-light protection. 
The results obtained from the work within this thesis are of vital importance when 
considering the safety of lipid emulsions for intravenous nutrition. This work 
provides an initial data set on the levels of peroxidation occurring within two 
commercially available in-use lipid emulsions and highlights the necessity for the 
stability and storage limits of these emulsions to be re-assessed.  
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 Parenteral Nutrition  
1.1.1 History and development of parenteral nutrition 
 
Parenteral Nutrition (PN) has since the late 1960’s, been a vital method of delivering 
essential nutrition to patients who are unable to meet their daily nutritional 
requirements orally (Dudrick 2009). Early advances in PN saw the development of 
simple mixtures of  glucose as a source of energy, fibrin hydrolysate to provide 
amino acids and nitrogen, and combinations of trace elements, electrolytes and 
vitamins added in quantities dependent upon the daily blood results of the patient 
(Dudrick 2003). Such infusions were initially administered peripherally via peripheral 
vein cannulation. The large volume of fluids given, often several litres to control 
tonicity, resulted in phlebitis and collapse of cannulated peripheral veins and loss of  
intra venous (IV) access to the patient. The high glucose content of early PN also 
provided ideal environments for bacterial growth and subsequent infections 
(Hamilton et al. 2006).  
Whilst limited early trials proved to be relatively successful, early PN mixtures 
proved inadequate in providing a total nutrition source to the patient. Patients who 
were solely dependent on PN for nutrition developed essential fatty acid deficiencies 
due to the lack of a lipid component to the PN formulation. Fat soluble vitamins were 
also lacking in such patients intake causing deficiencies in Vitamin K, D, A and E 
(Barr et al. 1981). To overcome such deficiencies, intravenous lipid emulsions 
(IVLEs) were introduced as part of the PN regimen, initially as cottonseed oil 
emulsion which was quickly withdrawn due to the development of fat overload 
syndrome causing severe anaphylaxis and an immune mediated allergic response 
(Hamilton et al. 2006). Subsequent research and development led to the use of 
soybean oil as an aqueous emulsion, marketed and still in use today as Intralipid® 
(other brands also available). This IVLE has become a staple to PN, allowing in 
some circumstances for the entire nutritional needs of a patient to be met 
intravenously. IVLE’s have also enabled the addition of fat-soluble vitamins to PN 
preventing deficiencies from occurring. 
Venous access has moved in accordance with medical advances, addressing the 
problems of venous collapse and the limited volume tolerances of peripheral lines. 
From the first instance of central venous access being used in a neonatal infant 
reliant upon PN due to near total bowel resection (Dudrick 2003), central access 
has become a staple in the delivery of PN, especially within the secondary care 
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setting where acutely ill patients, commonly within an intensive care setting, are 
reliant on PN and require central access for the delivery of drugs and analysis of 
biochemical status. Within the home PN setting, where patients are reliant on PN for 
nutrition due to chronic conditions, venous access is achieved usually through 
peripherally inserted central catheters (PICC line). These lines reduce the risk of 
infection with appropriate aseptic training given to the patients and carers, allowing 
long term patients on stable regimens of PN to receive their PN in a home care 
setting (Pittiruti et al. 2009). Peripheral venous access is still used for the delivery of 
PN, but is usually only employed when low volume, short term therapy is required 
within an acute setting. 
1.1.2 PN indications 
 
Dependence on PN as a nutritional source is the result of many different chronic 
and acute medical conditions. PN is indicated when there is an overarching 
diagnosis of the inadequacy of the gastrointestinal (GI) tract to meet the daily 
nutritional needs of the patient. Within an acute secondary care setting, indication 
for PN is most commonly due to surgical trauma or resection of the bowel, bowel 
rest post GI surgery (fistulae removal, cancer resection), or due to trauma causing 
GI malfunction. Typically acute indications for PN lead to short term use averaging 
7-10 days in length allowing GI recovery and eventual reversion to enteral feeding 
and nutritional support (Gibson 2012).  
Home PN (HPN) as a result of chronic intestinal failure (IF) is required over long-
term periods and is often the sole form of nutrition in patients. In 2011, the number 
of HPN patients within the UK was 523 (Smith et al. 2011), a number that has 
continually risen per annum to 1360 in 2015 (Smith and Naghibi 2016) All HPN 
patients have IF due to a variety of conditions, the most common being 
inflammatory bowel diseases and bowel ischemia leading to surgical bowel 
resection and subsequent short bowel syndrome. Malabsorption conditions and 
cancer are also indicators for long term HPN (Smith et al. 2011). 
Neonatal patients are a cohort where the delivery of PN can be required due to 
insufficiency of the GI tract due to prematurity. Such patients have very unique 
nutritional requirements, discussed in the following sections, resulting in PN being 
separated into lipid and aqueous portions.  
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1.1.3 PN formulations and components 
 
Nutritional requirements and therefore regimen requirements in PN will be unique to 
the patient and regular biochemical monitoring is necessary to allow adjustments to 
a patients PN regimen to be made to maintain adequate requirements. The stability 
of a patient’s condition will govern the frequency of monitoring required and 
subsequently if the patient is able to continue to receive HPN. It is worth noting that 
although a chronic patient on HPN may be stable in the disease status requiring PN, 
acute illness, infection and inflammation will change their nutritional requirements 
rapidly. As such, patients and carers are educated in how to recognise the signs 
and symptoms in changes in their condition/acute illnesses and how to seek 
medical assistance to have their PN regimen reviewed and altered if necessary. 
Inflammation and the resultant oxidative stress that is placed on the body in 
incidences of acute infection, trauma or disease alter how the body deals with 
nutrition. This includes a patient’s insulin response to glucose, fat utilisation and 
breakdown at a cellular level and nitrogen (amino acid) requirements (Beisel 1975). 
Modern PN typically consists of an all-in-one (AIO) mixture of the components 
outlined in table 1.1. 
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Table 1.1 Components of PN and nutritional requirements. 
 
PN as described in table 1.1 is given as an AIO mixture commonly in two to three 
litres total of fluid. When patients are purely reliant on PN for their nutritional needs, 
this fluid volume is typically given every day. Patients with some enteral feeding will 
receive PN to top-up enteral nutrition, commonly 2-3 times a week.  Patient specific 
requirements can often alter this total volume. For example, in fluid restricted 
patients due to renal failure, typically low volume, high calorific regimens are 
employed. AIO mixtures offer a complete nutritional source to the patient but have 
inherent risks associated with them. Such mixtures often contain upwards of 50 
Nutrient Group PN formulation and requirement. 
Carbohydrates Glucose solution – source of calories. 
Proteins 
Amino acid solution – provides essential 
and non-essential amino acids and 
nitrogen source. 
Water 
Water for injection – maintains tonicity 
of PN and hydration of patient. 
Fats Lipid emulsion – see below (page 8). 
Vitamins 
Fat and water soluble multivitamins – 
prevent vitamin deficiencies and 
subsequent disease development. 
Trace elements 
Micronutrients as essential elements 
(zinc, selenium, iron etc.) – essential 
within the body in complexation with 
enzymes and bioactive pathways. 
Electrolytes 
Inc. sodium, magnesium, calcium etc. – 
essential nutrients to maintain a wide 
variety of physiological functions 
including muscle contraction. 
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different components, each potentially having an effect on the others. As such AIO 
PN is inherently unstable and liable to physically break down. Development of PN 
into an AIO mixture has enabled these components to be tested in varying 
concentrations and stability parameters to be established. As such there are limits 
on the volumes and ratios of each component that can be added to an AIO mixture 
to ensure its physical stability. 
The uniqueness of the situation of trying to prescribe a ‘set’ regimen to an individual 
patient calls for the use of component volumes in PN that sometimes fall outside of 
the known ranges of stability for AIO mixtures. In such cases the lipid component of 
PN is often delivered separately from the aqueous portion, allowing for 
concentrations of components to be increased where necessary. This is often done 
in cases where high levels of calcium are required. Calcium in the presence of 
phosphorous is liable to cause complexation and the subsequent precipitation of 
calcium phosphate. This is a particular problem in PN regimens that require high 
levels of calcium due to either metabolic bone disease in adults or simply in order to 
meet the nutritional requirements of neonatal patients to support bone growth and 
development (Machmon et al. 1990). Lipid emulsions are cream/white in colour and 
as such can obscure visualisation of precipitation within PN. To overcome this 
problem and allow for further separation of certain PN components to maintain 
stability, the lipid portion of PN is separated from the aqueous portion and stored in 
two separate containers. These are then given concomitantly through separate lines 
that join at a Y-junction at the point of cannulation. This enables regimens to be 
altered to meet patient needs whilst maintaining the physical stability of PN and 
allowing visualisation to confirm stability to occur. Infusion times are also maintained 
by running both aqueous and lipid portions together. 
1.2 Intravenous lipid emulsions 
 
All lipid emulsions in use within PN are oil-in-water emulsions with an average fat 
globule diameter of 0.5 microns (Eriksson 2001). The development of IVLEs for 
utilization as a nutritional source aims to reflect the natural metabolism and 
elimination of chylomicrons. Lipid utilization, distribution and storage through the 
body is complex and dependent on many factors, of which the type of lipid and its 
formulation to an IVLE becomes the controlling factor when lipid nutrition is 
delivered solely via the intravenous route. Emulsified lipid droplets are produced to 
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0.5 µm diameter to mimic the dimensions of naturally occurring chylomicrons which 
transport absorbed fats formed by enterocytes of the GI tract.   
PN lipid emulsions broadly contain an aqueous base, a proportion of  appropriate oil 
formed into droplets through emulsification with phospholipids and glycerin to 
achieve an isotonic emulsion. 
1.2.1 Phospholipids/emulsifiers  
 
Phospholipids used within currently available lipid emulsions are extracted from egg 
yolk, acting as anionic emulsifying agents (Driscoll et al. 2008). These form a layer 
surrounding the oil droplets, creating a net negative charge across the surface of 
the lipid droplets. This repulsive charge forms the key to emulsion stability and helps 
prevents droplets from flocculating which can lead to coalescence and eventual 
cracking (breakdown) of the emulsion into its oil and water components. 
Within IVLEs, egg yolk phospholipids account for around 1.2% of the lipid emulsion 
(Tashiro et al. 1992; Kabi 2009). Although only accounting for 1.2%, the 
phospholipids are provided in excess to ensure full coverage of all oil droplets 
present. Excess phospholipids form sub 80nm liposomes which are of little nutrient 
use. Through the development of lipids for PN, the emulsifier limit has been formed 
of around 1.2%, a value that was initially much higher. The production of larger 
numbers of liposomes from an increased excess of emulsifier has proven to have 
detrimental effects. Infused liposomes can have two negative impacts on lipid 
metabolism. Initially liposomes reduce lipolysis of artificial chylomicrons from 
infused oil. Secondly they interact with cholesterol present within the blood, forming 
complexes known as Lipoprotein X, a harmful substance that mimics low density 
lipoproteins and results in hypercholesterolemia and the mis-management of free 
fatty acids (Calder et al. 2015; Waitzberg et al. 2015). 
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Table 1.2 Components of Intralipid® 20% emulsifiers. R-groups represent different fatty acids in IVLE. R1 and R2 
denote fatty acid chains. 
 
1.2.2 Fatty acids 
 
The fatty acids that form the oil proportion of IVLE’s varies and is dependent on the 
type of oil used to form the emulsion. Traditional lipid emulsions were formed of 
soybean oil which is predominately comprised of the omega 6 long chain 
polyunsaturated fatty acids (PUFA’s) shown in table 1.3. 
 
 
 
 
Phospholipid Chemical structure 
% component of 
Intralipid® 20% 
(Wabel 1998) 
Phosphatidylcholine 
 
87.1 
Phosphatidylethanolamine 
 
7.8 
Lyso-phosphatidylcholine 
 
2.5 
Lyso- 
phosphatidylethanolamine 
 
2.5 
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Table 1.3 Fatty acid components of Intralipid emulsion for injection (Wabel 1998) 
 
The highest proportion fatty acid seen in soybean oil is that of Linoleic acid 
(C18H32O2). Linoleic and α-linolenic acid are considered the only two true essential 
fatty acids (EFA). This is due to the fact that humans lack Δ12 and Δ15 desaturases 
and therefore cannot synthesize either of these fatty acids (Calder et al. 2015). 
When these EFA’s are removed from a patients’ nutrition, metabolism of available 
oleic acid is increased leading to the production of Mead acid. This is used as a 
marker for the diagnosis of EFA deficiency which, where present, can cause skin 
rashes, lack of growth and can prove fatal (Barr et al. 1981; Hamilton et al. 2006). 
Long chain fatty acids have been traditionally used very effectively in PN for a 
prolonged period of time, preventing EFA deficiency from occurring. There are 
however limitations to their use and they have been proven to have detrimental 
effects to the body through prolonged use. In order to understand the mechanisms 
behind these unwanted side effects it is important to look at the initial metabolism 
pathway of long chain PUFA’s including the EFA’s linoleic and α-linolenic acid as 
shown in figure 1.1.  
Fatty 
acid 
(FA) 
Structure Formula 
% in 
Intralipid 
emulsion 
Type of Fatty 
acid 
Linoleic 
acid  
C18H3202 44-62 Omega 6 PUFA 
Oleic 
acid 
 
C18H34O2 19-30 
Monounsaturated 
FA 
α-
Linoleni
c acid  
C18H30O2 4-11 Omega 3 PUFA 
Palmitic 
acid 
 
C16H32O2 7-14 Saturated FA 
Stearic 
acid 
 
C18H36O2 1.4-5.5 Saturated FA 
10 
 
 
Figure 1.1 Initial metabolism of PUFA's present in Soybean emulsion. 
Linoleic acid in soybean oil emulsions has been proven to have implications in the 
inflammatory pathways of the body. Production of pro-inflammatory mediators due 
to excess metabolism of linoleic acid has been associated with impaired lymphocyte 
function, limiting the body’s ability to deal with infection. The production of 
leukotriene 4 and prostaglandin 2, inflammatory mediators, also serve to increase 
inflammation within an already stressed system that is an acutely ill patient on PN 
(Wischmeyer 2015). Soybean oil as a plant derived oil also contains phytosterols, a 
substance that when infused over a prolonged period of time has been shown to 
cause intestinal failure-associated  liver disease (IFALD) (previously known as 
parenteral nutrition associated liver disease (PNALD)) (Gura et al. 2005; Gura et al. 
2006).  IFALD is a particular problem within neonatal patients who require PN from 
birth due to prematurity. Burrin et al. (2014) reported that in neonatal infants 
receiving soybean based PN for at least 2 months there is up to a 50% incidence of 
INFALD or a graduation of cholestatic liver dysfunction, that ultimately if not treated, 
leads to total liver failure and the requirement for liver transplantation. This statistic 
is further supported by Paltrinieri et al. (2016) who reported an incidence of IFALD 
of between 40-60% in neonates within a London trust hospital. 
1. Hepatic enzymes produce desaturation and elongation of carbon chain.  
2. Eicosapentaenoic acid converted to docosahexaenoic acid then further broken down to prostaglandin 3,  
leukotriene 5 and thromboxane 3. 
3. Pro-inflammatory mediators prostaglandin 2, leukotriene 4, thromboxane 2 (Hamilton et al. 2006) 
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1.2.3 New intravenous lipid emulsions 
 
Within the above association of IFALD, the omega 6 PUFAs and phytosterols has 
been one of the driving factors in the development of new IVLEs where soybean oil 
is either replaced or complimented by different oils. Olive oil, coconut oil derived 
medium chain triglycerides and fish oils have all been formulated into PN emulsions. 
Each of these oils provides different fatty acid combinations to that of the omega 6 
FA’s in soybean oil as seen in table 1.4. 
Table 1.4 Proportions of lipid in new IVLE's: *Medium chain triglycerides. (1) Fresenius Kabi, (2) Baxter 
Healthcare, (3) B Braun. (Burrin et al. 2014) 
 
The introduction of newer formulations of IVLE’s has aimed to reduce incidences of 
IFALD, improve patients’ lipid tolerance and more closely mimic the body’s naturally 
occurring processes of lipid metabolism. With reference to Figure 1.1, fish oil 
provides both EPA and DHA and therefore promotes the production of anti-
inflammatory products. Omegaven® (100% fish oil) is licensed for use as a 
component of lipid PN due to its lack of EFA’s, but has been used off license as a 
sole lipid agent to treat neonatal PNALD (Gura et al. 2006).  
SMOFlipid® contains a mixture of soybean, olive, fish oil and MCTs (see table 1.4). 
The reduction in omega 6 PUFAs coupled with the addition of anti-inflammatory 
omega 3 PUFAs from fish oils aims to reduce the inflammatory response to lipid PN 
by providing a more adequate ratio of omega 6 and omega 3 PUFAs (Waitzberg et 
al. 2015). Olive oil, high in omega 9 FAs was introduced post studies into the 
‘Mediterranean diet’, that showed reduced levels of atherosclerosis and liver 
disease (Sala-Vila et al. 2007; Waitzberg et al. 2015). MCTs are metabolized faster 
than longer chain PUFAs and provide a rapid energy release. This reduces liver 
Intravenous 
Lipid 
Emulsion 
% Proportion of oil component & source 
Soybean Olive Fish MCT’s* 
Intralipid1 100    
SMOFlipid1 30 25 15 30 
Omegaven1   100  
Clinoleic2 20 80   
Lipofundin3 50   50 
Lipoplus3 40  10 50 
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accumulation of fatty acids and, as they are unsaturated and of short carbon chains, 
are resistant to oxidation (Hippalgaonkar et al. 2010). SMOFlipid® also contains a 
higher proportion of vitamin E which is postulated to act as an antioxidant 
preventing peroxidation of PUFAs. Whilst a marked reduction in pro-inflammatory 
omega 6 PUFAs provides beneficial effects to the patient, SMOFlipid® still contains 
appreciable levels of phytosterols and therefore still has a potential link to IFALD 
processes. Data from Burrin et al. (2014) indicates however that the reduction in 
phytosterols in SMOFlipid® reduces the development of IFALD in an animal model 
and hypothesises that phytosterols may be the causative component of IFALD. 
1.3 Stability of IVLE’s 
1.3.1 Physical stability 
 
Physical stability of IVLEs is well quantified and dependent on a raft of internal and 
external factors. In PN where IVLEs are incorporated into AIO mixtures, each 
component of the PN will have stabilizing or destabilizing effects on the lipid 
emulsion: 
- Amino acids: provide a buffering capacity to PN. Large volumes of amino 
acid solutions buffer against the pH changes caused by additions of 
other components (Hardy and Puzovic 2009).  
 
- Glucose: Used as a rapid energy source. High concentration, low 
volumes provides an energy source as the low pH of glucose is a 
destabilizing factor for lipid emulsions. Glucose in high concentrations 
can interact with lecithin in IVLEs and lead to discoloration of PN 
mixtures, obscuring changes in physical stability (Hippalgaonkar et al. 
2010). 
 
- Electrolytes – Whilst added in small volumes as a necessity within AIO 
PN, electrolytes can interfere with the zeta potential and surface charges 
of oil droplets leading to emulsion destabilization (Hippalgaonkar et al. 
2010).  Electrolytes within standard PN mixtures include potassium, 
sodium, magnesium, calcium and phosphate. Potassium and sodium as 
monovalent ions are relatively stable within PN. Divalent ions, in 
particular calcium, are liable to form precipitates with phosphate. The 
factors affecting precipitation of calcium phosphate occurring are 
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multiple. pH of a PN mixture is critical in controlling the equilibrium for the 
three possible phosphate states than occur within a mixture. Tribasic 
phosphate is uncommon within PN due to its requirement for high pH. 
Mono and dibasic phosphate can readily occur within PN, the most 
problematic being dibasic phosphate as it readily combines with free 
calcium ions and forms a relatively insoluble precipitate. The 
concentration of amino acids present and the glucose concentration will 
govern the final pH of the PN mixture and therefore will contribute to 
buffering pH and preventing calcium phosphate precipitation from 
occurring. Other factors including temperature, calcium concentration, 
calcium formulation and concentration of magnesium will all also have an 
effect on calcium phosphate precipitation (Allwood and Kearney 1998).     
 
- Vitamins – Vitamin E (fat soluble) acts as an scavenger for free radicals, 
limiting but not preventing the peroxidation and subsequent breakdown 
of PUFA’s contributing to the chemical stability of PN (Steger and 
Mühlebach 1998; Grand et al. 2011). Vitamin C (water soluble) in itself is 
not a destabilizing factor of PN. It is however rapidly oxidized and broken 
down into oxalic and threonic acid, both acidic and can therefore reduce 
the pH of AIO PN, destabilizing lipid emulsions. Riboflavin (water 
soluble) acts within PN as a photosensitizer therefore promoting the 
production of reactive oxygen species which can cause peroxidation 
(Ferguson et al. 2014).  
 
- Trace elements – Including chromium, selenium, copper, iron, zinc, 
manganese, iodine, fluorine and in certain PN mixtures molybdenum. 
The majority of these trace elements are relatively stable within standard 
PN mixtures. Of note however, the following trace elements can cause 
stability issues within PN: 
• Iron – Ferric (Fe3+) ions are not stable in lipid PN as they can 
reduce the zeta potential charge on the surface of the lipid 
globules thereby destabilizing the lipid emulsion. Iron has also 
been implicated in the lipid peroxidation of IVLE’s though data 
suggests that light protection of PN can reduce this (Grand et al. 
2011). 
• Chromium – Is considered stable unless is in the presence of 
metal chelating agents which can lead to precipitation occurring.  
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• Zinc – Stable in PN mixtures but is known to bind to certain 
amino acids within PN mixtures affecting its bioavailability. Is also 
present in materials and consumables used during compounding 
and as such research has suggested that patients can receive 
higher doses than prescribed (Hardy et al. 2009).  
The separation of PN into lipid and aqueous portions as described above is 
employed when high concentrations of electrolytes or trace elements is required as 
described for neonatal PN above.  
External destabilizing factors of PN include temperature, oxygen and light. High 
temperatures are known to promote the peroxidation and chemical breakdown of 
PUFA’s as well as cause physical destabilization of lipid emulsions (Steger and 
Mühlebach 1997). Oxygen permeation of susceptible PN containers leads to 
chemical and physical instability. Oxygen can promote ascorbic acid breakdown 
leading to lower pH conditions and destabilization of emulsions. Peroxidation of 
lipids is also catalyzed by the presence of oxygen (Gonyon et al. 2013; Ozcan and 
Ogun 2015). 
1.3.1.1 Physical stability testing  
 
The physical stability of IVLE’s in their constituent parts (licensed) and when mixed 
as AIO PN (unlicensed) is well categorized. Multiple methods exist and are well 
used to categorize physical attributes of lipid emulsions used in PN and therefore 
are used as a measure of PN stability. Physical stability of PN is assessed mainly 
through the quantification of particle size distribution. This aims to identify particles 
of large size, typically >5μm (Calder et al. 2015). Whilst the British Pharmacopeia 
doesn’t specifically currently contain any monographs pertaining to the globule size 
distribution of IVLE’s, manufactures tend to follow the United States Pharmacopeia 
monographs (USP). Testing methods for lipid globule size and particle size 
distribution laid out in USP monograph 729 enable accurate and quantifiable 
monitoring of the physical stability of IVLE’s (United States Pharmacopeia and 
National Formulary (USP38 - NF 33) 2016b). When used in AIO PN mixtures or 
when licensed lipid emulsions are used with additions of fat soluble vitamins their 
stability limits will be altered due to the factors discussed previously. USP 729 
methods are then used to monitor for lipid degradation and to quantify usable 
stability parameters and storage limits. Common physical stability testing regimes 
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use PN bags under fridge storage up to 84 days to give data on extended storage 
periods. 
 
1.3.2 Chemical stability 
 
Unlike the relatively well quantified parameters of IVLE’s and subsequent PN’s 
physical stability, their chemical stability has been only limitedly explored and 
quantified. Chemical parameters such as pH, concentrations of trace elements and 
electrolytes have all been successfully monitored but always with relation to their 
effect on the physical stability of AIO PN. Vitamin concentrations have been 
explored and shown to chemically alter and breakdown during PN storage and 
administration, again leading to emulsion destabilization and vitamin loss 
(Nonneman et al. 2002; Ferguson et al. 2014). With specific regards to the chemical 
stability of IVLEs it has been proven that lipids break down under the influence of 
both internal and external factors (Hardy and Puzovic 2009). This breakdown 
primarily is due to lipid peroxidation. Whilst the process of lipid peroxidation has 
been well studied, little has been done to quantify peroxidation levels within PN and 
the subsequent differing amounts of lipids that are infused to the patient post 
peroxidation during storage. This gap in knowledge in the area of chemical stability 
of IVLE’s is addressed within this work and forms the basis of the research aims 
and objectives set out overleaf.  
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1.4 Lipid peroxidation 
1.4.1 Principles 
 
The principles of lipid peroxidation can broadly be split into endogenous and 
exogenous processes. Endogenous stages of peroxidation concern the enzymatic 
breakdown of lipids within the metabolism pathways in the body. Whilst this is a 
naturally occurring process within the body, as this work is focusing on peroxidation 
occurring in PN before administration, only exogenous processes will be considered 
here.  
Lipid peroxidation is the process by which PUFA’s present in PN lipid emulsions are 
degraded by a self-propagating chain reaction initiated by a reactive oxygen species 
(ROS) or other free radical (Mühlebach and Steger 1998; Kamal-Eldin 2003). This 
reaction also takes place naturally during many pathways in the body, but a healthy, 
non-stressed human deals effectively with this. However, within a chronic or acutely 
unwell patient where endogenous ROS levels will already have stretched the bodies 
coping and detoxification mechanisms to their limit, this can cause a potentially 
catastrophic problem when peroxidation products are then administered within PN 
to the patient. Therefore, quantifying the levels of peroxidation occurring in PN and 
IVLE’s is of vital importance and the focus of this work. 
Peroxidation can be broadly broken down into three areas, initiation, propagation 
and termination. 
 
1.4.1.1 Initiation 
 
The initiation of lipid peroxidation relies upon the creation of a ROS or free radical 
that can then go on to abstract a hydrogen from a PUFA. Essentially a free radical is 
any atom that has an unpaired electron and can exist as a single entity, therefore 
having the ability to gain an electron, usually in the form of a hydrogen atom 
(unpaired electron) (Halliwell and Chirico 1993). The availability of oxygen within a 
PN system is a crucial factor with regards to the initiation step of lipid peroxidation 
when ROS are considered as the initiating radical. Oxygen levels are limited in the 
components of PN by their preparation in oxygen free environment during bulk 
manufacture. However, during the manufacture of PN it is almost inevitable that a 
small amount of oxygen will be introduced to the PN bag. Whilst as much air as 
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possible is standardly removed from PN bags at the end of the compounding 
process, small volumes remain, as does oxygen within the giving sets connected to 
PN bags upon administration.  
Transition metals such as iron (present in standard PN mixtures) promote the 
formation of hydroxyl radicals (OH.) through the Fenton reaction (Fe2+ + H2O2 -> 
Fe3+ + OH. + OH-). Hydroxyl radicals are one of the most reactive free radical 
species (Sodergren 2000; Kamal-Eldin 2003). Transition metals also have a role in 
the production of (OH.) radicals from oxygen. Oxygen can accept an electron 
creating a free radical, either a superoxide anion (O2-) or a peroxide ion (2O2-). 
Peroxide ions, at physiological pH and pH present within a PN lipid emulsion, 
rapidly protonate forming hydrogen peroxide (H2O2). Hydrogen peroxide and 
superoxide are strong oxidising agents and in the presence of transitional metals 
create hydroxyl radicals (OH.).  
Light exposure also plays a role in free radical generation within IVLE’s. Known as 
photo-oxidation, UV exposure from ambient light sources can lead to electron 
rearrangement and creation of a singlet oxygen molecule (O21). Though not a true 
free radical with respect to the initiation step of peroxidation, singlet oxygen 
interacts directly with lipid molecules creating lipid peroxides. This bypasses the 
initiation step of abstraction of a hydrogen atom from the lipid. As such it is a 
catalyst for both the initiation and propagation processes (Halliwell and Chirico 
1993; Kamal-Eldin and Min 2008). Singlet oxygen can also be produced when 
certain compounds, including riboflavin (component of AIO PN) are exposed to light. 
Such compounds absorb light, enter a higher electron excitation state and then 
transfer this energy to oxygen thereby creating singlet oxygen molecule which can 
then react with PUFA’s.  
 
Figure 1.2 Initiation scheme for peroxidation through abstraction of a hydrogen from a lipid creating a lipid radical. 
 
Within IVLE’s, the susceptibility of the lipid to peroxidation is centred on the 
presence of double carbon bonds i.e. the level of unsaturation of the fatty acid. A 
double bond within a chain of carbons weakens the C-H bond on the adjacent 
carbon from the double bond due to electron delocalisation through the double 
bond. This makes abstraction of a hydrogen atom from said carbon easier (Kamal-
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Eldin 2003). The more double bonds within a PUFA, the more likely peroxidation is 
to occur. Hence why of the lipids present in IVLE’s linoleic acid with two double 
bonds is the most susceptible to peroxidation.  
Once a hydrogen has been removed from a lipid molecule, the lipid radical is 
unstable and undergoes a molecular rearrangement to stabilise the system. This 
leads to the formation primarily of a conjugated diene (molecule where two double 
bonds within a carbon chain are separated by a single carbon bond, allowing 
delocalisation of electrons to occur, stabilizing the system) as shown in figure 1.3. 
Lipid radicals are themselves reactive and therefore readily combine with oxygen 
present in a PN system to form a peroxyl radical (ROO.). 
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Figure 1.3 Molecular rearrangement of linoleic acid radical and subsequent reaction with oxygen to yield peroxyl 
radicals. 
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1.4.1.2 Propagation 
 
Lipid peroxidation is a self-propagating process. The production of a lipid peroxyl 
radical in the initiation steps means that this radical itself is then able to interact with 
other PUFA’s, abstracting a hydrogen from an adjacent PUFA, thereby creating 
another lipid peroxyl radical and a lipid hydroperoxide (Repetto et al. 2012).  Lipid 
hydroperoxides are always the first products of lipid peroxidation. 
 
 
Figure 1.4 Propagation step of peroxidation. Lipid peroxyl radical is able to abstract a hydrogen from another PUFA, 
creating a lipid hydroperoxide and another lipid radical. 
 
This process of lipid radical production, rearrangement to a conjugated diene, 
reaction with oxygen to form a peroxyl radical and then subsequent further lipid 
radical production continues until either a termination reaction occurs, or the 
availability of oxygen becomes a limiting factor.  
Transition metals can abstract the oxygen and hydrogen atoms from a lipid 
hydroperoxide, forming a lipid radical and re-initiating the process of peroxidation. 
Hence within PN, the presence of transition metals has an effect on the levels of 
peroxidation seen (Repetto et al. 2012). 
1.4.1.3 Termination 
 
The process of lipid peroxidation has several ways in which it can be terminated. 
The principle of termination of peroxidation is when either two lipid radicals come 
into contact with each other, or when a lipid radical comes into contact with an anti-
oxidant molecule. Two lipid radicals have the ability to bond together and form a 
stable lipid dimer molecule or form two lipid hydroperoxides. The presence of anti-
oxidant molecules within PN such as α-tocopherol (vitamin E) or riboflavin has a 
definitive effect on limiting the level of lipid peroxidation that occurs (Lavoie et al. 
1997; Steger and Mühlebach 1998). Lipid hydroperoxides can also be rearranged to 
form cyclic endoperoxides, particularly those from PUFA’s such as Arachidonic acid 
(Leray 2016). 
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Figure 1.5 - Pathways for termination of lipid peroxidation. 
1.4.2 Lipid peroxidation products 
 
The initial products of PUFA peroxidation are always mono-hydroperoxides. The 
number of positionally different hydroperoxides that can be formed from a PUFA 
can broadly be defined using the formula 2n-2 where n stands for the number of 
double bonds within a PUFA (Esterbauer 1993). Using linoleic acid as an example, 
this PUFA has the formula 18:2 (2 double bonds) and therefore if capable of forming 
2 different hydroperoxides, hence the greater degree of unsaturation of the PUFA, 
the greater the number of possible hydroperoxides. Eicosapentaenoic acid (EPA) 
found in fish oil PN is 20:6 in structure and therefore can create 10 different 
hydroperoxides upon peroxidation.  
The position along the carbon chain of the PUFA where the hydroperoxide forms is 
dependent on the position of the double bonds within the PUFA. As shown in figure 
1.3, peroxidation of linoleic acid results in C13 and C9 hydroperoxides. This is 
correct for the case of peroxidation due to auto-oxidation, or free radical initiated 
peroxidation. However, when looking at photo-oxidation of PUFA’s by light exposure 
and the creation of singlet oxygen molecules, the carbon centres of 12 and 13 are 
targeted by singlet oxygen, therefore creating different hydroperoxides. It has been 
proven however that the vast majority of hydroperoxides generated when auto-
oxidation and photo-oxidation are simultaneous will be those of C13 and C9 
hydroperoxides in the case of linoleic acid, i.e. auto-oxidation is the dominant 
peroxidation pathway (Mlakar and Spiteller 1996). 
Primary hydroperoxides are relatively stable in isolation, but in the presence of 
transitional metals, vitamins, an acidic pH or increased temperatures rapidly 
degrade to secondary products of peroxidation. Within an AIO PN system or within 
a lipid emulsion with fat soluble vitamins the rate of degradation of primary 
hydroperoxides will make measurement of them inaccurate in quantifying levels of 
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peroxidation.  Hydroperoxides always rapidly undergo secondary and tertiary 
reactions to form a multitude of peroxidation products including reactive aldehydes, 
complex lipid endoperoxides and larger lipid structures. These products are formed 
in a variety of different ways, many of which are not fully understood. The main 
principles of these secondary and tertiary reactions are explained below. For the 
purposes of this body of work, the formation of the reactive aldehydes will be 
focused on and therefore are explained due to their inherent toxicity and risk they 
pose to the patient. 
- Chain-breaking reactions: Involves splitting of the carbon 
backbone of the PUFA chain, creating two smaller molecules, 
one from the methyl end of the PUFA and the other from the acyl 
end which is often still attached to a phospholipid molecule. The 
type of methyl molecule created will always be a volatile 
aldehyde. Which aldehyde is formed is dependent on the type of 
PUFA the parent molecule is.  
Omega 6 PUFA’s, as shown with linoleic acid in figure 1.6, will 
always form several possible aldehydes the most reactive being 
4-hydroxynonenal (HNE) whereas omega 3 PUFA’s will form 4-
hydroxyhexanal (HHE) (Esterbauer 1993).   
 
Figure 1.6 Production of 4-Hydroxynonenal from omega 6 fatty acids (Schneider et al. 2008). 
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- Formation of cyclic hydroperoxides is a complex process 
involving the rearrangement of PUFA’s to form endoperoxides. 
These subsequently then further break down into smaller 
molecules including the aldehyde malondialdehyde (MDA) 
(Schaur et al. 2015).  
 
Figure 1.7  Production of MDA from unsaturated fatty acids. 
 
Whilst numerous other secondary and tertiary products are formed, their processes 
of formation and their biological activity within the body are not well understood and 
therefore will be excluded from this body of work. 
With regards to the production of secondary and tertiary products from the 
peroxidation of PN lipids, as described above these are due to either auto-oxidation 
or photo-oxidation. This to a certain extent limits the number of end products 
created, as within the body many tertiary products created are a result of the 
metabolism of primary hydroperoxides through enzymatic actions. This limits the 
number of peroxidation products possible in vitro within PN systems due to the lack 
of any enzymatic processes. The numerous other components within PN such as 
amino acids etc. will however interact with volatile peroxidation end products. This 
interaction will form adducts of aldehydes with amino acids etc. and numerous 
products with unknown biological significance. Therefore, quantification of 
peroxidation is a complex area as discussed below.  
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1.5 Peroxidation testing 
 
Currently in the release criteria within the available pharmacopeia monographs for 
IVLE’s there are no limitations on the level of peroxidation present. We hypothesise 
that this is however an area that requires quantifying due to the potential toxicity of 
the products produced from peroxidation.  
Lipid peroxidation has been quantified in a variety of ways. Each type of testing has 
its own limitations and merits. With regards to PN, the main testing methods are 
reviewed in the following text. 
1.5.1 Peroxide value 
 
Peroxide value is to date the only specified test for peroxidation within the United 
States Pharmacopeia (USP). Whilst existing within the USP monograph for fats and 
fixed oils, this test is based on the reaction between peroxides and iodine which is 
then titrated against sodium thiosulfate. This gives a peroxide value, defined as the 
amount of peroxide oxygen per 1 kg of fat or oil. The limit for fats and fixed oils is 
set as 5 nM (United States Pharmacopeia and National Formulary (USP38 - NF 33) 
2016a). Whilst used effectively to quantify overall peroxide levels within fats and 
fixed oils, this method needs an adaptation step for use within PN. Due to the other 
components within PN AIO mixtures that can interact with iodine, a lipid extraction 
step is required prior to testing peroxide value (Steger and Mühlebach 1998; 
Muhlebach 2015). Peroxide value testing, whilst relatively quick and low cost, has 
questionable specificity as a test for lipid peroxidation. It is known that hydrogen 
peroxide present will also reduce iodine, thereby giving a false positive reading for 
peroxidation (Halliwell and Chirico 1993). 
1.5.2 Thiobarbituric Acid Reactive Substances Test (TBARS) 
 
TBARS is the most commonly used test for peroxidation. The sample is heated with 
thiobarbituric acid at a low pH and the intensity of the resulting pink adduct is 
quantified by measuring its absorbance at 532 nm or through the use of 
fluorescence at 553nm (Halliwell and Chirico 1993; Marrow 2010). Whilst the 
TBARS assay is one of the quickest, cheapest and easiest test available for defining 
peroxidation levels within a system, it has marked limitations, proven by results from 
its use as a testing mechanism for peroxidation within PN solutions (Picaud et al. 
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2004; Grand et al. 2011). Looking at the testing procedure itself, the heating step 
within the method is problematic when considering peroxidation. Heat is a known 
catalyst for the breakdown of primary hydroperoxides and therefore secondary and 
tertiary products can be created providing a false result.  
The TBARS assay has been used within the testing of PN and IVLE’s for 
peroxidation (Pitkanen et al. 1991; Basu et al. 1999b; Sala-Vila et al. 2007) but due 
to the fact that other aldehydes and amino acids can also interact with TBA 
(Sodergren 2000; Shintani 2013), the assay is largely disregarded when looking at 
peroxidation within PN. 
1.5.3 Ferrous oxidation in xylenol orange assay (FOX) 
 
The FOX assay exists as a bench top low cost assay for the measurement of lipid 
hydroperoxides, the primary products within the peroxidation process. The test 
works on the bases of oxidation of Fe2+ ions to Fe3+ ions by hydroperoxides. Then 
the subsequent reaction of Fe3+ ions with xylenol orange to form a coloured complex 
read by its UV absorbance at 560nm (Sodergren 2000). The initial FOX assay, 
known as FOX-I, was developed for quantification of aqueous peroxides. This was 
then modified with addition of butlylated hydroxytoluene (BHT) and methanol for the 
measurement of lipid hydroperoxides (FOX-II assay). The sensitivity of FOX-II is 
approximately five times lower than that of FOX-I (Nourooz-Zadeh et al. 1995). The 
FOX-II assay has been further developed where methanol was replaced with n-
propanol to enable full dispersion of lipid emulsions to occur (FOX-III).  
The issues of using FOX-III for the quantification of lipid peroxidation in PN lipids 
revolves around those similar to that of the TBARS assay. Many substances can 
interfere with the results of the FOX-III assay including ascorbate, included in 
multivitamin preparations used within PN mixtures (Karen and Winterbourn 2001). It 
has also been established that if lipids and lipid peroxides are not extracted from the 
aqueous portion of PN prior to quantification, any hydrogen peroxides present not 
due to lipid peroxidation will give false readings. Silvers et al. (2001) confirmed this 
by comparing the effect of multivitamin addition to lipid infant PN through the use of 
the FOX-III assay with an added initial lipid extraction method against a high 
performance liquid chromatography (HPLC). Their results concluded that in AIO PN 
mixtures the FOX-III assay gave values of peroxidation approximately double to that 
of the HPLC quantification method confirming that substances other than peroxides 
interfere with the FOX assay. Further work comparing all three versions of the FOX 
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assay in PN testing was carried out by Karen & Winterbourn (2001). Their 
conclusions discounted the use of the FOX assay for testing peroxidation levels in 
lipid PN mixtures due to interactions with multivitamins and aqueous 
hydroperoxides.  
The measurement of lipid hydroperoxides by any method is limited by the stability of 
such primary products of peroxidation. Primary hydroperoxides are rapidly degraded 
into secondary and tertiary products, making any method quantifying primary 
peroxidation products questionable as an effective assay for assessing overall 
peroxidation within a system. 
1.5.4 Existing high-performance liquid chromatography methods 
 
The lack of sensitivity of the TBARS assay has been addressed by the adaptation of 
the assay through use of HPLC to increase the accuracy of the measurement of 
MDA production due to peroxidation. The TBARS assay is carried out as above, 
creating a TBA-MDA adduct which is then subjected to HPLC (Marrow 2010). Whilst 
HPLC can increase the accuracy of quantifying the levels of TBA adducts present, 
this system does not remove the inherent inaccuracies of the TBARS test itself 
neither does it address the issues of substances other than malondialdehyde 
reacting with TBA to form adducts, although these will be separated and may be 
identifiable by HPLC.  
HPLC has been employed in the testing of MDA within lipid PN through 
derivatisation of MDA with diaminonaphthalene. The derivatised MDA forms a 
distinct peak at 311 nm under UV detection and this method has been used to 
quantify the levels of MDA within neonatal lipid PN solutions (Steghens et al. 2001; 
Picaud et al. 2004). 
With regards to measuring the total aldehyde load of a sample as a measure of 
peroxidation, HPLC  methods with UV detection and fluorescence detection have 
been developed, again through derivatisation of reactive aldehydes (Lovell 2003). 
Both detection procedures have been used to quantify aldehydes within lipid 
system, but there have been no published reports of their use within PN systems. 
The measurement of total aldehyde content as a measure of peroxidation is a 
contentious issue especially when considering the multiple components present 
within a PN AIO system. It is unlikely, without an extraction procedure employed 
prior to HPLC analysis, that a measure of total aldehyde content could be achieved. 
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Aldehydes will also be present that will not be a result of lipid peroxidation and 
therefore may give anomalous results.  
Chemiluminescence is a relatively well exploited technique for the HPLC 
measurement of lipid hydroperoxides. Yamamoto & Ames (1987) developed the 
technique for identification of lipid hydroperoxides and hydrogen peroxide. The 
technique has been modified using methanol lipid extraction followed by HPLC 
separation, post column reaction with isoluminol and fluorometer detection and 
employed by Helbock et al. (1993) for the testing of peroxidation in neonatal lipid 
emulsions. Whilst the assay appears to give a sensitive tool for the detection of lipid 
hydroperoxides, Yamamoto & Ames (1987) noted that the presence of antioxidants 
within the sample could interfere with the result through interaction and removal of 
lipid hydroperoxides prior to HPLC separation. Whilst the assay appears effective, 
with regards to the testing of PN lipids, it again detects the primary lipid peroxidation 
products, which can rapidly degrade to further products as discussed above making 
the rate of the assay a limiting factor.  
HPLC with UV detection has been used as a direct testing method for the 
identification and quantification of HNE and MDA. The assay for both MDA and 
HNE uses standard conditions for reversed phase HPLC (RP-HPLC) and provides 
effective separation using a C-18 column (Esterbauer and Zollern 1989; Emerit et 
al. 1991; Karatas et al. 2002). Neither method requires a lipid extraction method to 
be employed, reducing lab testing time and increasing reproducibility. Neither 
testing method has been employed within the lipid PN testing of peroxidation. The 
direct analysis of MDA through RP-HPLC would require a sample clean up step with 
regards to the removal of amino acids from the sample, as MDA interacts with free 
amino acids, which would be problematic with regards to PN solutions. The 
rationale for the decision to focus on the identification and quantification of HNE or 
MDA is discussed below in the form of a review of their known toxicities within the 
body.  
1.6 Review of the biological actions of 4-hydroxynonenal and Malondialdehyde 
 
HNE and MDA are two of the most studied products of peroxidation with regards to 
their respective actions within the body. Both are known to be toxic and have been 
linked to a variety of different pathophysiological disease processes. 
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Esterbauer (1993) provided an extensive review paper on the cytotoxicity’s of lipid 
peroxidation products, mainly focusing on HNE and MDA research work. Looking at 
HNE, the paper reviews research that suggests HNE is highly toxic to cells. It 
establishes concentrations of HNE required to produce different effects, outlined in 
table 1.5. 
Table 1.5 Effects of HNE on mammalian cells - adapted from Esterbauer 1993. 
 
The review also looks at the work performed on lipid hydroperoxide toxicities, and 
MDA toxicity, establishing that MDA is generally considered to be less toxic than 
HNE. MDA levels have however been quantified to be significantly increased in 
incidences of atherosclerosis, cardiovascular disease (CVD) and myocardial 
infarctions (MI). 
The role of HNE in the mechanisms of cancer has been extensively studied and is 
reviewed by Zhong & Yin (2015). The interactions between HNE with DNA, 
mitochondria and proteins are discussed within this paper. This suggests several 
complex mechanisms by which HNE may be involved in the proliferation and spread 
of cancer cells through the body. Csala et al. (2015) and Hauck & Bernlohr (2016) 
further reviewed the cytotoxic nature of HNE within the body, including its 
involvement in cell signalling, proliferation, apoptosis. HNE’s effects on the 
pathogenesis of several diseases including Huntington’s disease, other 
neurodegenerative conditions, cancer and cardiovascular diseases are also 
considered. Schaur et al. (2015) is a large body of work on the production, 
metabolism and actions of endogenous HNE in the body. Conclusions from the 
work include the important finding that the concentration of HNE is a key factor in 
the modulation of its effect on the body. When present in lower concentrations, the 
bodies’ detoxification systems can deal with HNE. At higher concentrations HNE 
often forms adducts with proteins and enzymes, thereby altering signalling 
HNE concentration Effects 
>100 μM Cell lyses occurs 
1-50 μM 
Inhibition of protein and DNA synthesis 
and cell proliferation. 
<1 μM 
Genotoxic to lymphocytes, disturbances 
in gap junction signalling, phospholipase 
C stimulation. 
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pathways, receptor sites and cellular processes, leading to alterations in cell growth, 
development and death. This establishes again the relationship between HNE and 
many pathophysiological disease states. 
Adams et al. (1999) paper looked at the effects of MDA and HNE on plant cell 
proliferation and development, concluding, in support of Esterbauer (1993) that 
MDA is less toxic than HNE, in this case towards embryonic plant cells.  
Basu et al. (1999a) specifically commented upon the levels of MDA present within 
neonatal PN and the resulting effects within the body. The results showed that PN 
administration to both stable and acutely unwell critical neonatal patients resulted in 
an increase in free radicals within the body measured by the presence of MDA.  
The cytotoxicity of linoleate hydroperoxide (a pre-cursor to HNE) within rats was 
summarized by Cutler & Schneider (1974) whose work found that said 
hydroperoxides increased numbers of mammary and pituitary tumours thereby 
concluding that hydroperoxides were both cytotoxic and mutagenic. 
1.7 Conclusions and review of research aims and objectives 
 
The above review encompasses the biological effects of both HNE and MDA. Whilst 
both have been studied extensively, emphasis has been placed upon HNE rather 
than MDA. This is due to the toxicity of HNE being far greater than MDA at 
concentrations that are likely to be found within cells of the body. With regards to 
lipid peroxidation in IVLE’s the only papers found bore relevance to the 
quantification of MDA through the use of the TBARs assay and HPLC as discussed 
above.  
When considering the objectives of this work, the goal is to identify the level of lipid 
peroxidation occurring within lipid PN formulations. The merits and limitations of the 
current available assays are discussed above and conclude that there currently isn’t 
an appropriate assay available to accurately and reproducibly measure the 
peroxidation occurring in such formulations. Likewise, when considering the 
products of peroxidation, the multiple different compounds formed means that it 
would be impossible to develop an assay to quantify all these products. Therefore, it 
was decided to look specifically for the presence of HNE within PN solutions. It has 
been hypothesised that HNE is one of the most toxic breakdown products of 
peroxidation and as such will serve as a marker for the level of peroxidation 
occurring within lipid emulsions.  
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As HNE levels can only be viewed as a marker for lipid peroxidation occurring within 
lipids, it was decided that a complementary assay should also be developed to look 
at the amount of lipids that are lost in the process of peroxidation within PN 
solutions. Developing an assay that would quantify the amount of triglycerides 
(TAGs) that are initially within a PN solution and then comparing this to PN 
subjected to differing storage conditions will show the amount of TAGs that have 
been lost through their breakdown. This will also act as a comparison, aiming to 
equate the amount of lipids lost with the level of HNE produced through 
peroxidation.  
The availability of HPLC instruments within the research laboratory, along with the 
merits of direct analysis of HNE as discussed above will focus this research on the 
development of an assay that will directly quantify the level of HNE within lipid PN 
solutions through the use of reverse phase HPLC with UV detection.  
Concurrently with the above assay and through the use of HPLC coupled with a 
charged aerosol detector (CAD) (see chapter 2 for details) an assay will be 
developed to accurately quantify the amount of TAGs present within each lipid 
emulsion. This CAD allows the direct quantification of lipids without the need for 
derivatisation.  
Once assay development has been achieved, IVLE’s will be tested in a variety of 
differing conditions. This aims to establish the chemical stability of new and 
established IVLE’s with regards to the levels of lipid peroxidation occurring and the 
level of toxic HNE produced in vitro before administration to the patient.
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1.8 Research aims and objectives 
1.8.1 Research aim 
 
Explore how different storage conditions and containers affect the level of lipid 
peroxidation occurring within both gold standard and new generation intravenous 
lipid emulsions (IVLEs).  
 
1.8.2 Research objectives 
 
- Development and validation of an accurate and repeatable assay to 
quantify peroxidation levels to ensure stability of PN products and to 
provide a quality assurance testing method for peroxidation values in PN.  
 
- To quantify the level of lipid peroxidation occurring within IVLEs during in 
vitro storage before administration to the patient: Whilst the process of 
peroxidation itself has been extensively studied, little is known with 
regards to its detrimental effects on lipid emulsions found in parenteral 
nutrition (PN) particularly when considering the stability of PN emulsions 
in vitro.  
 
- To quantify levels of chemical stability of new IVLEs: Intravenous lipid 
emulsions form a staple part of parenteral nutrition (PN). The limited 
stability testing that has been carried out with the newer emulsions 
indicates that the fatty acid compositions of the oils will afford differing 
levels of stability to PN.  
 
- Stability testing of small volume PN in infusion bags: Specifically, with 
regards to neonatal PN, current clinical practise is to use a syringe as a 
storage device for the lipid proportion. Local PN providers are 
considering a move from a syringe to storage in an infusion bag and 
therefore stability testing of small volume lipid PN in infusion bags is 
required to establish safe shelf lives. 
32 
 
 
 
 
  
Method Development
33 
 
2.1 HPLC principles  
 
HPLC separates compounds within a sample by passing them through a 
chromatographic column at high pressure. Normal phase HPLC uses a polar 
stationary phase column and a non-polar mobile phase whilst reverse phase HPLC 
uses a non-polar stationary phase and a polar mobile phase. Depending on an 
individual compound’s chemical characteristics it will partition between the mobile 
phase and the stationary phase of the column at a different rate, thereby separating 
multiple compounds within the sample (Hamilton and Hamilton 1992). When 
considering lipid chromatography, the selection of chromatography conditions is 
dependent on a) the composition of the lipid being analysed and b) the type of 
separations that are required. Different column choices can be employed depending 
on whether lipids need to be separated simply by class (phospholipids, mono, di 
and triglycerides etc.), if inter-class separation is required i.e. TAGs based on their 
partition number, or if further separations are required for example distinguishing 
between triglycerides with the same fatty acid chains but at different sn1, 2 and 3 
positions. Typically when distinguishing between classes of lipids using HPLC, 
normal phase HPLC is employed, using a stationary phase such as silica or 
cyanopropyl and organic mobile phases (Lin and McKeon 2005), mimicking the TLC 
(thin layer chromatography) conditions from which lipid analysis via HPLC has 
developed.  
 
Reverse phase HPLC (RP-HPLC) employs a stationary phase formed of carbon of a 
specific chain length bonded to an inert basement substrate, commonly silica and 
has developed to become the staple mode of HPLC for inter-class lipid analysis. 
RP-HPLC is typically more robust than normal phase due to the stability of the 
stationary phases, resulting in satisfactory repeatable assay development (Synder 
et al. 1997).  RP-HPLC mobile phases commonly employ an organic phase and an 
aqueous phase, providing a balance that when developed correctly, will elute 
molecules from the hydrophobic stationary phase by producing an environment for 
small molecules, often with mixed hydrophobic and hydrophilic properties to 
partition into, thus creating separations. The issue however, when considering lipid 
analysis by RP-HPLC is the presence of water within the mobile phase. Lipids are 
highly hydrophobic molecules and therefore when presented with a mobile phase 
with a degree of aqueous phase within it, will simply partition onto the carbon 
hydrophobic stationary phase and thus will not be eluted from the column, leading to 
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undetectable signals, column blockages and high pressures.  To circumvent this 
issue, all organic mobile phases can be employed, eliminating water and therefore 
creating a hydrophobic mobile phase, allowing partition from the stationary phase to 
the mobile phase to occur which, when optimised effectively, will achieve desired 
separations (Sewell 1992; Lin et al. 1997). 
 
2.2 Non-aqueous Reversed Phase (NARP) HPLC 
2.2.1 NARP introduction 
 
Using non-aqueous mobile phases with a carbon stationary phase allows the 
effective separation and elution of hydrophobic molecules. Effective separations 
under such circumstances are dependent on multiple factors, the most influential 
being stationary phase chain length and choice of organic mobile phases.  
The principles of NARP HPLC have been employed successfully for the separation 
and quantification of lipids, including TAGs which form the staple component of all 
lipid emulsions used for parenteral nutrition. NARP has been used to separate 
TAGs within oils by multiple researchers (Swe et al. 1996; Lísa et al. 2007; Hmida et 
al. 2015). Byrdwell et al. (1996) successfully separated TAGs present within 
soybean oil, the primary oil found within the PN lipid formulation Intralipid® and 
within newer lipid emulsion formulations (SMOFlipid® etc.). Lisa et al. (2007) 
successfully separated 19 triglycerides using an C18 stationary phase with a mobile 
phase gradient comprised of Acetonitrile (ACN), Isopropanol (IPA) and hexane, with 
a charged aerosol detector.  
2.2.2 Mobile phases 
 
Choice of organic solvents employed within NARP varies depending on the 
formulation being assessed. NARP requires the use of a weak solvent, commonly 
acetonitrile (Hmida et al. 2015) and a strong solvent. With regards to NARP where a 
carbon non-polar stationary phase is employed, the difference in strength of organic 
solvents used is the governing factor on elution of compounds. Said strength of 
solvent is inversely proportional to the polarity index of the organic solvent.  The 
lower the polarity index of the organic solvent, the stronger it’s eluting strength due 
to its ability to interact with the non-polar components of lipid molecules, 
counteracting the lipids attraction to the non-polar stationary phase.  Conversely, 
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when considering the phospholipids present within an emulsion their more polar 
nature results in them being eluted slower by lower polarity or strong solvents and 
faster by more polar weaker solvents. Therefore, the choice of organic solvents 
used is crucial to the separation of a lipid emulsion. Solvent choice however is 
limited depending on the type of detector employed. When considering UV 
detection, certain solvents cannot be employed at low wavelength detection as they 
will be detected and produce an unstable baseline (Synder et al. 1997). With 
regards to charged aerosol detection (CAD), the choice of organic solvents is 
unlimited as CAD detection will be unaffected due to the volatility of the solvents. 
Hmida et al. (2015) established a solvent strength scale for organic solvents in 
NARP HPLC conditions when looking at the separation of nine different seed oils at 
varying temperatures. The work showed that all combinations of iso-eluotropic 
organic mobile phases used could be employed for the separation of TAGs from 
oils. A combination of Acetonitrile (ACN) /Isopropanol (IPA) sits in the middle of the 
scale produced within this work (represented in table 2.1), making it a good starting 
point for assay development with respect to separations of TAGs within lipid 
emulsions. Both IPA and ACN are applicable to UV analysis across the majority of 
wavelengths.  
Table 2.1 – Data summarised from Hmida et al. (2015) showing effectiveness of strong solvents with Acetonitrile 
in detection of triglyceride peaks within oils. 
 
BuOH 26% | 
ACN 
AcMe 50 % | 
ACN 
AcOEt 34 % | 
ACN 
IPA 34 % | 
ACN 
Oil Number of peaks identified 
Tamanu 20 16 17 18 
Soya 19 14 16 18 
Pistachio 16 13 15 16 
Olive 17 14 16 16 
Black currant stone 24 23 23 24 
Tung 24 11 23 23 
Pine nut 15 14 15 14 
Pomegranate 21 15 20 17 
Babassu 17 15 16 16 
Rank 1st 4th 3rd 2nd 
 
2.2.3 Column choice 
 
The standard choice of stationary phase for RP-HPLC is a carbon column (C18) 
with an 18-carbon chain length. Carbon stationary phase columns are formulated 
with C18 organosilanes covalently bonded onto an inert silica base. The structure 
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created and the three-dimensional positioning of the C18 chains and therefore their 
availability to interact with sample components is governed by the basement particle 
size and shape. Optimum column efficiency is achieved by maximising the C18 to 
basement silica particle ratio. Over packing of basement particles will cause steric 
hinderances to interacting molecules and the potential for unreacted silica to interact 
with sample molecules, whilst over bonding of C18 chains will alter pore size of the 
column, limiting the proportion of each C18 chain available for interaction (Synder et 
al. 1997; Scientific 2011). Certain columns undergo a process known as end-
capping where any silica support molecule that is not bonded to C18 chains is 
reacted with a small silane such as di or trimethylchlorosilane to produce an inert 
base, preventing solute molecules from interacting with the silica base and altering 
the column properties (Synder et al. 1997; Scientific 2003). Carbon chain length of 
the stationary phase will change the retention time of sample molecules. Sample 
retention in reverse phase increases with increasing carbon chain length of the 
stationary phase. C18 chains fall within the middle of the chain lengths available as 
stationary phases, making such a length a good starting point for method 
development. C18 columns have also been used in multiple methods for the 
effective separation of lipids and fatty acids (Lísa et al. 2007; Makahleh et al. 2010; 
Gonyon et al. 2013). 
 
When considering lipid chromatography in NARP mode, the carbon chain length of 
the sample TAGs will have a governing factor on the separations achieved. Chain 
length establishes the ‘strength’ of the hydrophobic environment achieved by the 
column, thereby directly affecting the retention or k of compounds. TAGs are 
broadly structured as seen in figure 2.1, where each R group corresponds to a 
specific fatty acid of varying chain length and level of saturation.  
 
Figure 2.1 General chemical structure of triglycerides. R1, R2 and R3 represent fatty acid chains conferring 
varying levels of saturation. 
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The chain length of each R group will initially govern the interaction between the 
C18 chains of the stationary phase and the R group fatty acid. The greater the chain 
length of each R group, the greater the level of interaction with the C18 chains, 
increasing the retention time of the TAG on the column. Therefore, higher chain 
length TAGs will elute later than TAGs with lower chain lengths. There is however 
exceptions to this guide as the level of unsaturation present in each R group and 
mobile phase choice will alter retention times of TAGs of similar components. 
Broadly speaking the partition number or elution order of each TAG can be 
estimated using the formula shown in figure 2.3 i.e., can be used to estimate TAG 
elution order of triglycerides with the same lengths of fatty acid chains but differing 
levels of saturation. The greater the level of unsaturation, the lower the partition 
number expected. As assay development will initially be employed to look at the 
triglycerides present within Intralipid® 20%, this is important when considering the 
elution order of TAGs as Intralipid® has high levels of fatty acids with multiple levels 
of unsaturation within their chains.  
 
Figure 2.2 - Elution order equation, PN = partition number, CN = carbon number, DB = 
number of double bonds. 
Due to the levels of fatty acids within Intralipid® 20% as seen in table 2.2 the 
triglycerides formed will potentially vary by a single level of unsaturation and as 
such the assay developed will need to distinguish between such TAGs. Therefore, 
column choice as explained above is of vital importance in providing sufficient 
carbon chain length and density to facilitate such separations.  
Table 2.2 – Fatty acid composition of Intralipid® 20%. 
Fatty acid component Average % in 
Intralipid® 20% 
Amount in 50mg of 
Intralipid® (mg) 
linoleic acid (18:2) 51 5.1 
oleic acid (18:1) 24.5 2.45 
palmitic acid (16:0) 10.5 1.05 
α-linolenic acid (18:3) 7.5 0.75 
stearic acid (18:0) 3.45 0.345 
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2.3 HPLC detector choice  
 
The required assay needs to facilitate the rapid detection of TAGs within lipid 
emulsions and the presence of the secondary aldehydic peroxidation product 4-
Hydroxynonenal. Due to the chemical structures and properties of each of these 
molecules, simultaneous detection of both proves to be a challenge.  
Triglycerides are relatively bulky large molecules, with relatively high boiling points, 
but lacking the desired chromophores that would enable them to be detected 
effectively through UV detection. Existing methods for TAG detection using HPLC 
often require extensive sample preparation, extraction and/or argentation to produce 
molecules that can be detected through UV detection. The assay being developed 
is designed for use as a relatively simple assay to monitor the stability of lipid 
emulsions over storage before delivery to the patient and therefore expensive and 
extensive sample preparation is unsuitable. This makes UV detection of TAGs 
unsuitable for the assay and as such a different mode of detection is required. 
Charged aerosol detection (discussed further in section 2.5) provides a means to 
detect TAGs and larger non-volatile molecules without a chromophore without the 
need for complex sample preparation or any form of derivatisation (Moreau 2009; 
Gamache 2018). The CAD can be utilised in-line with a UV detector to facilitate the 
detection of TAGs and simultaneous detection of 4-Hydroxynonenal (HNE). 
 HNE is a relatively short chain (C9) secondary aldehyde that is too volatile in nature 
to be detected by the CAD. HNE however, can be successfully detected as free 
HNE without derivatisation using UV detection (Emerit et al. 1991; Esterbauer et al. 
1991). Whilst this detection method is somewhat dated, the detection of free HNE 
has been utilised less since the period where initial HNE discovery was undertaken 
due to the move to quantify HNE within complex biological systems. The study of 
HNE presence within cellular components requires complex extractions of HNE to 
occur and result in HNE that is often complexed with other cellular components 
such as proteins. As such derivatisation techniques for the detection of HNE has 
become the recent focus on HNE detection (Ligor et al. 2015; Sousa et al. 2017).  
Within this assay development the focus is on the detection of HNE within a 
relatively simple matrix with regards to its number of components and the lack of 
potential molecules for free HNE to complex too. Therefore, the direct detection of 
free HNE by UV detection is appropriate for assay development.  
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2.4 Initial method development split – CAD and UV 
 
CAD and UV detection are inherently very different detection techniques and as 
such initial assay development for each needs to be approached individually. The 
aim of the CAD detection section of the assay is to develop a repeatable assay to 
monitor the potential loss of TAGs within each lipid emulsion. The UV detector will 
aim to detect HNE occurring through the peroxidation and breakdown of the lipids 
within each emulsion. As such, initial assay development for TAGs will use the 
desired lipid emulsion whereas for initial HNE method development an HNE 
standard will be used as the levels of HNE produced from the lipid emulsions tested 
is, as yet, unknown. Whilst optimally the assay conditions developed to achieve this 
need to be the same for each section of the assay (i.e. for TAGs and HNE) and the 
detectors will be placed in-line with each other, initially assay development will be 
split into different sections. Once initial development is completed and conditions for 
the detection of HNE within the tested lipid emulsion has been achieved then the 
assay conditions and detectors will be combined. This will further develop a set of 
final assay conditions with in line UV and CAD detection.  
 
2.5 HPLC-CAD method development 
 
2.5.1 CAD principles 
 
The CAD works on the principle of transferring positive charge, from a positively 
charged nitrogen gas source, to compounds in the eluent from the HPLC column. 
The larger the mass of the compound, the more charge the compound can hold and 
therefore the larger the detection peak seen. The schematic below in figure 2.3 
taken from Plante et al. (2013) explains the principles of the detector: 
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Figure 2.3 CAD process of detection 
 
2.5.1.2  Nebulisation 
 
The pneumatic nebulisation process involves the process of nebulising the eluent 
from the column and drying it to leave an aerosolised residue which then gains a 
positive charge. This process somewhat governs the choices of mobile phases 
acceptable by the CAD. Organic phases are volatile in nature so will be ‘dried off’ 
with the evaporation process making them compatible with the CAD and achieving 
good constant baselines and minimal noise. Mobile phases should however be as 
pure as possible as non-organic contaminants will be dried and passed onto the 
detection process, disrupting the baseline. Therefore LC-MS grade solvents were 
used throughout (Plante et al. 2011; Gamache 2018). The use of non-organic 
buffers typically used in reversed phase chromatography is not ideal in CAD 
detection as, like non-volatile impurities, these will reach the detector of the CAD 
and as such can disrupt CAD response and baseline noise. This limits the mobile 
phase choice for method development. 
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2.5.1.3  Aerosol charging 
 
Analyte particles in the CAD are charged via a unipolar diffusion charging technique 
(Gamache 2018). This is where the aerosolised compounds are exposed to ions of 
a single charge; in the CAD’s case positively charge ions are used. The nitrogen 
entering the CAD passes over a corona needle which transfers a positive charge to 
the nitrogen ions. The positive charging of the nitrogen source briefly works by 
producing a nonuniform electrostatic field across the tip of a corona needle and an 
orifice plate. Electrons produced are of high enough velocity that when they collide 
with the nitrogen, they knock off electrons from the nitrogen, creating positively 
charged ions. These positive nitrogen ions then collide with the dried analyte 
compounds and on the basis of  Brownian motion and positive charge is transferred 
to the analyte. The size of the analyte present is directly proportional to the amount 
of charge that is transferred from the positively charged nitrogen source.  
2.5.1.4  CAD response curves 
 
The CAD is a non-linear detector and as such calibration curves and validation of 
methods should take this into consideration. Typically, with a linear detector 
calibration curves are plotted of response vs. concentration and linear regression 
lines plotted to define the R2 value of the desired peak. With the CAD however, due 
to the non-linear response over a range of concentrations typically plotted to form a 
calibration curve, the regression line plotted needs to be adjusted to allow for this 
non-linear response. Typically a second-order polynomial (quadratic) function is 
applied to the regression curves to obtain an accurate fit and therefore this fit will be 
used during the assay validation process (Crafts et al. 2011; Ilko et al. 2014; 
Gamache 2018). 
2.5.1.5 Gradient vs. isocratic elution in CAD detection 
 
Gradient elution is commonly used within reversed phase chromatography to 
enhance separations achieved between molecules. There are however issues that 
gradient elution raises with CAD detection. Changing a mobile phase composition 
entering the CAD will result in a change in baseline observed on the chromatogram. 
Organic phases are evaporated by the CAD as explained above; however, changing 
the proportion of organic phase will have an effect on its evaporation from the 
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CAD’s drying tube and alter the drying speeds of the analyte molecules, resulting in 
baseline drift during gradient elution. Ideally isocratic mobile phase programs should 
therefore be used for CAD methods. If a gradient is necessary, a secondary HPLC 
pump can be employed to provide a reverse gradient to the CAD at the point of 
entry to the detector. This permits a gradient elution to be run through the 
chromatographic column, but an isocratic phase adjustment to be made at the point 
of entry to the CAD, achieving a stable non-drifting baseline (Lísa et al. 2007).  
2.5.2 Non-volatiles and semi-volatiles 
 
Due to the nebulization process, the detector is only able to analyse non-volatile or 
semi-volatile substances. Volatile substances along with organic mobile phases will 
be evaporated during the nebulization process and removed via the waste exhaust. 
Typically, the CAD can analyse any non-volatile substance with a boiling point 
>400oC and any semi-volatile (300-400oC), although with semi-volatile compounds 
detector response and sensitivity can be reduced (Gamache 2018). This therefore 
renders the CAD inadequate to detect HNE due to the volatile nature of the short 
chain aldehyde and thus the requirement for UV-CAD inline detection.  
2.5.3 Method development and optimisation 
2.5.3.2  Initial Method 
 
Upon consultation of the literature with regards to emulsion separation and 
quantification through NARP, a manuscript of particular interest has been written by 
Gonyon et al. (Gonyon et al. 2013). This research effectively used NARP HPLC with 
a mobile phase of ACN/IPA and a C18 column to look at the effect of container 
materials on a PN mixture. Whilst the data is centred on looking for extractable and 
leachables from EVA versus glass containers, the lipid residues post emptying of 
the containers were analysed successfully through NARP HPLC coupled with a 
charged aerosol detector (CAD). The lipid emulsion used in this particular PN 
formulation was ClinOleic® 20 %, an emulsion of soybean and olive oils. This thesis 
will focus on Intralipid®, the most established and most commonly used lipid 
emulsion within the United Kingdom for PN formulations. Gonyon et al.’s research 
provides an initial set of chromatographic conditions from which method 
development can commence. The aim is to achieve chromatographic separation of 
the TAGs and phospholipids present within Intralipid® 20%. Upon achieving 
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adequate separations, the method will be used to quantify the amount of selected 
TAGs present at time point zero versus the amount of TAGs after storage for a 
period of time under specified conditions. 
Gonyon et al. (2013)’s method was used as a basis for the detection of TAGs within 
Intralipid® 20% and was employed in the following way during initial method 
development: 
- C-18 column 150 mm x 3 mm, 5 μm particle size 
- Mobile phase: IPA:ACN 60:40 
- CAD nebuliser temperature: 50oC 
- Column temperature: 25oC 
- Auto sampler temperature: 20oC 
- Flow rate: 750 μl/min 
- Injection Volume 20 μl 
- Intralipid® serially diluted in IPA to 1000 μg/ml and 100 μg/ml 
samples. 
 
All injections were repeated in triplicate to ensure reproducibility. Method 
development for the CAD assay was carried out on an Ultimate 3000 HPLC system 
and a Corona Charged Aerosol Detector (Thermo Scientific, West Palm Beach, 
United States). All reagents were HPLC grade (Fisher Scientific). Intralipid® 20% 
was obtained from Fresenius Kabi and once opened stored in the fridge at 2-8oC for 
a maximum of two weeks before replacement. 
The chromatograms (figures 2.4 and 2.5) show that concentrations of Intralipid® 
below 1000 μg/ml are insufficient for lipid detection due to the lack of discernible 
peaks at 100 µg/ml.  The lack of resolution between peaks was identified as an 
issue and therefore the governing factors over effective resolution were researched. 
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Figure 2.4 NARP-HPLC with CAD detection of Intralipid 1000 μg/ml. C-18 column, mobile phase 
IPA:ACN 60:40 
 
Figure 2.5 NARP-HPLC with Intralipid 100 μg/ml. C-18 column, mobile phase IPA:ACN 60:40. 
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2.5.3.3  Resolution theory 
Principally, the longer the column, the more C-18 chains present within the 
stationary phase, therefore the greater the availability for lipid interaction/bonding to 
occur, slowing the elution of the components from the column. This relates to the 
resolution equation shown in figure 2.6, which indicates the governing factors in 
chromatographic resolution achieved from a particular column. 
 
𝑅 =
1
4
(√𝑁) 𝑥
𝑘
𝑘 + 1 
 𝑥 (𝛼 − 1) 
               (efficiency)     (retention)    (selectivity) 
Figure 2.6 Resolution expressed as a combination of three factors, efficiency, retention and selectivity. N = 
theoretical plate number, α = separation factor, k = average retention factor for two specified bands.(Synder et 
al. 1997) 
When looking at the resolution achieved from a particular column, the factors within 
the equation above can be considered individually.  k and α are parameters that are 
primarily determined by the factors that govern the partitioning of a compound from 
mobile to stationary phases. These controllable factors include column stationary 
phase composition, mobile phase composition and temperature. Changes in all the 
above factors can be easily achieved and therefore these factors can be used to 
achieve method optimisation.  
The theoretical plate number of a column and therefore its efficiency is related to the 
column dimensions and particle size. The larger the plate number (N) the more 
efficient the column. Plate number is directly proportional to the length of the column 
(mm) and inversely proportional to the particle size (μm). With regards to 
chromatography columns, particle size refers to the spherical diameter of the 
basement supports used to attach the stationary phase and pack the column.  
Therefore, generally speaking, the longer the column and the smaller the particle 
size, the more efficient the column. Selectivity of the stationary phase, as seen in 
figure 2.6 is the most powerful factor affecting retention. From these theoretical 
factors, and with reference to the method of Gonyon et. al., (Gonyon et al. 2013) a 
C-18 250mm x 3mm column with a 3μm particle size was purchased (Acclaim 120, 
Thermo Scientific) and substituted into the assay instead of the 150 mm /5 μm 
column with the aim to optimise the selectivity of the stationary phase prior to 
optimisation of mobile phase, column temperature etc. 
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Upon running the same chromatographic conditions as above with the new 250 mm 
C-18 column, the chromatogram seen in figure 2.7 was achieved. Intralipid® 
concentrations of 1000 μg/ml, 2000 μg/ml and 4000 μg/ml were run in triplicate 
under the above conditions to establish the optimum concentration of Intralipid with 
which to continue assay development. The concentration of 1000μg/ml gave a 
detection level with clear peaks and was chosen as appropriate for further use 
within assay development. 
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Figure 2.7 Initial assay conditions run on C-18 250 mm x 3 mm column. Intralipid® 20 % at 1000 µg/ml. 
 
2.5.3.4 Column temperature optimisation 
 
Once the C-18 250 mm x 3 mm column was established as the column to be used 
for initial method development and with regards to the resolution equation (figure 
2.6), controllable factors including mobile phase composition and column 
temperature can be varied to optimise separations. As the mobile phase 
composition of 60 %  IPA / 40 % ACN had been used effectively for the separation 
of Clinoleic® (Gonyon et al. 2013),  it should be able to be used to create adequate 
separations of Intralipid®. Therefore, at this stage mobile phase composition was 
held at 60:40 IPA:ACN.  
Column temperature control is critical to controlling resolution between eluting 
compounds within HPLC. Altering column temperature is a simple tool in regulating 
separations from a column and therefore the next focus of assay development. Until 
relatively recently column temperature optimisation was not an area used for assay 
optimisation due to the lack of availability of column thermostats. With regards to 
resolution theory, increasing temperature by 1oC can decrease k by between 1 and 
2 %, thereby reducing resolution between peaks (Synder et al. 1997). Using the 
chromatographic conditions stated below, the temperature of the column was varied 
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in a systematic fashion as displayed in table 2.3. Initially temperature was increased 
from the 25oC to a maximum of 45oC to prove the above theory was relevant for 
these chromatographic conditions. After this column temperature was reduced to 
enhance resolutions. Each was run in triplicate and the results of the separations 
noted. 
- C-18 column 250 mm x 3 mm, 3 μm particle size 
- Mobile phase: IPA: ACN 60:40 
- CAD nebuliser temperature: 50oC 
- Auto sampler temperature: 20oC 
- Flow rate: 750 μl/min 
- Injection Volume 10 μl 
- Intralipid 1000 μg/ml in IPA 
Table 2.3 Temperature variations employed in assay development 
Assay 
Number 
Column 
temperature 
(oC) 
Chromatogram observations 
1 25 Initial assay 
2 35 Worse than 25oC – split peaks 
3 45 Completely unresolved chromatogram 
4 20 Longer retention times but better peak 
resolution than 25oC. 
5 15 Longer retention times but better peak 
resolution than 20oC. 
6 10 Longer retention times but better peak 
resolution than 15oC 
 
As shown in figure 2.8 peak resolution is improved with reducing temperatures. As 
temperature increases, k (average retention factor) is decreased, thereby reducing 
retention times. As the initial chromatogram obtained under 25oC conditions did not 
obtain adequate resolutions, the temperature was lowered through 20oC to 10oC to 
improve it. A temperature change of 20oC showed the most significant change from 
the chromatogram separation at 25oC and therefore 20oC was used for continuing 
assay development.  
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Figure 2.8 Comparison of effects of temperature on HPLC analysis of Intralipid. 6a = 15oC, 6b = 20oC, 6c = 25oC 
 
 
 
A 
 
B 
 
C 
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2.5.3.5  Mobile phase optimisation  
 
Whist the composition of Intralipid® is referenced as individual fatty acids (Eriksson 
2001) as shown in table 2.2, these will be formulated as TAGs within lipid globules 
surrounded by phospholipids ensuring a disperse oil within a continuous aqueous 
phase. Therefore, when looking at the separations and identifications of compounds 
through the HPLC assay peaks detected will be TAGs containing different 
combinations of fatty acids and the two phospholipids used within Intralipid® as 
emulsifiers.  
Both phospholipids and the TAGs present have similar general structures (figure 
2.9), the main difference being the replacement of one of the three fatty acid chains 
with either the choline or ethanolamine ester of phosphoric acid in the case of the 
phospholipids (Eriksson 2001).  
 
 
 
Figure 2.9 General structures of triglycerides and phospholipids present within Intralipid® 20%. R groups denote 
position of fatty acid chains (Eriksson 2001) 
Due to the nature of the mobile phase currently being used (IPA:ACN 60:40), the 
strength of the IPA will pull TAGs from the column before phospholipids. IPA is a 
strong organic solvent in respect to NARP because it has a low polarity index. 
Therefore, TAGs that are hydrophobic will be eluted before hydrophilic 
phospholipids.  
To confirm that IPA was the driving force behind elution from the column, a gradient 
elution was performed over 60 minutes from 80% IPA to 40% IPA. The increased 
runtime was due to the need to reduce the flow rate from 0.75 ml/min to 0.6 ml/min 
due to the increased percentage of IPA present. IPA has a much higher viscosity 
(2.04 mPA s) than ACN (0.369 mPA s) (Chromacademy 1999) and therefore will 
create an increased pressure within the column. The reduction in flow rate allows for 
this pressure to be maintained at an acceptable level.  
Triglycerides Phosphatidylcholine Phosphatidylethanolamine 
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As predicted, the increase in IPA % through the run resulted in all components 
eluting off the column within the first 10 minutes, resulting in a poor chromatogram 
with no resolution between peaks. At this point with the IPA % being established as 
a critical factor in elution and better resolutions and separation being required, the 
gradient was reversed to reduce the initial IPA %. Whilst this required an extended 
run time due to the slower elution of compounds, slowing the elution of compounds 
from the column with a slow gradient change increasing the IPA % over time was 
designed to improve separations. The gradient in table 2.4 shows the mobile phase 
changes through the assay. Flow rate was maintained at 0.6 ml/min and the run 
time was set at 60 minutes to allow for complete elution of all compounds. The last 
10 minutes of the run was a reverse gradient to allow for re-equilibration of the 
column back to the initial conditions for subsequent runs.  
Table 2.4 Gradient composition 
Time (minutes IPA % ACN % 
0 20 80 
40 60 40 
50 60 40 
55 20 80 
 
Initially at 20oC, the gradient was repeated with lowering temperatures as previously 
investigated for the isocratic runs to try and improve separations. The optimum run 
that was achieved from this was using the gradient as set out in table 2.4 at a 
column temperature of 5oC with the auto sampler temperature being introduced as a 
further temperature control, set at 8oC to hold the samples at a low temperature. 
The reduction in temperature, whilst increasing the pressure due to the increasing 
viscosity of the mobile phases at lower temperature, was not sufficient to warrant a 
further flow rate reduction at this stage and therefore the flow rate was maintained 
at 0.6 ml/min. The run time was extended to 70 minutes to ensure column cleaning 
and re-equilibration between runs. The resulting chromatogram is shown in figure 
2.10. 
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Figure 2.10 HPLC of Intralipid® 20% using gradient elution detailed in table 2.4 of IPA: ACN. 
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From the chromatogram in figure 2.10, the first four main peaks eluting from the 
column were of interest as their retention times were significantly different from the 
other components. To identify if these peaks were due to contamination of the 
sample, the assay was re-run with samples of blank mobile phase and IPA and 
ACN individually. All samples gave the same initial peak pattern (figure 2.10), 
proving that the four peaks observed from 0 – 10 minutes were due to some form of 
contaminates.  
At this point all solvents were replaced, the column was cleaned using a column 
cleaning protocol and the CAD was cleaned by running low flow rate methanol: 
water over 12 hours. Due to the highly sensitive nature of the CAD and its ability to 
detect small levels of contamination, the HPLC vials and septa being used were 
also changed from amber vials with separate screw caps and rubber septa to clear 
vials with pre-fabricated caps (PTFE) (Thermo Scientific). Rubber septa are well 
known to be potential sources of contamination of chromatography samples 
(Pereira et al. 2000). To further reduce the possibility of contamination from mobile 
phases and to ensure low baseline noise LCMS grade solvents IPA and ACN 
(Fisher Chemical) were purchased and used for subsequent assay development. 
Post aforementioned cleaning, samples of blank mobile phase were run through the 
assay conditions as above to confirm the removal of contamination. Baseline was 
achieved for all blank runs. From this new Intralipid® 20% was prepared in IPA 
(1000μg/ml) and the assay was run using the gradient run conditions as per table 
2.4 Column temperature was maintained at 5oC and auto sampler temperature at 
8oC. 
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Figure 2.11 HPLC analysis of Intralipid® 20% using gradient elution post column clean and using LCMS grade 
solvents, column temperature 50C, flow rate 0.6ml/min.  
 
As shown in figure 2.11 the initial 25 minutes of the gradient show no peak elution 
now that the contamination peaks had been successfully removed from the 
sample/assay. At approximately 25 minutes the IPA % present was estimated to be 
50 %. Due to the fact that the initial isocratic runs contained 60 % IPA but at a 
higher flow rate and higher temperature, an isocratic run of 60 % IPA: 40 % ACN at 
5oC with a flow rate of 0.5 ml/min was used. If possible, an isocratic run would be 
beneficial versus a gradient run due to the aim to combine this assay at a later 
stage in development with a HPLC-UV assay for the detection of HNE within 
samples. The above isocratic run within 60:40 IPA: ACN gave a relatively well 
resolved series of peaks; however significant peak splitting was observed. After 
further investigation through injection of a caffeine standard which gave a split peak, 
this was identified to be due to column stationary phase breakdown and therefore a 
new column was required. 
2.5.3.6 Column stationary phase choice 
 
It is well known that within NARP chromatography a C-18 stationary phase can be 
utilised for the separation of TAG molecules under a variety of chromatographic 
conditions (Lin et al. 1997; Schönherr et al. 2009; Gonyon et al. 2013; Hmida et al. 
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2015). Most of this work has been the identification of TAGs present within an oil as 
opposed to an emulsion. As the body of this work is focused on the quantification of 
key TAGs within lipid emulsions, the ability to separate TAGs from phospholipids is 
an essential requirement. Liu et al. (2014) showed effective separation of both 
TAGs and phospholipids using a C-30 stationary phase. The increase in chain 
length of the stationary phase will increase the interactions occurring from the fatty 
acid chains within TAGs and phospholipids. Whilst this may increase the retention 
times observed versus a C-18 column, the increased interactions should increase 
the selectivity of the assay, allowing for the separation of TAGs and phospholipids 
to occur. With reference to resolution theory (figure 2.6), changing the stationary 
phase of the column will affect α and k and potentially also the theoretical plate 
number of the column, therefore having a potentially large effect on resolution 
(Synder et al. 1997). Elution order again will be based initially on the partition 
number of fatty acids within phospholipids, however the hydrophilic nature of the 
phospholipid head group will govern its elution time. The availability of a C-30 250 
mm x 3 mm column with a 3 μm particle size allowed for a direct method transfer to 
occur from a C-18 stationary phase to a C-30 phase and a comparison on the 
optimum stationary phase to use for further assay development to be made. As the 
length, diameter and pore size of the C-30 column is the same as the C-18 column 
the theoretical plate number will remain constant.  
Isocratic runs of 60:40 IPA: ACN were carried out using the C-30 and new C-18 
column with the following conditions: 
- C-30 column 250 mm x 3 mm 3 μm particle size or C-18 column 
250 mm x 3 mm 3 μm particle size. 
- Mobile phase: IPA: ACN 60:40 
- CAD nebuliser temperature: 50oC 
- Auto sampler temperature: 8oC 
- Column temperature: 5oC 
- Flow rate: 0.30 μl/min 
- Injection Volume 10 µl 
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Figure 2.12 HPLC analysis of Intralipid® 20% using A - C-18 column and B - C-30 column. 
 
A 
 
 
 
 
 
B 
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As observed in figure 2.12 the C-30 column chromatogram under identical 
conditions to the C-18 column showed superior separations of the Intralipid® 
emulsion. Increased numbers of clear peaks are identifiable and resolution (Rs) 
between peaks is adequate for quantification. An Rs of over 1.5 (as calculated using 
the equations shown in figure 2.44) between peaks from 14 minutes onwards 
suggested definite baseline resolution between them. It is worth noting the drop in 
flow rate further to 0.3 ml/min at this stage was due to a column pressure increase 
due to the addition of a C30 guard column to increase column lifespan and protect 
the column from damage. At this stage the development of the CAD assay was at 
an appropriate stage to combine with the UV assay for the detection of HNE. This 
process is detailed in section 2.8 after the following UV method development.  
 
2.6 HPLC-UV method development 
 
2.6.1 Principles of UV detection 
 
UV detection works on the principles of measuring the absorption of monochromatic 
light in the UV spectrum against a reference beam of light and comparing this to 
calculate sample absorbance and therefore concentration. Light from the lamp is 
directed through a flow cell and impinges on a diode that reads the light intensity. 
Light is also directed to the reference diode to allow a comparison in intensity to be 
calculated (Synder et al. 1997). The optical path that UV light takes through a 
detector is briefly as follows: Polychromatic light is formed from a tungsten or 
deuterium lamp and focused onto the entrance of a monochromator which 
selectively transmits the desired wavelength(s) through an exit slit. This then reflects 
of a series of mirrors to the reference diode and through the sample flow cell to the 
sample diode for detection. The wavelength of measurement i.e. the specific 
wavelength desired is selected using the data system and a grating mounted on a 
turntable within the detector. Figure 2.13 shows this process in further detail. 
58 
 
 
Figure 2.13 Expanded diagram of the UV detector and pathway of light. 
 
Analyte concentration in UV detection is calculated using absorption (A) (calculated 
from sample and reference diode intensity readings) and Beer-Lambert’s Law 
(figure 2.14) 
𝐴 = 𝐶𝜀𝐿𝑓𝑐 
Figure 2.14 Beer-Lamberts Law. A = Absorption, ɛ = molar absorption coefficient (dm3mol-1cm-1), L = flow cell 
length (cm), C = analyte concentration (mol dm-3). 
 
UV detection relies upon the sample molecule possessing a chromophore e.g. 
structures with double bonds or conjugated systems that can absorb UV light and 
enter a higher excitation state at a specific wavelength. This is where there is an 
inherent problem with the UV detection of TAGs. Triglycerides possess no 
chromophores above ≈ 190 nm i.e. double carbon-carbon bonds in polyunsaturated 
fatty acid chains (Plattner 1989). The vast majority of organic mobile phases used 
within HPLC identical to the TAGs have carbon-carbon bonds as their structure. 
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Therefore, organic phases will also have a UV absorbance under 200 nm, creating 
a baseline level of absorbance that will negate any absorbance from the sample 
TAGs and as such making them unable to be detected via UV absorption.  HNE 
however has a strong UV absorbance based from its UV spectra (figure 2.15) at 222 
nm making it easily detectable with UV detection.  
 
Figure 2.15 UV spectrum of HNE. (A) biogenic 4-HNE isolated from the experimental sample by high-pressure 
liquid chromatography. (B) synthetic 4-HNE. Solvent: acetonitrile/water (1:1 v/v) taken from Benedetti et al. 
(1980). 
2.6.2 Initial HNE UV method  
 
There are several existing papers documenting the UV detection of free HNE within 
a variety of samples and different matrices. These are discussed below and provide 
a base from which assay development can be initiated. The key differences 
between the existing assays as described vs. the desired assay are the sample 
matrix. The aim is to detect HNE within IVLE’s, so emulsion properties will influence 
assay development.  
 
Esterbauer and Zollern (1989) were considered the pioneers for the detection and 
classification of HNE as a substance. Their direct detection method uses an ODS 
60 
 
(C-18) column with an isocratic mobile phase of acetonitrile: water 40:60 at a flow 
rate of 1ml/min. UV detection was set at 220nm. The method was able to detect 
HNE with a limit of detection of around 2 pmole. The method is used to detect HNE 
within cellular fractions and uses an initial sample clean up step to remove these 
subcellular fractions, a step that can be excluded in the analysis of IVLEs in PN due 
to the in vitro nature of the samples.  
 
Laing et al. (1985) used a similar HPLC method and compared this with derivatised 
HNE and free HNE detected with gas chromatography (GC) and flame ionisation 
detection. The HPLC method was found to be around one order of magnitude more 
sensitive than the GC method. The RP-HPLC was carried out on a C-18 column 
with acetonitrile: water 40:60 or methanol: water 65:35 as the mobile phase. Flow 
rate was 1 ml/min and the absorbance set at 220 nm with an injection volume of 20 
μl. Standard calibration curves were created from 0.1μM to 500 μM concentrations.  
 
Benedetti et al. (1986) used a similar method using a C-18 column with a mobile 
phase of acetonitrile: water 50:50 at a flow rate of 1 ml/min. This method was used 
to detect HNE in liver cell fractions in the form of free HNE and in parallel a 
derivatisation method of identification of HNE with DNPH. Both assays gave 
repeatable and accurate results of HNE in liver cells.  
 
The above papers provide a set of assay conditions that can be used as a base for 
initial assay development. All employ a water: acetonitrile mobile phase system with 
a flow rate of 1ml/min. A C-18 column was chosen for initial assay development due 
to both its proven ability to separate HNE as described above but also with mind to 
its ability to separate TAGs efficiently.  
 
2.6.2.2 Initial Method 
 
The work was carried out on a Spectra system (Thermo Scientific, West Palm 
Beach, United States). Reference standards of 4-HNE were obtained from Santa 
Cruz Biotechnology (Dallas, Texas) and were supplied under dry ice storage (-70oC) 
in ethanol. Standards were supplied at a concentration of 10 mg/ml (1 mg/100μl). 
An OmniSpher 5 C18 150 x 3 mm, 5μm particle size (Varian, Palo Alto, USA) 
column was chosen for initial method development. Reagents (acetonitrile, propan-
2-ol (IPA), methanol, water and ethanol) were all HPLC grade (Fisher Chemical). 
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Initial method used was as follows for the identification of HNE from standard 
reference: 
- C-18 column 150 mm x 3 mm, particle size 5 μm 
- Mobile phase: Acetonitrile: water 40:60 
- Injection Volume: 20 μl 
- Flow rate: 1 ml/min 
- UV wavelength: 222 nm 
- Run time: 20 mins 
HNE sample: 12.5μl of standard (1mg/100μl) diluted in 250μl of ethanol. 
 
 
Figure 2.16 HPLC of HNE standard, mobile phase acetonitrile: water 40:60. The flattening of the peak is due to 
the concentration of HNE standard being too high. 
 
2.7 Method development and optimisation 
2.7.1 HNE standard concentration 
The initial run detailed above proved that HNE was easily detectable using the 
above assay through RP-HPLC and UV detection.  
This method was then adjusted to look at a sample of Intralipid® 20%. From the 
literature search detailed above with regards to the method development with the 
CAD for Intralipid® 20%, the use of NARP chromatography was chosen for the 
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analysis of lipids. Whilst the lipids themselves within Intralipid® are not the subject of 
the UV section of the assay for the detection of HNE, they still need to be effectively 
eluted from the stationary phase and the combination of both assays is the aim. 
Therefore, a change of mobile phase from acetonitrile: water to acetonitrile: IPA was 
undertaken to allow effective elution of the Intralipid® from the column. 
Initially a sample of HNE standard was run through the HPLC system under the 
following conditions to ensure the detection of HNE was still effective with a 
changed mobile phase: 
- C-18 column 150 mm x 3 mm, 5 μm particle size 
- Flow rate: 0.75 ml/min 
- Injection Volume: 20 μl 
- Mobile phase: IPA: Acetonitrile 60:40 
- UV wavelength: 222 nm 
- HNE standard 6.25 μl in 250 μl (halved concentration due to 
previous cut out of detection due to high concentration  
 
 
Figure 2.17 HNE standard (6.25 µl in 250 µl ethanol), mobile phase IPA: acetonitrile 60:40. 
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Whilst this mobile phase clearly moved the elution time of HNE from around 2.5 
minutes to around 1 minute, the peak was still easily identifiable. Whist within the 
solvent front this is appropriate for this stage of development.   
This same method was then used as a basis for the introduction of Intralipid® 20 % 
to the sample, spiked with HNE standard. 
Sample preparation involved the creation of an HNE stock solution through the 
addition of 12.5 μl of HNE to 500 μl of ethanol. 125 μl of this was then added to 
125μl of Intralipid® 20% giving a concentration of 83.3 µM (3.125 µl HNE in 250 µl). 
Samples were prepared in amber glass vials (National Scientific) with fixed 250 μl 
glass inserts to allow for the testing of small volumes. 
 
Figure 2.18 RP-HPLC of HNE in Intralipid®. Mobile phase IPA:ACN 60:40. 
 
The large peak at 1 minute is the HNE standard with subsequent peaks being 
attributed to the triglycerides and phospholipids present in the Intralipid® sample. 
Whilst these peaks are not well defined, nor do they achieve baseline resolution, for 
the purposes of the UV assay this is not important as these lipids will not be 
quantified through UV detection. The peak co-eluting with the HNE standard is the 
issue that further work aimed to separate as baseline resolution needs to be 
achieved to allow quantification of HNE to occur. The HNE created in the 
peroxidation of lipids will be at a much lower concentration than the standard used 
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within this section of the assay and therefore baseline separation of all other 
components from the HNE peak is vital.  
2.7.2 Mobile phase optimisation 
 
Mobile phase composition in NARP chromatography is all organic and as such the 
polarities of the organic components is a governing factor on the elution times of 
compounds.  
Alteration of mobile phase composition was trialled using the following scheme 
(table 2.5). All trials were run in triplicate. The run time was reduced to 10 minutes 
per run as indicated by the above assay time (figure 2.18). Injection volume was 
also reduced to 10 μl to increase the number of runs possible from each sample 
and preserve stocks of HNE standard. 
Table 2.5 Mobile phase changes in NARP-HPLC of Intralipid® with HNE standard. 
 
The polarity factor of IPA is 3.9 and of acetonitrile is 5.8 (as reference water has a 
polarity factor of 10.2) (Christie 2003). The relative closeness in polarity between 
the two mobile phases being used may account for the lack of movement in the 
chromatogram upon alteration of the percentage composition of the mobile phase.  
The lack of movement of the co-eluting peak along with the HNE standard in 
response to mobile phase alteration resulted in reverting to the initial mobile phase 
of IPA: acetonitrile 60:40 as this gave the optimal chromatogram. 
 
2.7.3 Column change 
 
At this stage, as assay development was running in parallel to that of the HPLC-
CAD assay, the column change in the CAD assay to a C-30 column (section 
2.5.3.6) prompted the same column to be tried for the HNE assay. From this point 
Mobile phase composition Effect on assay result 
IPA: Acetonitrile 70:30 
No appreciable changes to 
chromatogram. 
IPA: Acetonitrile 50:50 
All components eluted later except HNE 
and co-eluting molecule. 
IPA: Acetonitrile 30:70 
Loss of chromatogram, 
indistinguishable peaks. 
IPA: Acetonitrile 90:10 
Components eluted earlier on 
chromatogram. 
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forward, assay development for the HNE-UV assay was transferred to the Ultimate 
3000 HPLC system as used for the HPLC-CAD assay, with the Spectra UV detector 
being added to the system in-line with the CAD detector. The UV detector is placed 
before the CAD as the CAD detector is destructive in nature. This set-up allows the 
assays once optimised to be combined and run as one assay.  
Initially with the new C-30 column HNE and Intralipid® were run with the optimised 
CAD assay conditions. Figure 2.19 shows both HNE and Intralipid® 20% 
chromatogram run with the new C-30 column, achieving a superior separation 
between the HNE and initial Intralipid® peaks.  
Optimised CAD assay conditions were: 
 
- C-30 column 250 mm x 3 mm 3 μm particle size  
- Mobile phase: IPA:ACN 60:40 
- Auto sampler temperature: 8oC 
- Column temperature: 5oC 
- Flow rate: 0.30 μl/min 
- Injection Volume 10 μl 
- Samples of Intralipid® 20% were prepared at 1000 μg/ml in IPA.  
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Figure 2.19 UV chromatogram of HNE in Intralipid® 20% showing good separation between Intralipid peaks and HNE standard. 
HNE 
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At this stage the HNE assay is sufficient for validation of the assay to occur, 
however combination of the UV and CAD assays was the aim and therefore the 
next stage in assay development.  
2.8 Combination of CAD and UV assays. 
 
Both the CAD assay of TAGs and the UV assay of HNE were now at an appropriate 
stage that they could be combined to run simultaneously. Therefore, the assay 
conditions of each were matched and the UV detector placed in-line with the CAD 
detector. Sample preparation was also changed at this stage to simplify the system 
with a view to making the assay as accessible as possible for future stability testing. 
Until this point the Intralipid® 20 % has been diluted in IPA to a concentration of 
1000 µg/ml and an injection volume of 10 µl used. It was noted however as the run 
time has now increased to 90 minutes that the IPA diluting the Intralipid® in the 
sample preparation was resulting in oil separation over time whilst samples are 
standing prior to use. Therefore, to overcome this, samples were changed to neat 
Intralipid® with no dilution to maintain stable emulsions during extended testing 
times. To compensate for this 100 % concentrated sample, injection volume was 
reduced from 10 µl to 1 µl, maintaining adequate responses by the detectors and 
achieving repeatable responses through the HPLC system.  
 
2.9 Final assay conditions 
 
Using the combined in line detectors as described above, the following assay 
conditions were used to form the completed assay: 
- C-30 column 250 mm x 3 mm 3 μm particle size  
- Mobile phase: IPA: ACN 60:40 
- CAD nebuliser temperature: 50oC 
- Auto sampler temperature: 8oC 
- Column temperature: 5oC 
- Flow rate: 0.20 μl/min 
- Injection Volume 1 μl 
 
The above conditions gave the chromatograms as seen in figures 2.20 and 2.21. 
Figure 2.20 Shows the UV chromatogram of Intralipid® spiked with 6 µg/ml of HNE 
clearly showing the separation of HNE from the less well defined Intralipid® peaks. 
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Figure 2.21 Shows the combined CAD and UV traces of Intralipid® with spiked HNE 
standard, showing that the CAD trace provides quantifiable peaks of the TAGs 
within the emulsion.  
 
Figure 2.20 HPLC-UV chromatogram using final assay conditions. HNE clearly separated from other less defined 
Intralipid® peaks. 
  
 
Figure 2.21 HPLC-UV-CAD chromatograms of final assay conditions. A – HPLC-CAD chromatogram of Intralipid® 
20 %. B – HPLC-UV chromatogram of Intralipid® 20 % with added 6 µg HNE standard. 
HNE 
HNE 
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At this stage in assay development, whilst the HNE peak has been confirmed by the 
addition of a standard of HNE to the emulsion, the aim is also to monitor the 
changes in the levels of TAGs present. The peaks of the HPLC-CAD chromatogram 
as yet remain unidentified and as such identification of these peaks formed the next 
stage in assay development for Intralipid®.  
2.10 SMOFlipid® chromatogram and peak selection 
 
Current method development had now succeeded in creating an assay capable of 
separating TAGs and HNE in Intralipid® samples and so the assay conditions were 
used to run another lipid emulsion used within parenteral nutrition. As discussed in 
the introduction (section 1.2.3) SMOFlipid® 20% is a newer generation intravenous 
lipid emulsion containing a mixture of soybean, olive and fish oils with added 
chemically synthesised medium chain saturated triglycerides. Percentage 
composition of SMOFlipid® is described in table 2.6. 
Table 2.6 Fatty acid composition of SMOFlipid® 
Fatty acid Carbon number: 
double bond 
SMOFlipid® 20 % 
Oleic acid C18:1 23-35% 
Linoleic acid C18:2 14-25% 
Caprylic acid C8:0 13-24% 
Palmitic acid C16:0 7-12% 
Capric acid C10:0 5-15% 
Stearic acid C18:0 1.5-4% 
α-linolenic acid C18:3 1.5-3.5% 
EPA C20:5 1-3.5% 
DHA C22:6 1-3.5% 
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From these % combinations of fatty acids formulated as TAGs it was predicted that 
the chromatogram for SMOFlipid® would differ from that of Intralipid®. The presence 
of soybean oil in both emulsions however was predicted to produce an identical 
predictive peak pattern within both chromatograms. To ensure that the above assay 
conditions achieved adequate separations for SMOFlipid® the emulsion was run and 
gave the chromatograms seen in figure 2.22 The same sample but spiked with HNE 
is shown in figure 2.23. 
 
Figure 2.22 HPLC-CAD chromatogram of SMOFlipid® 20 %. 
 
Figure 2.23 HPLC-UV chromatogram of SMOFlipid® with added HNE standard. 
HNE 
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As seen in the above figures the assay achieved adequate separations for 
SMOFlipid® and HNE. The peaks within the CAD chromatogram show the greater 
number of TAGs present compared to the Intralipid® chromatogram (figure 2.21) as 
predicted due to the increased number of oils present within SMOFlipid®. The peak 
pattern as seen in the overlaid chromatograms in figure 2.24 show the peaks within 
the SMOFlipid® chromatogram that are attributed to the soybean oil present within 
Intralipid® giving a distinct peak pattern with peaks 5 to 10 in figure 2.24 matching 
peaks 1 to 6 in figure 2.21. 
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Figure 2.24 HPLC-CAD chromatogram of SMOFlipid® showing the identical peaks attributed to the soy bean oil present in the Intralipid® chromatogram insert. 
 
®  
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As seen in figure 2.24 the ten major peaks within SMOFlipid® were selected for 
identification. Following the theoretical partition number equation as explained in 
section 2.2.3 (figure 2.2) the initial peaks seen in the SMOFlipid® chromatogram 
were predicted to be attributed to the shorter chain saturated medium chain TAGs 
present from the chemically synthesised medium chain fatty acids (C8 to C10 
carbon numbers). These peaks were therefore labelled 1 to 4 and selected for 
identification. The other 6 major peaks within the chromatogram matched the 
Intralipid® trace and were therefore attributed to soybean oil and the TAGs with the 
highest % fatty acids according to table 2.6. These peaks were labelled 5 to 10 and 
selected for identification.  
2.11 Triglyceride identification 
 
The presence of a mixture of fatty acids in the form of TAGs and phospholipids 
present in the lipid solutions means that peak identification using fatty acid 
standards is not possible. As there are five fatty acids present (table 1.3) within 
soybean oil that forms Intralipid®, the possible combinations created in the formation 
of TAGs are too numerous (~125) to be able to take the approach of acquiring 
standard TAGs and trying to identify peaks using these standards. As the 
formulation in question is an emulsion, using TAG standards that are formulated as 
an oil will also result in a different chromatogram to that seen from Intralipid 
emulsion, making the traditional approach of using standards to spike peaks for 
identification unusable in this assay. As the purpose of the assay is to monitor the 
lipid emulsion being tested for peroxidation and subsequent TAG breakdown and 
loss, the identification of the main primary TAGs present within each emulsion is 
necessary. These can then be used as markers to monitor the losses of TAG 
occurring during peroxidation and storage.  
The combination of fatty acids within Intralipid® and SMOFlipid® when formulated 
into TAGs will produce numerous different TAGs as represented by the peaks seen 
within the HPLC-CAD chromatograms. It is predicted that peroxidation and 
breakdown of the fatty acid chains present within the TAGs will produce two main 
effects to the chromatogram being observed. Firstly, a loss of peak size should be 
observed as specified TAG concentrations are lost/altered by their changing 
chemical structure and carbon numbers. As the CAD signal observed is one of 
charge that is directly proportional to the mass of the analyte present, peak area 
loss will directly represent the loss of a specific TAG mass. Secondly, the presence 
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of new peaks within the chromatogram would be expected to be observed. The 
breakdown products of peroxidation from the hydroxyl end of the fatty acid chain, in 
several forms, including reactive aldehydes and longer fragments will also be 
detected. It is worth noting here that these peaks will be limited in their presence in 
the CAD chromatogram due to the volatile nature of the aldehydes created. Shorter 
chain aldehydes such as HNE and hydroxyhexanal (HHE) will not be detected by 
this part of the assay employing the CAD as a detector as they are too volatile and 
are completely lost during the nebulisation process. Longer chain fragments from 
TAGs and the fatty acids now remaining as effectively different TAG ‘remnants’ 
should however be effectively detected by the CAD resulting in new peaks being 
observed in the chromatogram.  
As it is not practical to identify all the TAGs present, it was decided that initial 
identification of the six clear and substantial peaks within the Intralipid® 
chromatogram should occur. Peaks chosen for identification are shown as peaks 1, 
2, 3, 4, 5 and 6 in figure 2.25. Within the SMOFlipid® chromatogram 10 main peaks 
were selected for analysis as seen in figure 2.24. 
 
 
Figure 2.25 HPLC of Intralipid® 20%. Peaks 1 to 6 identified as peaks to be collected. Typical pre-collection run 
chromatogram. 
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2.12 Mass spectrometry 
2.12.1 Mass spectrometry introduction 
 
Eluent collected from the six major peaks in Intralipid® and the ten major peaks in 
SMOFlipid® were subjected to mass spectrometry (MS) to identify their mass/charge 
(m/z) ratio and therefore the potential TAGs responsible for each peak.  
Electrospray Ionisation (ESI) MS has been used effectively to analyse TAGs in a 
variety of edible oils and seeds (List et al. 2000; Li et al. 2014). The fundamentals of 
ESI involve the introduction of a continuous stream of sample solution into a 
capillary tube which is at a high (2-6 Kv) voltage. This produces highly charged 
(either positive or negative depending on the mode) droplets. The addition of a 
nebulising gas (usually nitrogen) and high temperatures leads to the evaporation of 
the solvent from these charged droplets. Droplet diameter reduces, and surface 
charge increases to a point where ions within the droplet have sufficient kinetic 
energy to be ejected into a gaseous phase. These charged ions are sampled via a 
skimmer and accelerated into the mass analyser being used (Ho et al. 2003).  Due 
to the ‘soft’ nature of ESI as the sample is ionised by the addition (+ve) or 
abstraction (-ve) of a proton with little surplus energy remaining, molecules analysed 
via this method are more likely to remain intact and be identified as such in the 
spectrum obtained.  
Molecules up to a size of approximately 1200 Daltons give rise to singly charged 
protonated / de-protonated ions (M-H+ or M-H-). Commonly where sodium ions are 
present within mobile phases due to minute contamination or background ions 
present, M-Na+ ions will also be detected in positive modes (Christie 2003).  With 
respect to positive or negative modes of ionisation, this relates to the charge that is 
applied to the tip of the capillary tube and therefore the charge transferred to the 
analyte. If the sample contains functional groups that are easily protonated, positive 
mode should be selected. Conversely samples containing groups that readily lose 
protons should be scanned in negative mode. As seen in figure 2.1 the general 
structure of all TAGs results in the carboxylic acid groups of the fatty acids present 
being unavailable for deprotonation due to their bonds with glycerol. Therefore, 
negative mode will be ineffective in scanning for TAGs and positive mode should be 
used. Mobile phases comprised of Methanol (MeOH) with 0.1% Formic acid and 
water with 0.1% Formic acid was selected for analysis of the fragments collected. 
Formic acid is added into mobile phase at a low concentration to enhance 
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protonation of samples in positive mode (Waters 2018). Samples collected from the 
HPLC-CAD assay were in IPA/ACN 60/40 making them compatible for analysis.  
Time of flight (TOF) analysers are relatively simple mass analysers used within 
mass spectrometry. TOF analysers are comprised of a flight tube under vacuum 
with no electric fields. Ions collected post ESI are accelerated by an electric field 
and delivered to the TOF analyser. Ions proceed to ‘drift’ through the flight tube via 
the kinetic energy obtained from the potential energy of the electric field employed 
for acceleration. The specific kinetic energy that the ion obtains related to the 
equation in figure 16 that gives the mass/charge (m/z) ratio for the compound. 
𝑚
𝑧
= (2𝑡2𝐾)/𝐿2 
Figure 2.26 – t = drift time, L= drift length, m = mass, K = kinetic energy of ion, z = number of charges 
on ion. 
If the electric field applied is constant, the kinetic energy each ion will obtain will 
again be constant. Therefore, the velocity of each ion will be dependent on its 
mass/charge ratio i.e. the size of the ion. The smaller the ion, the larger the velocity 
and the shorter the time of flight recorded by the detector at the end of the flight 
tube and conversely the larger the ion the lower the velocity. Time of flight is 
recorded for each ion passing through the analyser and is initially plotted as 
abundance of ion vs time. This can be calibrated and re-plotted as m/z vs intensity 
to give the typical mass spectrum observed.  
2.12.2 Mass Spectrometry experimental method 
The use of mass spectroscopy was employed to obtain a mass/charge ratio for 
each of the labelled peaks, with the aim to identify the TAG responsible for each 
selected peak. Fragments from the HPLC-CAD were collected at the respective 
time points for each peak to be identified. The chromatogram observed in figure 
2.27 shows a typical collection run where peaks 1, 2 and 3 of Intralipid® were 
collected through collection of the eluent from the column at the point of entry to the 
CAD detector. As the CAD detection process is a destructive one, fragments had to 
be collected pre-entry to the detector. Each pre-collection run was carried out in 
duplicate, allowing for the times of the peaks 1 to 6 of Intralipid® and 1 to 10 of 
SMOFlipid® to be identified from the chromatograms present, accounting for inter-
day variability.  Subsequent runs were then carried out per the example in figure 
2.27. And the fragments collected and stored in amber HPLC vials at 2-8oC until 
analysis with mass spectroscopy. 
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Figure 2.27 Collection run of selected peaks 1, 2 and 3. Red * and gaps identify where fragments eluted from the column have been collected. 
 
    *   *        *    
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All fragments were analysed using an Agilent 1100 series auto-sampler (Agilent 
Technologies, Santa Clara USA) and a Bruker MicroTOF (Bruker Daltonics, 
Massachusetts, USA) in positive mode with ESI of samples. ESI-MS spectra were 
obtained for all fractions using the source parameters:  
- Capillary voltage: 4500 V 
- End Plate offset: -500 V 
- Nebuliser pressure (N2): 0.4 Bar 
- Dry Gas (N2): 4 L/min 
- Dry heater: 200oC 
 
Collected fragments from HPLC-CAD analysis were labelled with respective fraction 
number (1 to 6 and 1 to 10). Each fraction for MS analysis was collected in triplicate.  
Sample volume for MS was optimised to 30μL to achieve an acceptable response 
defined as above 6000 intensity (see figure 2.28). Each sample was directly injected 
into the analyser using MeOH (+0.1% Formic acid) and H20 (+0.1% Formic acid) 
90%:10% as mobile phase at a flow rate of 1ml/min. Each run was 3 minutes. 
Spectra for each peak obtained was recorded and analysed. Figure 2.28 shows a 
typical mass spectrum report generated for each sample analysed. 
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Figure 2.28 ESI-MicroTOF mass spectra report for fraction corresponding to peak 1 in HPLC-CAD chromatogram 
of Intralipid®. 
2.12.2.1 Intralipid® mass spectrometry results and triglyceride identification. 
As reported in figure 2.29 to 2.34 the mass spectra for peaks 1 to 6 in 
Intralipid® 20 % give clear m/z data. Table 2.7 reports the m/z data of 
multiple runs for each peak.  
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Figure 2.29 Intralipid® Peak 1 mass spectrum. 
 
Figure 2.30 Intralipid® Peak 2 mass spectrum. 
 
Figure 2.31 Intralipid® Peak 3 mass spectrum. 
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Figure 2.32 Intralipid® Peak 4 mass spectrum 
 
Figure 2.33 Intralipid® Peak 5 mass spectrum. 
 
Figure 2.34 Intralipid® Peak 6 mass spectrum. 
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Table 2.7 Mass spectra data for Intralipid® 20 % Peaks 1 to 6. Data in bold represent the main peaks in each 
repetition and match the predicted TAG data as shown in table 2.8. Data in blue represents [M+Na]+ or [2M+H]+ 
peaks also seen in spectra. 
  Rep 1 Rep 2 Rep 3 Rep 4 Rep 5 
Peak 1  879.7488 879.7428 879.7418 879.7425   
    901.7294 855.7412 855.7435   
    855.7424   901.7338   
        599.4886   
            
Peak 2  881.7588 881.7632 881.7615 881.7397 881.7578 
    855.7414 903.7508 855.7364 903.7478 
      855.7375 903.7301   
        599.4911   
        1762.487   
            
Peak 3 883.8 883.805 883.795     
            
Peak 4 881.7596 855.7356 855.7424 855.7414 881.761 
  855.7405 881.7595 881.7585 881.7601 855.748 
  903.748     903.7437   
            
peak 5 855.7744 855.77 855.77     
  603.5195 355.28 767.64     
  369.38         
            
peak 6 879.792 879.773 857.756     
  857.7762 857.756 879.442     
 
From this data the aim of the mass spectrometry was to identify the TAGs 
responsible for each peak. As per table 1.3 Intralipid® 20% contains 5 fatty acids, 
linoleic acid (L), oleic acid (O), palmitic acid (P), linolenic acid (Ln) and stearic acid 
(S). Using the online RCM lipid analysis tool (Murphy 2017) and the LipidMAPS 
Mass spectrometry peak predictor (Fahy et al. 2007) the average m/z ratios were 
analysed to identify the possible TAGs present. Table 2.8 displays the possible 
TAGs that can be attributed to each peak and the occurrence of either the [M+H]+ or 
[M+Na]+ ion in each chromatogram.  
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Table 2.8 Predicted TAGS from spectra data using the RCM lipid analysis tool (Murphy 2017) and the LIPIDMAPS 
peak predictor (Fahy et al. 2007). 
Peak 1 Ion 
Predicted 
m/z  Peak 4 Ion 
Predicted 
m/z 
C18:2/18:2/18:2 
[M+H]+ 879.744   C18:2/18:2/16:0 [M+H]+ 855.744 
[M+Na]+ 901.7259   C18:1/18:3/16:0 [M+H]+ 855.7439 
C18:3/18:2/18:1 
[M+Na]+ 879.7434   Peak 5   
[M+Na]+ 901.258   
C18:1/C18:1/C18:1 
[M+H]+ 885.7908 
C18:3/18:3/18:0 
[M+Na]+ 879.7439   [M+Na]+ 907.7727 
[M+Na]+ 901.7258   2[M+Na]+ 1792.5557 
Peak 2      
C18:2/C18:1/C18:0 
[M+H]+ 885.7908 
C18:2/18:3/18:0 
[M+H]+ 881.7596   [M+Na]+ 907.7727 
[M+Na]+ 903.7415   2[M+Na]+ 1792.5557 
2[M+H]+ 1762.5036   
C18:0/C18:0/C18:3 
[M+H]+ 885.7908 
C18:3/18:1/18:1 
[M+H]+ 881.7595   [M+Na]+ 907.7727 
[M+Na]+ 903.7414   2[M+Na]+ 1792.5557 
C18:2/18:2/18:1 
[M+H]+ 881.7596       
[M+Na]+ 903.7415   Peak 6   
Peak 3      C18:3/18:0/16:0 
[M+H]+ 857.75 
C18:2/C18:2/C18:0 [M+H]+ 883.78   [M+Na]+ 879.75 
C18:3/C18:1/C18:0 [M+H]+ 883.7863   
C18:1/C18:2/C16:0 
[M+H]+ 857.75 
C18:1/C18:1/C18:2 [M+H]+ 883.7862   [M+Na]+ 879.75 
 
As seen in table 2.8 from the mass spectrometry data for each of the peaks 1 to 6 in 
Intralipid® can be attributed to 2 or 3 TAGs. The mass spectrometry equipment used 
as detailed above was only sensitive to the level as shown and as such was 
incapable of looking at distinguishing between TAGs of the same m/z through 
identifying the fragments of each TAG. If a non-ion trap system was available, TAGs 
of the same overall m/z can be identified by looking for the loss of each individual 
fatty acid chain and calculating the remaining fragments m/z (Christie 2003). As 
such the fatty acid combination in each TAG can be identified. This was as 
discussed not possible due to the low sensitivity of the mass spectroscopy 
equipment available.  
As an alternative method to enable the prediction of the highest probability TAG 
attributed to each peak, work by Li et al. (2014) looked in detail at the composition 
of soy-bean oil, the oil used in Intralipid®, and the TAGs present and the percentage 
occurrence of each of them within the oil. Figure 2.35 adapted from this work 
displays the percentage occurrence of each of the TAGs present within the oil. From 
this data and from the data displayed in table 1.3 showing the percentages of each 
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fatty acid present within Intralipid®, with the mass spectroscopy data acquired, a 
reliable prediction was made to attribute an individual TAG to each of the peaks 1 to 
6 collected.   
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Figure 2.35 Adapted from Lin et al. 2014. Percentage occurrences of TAGs formed in soybean seed oil from two acyl chains (C18 and C16). Each arrow denotes a change in saturation by one 
double bond Yellow highlighted TAG's and red notations indicate the TAGs with the highest probability of being responsible for the peaks analysed in the HPLC-CAD assay of Intralipid®. 
Peak 1 
Peak 2 
Peak 4 
Peak 5 
Peak 6 
Peak 3 
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From this data the six peaks collected and analysed within the HPLC-CAD 
chromatogram of Intralipid® can be attributed to the TAGs within figure 2.35 with a 
high degree of probability. With regards to the elution order of the TAGs, as 
predicted by the partition number equation (figure 2.2), the TAG elution order that 
the mass spectrometry data indicated matches the predicted elution order with 
reference to carbon bond number and level of unsaturation. As the assay was 
designed to monitor the main TAGs within such a lipid emulsion and monitor their 
breakdown and subsequent loss of peak area during storage, the level of probability 
achieved is satisfactory to establish that the main TAGs present will indeed be 
monitored by the assay. It is worth noting however that as this is only a prediction of 
the TAG responsible for each peak, albeit with a high level of probability, the other 
TAGs shown in table 2.8 for each peak may also form a component of the 
corresponding peak shown within the HPLC-CAD chromatogram. This however 
does not present a problem when looking at the potential peroxidation and 
breakdown of these TAGs as the peaks being monitored form the bulk of the 
Intralipid® TAGs observed and as such a sufficient level of monitoring to indicate 
stability of each TAG through storage.  
 
2.12.3 SMOFlipid® mass spectrometry and triglyceride identification 
 
As shown in detail in figure 2.36 peaks 5 to 10 of SMOFlipid and peaks 1 to 6 of 
Intralipid have the same elution times and chromatographic shapes. Mass 
spectrometry of each of these peaks in SMOFlipid® was done to confirm their 
identical m/z data to that of Intralipid®. Table 2.9 shows the mass spectrometry data 
from peaks 5 to 10 of SMOFlipid. When compared to table 2.8 showing the mass 
spectrometry data from peaks 1 to 6 of Intralipid® this confirmed the identical TAGs 
present and that peaks 5 to 10 of SMOFlipid® are indeed attributed to that of 
soybean oil.  
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Figure 2.36 A = HPLC-CAD chromatogram of Intralipid®. B = HPLC-CAD chromatogram of SMOFlipid®. Peak 5 to 10 on the SMOFlipid® chromatogram showing the same elution times and peak 
pattern as Intralipid®.  
A 
 
 
 
 
B 
Peak 3 
Peak 1 
Peak 2 
Peak 4 
Peak 5 
Peak 6 
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Table 2.9 Mass spectrometry data for SMOFlipid® peaks 5 to 10. 
Peak 
number 
M/z data  Predicted TAG attributed to 
peak.  
5 879.75 [M+H]+ 
901.73 [M+Na]+ 
TG (18:2/18:2/18:2)  
 
6 881.76 [M+H]+ 
903.75 [M+Na]+ 
TG (18:2/18:2/18:1) 
7 883.775 [M+H]+ TG (18:1/18:1/18:2) 
8 855.74 [M+H]+ TG (18:2/18:2/16:0) 
9 855.78 [M+H]+ 
907.76 [M+Na]+ 
TG (18:1/18:1/18:1) 
10 857.75 [M+H]+ 
879.75 [M+Na]+ 
TG (18:2/18:1/16:0) 
 
It is significant however, that when comparing the overlaid HPLC-CAD 
chromatograms of Intralipid and SMOFlipid as seen in figure 2.37  the peak areas 
observed are different. 
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Figure 2.37 Overlaid chromatograms of SMOFlipid® (blue trace) and Intralipid® (black trace). Peaks 5 to 10 of SMOFlipid® are highlighted in red to show the differences in peak size relative to 
the same Intralipid® peaks. 
Peak 9 
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With regards to the percentage composition of fatty acids in SMOFlipid® vs 
Intralipid® as shown in table 2.10 the higher % of oleic acid (18:1) is due to the 
presence of oleic acid in both soybean oil and olive oil found in SMOFlipid®.  When 
looking specifically at the peaks highlighted in figure 2.37 peak 9 is significantly 
higher in SMOFlipid® than Intralipid®. Looking at the mass spectrometry data for this 
peak the TAG option attributed to this peak for Intralipid® was 18:2/18:1/18:0 due to 
its higher occurrence in soysbean oil than TAG 18:1/18:1/18:1. The 
chromatographic data for SMOFlipid® and the summary of product characteristics 
(SPmC) for this lipid showed an increase in oleic acid (18:1) and a reduction in 
linoleic acid (18:2) concentration when compared to Intralipid®. This therefore was 
used to predict peak 9 of the SMOFlipid® chromatogram to predominately be due to 
the TAG 18:1/18:1/18:1. This also confirmed that it is probable that whist both the 
TAGs present with the same m/z data are attributing to the single chromatographic 
peak seen within the lipid, the predominant TAG responsible for each peak can 
accurately be predicted. This is sufficient as for Intralipid® to monitor the level of 
peroxidation and breakdown occurring within the main TAGs with the lipid.   
Table 2.10 Fatty acid compositions of SMOFlipid® and Intralipid® as taken from their respective product summary 
of product characteristics data. 
Fatty acid Carbon number: 
double bond 
SMOFlipid® 20 % Intralipid® 20 % 
Oleic acid C18:1 23-35% 19-30% 
Linoleic acid C18:2 14-25% 44-62% 
Caprylic acid C8:0 13-24% - 
Palmitic acid C16:0 7-12% 7-14% 
Capric acid C10:0 5-15% - 
Stearic acid C18:0 1.5-4% 1.4-5.5% 
α-linolenic acid C18:3 1.5-3.5% 4-11% 
EPA C20:5 1-3.5% - 
DHA C22:6 1-3.5% - 
 
91 
 
With respect to peaks 1 to 4 of the HPLC-CAD chromatogram of SMOFlipid® it was 
predicted using partition number that the early eluting peaks would be attributed to 
TAGs containing fatty acids of lower carbon numbers. In the composition of 
SMOFlipid, such TAGs would be comprised of the unsaturated medium chain fatty 
acids capric acid (C10) and caprylic acid (C8) sourced from the chemically 
synthesised coconut oil component of the lipid emulsion. To confirm this and to 
identify each individual peak 1 to 4, fragments from HPLC elution were collected 
and subjected to mass spectrometry under the same conditions as above.  
Mass spectra for each are displayed in figures 2.38 to 2.41. The mass/charge m/z 
data was again analysed using the RCM lipid analysis tool (Murphy 2017) and the 
LIPIDMAPS peak predictor (Fahy et al. 2007). Due to the unsaturated nature of the 
medium chain triglycerides present only one TAG could be attributed to each of the 
peaks 1 to 4 of SMOFlipid®, providing a positive identification of these peaks within 
the chromatogram as shown in table 2.11. 
 
 
Figure 2.38 Mass spectra of Peak 1 SMOFlipid®. 
TAG C8:0/C8:0/C8:0 
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Figure 2.39 Mass spectra of Peak 2 SMOFlipid®. 
 
Figure 2.40 Mass spectra Peak 3 SMOFlipid®. 
 
Figure 2.41 Mass spectra Peak 4 SMOFlipid®. 
TAG C8:0/C8:0/C10:0 
TAG C8:0/C10:0/C10:0 
TAG C10:0/C10:0/C10:0 
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Table 2.11 Mass spectra data for Peaks 1 to 4 of SMOFlipid with identified TAG for each peak. 
Peak  TAG attributed  
M/z theoretical data 
  
M/z experimental data 
Peak 1 C8:0/C8:0/C8:0 
[M+Na]+ 493.35 493.3448 
2[M+Na]+ 963.71 963.7065 
Peak 2 C8:0/C8:0/C10:0 
[M+Na]+ 521.38 521.3652 
[2M+Na]+ 1019.77 1019.7476 
Peak 3 C8:0/C10:0/C10:0 
[M+Na]+ 549.41 549.3985 
[2M+Na]+ 1075.83 1075.8214 
Peak 4 C10:0/C10:0/C10:0 
[M+Na]+ 577.44 577.4292 
[2M+Na]+ 1131.89 1131.8862 
 
The mass spectra for peaks 1 to 4 of SMOFlipid® gave data that only showed the 
sodium adduct of each TAG. Both the spectra data for all Intralipid® peaks and 
peaks 5 to 10 of SMOFlipid® showed both the sodium adduct of each TAG and the 
molecular [M+H]+ ion. The presence of sodium within the mass spectrometry data 
was due to trace sodium contamination of the mobile phases used within the 
system. The next phase of development was the validation of the HPLC-UV-CAD 
assay for both Intralipid®, SMOFlipid® and HNE. 
2.13 Assay validation 
 
Assay validation for this assay is an integral part of method development and 
ensures that the assay developed for both Intralipid®, SMOFlipid® and the detection 
of the breakdown product HNE is accurate, repeatable and reliable for use as an 
effective tool in monitoring the stability of such lipid emulsions.  
2.13.1 International conference on harmonisation. 
 
The International Council for Harmonisation of Technical Requirements for 
pharmaceuticals for Human Use (ICH) is a body that was formed in 1990 to co-
ordinate the process of pharmaceutical product registration across the different 
world-wide regulatory bodies. The aim of the ICH is to ensure the same regulatory 
standards are met throughout the registration process of every pharmaceutical 
products across the world regardless of the location and regulatory body 
responsible for the registration procedures (Harmonisation 2018). As such the ICH 
has released a series of technical documents that are designed for use during the 
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validation procedures and registration procedures of pharmaceutical products to 
ensure testing of such products is comparable in every registration. Whilst this body 
of work is aimed at developing a stability indicating assay for lipid emulsions and as 
such will not be used for product registration, the ICH guidelines for assay validation 
provide an in-depth testing regime that was used as a guide for this assay 
validation.  
The ICH guideline ‘Validation of analytical procedures Q2R1’ (Q2R1) (Shabir 2004; 
ICH 2005) is the technical document that was produced by the ICH to facilitate 
assay validation of testing procedures used for product registration. This document 
will be adapted and used as a guide for this stability indicating HPLC assay. Each 
section of the assay (HPLC-UV assay of HNE and HPLC-CAD assay of TAGs) will 
be validated separately due to their differing requirements for validation.  
 
2.13.2 HPLC-UV of HNE assay validation 
2.13.2.1 Linearity 
 
Linearity of a method is a measure the accuracy of detector response to a range of 
concentrations of a particular compound. This is vital to determine for a stability 
indicating assay as HNE is a degradation compound of the lipid emulsions being 
tested and as such the concentration of HNE is expected to change during storage 
as it is produced by peroxidation of the fatty acids within the TAGs of the lipid 
emulsion. Therefore, the change in peak area needs to accurately represent the 
concentration change of HNE during testing. The ICH guidelines state that a 
minimum of five different concentrations should be tested across a representative 
range of HNE concentrations that will likely be found during degradation of the lipid 
emulsions. This is an area that is difficult to quantify before testing has occurred due 
to the fact that it is unknown how much HNE is likely to be produced within a 
stability study. In an aim to overcome this issue and give a guide for the 
concentrations that should be used for the linearity calculations for the assay, 
degraded Intralipid® 20 % that was held in a 50 ml oxygen permeable syringe (BD 
Plastipak, Beckton Dickinson, SA), at room temperature with no light protection for 
90 days was run through the developed assay and the level of HNE calculated 
against a standard run of HNE at 6 µg/ml. Figure 2.42 Shows the degraded 
Intralipid® sample HPLC-UV chromatogram.  
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Figure 2.42 Old Intralipid® degraded over 90 days at room temperature with no light protection in a 50 ml syringe. 
HNE 
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From this the peak area of HNE in degraded Intralipid® was averaged (triplicate 
runs) and gave 149.476 AU. HNE standard 12 µg in 2 ml new Intralipid® gave an 
average peak area of 29.436. From this is was calculated as an estimate that the 
maximum concentration of HNE likely to be created through the stability studies 
would be around 60.93 µg in 2ml of Intralipid®. This amount was therefore used as 
the 100% concentration for the production of calibration curves for HNE. Five 
concentrations of 12.5, 25, 50, 75 and 100% of estimated HNE production were 
calculated and 2 mls of IPA with addition of HNE standards were created as per 
table 2.12. As the stock solution of HNE was at a concentration of 1mg/100µl, 20 µg 
of this stock was diluted in 180µl of IPA to give a concentration of 1µg/µl. From this, 
required volumes of this diluted stock were added to each vial as per table 2.12. IPA 
was used instead of Intralipid® for HNE calibration runs to ensure clean peaks were 
observed for the HNE standards. The elution time and peak size was comparable to 
HNE in Intralipid®, confirming that substituting IPA for Intralipid® was acceptable for 
HNE calibration.  
Table 2.12 Calibration concentrations for HNE. 
Calibration 
Concentration 
HNE amount 
(µg) 
HNE concentration 
(µM) 
IPA volume 
(ml) 
100% 64  204.83 1.946 
75% 48  153.62 1.962 
50% 32  102.51 1.978 
25% 16  51.21 1.984 
12.5% 8  25.62 1.992 
 
All concentrations were run in triplicate and calibration curves of peak area 
(absorbance) and concentration were calculated with standard deviation error bars. 
Figure 2.43 shows the calibration curve created for HNE. As the UV is a linear 
detector a linear regression line was added to the graph. Linearity is expressed as a 
value of R2 which is how well the data points plotted fit the linear regression line. 
Usually an R2 value of greater than 0.999 is acceptable however, this limit is less for 
impurities (0.98) (Shabir 2004). As HNE being monitored is a degradation product of 
the lipid emulsions being tested a level above 0.99 was deemed to be acceptable.  
The calibration graph plotted gave an R2 value of 0.9972 showing an acceptable 
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level of linearity across all concentrations predicted to be seen through assay use in 
stability-testing.  
 
 
Figure 2.43 Calibration plot for HNE in IPA. 
2.13.2.2 Precision and accuracy 
 
Accuracy of a method is defined as the closeness of agreement between the value 
which is accepted as a true value and the value recorded during the test procedure 
(ICH 2005). Acceptable values lie between 80 % and 120 % (Synder et al. 1997).  
As shown in table 2.13 the accuracy of the assay across five concentrations of HNE 
all lie within 84.35 to 117.5 % showing an acceptable level of accuracy for the 
method.  
Precision is a measure of how reproducible results from a method are and is 
measured in a variety of ways according to the ICH guidelines. Precision is 
expressed as relative standard deviation (RSD), the lower the RSD achieved the 
better. No set limits exist, and RSD levels will vary depending on the detector 
chosen. 
ICH guidelines state that repeatability, intermediate precision and reproducibility are 
all ways of measuring the precision of a particular method (ICH 2005). Repeatability 
also termed intra-day repeatability is calculated as the RSD of multiple runs of the 
sample over a short period of time one after the next. Intermediate precision is a 
measure of inter-day repeatability where injections are carried out using the same 
y = 0.2476x + 1.0452
R² = 0.9972
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concentrations over different days and different weeks to measure repeatability 
during different days and therefore different laboratory environmental conditions. 
Intra-day repeatability was carried out in triplicate runs of each concentration used 
for calibration curve creation and inter-day repeatability was carried out on separate 
days on different weeks giving an n of 6 runs (Synder et al. 1997; Shabir 2004). 
Data in table 2.13 shows the RSD results for each of the concentrations. All RSDs 
fall under 7.5% showing an acceptable level of repeatability. Reproducibility is a 
measure of precision between different laboratories and as such was not tested due 
to lack of availability of equipment in a different laboratory for testing. Whilst the 
assay being developed is a stability assessing one that ideally will be used to test 
lipid emulsion stability during development and when testing different parenteral 
nutrition regimes, for the purpose of this body of work all stability testing will be 
carried out in the same laboratory as assay development and validation and as such 
reproducibility was not tested.  
Table 2.13 Accuracy and Precision values for HNE assay validation. 
 
Precision Accuracy 
HNE concentration 
(µM) 
RSD1 (%) 
(n=3) 
RSD2 (%) 
(n=6) 
(%) 
25.6 7.33 1.05 117.50 
51.21 3.07 1.70 84.35 
102.51 7.19 3.76 96.90 
153.62 5.40 4.37 90.14 
204.83 5.53 3.75 97.39 
 
2.13.2.3 Resolution  
Resolution is defined as the level of baseline resolution or separation between two 
peaks within a chromatogram (Synder et al. 1997). The better the resolution the 
superior the integration of each peak and therefore the more accurate the data 
recorded. Whilst resolution as a measure is not within the ICH Q2R1 technical 
document, it is a good indicator of the ability of an assay to accurately quantify 
specific peaks within a chromatogram. Resolution was measure for the HNE peak 
against the next eluting peak from Intralipid® and SMOFlipid® calculated using 
Chromeleon (Thermo Scientific) chromatography software. The resolution equation 
used is detailed in figure 2.44.  
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𝑅𝑠 =  
1.18 (𝑇2 − 𝑇1)
(𝑊501 + 𝑊502)
 
Figure 2.44 Resolution equation based on the European Pharmacopeia method. T1 and T2 = retention times of 
two adjacent peaks, W501 and W502 = width of adjacent peaks at 50% of peak height. 
 
A resolution of over 1.5 is optimal and shows definite baseline resolution between 
eluting peaks. Figures 2.45 and 2.46 shows the chromatograms of HNE standard 
added to Intralipid® and SMOFlipid® to enable resolution to be calculated. As shown 
the resolution for HNE in both lipids is well above the 1.5 minimum for baseline 
resolution.  
 
Figure 2.45 HPLC chromatogram of HNE in Intralipid® with Chromeleon calculated resolution for each peak. 
 
 
 
 
 
 
 
HNE Resolution 
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Figure 2.46 HPLC chromatogram of HNE in SMOFlipid® with Chromeleon calculated resolution for HNE peak. 
 
2.13.2.4 Limits of detection and quantification 
  
Limit of detection (LOD) is recognised as the smallest amount of analyte that can be 
detected from the baseline of the chromatogram. Limit of Quantification (LOQ) is the 
smallest amount of sample that can be quantified with a repeatable and 
reproducible level of accuracy. There are multiple methods available for calculating 
both LODs and LOQs that are recognised as acceptable by the ICH. Using signal to 
noise ratio is one way of determining each with a signal to noise ratio of 3 and 10 
being calculated as the LOD and LOQ respectively. From the calibration 
chromatograms for HNE using this signal to noise method LOD was calculated as 
3.123 µM and LOQ as 8.974 µM. As a comparison both LODs and LOQs were 
calculated from the linear regression plot (figure 2.43) using the standard deviation 
from triplicate runs from each calibration concentration (table 2.13). These figures 
were calculated using the equation shown in figure 2.47 and gave a LOD of 2.958 
µM and an LOQ of 8.765 µM.  
𝐿𝑂𝐷 =
3.3𝜎
𝑆
       𝐿𝑂𝑄 =
10𝜎
𝑆
 
Figure 2.47 Limit of detection and Limit of Quantification equations based on response and shape of calibration 
plot. 
HNE Resolution 
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For the best results possible, the higher LOD and LOQ from the signal to noise 
baseline calculations were therefore used.  
2.13.2.5 Degradation 
 
As per the ICH guidelines on assay validation (ICH 2005) it is typical for degradation 
studies of a sample to be carried out to ensure upon degradation that no 
degradation products interfere with the peak being analysed. This is important as 
this is a stability indicating assay, but as HNE is a degradation product itself and the 
method has been developed to separate this from any eluting TAG peaks that will 
be studied, a degradation study per say has not been carried out for the HNE 
portion of the assay. As shown from the chromatogram in figure 2.42 degraded 
Intralipid® showing the production of HNE was run through the final method and 
clearly separated the degradation products from the TAGs. It is also worth noting 
that the only peak being monitored by the UV detector within the assay is that of 
HNE and therefore as this peak showed good resolution from TAGs, it is sufficient 
to validate the assay for HNE.  
2.13.3 Triglyceride HPLC-CAD validation 
2.13.3.1 Intralipid® validation 
2.13.3.1.1 Linearity  
 
The CAD detector is a non-linear detector and therefore calibration curves created 
are subjected to a second order polynomial regression line fit. SPC data for both 
IVLEs provides ranges of concentrations for each fatty acid present. This prevents 
the individual concentrations of specific triglycerides from being calculated due to 
the variability of fatty acid concentrations in each IVLE. Individual triglyceride 
standards cannot be used as internal standards due to the formulation properties of 
the emulsion. Therefore, to overcome these issues concentrations of 12.5, 25, 50, 
75 and 100 % v/v of each IVLE diluted with water were created to enable calibration 
curves to be created. Figures 2.48 to 2.53 show the calibration curves for each of 
the six peaks selected within Intralipid®.  
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Figure 2.48 Calibration plot for Intralipid® Peak 1. 
 
Figure 2.49 Calibration plot for Intralipid® Peak 2. 
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Figure 2.50 Calibration Plot for Intralipid® Peak 3. 
 
Figure 2.51 Calibration plot for Intralipid® Peak 4. 
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Figure 2.52 Calibration plot for Intralipid® Peak 5. 
 
Figure 2.53 Calibration plot for Intralipid® Peak 6. 
 
As summarised in table 2.14 The R2 values for all of the six peaks validated gave 
values of above 0.99 with the exception of peak 6 which gave an R2 value of 
0.9773. Whilst this is less than the optimal 0.99 value, as the assay is not being 
used for product registration and all other peaks are within the optimal 0.99 value it 
was decided that this level of 0.977 was acceptable for one TAG peak within the 
chromatogram.  
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Table 2.14 Calibration linearity summary for all selected Intralipid® peaks. 
 
Peak number R2 
Intralipid® 20 % 
1 0.996 
2 0.992 
3 0.997 
4 0.995 
5 0.998 
6 0.977 
 
 
2.13.3.1.2 Precision and accuracy 
 
Precision both inter and intra-day were tested for all six peaks in the same way as 
for HNE (2.12.2.2). Table 2.15 shows the precision results for each of the six peaks 
within Intralipid®. 
 
Table 2.15 Precision results for Intralipid®. 
Intralipid® peak 
number 
Precision 
Intra-day (RSD %) n 
= 3 
Inter-day (RSD %) n 
= 6 
1 1.689 1.931 
2 3.679 1.567 
3 2.079 4.534 
4 5.209 4.225 
5 0.566 3.812 
6 3.879 
 
6.337 
 
The RSD precision results show a maximum RSD of 6.337 with most of the results 
within a maximum RSD of 5 %. The CAD detector factory testing shows an ideal 
RSD of around 2 %, however, multiple assays have shown that precision RSD up to 
a limit of 5 % is acceptable (Crafts et al. 2011). Therefore, the results from the 
peaks for Intralipid® were considered to be acceptable.  
As shown in table 1.3 the SPC data for Intralipid® is given as a percentage range of 
each fatty acid present. Therefore, as such both the amounts of each TAG created 
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from these fatty acids and the ultimate concentration of each TAG present cannot 
be accurately calculated. If considering oils rather than emulsions, normal practise 
would be to spike each TAG with a known amount of standard to ascertain the 
concentration of each TAG present. This however is not possible for this analyte 
due to the nature of the emulsion being tested. As discussed earlier in this chapter, 
spiking an emulsion with a TAG standard will not produce the same elution peak as 
the TAG within the emulsion. Therefore, in this case accuracy of the assay cannot 
be calculated. However, as all other validation parameters were tested successfully 
this was deemed as acceptable for this assay as the aim of the assay is to monitor 
the changes and loss of particular TAGs during storage. This data will not be able to 
be shown in terms of molarity concentration change of each TAG but will be 
presented as a percentage loss against a control reference standard of new lipid. 
  
2.13.3.1.3 Limits of Detection and Quantification 
 
When considering the validation of the CAD section of the assay for the 
quantification of TAGs, LOD and LOQ cannot be calculated due to the limited 
information given in each of the IVLE’s SPC. As discussed above, amounts are 
given as a range of concentrations of individual fatty acids. Due to this, exact 
concentrations of each triglyceride attributed to each selected peak cannot be 
calculated, preventing LOD and LOQ from being calculated as a molarity. However, 
LOD and LOQ can be expressed as a percentage concentration from a neat 
standard (100 %) of IVLE. For Intralipid® 20 %, the LOD and LOQ for the smallest 
measured peak (peak 6) were 0.64 % and 2.32 % respectively. For the purposes of 
the use of the assay, such LOD’s and LOQ’s are sufficient validation as, during 
storage before delivery to the patient, the amount of TAGs lost will be no more than 
50 % as shown through the testing of a 90-day sample of Intralipid®. 
2.13.3.1.4 Resolution  
 
Resolution for each of the six peaks was calculated using Chromeleon software 
using the formula described in figure 2.44. Figure 2.54 shows the resolution 
calculated for each Intralipid peak. All peaks gave a resolution above 1.5 except 
peak 3 where the resolution was 1.20, however due to the number of peaks being 
analysed and the complexity of the sample present this was deemed as acceptable. 
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It would not be possible to optimise the method further to increase the resolution of 
one particular peak without disrupting all other peaks within the chromatogram.  
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Figure 2.54 Chromatogram of Intralipid® showing the calculated resolution of each peak. 
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2.13.3.1.5 Degradation 
 
To simulate the effects of degradation, Intralipid® was subjected to 90 days storage 
at room temperature in a non-light protected oxygen permeable syringe. The HPLC-
CAD chromatogram of this degraded sample is shown in figure 2.55. The 
chromatogram clearly shows that the degradation products made do not interfere 
with the six selected peaks for calibration and monitoring.  
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Figure 2.55 HPLC-CAD chromatograms of new and degraded Intralipid®. Primary degradation products highlighted in red. 
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2.13.4 SMOFlipid® validation 
2.13.4.1 Calibration curves 
 
As per Intralipid®, SMOFlipid® 20 % was tested and calibration curves for 
each of the ten selected peaks created as shown in figures 2.56 to 2.65 with 
standard deviation error bars. All results were in triplicate for each 
concentration. R2 values are summarised for each peak in table 2.16. 
 
 
Figure 2.56 Calibration plot for SMOFlipid® Peak 1. 
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Figure 2.57 Calibration plot for SMOFlipid® Peak 2. 
 
Figure 2.58 Calibration plot for SMOFlipid® Peak 3. 
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Figure 2.59 Calibration plot for SMOFlipid® Peak 4. 
 
Figure 2.60 Calibration plot for SMOFlipid® Peak 5. 
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Figure 2.61 Calibration plot for SMOFlipid® Peak 6. 
 
Figure 2.62 Calibration plot for SMOFlipid® Peak 7. 
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Figure 2.63 Calibration plot for SMOFlipid® Peak 8. 
 
Figure 2.64 Calibration plot for SMOFlipid® Peak 9. 
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Figure 2.65 Calibration plot for SMOFlipid® Peak 10. 
 
Table 2.16 SMOFlipid® Calibration curve results summary. 
SMOFlipid® peak number R2 coefficient 
1 0.9869 
2 0.9862 
3 0.9877 
4 0.9916 
5 0.9882 
6 0.9895 
7 0.9864 
8 0.9877 
9 0.9902 
10 0.9926 
 
All the calibration coefficients calculated were above 0.98 which is deemed 
acceptable for an assay where there are 10 or more peaks present (Synder et al. 
1997).  
 
2.13.4.2 Precision and accuracy 
 
As discussed in section 12.2.3.1.2 for Intralipid®, SMOFlipid’s SPC gives the 
percentage composition of each fatty acid present as a range. Therefore, as 
discussed for Intralipid® SMOFlipid® accuracy cannot be calculated in terms of % 
recovery of each peak. The stability data gathered during the following studies on 
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SMOFlipid® will like Intralipid® be presented as a % loss of peak area in comparison 
to a new sample of lipid taken on each testing day.  
Precision of each of the ten selected peaks within SMOFlipid® was calculated with 
inter and intra-day repeatability. Each of the relative standard deviations for each 
peak are displayed in table 2.17 the maximum value recorded gave a RSD of 5.158, 
well within the acceptable levels for the CAD detector(Crafts et al. 2011).  
Table 2.17 Inter and intraday repeatability results for SMOFlipid®. 
SMOFlipid® peak number Precision 
Intra-day (RSD %) (n=3) Inter-day (RSD %) (n=6) 
1 0.831 3.740 
2 0.618 2.597 
3 0.498 2.258 
4 2.319 1.614 
5 0.863 2.048 
6 0.342 2.384 
7 1.652 5.158 
8 0.055 3.544 
9 0.373 2.607 
10 2.855 4.745 
 
2.13.4.3 Limits of detection and quantification 
LOD and LOQ for SMOFlipid® were again calculated as a percentage of the peak 
area of a 100% sample due to the inability to calculate a molarity concentration. 
SMOFlipid® 20 % produced LOD and LOQs of 1.57 % and 5.57 % for the smallest 
peak quantified. This again is acceptable levels as the maximal degradation over 
storage will be less than 60% loss of each peak area.  
 
2.13.4.4 Resolution 
Calculated using the European Pharmacopeia method and Chromeleon software, 
the resolutions for each of the ten peaks of SMOFlipid are shown in figure 2.55 and 
show that peaks 1 to 4, 5, 6, 8 and 10 all have a resolution well above 1.5 showing 
a good level of resolution between peaks. Peaks 7 and 9 have resolutions of 1.13 
and 1.32 respectively and whist not ideal, with regards to CAD assays and for 
example Gonyon’s (Gonyon et al. 2013) work with lipid emulsions and the CAD, the 
acceptable level of resolution that can be accurately quantified through this form of 
detection is lower than is seen in other types of detectors. As such the two 
resolutions for peaks 7 and 9 along with their proven repeatability RSDs are 
acceptable.  
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Figure 2.66 HPLC-CAD chromatogram pf SMOFlipid® showing calculated resolutions for each peak.
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2.13.4.5 Degradation 
 
As per Intralipid® validation, a 90-day sample of SMOFlipid® held at room 
temperature in an oxygen permeable syringe with no light protection was used to 
show the degradation peaks seen through the CAD detection. Figure 2.67 shows 
the chromatogram of this degraded SMOFlipid® in comparison to a new sample of 
the same lipid. One of the advantages of the CAD is that only semi or non-volatile 
analytes will be detected by the CAD and as such many of the degradation products 
of triglyceride breakdown will be evaporated by the higher temperature of the CAD 
detector and as such will not be detected. This is also one of the reasons why the 
CAD assay is coupled with a UV assay to detect these semi and volatile products of 
TAG breakdown.  As figure 2.67 shows the degradation peaks do not elute near any 
of the ten peaks being monitored for SMOFlipid®.  
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Figure 2.67 HPLC-CAD chromatograms of new and degraded SMOFlipid®. Red boxes indicate degradation peaks seen. 
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2.14 Assay validation conclusions 
 
The above assay validation procedure, led by the ICH guidelines (ICH 2005) 
supports the creation of a repeatable and accurate assay for the detection of HNE 
via UV detection and the monitoring of six and ten peaks within Intralipid® and 
SMOFlipid® respectively using CAD detection. This shows that the results obtained 
through using this assay for the stability testing of both lipids are reliable and 
repeatable with a high level of confidence.  
 
2.15 Method development conclusions 
 
The aim of this project is to quantify and monitor the changes within different IVLE’s 
during storage under a variety of conditions. The assay developed and validated 
enabled this to be undertaken as shown in the following work. The production of the 
toxic secondary peroxidation product HNE along with the changes in TAG 
composition can be accurately and repeatedly monitored allowing an analysis of 
storage parameters for such lipids to take place. The combination of the UV and 
CAD to monitor such parameters and the assay conditions achieved are novel and 
as such the following body of work is novel and will give detailed stability data for 
IVLEs used within parenteral nutrition. It is also of note that the assay developed 
could be used theoretically for the testing of a wide variety of lipid emulsions across 
many different industries and sectors. As such the method was submitted accepted 
and published in Clinical Nutrition ESPEN as a method paper as shown in appendix 
1.
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Intralipid® Light Protected 
Syringes, Bags and Vials
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3.1 Introduction to stability testing of Intralipid® 
 
The remaining chapters of this thesis aim to utilise the assay developed in chapter 2 
to test a range of storage conditions for both the traditional lipid emulsion Intralipid® 
and the newer generation IVLE SMOFlipid®. The assay has been validated for 
monitoring TAGs within both lipid emulsions and the detection of the peroxidation 
product HNE. This chapter offers an introduction to the stability testing regimes and 
protocols that will be followed for all succeeding chapters for each emulsion under 
different storage conditions. This chapter also provides detailed descriptions of the 
container types being tested, the theory behind each container material and the 
principles of light and non-light protection. Each testing regime follows the same 
plan as detailed in section 3.4 which, in part, is laid out to match and complement 
the existing testing protocol used within the laboratory for the physical stability 
testing of both PN and IVLE’s.  
3.2 Containers  
 
3.2.1 50 ml Syringes 
 
BD 50 ml oxygen permeable plastic syringes were filled with 50 ml of each IVLE test 
emulsion. BD Plastipak® syringes (Beckton Dickenson) figure 3.1 were chosen for 
testing for several reasons. Syringes in principle were tested due to their use within 
the delivery of neonatal PN. Due to neonates’ unique requirements for differing 
levels of nutrients within PN cf. adult PN, neonatal PN is susceptible to precipitation 
particularly of the calcium portion of PN due to its complexation with phosphates 
present (Maruyama et al. 2018) . Such precipitation poses a risk to blockage of 
capillaries within neonatal circulation and such is contraindicated in the delivery of 
PN. Therefore, PN needs to be closely monitored for the occurrence of precipitation 
through turbidity testing and microscopy, physical stability tests that are routinely 
carried out when stability data is generated for a specific PN regime. IVLE’s used 
within neonatal PN are emulsions and are consequently a white to off-white colour 
which when mixed together with the aqueous portion of PN will obscure 
visualisation of any precipitation occurring. To circumvent this issue neonatal PN is 
separated into aqueous and lipid portions. 
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Figure 3.1 BD Plastipak® 50ml syringes used for lipid storage and delivery. 
 
Currently the lipid portion of neonatal PN is stored in 50 ml plastic syringes formed 
of polycarbonate with a polypropylene barrel and a latex free elastomer stopper. 
The barrel is lubricated using a medical grade silicone oil (BD Medical 2015). Such 
syringes are acceptable and licensed as such for “general purpose injection and 
aspiration of fluids from vials, ampoules and parts of the body below the surface of 
the skin.  Perfusion syringes, 50ml syringes, are designed for short term use in 
syringe pumps (active IIa devices) for the administration of pharmaceuticals” (BD 
Medical 2015) and are currently employed as containers for the storage and 
delivery of lipid PN. However, as described above, such syringes are optimally used 
for the delivery of pharmaceuticals and not the storage of them. Storage within 
syringes is not ideal due to the oxygen permeability of the materials used and the 
innate risk of oxygen ingress into the contents of the syringe due to the moving 
parts involved. The presence of lubricants within syringes also poses another issue 
when considering storing lipids as these oils and the plastics can cause extractables 
and leachables to enter the stored lipid. Recent work (Driscoll et al. 2007a; Dorival-
García et al. 2017) has focused on the extractables and leachables of syringes and 
concludes that a move away from the storage of lipids within syringes is desired. 
With regards to oxygen permeability and therefore the potential for lipid peroxidation 
and breakdown to occur this was the area of focus for the project and the 
subsequent stability testing of lipids within syringes was designed to test the storage 
limits with regards to peroxidation and lipid breakdown.  
3.2.2 Small volume PN bags 
 
Standard adult PN where lipid and aqueous portions of PN are mixed together are 
stored in multi-layer (ML) bags comprised of ethyl-vinyl alcohol-polyvinylidine 
combinations or ethyl-vinyl acetate (EVA) single layer large volume PN bags. When 
comparing the two bags and their effect on the stability of PN Balet et al.  (2004) 
studied the effects on each type of bag on four different lipid emulsions (Intralipid® 
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included) with respect to peroxidation and tocopherol content. Whilst peroxidation 
was measured through the FOX analysis method which, as discussed in section 
1.6.3, often leads to overestimations of peroxidation, when compared under the 
same method, peroxidation was more prevalent within EVA bags than multilayer PN 
bags. With regards to neonatal PN, as discussed above, current practise is the 
storage of lipids within syringes for delivery to the patient. The issues raised with 
syringes as storage containers are discussed above and there is a drive to move 
the lipid proportion of neonatal PN from syringe storage into small volume PN bags 
typically 250 ml or less to minimise surface area. Typically, 50 ml of lipid is 
prescribed per neonate and as such PN bag size should be as small as possible to 
match this volume. Reducing the PN bag size as much as possible will limit the 
amount of lipid exposed to light by reducing the surface area of lipid exposed to the 
surfaces of the PN bag. Small volume PN bags were chosen as a container to be 
tested to give a comparative data set to lipid storage in syringes providing essential 
stability data to investigate the hypothesis that syringes will cause a greater level of 
degradation within the lipid than PN bags. Small multi-layer PN bags of 250 ml 
volume (Baxa) as shown in figure 3.1 were chosen for analysis.  
 
Figure 3.2 Baxa ExactaMIx® Multilayer 250ml PN bag used for small volume lipid storage. 
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The evidence of multi-layer bags preventing peroxidation vs. EVA bags influenced 
the choice of bag for testing as eradicating peroxidation occurrence within neonatal 
PN is essential due to the potentially harmful effects peroxidation products would 
have on an already oxidatively stressed premature patient.  ML bags are 
impermeable to oxygen and have a protective effect against oxygen ingress and 
oxygen initiated and propagated lipid peroxidation (Balet et al. 2004). These ML 
bags were used for testing to provide a comparison against oxygen permeable 
syringes and therefore the type of peroxidation occurring during storage of IVLE’s 
prior to delivery.  
3.2.3 50ml glass vials 
 
Whilst glass vials are not typically used for the storage and delivery of formulated 
PN to patients, many of the individual components of PN are stored in glass for long 
term stability. SMOFlipid® until early 2018 was stored in glass vials until formulation 
into PN per individual patient requirements. Intralipid® is stored in overwrapped 
bags formed of a multilayer polymer film. The overwrap provides protection against 
oxygen ingress during long term storage and each container has an oxygen sensor 
which indicates the presence of oxygen inside the overwrap through a colour 
change. Glass vials are impermeable to oxygen and theoretically will protect against 
oxidative peroxidation though this is dependent on the internal space of the vial 
being filled with oxygen free lipid and an oxygen free headspace. There is a further 
issue with EVA bags where though relatively inert, Gonyon et al. (Gonyon et al. 
2013) showed that leachables from EVA potentially appeared within a parenteral 
nutrition lipid emulsion and that triglycerides had a higher association and uptake by 
EVA vs glass containers. As such, traditionally glass was used for lipid storage over 
EVA containers. Glass vials do however have certain disadvantages compared to 
EVA containers primarily being that the removal of any gaseous phase from EVA 
containers is easier than glass vials reducing the probability of oxygen 
initiated/propagated peroxidation. Due to the use of both glass vials and EVA bags 
for the storage of IVLE’s 50ml glass vials as shown in figure 3.3 were chosen for 
analysis to provide a standard from which syringe and ML bag storage could be 
compared.  
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Figure 3.3 50 ml glass vial with rubber septum and metal clasp filled with 50 ml lipid emulsion. 
 
Vials chosen were small volumes of 50 ml to match the small lipid volumes being 
tested within bags and syringes. The main aim of glass vial testing was to create 
and maintain an oxygen free environment from which lipid stability testing could 
occur providing an insight into the amount of oxygen dependant peroxidation 
occurring vs other potential peroxidation processes as discussed in section 1.5.1.  
To achieve an oxygen free lipid and an oxygen free headspace within each glass 
vials, 50 ml of each lipid was placed into a glass vial under atmospheric conditions 
due to the lack of availability of an oxygen free preparation area, and then nitrogen 
was bubbled through the lipid and headspace to remove any oxygen present. To 
validate this procedure and ensure a complete oxygen free environment was 
created, a model 9500 dissolved oxygen meter (Jenway, Staffordshire, UK) was 
used to create a protocol from which each vial tested was subjected to. The meter 
was calibrated as per its standard operating procedure (SOP). 50 ml of lipid was 
placed within a sterilised (heat autoclaved) glass vial and sealed with a rubber 
septum and metal clasp. Nitrogen was then bubbled through the lipid and 
headspace at a constant regulator pressure of 2000 psi through a 19G BD (Beckton 
Dickenson) needle and vented through another 21G BD needle as shown in figure 
3.4. Nitrogen flow was maintained in increments of 2 minutes and at each time point 
dissolved oxygen was measured. Each result was performed in triplicate to ensure 
validity of results. It was found that 10 minutes of Nitrogen flow created a 0% 
dissolved oxygen reading within each lipid. To ensure the headspace present within 
each vial was also oxygen free, each vial was vented with nitrogen for a further 2 
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minutes each time. Each vial tested underwent this sterilisation and oxygen removal 
process.  
 
Figure 3.4 50 ml glass vial with 50 ml Lipid emulsion showing oxygen removal procedure through nitrogen 
flushing. 
3.3 Light protection principles and relevance 
 
3.3.1 Relevance 
 
The relevance of protecting PN from light exposure is well established and 
extensive studies have been carried out on the effect of light exposure on vitamin 
stability and degradation. Studies by Allwood and Ferguson et al.  (2000; 2014) 
clearly demonstrate the liability of riboflavin and further water-soluble vitamins found 
within PN to light exposure induced degradation. Miloudi et al. (2012) studied the 
effects of different lipid emulsions on the generation of peroxides and HNE, 
comparing a lipids makeup as a possible strategy for preventing peroxidation vs. 
light protecting PN when considering all-in-one PN solutions and hypothesising that 
certain lipid formulations may provide a protective effect against peroxidation by 
preventing the breakdown of pro-oxidant vitamins. With regards to lipid stability and 
peroxidation within PN lipids, the presence of ascorbate within multivitamin 
preparations used within all-in-one PN has been shown by Silvers et al. (2001) to 
have a protective effect on peroxidation of lipids through its anti-oxidant pathways 
and free-radical scavenging functions. When considering lipid alone however, or 
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with the presence of fat soluble vitamins only as in the case of lipid separated PN 
delivery to neonatal patients, vitamin E is the only available free-radical scavenger 
within certain lipid emulsions (SMOFlipid®). The lack of effective free-radical 
scavengers within lipid emulsions heightens the need for light protection against 
photo-oxidative or light induced peroxidation.  
When considering the effectiveness of light protecting PN in neonatal patients a 
meta-analysis by Chessex et al. (2015) showed around a 50 % decrease in 
mortality of neonates receiving light protected PN vs. non-light protected PN. This 
finding is of great significance when considering the necessity of light protection. 
The reduction in mortality in two of the four studies reviewed was linked to a similar 
reduction in bronco-pulmonary dysplasia (BPD) a fatal condition that is associated 
potentially with the delivery of peroxidised lipids (Chessex et al. 2007). Recent work 
by Lavoie et al. (2018) compared Intralipid® and SMOFlipid® both light and non-
light protected and the development of hypo-alveolarization (linked with BPD) in 
guinea pigs. The principle findings of the study support the use of light protection 
within PN lipid emulsions but indicate that the newer SMOFlipid® lipid emulsion may 
have a greater pro-oxidant effect and increase hypo-alveolarization. This research is 
particularly interesting as SMOFlipid® contains added tocopherols as free-radical 
scavengers principally designed to reduce peroxidation whereas Intralipid® does 
not, indicating that tocopherols as anti-oxidants within lipid emulsions may not be as 
effective as previously thought, therefore placing further significance to the light 
protection of lipid emulsions in PN.  
3.3.2 Principles 
 
The principles of light protection revolve around the covering of the PN container 
(bag or syringe) with or without added coverage of the infusion lines from the 
container to the patient by a suitable material that will prevent light penetration, thus 
protecting the contained lipid emulsion from light exposure. The physical 
characteristics of the covering used will define the level and type of light able to 
penetrate to the lipid. Studies by Laborie et al. (1999) compared the effectiveness of 
plastic coverings of different colours (orange, yellow, black and clear) in protecting 
PN solutions from peroxidation. The study concluded that in PN with a lipid 
component present, protection with black covering reduced the peroxide value by 
up to two thirds. Results were however calculated using the FOX II method which is 
reported to give an over estimation of peroxides present, however all PN tested was 
subjected to the same testing method so the differences in peroxides present will be 
130 
 
comparable. The necessity for the protection of the delivery infusion lines with the 
same coloured protection to prevent peroxides forming is highlighted by the study.  
In a clinical setting whilst black covering of PN is optimal for protecting against 
peroxidation there are issues with such a covering being used. During infusion to 
the patient it is vital that clinical staff can observe the infusion being delivered, the 
container (bag/syringe) for signs of physical instability and the infusion line for air 
bubbles which need to be eliminated before reaching the patient. Many infusion 
lines contain an in-line filter typically 5 µm or smaller to prevent any particulates 
present from being infused into the patient. This need to observe the infusion makes 
covering them with black plastic not possible. Therefore, with reference to the 
studies above different colour plastics are used for infusion coverage. Red, orange 
and brown semi-transparent coverages are routinely employed for the protection 
against peroxidation within a clinical setting, all providing differing degrees of light 
protection. It is not always routine to protect the infusion lining in a clinical setting 
despite the above evidence clearly showing the optimal prevention of peroxidation 
includes the protection of the infusion lines.  
For the purposes of the following studies, the aim was to compare peroxidation 
occurring within syringes, bags and vials of lipids with and without light protection. 
Infusion lines will not be studied due to the variability of lines used and the aim of 
the study being to establish the chemical stability of lipids after formulation into PN 
before delivery to the patient and not during infusion. To create a complete level of 
light protection that guaranteed no light penetration would occur, aluminium foil was 
chosen as the cover for each container. Foil negates the issues with plastic covers 
and the partial control of different light wavelengths penetrating through the cover. 
To ensure each bag, vial and syringe was fully protected as shown in figure 3.5 foil 
was used to cover the entirety of each container including the sampling ports during 
storage, with ports being uncovered only when sampling took place or nitrogen top-
up was carried out in the vial samples.  
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Figure 3.5 Light protected 50 ml glass vial, 50 ml syringe and 250 ml multi-layer PN bag covered with aluminium 
foil. 
3.4 Testing protocol  
 
The following testing protocol and schedule was employed for all subsequent testing 
of all lipids in all conditions. The time frame for testing was set to reflect the physical 
stability protocols currently used within the laboratory for developing stability limits 
for PN regimes for adults and neonatal patients. Initial stability information 
assimilated for the first week is important due to the fact that the clear majority of 
neonatal PN is made and delivered within 24 hours to 7 days. Adult PN regimes are 
however often delivered to home PN patients and as such extended stability is 
favourable to allow patients to have convenient home delivery of PN. Therefore, 
physical stability testing regimes up to 90 days are used within the laboratory and 
reflected in the following studies for chemical stability. Whilst the testing was 
undertaken in small volume lipids, this extended time frame will give an introductory 
data set for the potential chemical stability of lipids over an extended period. The 
studies are with lipid alone and do not consider the addition of either fat-soluble 
vitamins or other components of all-in one PN where aqueous and lipid phases are 
combined. Theoretically lipid emulsions alone should provide chemical stability data 
on the most stable form of the lipid emulsions and therefore provides a good starting 
point for forming chemical stability data on PN lipids.  
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Initial testing at days 0, 1, 2, 5 and 7 was undertaken to provide detailed changes 
over the initial 7-day storage after formulation. After this testing was carried out on 
days 14, 28, 56 and 84 providing extended storage data and matching the physical 
stability testing regimes.  Temperature was controlled in all samples and designated 
at either fridge storage temperature (2 to 8oC) or room temperatures (22 to 24oC). 
Light protection was achieved as described above through complete wrapping with 
aluminium foil (figure 3.5). All samples were prepared in triplicate to achieve 
statistically significant results. Samples were prepared in a laminar air flow cabinet 
(BioQuell, Andover UK) using aseptic technique and marked with relevant identifiers 
and date. BD 50 ml syringes and 19G BD needles were used to manufacture each 
lipid syringe, bag or vial, batch numbers of all items used were recorded for 
posterity.  A control bag of lipid kept as per supply from the manufacturer was used 
as a control sample for each day of testing to ensure HPLC method reproducibility. 
Each control samples chromatogram was monitored for peak areas of selected 
peaks and the relative standard deviation from the day zero sample to ensure the 
method being used was consistent over a prolonged period of testing.  
Six samples of each lipid (Intralipid® or SMOFlipid®) were prepared for each 
container type (bags, syringes or vials), all light protected with aluminium foil. The 
vial samples were subjected to oxygen removal with nitrogen gas as described 
above in section 3.2.3. Three samples of each container were designated for fridge 
storage, mimicking the normal storage temperature for formulated PN prior to 
infusion to the patient. The other samples were held at room temperature between 
22 and 24oC for the entirety of the study to create a comparator to fridge 
temperature and investigate the effects of temperature on peroxidation levels.  
On every designated testing day each container was sprayed with 70 % IPA and 
placed into the laminar airflow cabinet where 1 ml of lipid was removed from each 
sample using BD syringes and needles and placed into an autosampler HPLC vial. 
Such vials were formed of amber glass to ensure light protection was achieved and 
sealed to prevent further oxygen ingress. Vials were held in the HPLC autosampler 
as per method at 8oC to achieve an optimal environment at which to hold the 
sample to prevent further peroxidation from occurring during testing.  
All samples were labelled according to their container, lipid, temperature of storage 
and repetition number. Due to the testing time of 90 minutes per run and each 
sample being tested in triplicate, the testing schedule was divided into different 
days. Intralipid® fridge and room temperature syringes were formulated and tested 
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on one day, fridge and room bags on another and fridge and room vials on another. 
Testing of each container set was scheduled to allow all days of testing to be 
completed without overlap to another containers schedule.  
Each sample was subjected to the final HPLC method as detailed in Chapter 2, with 
a blank 30-minute compressed run between samples to ensure column cleaning 
and re-equilibration. For Intralipid® samples the identified 6 TAG peaks were 
monitored through recording of peak area from the CAD chromatogram of each 
sample for each testing day. The UV chromatogram of each sample was monitored 
for the development of HNE or other unidentified peaks produced from peroxidation 
and breakdown of the lipid during storage.  
Results were recorded as peak area for each replicate and analysed using Microsoft 
excel software where averages, standard deviations (SD) and relative standard 
deviations (RSD) were calculated. RSD was used to monitor the level of precision 
for the method and ensure the identification of any potentially erroneous results. For 
the CAD chromatograms of Intralipid® and SMOFlipid® an acceptable level of RSD 
was set to be lower than 12%. As discussed in the method development of this 
work, factory settings from Thermo Scientific state the RSD for the CAD should 
ideally lie under 5 % (Crafts et al. 2011), however when considering CAD use as a 
detector for identification and monitoring of components within an emulsion 
formulation, RSD’s of up to 12% have been validated as acceptable (Fox et al. 
2013; Márquez-Sillero et al. 2013).  
3.5 Intralipid® light protected syringe results 
 
Results were recorded for all days of testing as per protocol as peak area and 
integrated using Chromeleon software (7.2, Thermo Scientific). For the CAD 
chromatogram each of the six TAG peaks were recorded and a % loss in peak area 
calculated from the day 0 readings. All were performed in triplicate as described 
above and RSD’s monitored for each sample and the control sample used 
throughout testing. The % loss for each peak is shown below in figures 3.7 to 3.12. 
Both room temperature and fridge temperature results are indicated on all graphs. 
SD error bars are present on all data points.  
As shown in the graphs the amount of triglyceride loss occurring increases with 
storage time at both fridge and room temperature to a maximal 35 % as seen for 
peaks 2 and 4 at room temperature. Maintaining storage at fridge temperature 
reduced and delayed the amount of TAG loss of all peaks but significantly for peaks 
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2,3,4 and 6, however a substantial amount of TAG loss still occurred for all 
monitored peaks. TAG results are discussed further in section 3.8.  
The amount of HNE produced is presented in figure 3.13 with standard deviation 
error bars on all results.  Chromatograms of day 0 and day 84 Intralipid® syringes 
stored at both fridge and room temperatures for both CAD and UV detection are 
shown in figures 3.14 and 3.15 with day 0 chromatograms for reference. 
The maximum peak area seen for HNE at room temperature was 3.537 AU (n=3) 
and for fridge temperature was 3.1206 AU (n=3). Using the equation from the 
calibration plot (figure 3.6) the concentration of HNE present was calculated to be a 
maximum of 10.209 µM HNE in room temperature syringes whilst fridge 
temperature storage yielded 8.38 µM HNE. The fridge level of HNE is under the 
LOQ of 8.974 µM and is therefore not considered to be quantifiable. However, the 
chromatogram and presence of HNE is still of relevance and shows the production 
above the level of detection (LOD) within syringes at fridge temperature.  
 
Figure 3.6 HNE calibration graph with linear regression equation used to calculate concentrations of HNE 
present within tested samples. 
Figure 3.16 shows the day 0 and day 84 room temperature syringe chromatograms 
overlaid. These figures show how the loss of TAGs affect the chromatogram peak 
area (see y axis scales on figure) and the identification of highlighted new peaks 
(figure 3.16) A and B attributed to degradation/peroxidation products discussed 
further in section 3.8.  
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Figure 3.7 HPLC-CAD results for peak 1 (C18:2/18:2/18:2) triglyceride of Intralipid® 20 % stored in light protected 
50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge (Blue) results 
shown with standard deviation error bars on all points. 
 
 
Figure 3.8 HPLC-CAD results for peak 2 (C18:2/18:2/18:1) triglyceride of Intralipid® 20 % stored in light protected 
50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red)  and Fridge (Blue) results 
shown with standard deviation error bars on all points. 
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Figure 3.9 HPLC-CAD results for peak 3 (C18:2/18:1/18:1) triglyceride of Intralipid® 20 % stored in light protected 
50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge (Blue) results 
shown with standard deviation error bars on all points. 
 
 
Figure 3.10 HPLC-CAD results for peak 4 (C18:2/18:2/16:0) triglyceride of Intralipid® 20 % stored in light 
protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. 
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Figure 3.11 HPLC-CAD results for peak 5 (C18:2/18:1/18:0) triglyceride of Intralipid® 20 % stored in light 
protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. 
 
 
Figure 3.12  HPLC-CAD results for peak 6 (C18:2/18:1/16:0) triglyceride of Intralipid® 20 % stored in light 
protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. 
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Figure 3.13  HPLC-UV data showing the production of 4-Hydroxynonenal in Intralipid® 20 % over 84-day storage 
and both room (red) and fridge (blue) temperatures in 50 ml syringes. 
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Figure 3.14  HPLC-CAD chromatograms of Intralipid® 20% stored in 50 ml syringes. Day 0 control (black), day 84 fridge temperature (blue trace) and day 84 room temperature (red trace). The 
y-axis of each chromatogram gives an indication of peak height and the corresponding drop in peak area seen in the 84 day chromatograms. Overlaid chromatogram shows changes in peaks 
in comparison to control. 
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Figure 3.15  HPLC-UV chromatograms of Intralipid® 20% stored in 50 ml syringes. Day 0 chromatogram (black trace), day 84 fridge temperature syringes (blue trace) and day 84 room 
temperature syringes (red trace). The production of HNE in both fridge and room temperature syringes can be seen and is indicated on the chromatogram. 
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Figure 3.16 Overlaid HPLC-UV chromatograms of day 0 (black trace) and day 84 room temperature (red trace) Intralipid® 20 % stored in 50 ml syringes. Peaks on the 84 day chromatogram 
highlighted in red show unknown degradation products A and B discussed in section 3.8. 
A 
B 
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3.6 Intralipid® light protected PN bag results 
 
As per testing protocol 250 ml Baxa EVA multi-layer PN bags were filled with 50 ml 
Intralipid® 20 %, light protected with aluminium foil and stored at room and fridge 
temperature. At each point of testing 1 ml of lipid was removed and tested. All 
possible air was removed from each PN bag at all testing points. A control sample in 
its original packaging was tested at each time point to ensure method precision. All 
results were performed in triplicate and standard deviations and relative standard 
deviations calculated for each point. Raw data is shown in appendix 2 and the 
following figures 3.17 to 3.22 show the data for all six TAGs monitored as a % loss 
from their day 0 amount.  
PN bags which are impermeable to oxygen produced a maximal % TAG loss of 
around 30 % at room temperature at the end of 84 days of storage. Temperature of 
storage had less of an effect on TAG loss. All peaks showed a significant loss of 
triglycerides throughout storage and this is further discussed in section 3.8.  
HNE was not produced in quantifiable concentrations during storage in light 
protected PN bags. The limit of quantification (LOQ) as discussed in chapter 2 
(section 2.12.2.4) was 8.974 µM which would give a peak area of 3.267 (calculated 
from the linear regression equation used for HNE calibration in Intralipid®). The 
largest area integrated in the HPLC-UV PN bag chromatograms was 1.670, thus 
making the level of HNE present un-quantifiable. However, the identification of 
another degradation/peroxidation product as highlighted in figure 3.25 is of interest. 
This product has the same elution time as peak B produced during the storage of 
Intralipid in 50 ml syringes at room temperature (figure 3.16) and further 
identification was undertaken as discussed in section 3.8. 
Figures 3.23 and 3.24 show the CAD and UV chromatograms of fridge and room 
temperature storage of Intralipid® at day 0 as a control and at day 84. The loss of 
TAGs can be visualised by the change in y-axis scale giving an indication of the 
change in peak size occurring.  
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Figure 3.17 HPLC-CAD results for peak 1 (C18:2/18:2/18:2) triglyceride of 50 ml Intralipid® 20 % stored in 250ml 
light protected PN bags. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. 
 
 
Figure 3.18 HPLC-CAD results for peak 2 (C18:2/18:2/18:1) triglyceride of 50ml Intralipid® 20 % stored in light 
protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. 
0
5
10
15
20
25
30
35
40
0 10 20 30 40 50 60 70 80 90
%
 lo
ss
Day of testing
Peak 1 (C18:2/18:2/18:2) % loss
Intralipid® Room temperature % loss Intralipid® Fridge temperature % loss
0
5
10
15
20
25
30
35
40
0 10 20 30 40 50 60 70 80 90
%
 lo
ss
Day of testing
Peak 2 (C18:2/18:2/18:1) % loss
Intralipid® Room temperature % loss Intralipid® Fridge temperature % loss
144 
 
 
Figure 3.19  HPLC-CAD results for peak 3 (C18:2/18:1/18:1) triglyceride of 50 ml Intralipid® 20 % stored in light 
protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. 
 
 
 
Figure 3.20 HPLC-CAD results for peak 4 (C18:2/18:2/16:0) triglyceride of 50 ml Intralipid® 20 % stored in light 
protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. 
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Figure 3.21 HPLC-CAD results for peak 5 (C18:2/18:1/18:0) triglyceride of 50 ml Intralipid® 20 % stored in light 
protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. 
 
 
 
Figure 3.22  HPLC-CAD results for peak 6 (C18:2/18:1/16:0) triglyceride of 50 ml Intralipid® 20 % stored in light 
protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. 
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Figure 3.23  HPLC-CAD chromatograms of 50 ml Intralipid® 20% stored in 250 ml PN bags. Day 0 control (black), day 84 room temperature chromatogram (red trace) and day 84 fridge 
temperature (blue trace). The y-axis of each chromatogram gives an indication of peak height and the corresponding drop in peak area seen in the 84 day chromatograms. Overlaid 
chromatogram shows changes in peaks in comparison to control. 
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Figure 3.24  HPLC-UV chromatograms of 50 ml Intralipid® 20% stored in 250 ml PN bags. Day 0 chromatogram (black trace), day 84 fridge temperature bags (blue trace) and day 84 room 
temperature syringes (red trace). The production of HNE in both fridge and room temperature syringes can be seen and is indicated on the chromatogram but was below the limit of 
quantification. 
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Figure 3.25 Overlaid HPLC-UV chromatograms of day 0 (black trace) and day 84 room temperature (red trace) Intralipid® 20 % stored in 250 ml PN bags. Peak on the 84 day chromatogram 
highlighted in red show unknown degradation product B discussed in section 3.8. 
  
B 
149 
 
3.7 Intralipid® light protected vials results 
 
As per protocol glass vials were filled with 50 ml Intralipid® and sealed with metal 
crimps. Oxygen was removed from the lipid and headspace using nitrogen as 
described in section 3.2.3. At each testing point 1 ml of lipid was removed from the 
vial and placed into autosampler vials for testing.  
Each of the graphs in figures 3.26 to 3.31 Show the TAG loss that occurred for each 
selected peak/triglyceride. The maximum peak loss observed was for vials stored at 
room temperature were peak 3 triglyceride which lost 22.58% over 84 days storage. 
Fridge storage in vials was much more successful in preventing TAG loss from 
occurring with a maximum of less than 10 % loss occurring with all monitored 
triglycerides.  
The incidence of TAG loss itself however, within an oxygen free environment, is of 
considerable interest. As no new peaks were produced during storage that were 
visualised at 222 nm UV or through CAD detection, peroxidation that was oxygen or 
temperature dependant would seem unlikely. This would potentially indicate either a 
different mechanism of TAG loss occurring or that the secondary peroxidation 
products produced were not able to be visualised at the 222 nm wavelength or 
through the CAD. Whilst the UV detector used could not wavelength scan during a 
method, a specific wavelength of 222 nm had to be used as the primary aim was to 
identify HNE occurring. If postulating that peroxidation was still occurring due to the 
TAG losses seen, oxygen ingress into the system must then be considered. Whilst 
every effort was taken to maintain an oxygen free environment throughout storage, 
samples at each testing point were taken via syringe and needle under oxygen. This 
potentially introduced a small amount of oxygen into each vial, initiating the 
peroxidation process and causing the TAG losses observed. To overcome this for 
the testing reported in glass vials in subsequent chapters a further step within the 
testing protocol was introduced. At each testing point, after 1 ml of lipid was 
removed, each glass vial was flushed with nitrogen again in the same process as 
described in the testing procedure (section 3.4) and thus maintaining an oxygen free 
environment throughout the testing process.  
No visible peroxidation products including HNE were produced through storage at 
either room or fridge temperatures as shown in figures 3.33 and 3.34.  
The lack of TAG loss occurring during the initial 7 days of testing would indicate a 
lack of peroxidation and a successful maintenance of an oxygen free environment. 
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When considering the fridge temperature results for all TAGs, day 28 testing results 
produced a data set that was 10 to 15 % over what was expected in relation to day 
7, 14, 56 and 84 result trends. Therefore, this day’s data set was identified as an 
outlier and excluded from further analysis. The cause of the anomalous result was 
unknown but could have been due to a change in lab temperature, mobile phase 
contamination or column contamination though contamination is unlikely due to the 
control sample for the day 28 results and the room temperature results being within 
RSD limitations and following the trend of all other results. Mobile phases were 
changed, and the column cleaned for further reassurance. Lab temperature 
fluctuations were limited as much as possible and all further analysis fell within 
expected ranges.  
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Figure 3.26  HPLC-CAD results for peak 1 (C18:2/18:2/18:2) triglyceride of Intralipid® 20 % stored in 50ml light 
protected glass vials. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge (Blue) 
results shown with standard deviation error bars on all points. Outlier identified in fridge temperature results 
and indicated on graph. 
 
 
Figure 3.27  HPLC-CAD results for peak 2 (C18:2/18:2/18:1) triglyceride of Intralipid® 20 % stored in light 
protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Outlier of day 28 fridge temperature result 
shown on graph but excluded from analysis. 
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Figure 3.28  HPLC-CAD results for peak 3 (C18:2/18:1/18:1) triglyceride of Intralipid® 20 % stored in light 
protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Outlier of day 28 fridge temperature result 
shown on graph but excluded from analysis. 
 
 
Figure 3.29  HPLC-CAD results for peak 4 (C18:2/18:2/16:0) triglyceride of Intralipid® 20 % stored in light 
protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Outlier of day 28 fridge temperature result 
shown on graph but excluded from analysis. 
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Figure 3.30  HPLC-CAD results for peak 5 (C18:2/18:1/18:0) triglyceride of Intralipid® 20 % stored in light 
protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Outlier of day 28 fridge temperature result 
shown on graph but excluded from analysis. 
 
 
Figure 3.31 HPLC-CAD results for peak 6 (C18:2/18:1/16:0) triglyceride of Intralipid® 20 % stored in light 
protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Outlier of day 28 fridge temperature result 
shown on graph but excluded from analysis. 
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Figure 3.32 HPLC-CAD chromatograms of Intralipid® 20% stored in 50 ml glass vials. Day 0 control (black), day 84 room temperature chromatogram (red trace) and day 84 fridge temperature 
(blue trace). The y-axis of each chromatogram gives an indication of peak height and the corresponding drop in peak area seen in the 84 day chromatograms. Overlaid chromatogram shows 
changes in peaks in comparison to control.  
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Figure 3.33 HPLC-UV chromatograms of Intralipid® 20% stored in 50 ml glass vials. Day 0 chromatogram (black trace), day 84 room temperature syringes (red trace) and day 84 fridge 
temperature syringes (blue trace). The lack of production of new peaks indicates a lack of degradation products. 
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Figure 3.34 Overlaid HPLC-UV chromatograms. Day 0 (back trace) and day 84 room temperature (red trace) Intralipid® stored in 50 ml glass vials. The presence of no new peaks indicates a lack 
of degradation/peroxidation products seen at this specific wavelength (222 nm). 
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3.8 Discussion of Intralipid® light-protected results 
 
3.8.1 Triglyceride loss 
 
Triglyceride losses occurred in all containers tested under light protected conditions. 
The level of loss occurring however was different in each container and temperature 
dependant. All % loss differences between containers and temperatures at 84 days 
were statistically significant (P<0.05) tested by ANOVA analysis using SPSS (IBM 
version 25) and summarised in table 3.1(see appendix 3 for data) and checked with 
Excel. As shown in figure 3.35 at 84 days testing room temperature syringes 
produced the maximum level of triglyceride loss for all monitored triglycerides 
except peak 5 (C18:2/18:1/18:0) where room temperature PN bags produced a 
maximal level of loss. When considering peroxidation, any TAG with a double bond 
is susceptible to peroxidation and breakdown, which is substantiated by the results 
seen, as double bond fatty acids are present in all TAGs monitored within 
Intralipid®. The higher number of double bonds present the greater the predicted 
extent of peroxidation and breakdown and as such peak 1 (C18:2/18:2/18:2) would 
be predicted to undergo the greatest amount of peroxidation. In contradiction to this 
however, the result with the greatest level of TAG loss was peak 2 
(C18:2/18:2/18:1) in room temperature syringes yielding a maximal loss of over 35 
%. The level of triglyceride loss observed in peak 1 was however the most constant 
between syringes and PN bags and independent of temperature at which each 
container was held. This suggests that TAG 1 as predicted was the most likely to 
peroxidise regardless of temperature of storage.  
Whilst syringes are permeable and PN bags are impermeable to oxygen, both 
showed significant peroxidation and TAG loss. In comparison to this, glass vials 
filled under nitrogen showed significantly less peroxidation and as stated above 
(section 3.7) the peroxidation that did occur was postulated to be due to these vials 
being testing under oxygen and as such a small level of oxygen ingress to the 
system, initiating peroxidation and the loss observed. The results indicate the 
necessity of oxygen for initiation of TAG loss, supporting the hypothesis that TAG 
losses seen are due to peroxidation of the lipids as oxygen is the limiting factor in 
peroxidation initiation (see intro section 1.5). The amount of oxygen needed to 
produce the significant levels of TAG losses seen is however minimal, as indicated 
by the PN bags and syringe results. PN bags when formulated under atmospheric 
conditions have the maximum amount of air possible removed at the end of the 
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production process, however a small amount (visibly less than the area of a 50 
pence piece) is deemed acceptable in current clinical manufacturing. The results 
obtained indicate that this small level of oxygen and the potential for dissolved 
oxygen to be present within the lipid are enough to initiate peroxidation of the TAGs 
monitored and produce a level of loss similar to syringes.  
When considering the effect of temperature on the level of peroxidation and TAG 
loss occurring, at day 84 after substantial storage time temperature had little effect 
on the level of TAG loss and peroxidation in PN bags. There was a statistically 
significant difference (P<0.05 ANOVA with post hoc Tukey HSD analysis) in the 
level of peroxidation within peak 1 (C18:2/18:2/18:2) TAG in vials stored at room 
and fridge temperatures at day 84 however syringe and bag data were not proven to 
be statistically significant between different temperatures. Table 3.1 summaries the 
significant results observed at day 84 between all container types at both 
temperatures. This would indicate that over a prolonged storage time temperature is 
less of a governing factor on the amount of peroxidation occurring. It is known 
however that temperature effects the rate of peroxidation occurring (Seppanen and 
Saari Csallany 2002; Yuan et al. 2018), with higher temperatures acting as a 
catalyst for peroxidation. To investigate this, results of the initial 7 days of testing 
were plotted as shown in figure 3.36. Syringe data showed that temperature had a 
significant effect within the first 7 days of testing with triglyceride loss being higher at 
room temperatures vs fridge temperatures. This follows the predicted pattern that 
fridge temperatures delay/reduce the rate at which peroxidation occurs. PN bag 
results show little differences between fridge and room temperatures for all 
triglycerides within the first seven days. This would indicate that the potential 
differences within syringe peroxidation are due to temperature affecting the physical 
characteristics of syringes and therefore the level of oxygen ingress occurring. As 
PN bags are impermeable to oxygen, the presence of any oxygen at the end of 
manufacturing will initiate peroxidation and results indicate that temperature of 
storage has little effect on the rate of this occurring. With regards to the glass vial 
results at 7 days, levels of triglyceride loss at fridge temperature far exceed that at 
room temperature. Whilst this result is the opposite of what was predicted in respect 
to temperature, as discussed in section 3.7 this could have been due to oxygen 
ingress due to sampling under atmospheric conditions. As such, the effect of 
temperature on glass vials will be compared further in subsequent chapters where 
oxygen was removed after each testing point. 
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Figure 3.35 Triglyceride loss at 84 days storage for Intralipid® stored in syringes, PN bags and glass vials. 
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Table 3.1 Light protected Intralipid in all containers at all temperatures for each of the six peaks monitored. * indicates significant differences between results as calculated through ANOVA 
analysis with post hock Tukey analysis between each container type. (significant defined as P<0.05). 
 
 
 
 
Peak 1 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 4 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe * * Room Syringe * * *
Room Bag * * Room Bag * *
Room Vial * * * * Room Vial * *
Fridge Syringe * * Fridge Syringe * *
Fridge Bag * Fridge Bag *
Fridge Vial * * * * * Fridge Vial * * * *
Peak 2 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 5 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe * * Room Syringe *
Room Bag * Room Bag * *
Room Vial * * Room Vial * *
Fridge Syringe * * Fridge Syringe *
Fridge Bag * Fridge Bag *
Fridge Vial * * * * Fridge Vial * * * * *
Peak 3 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 6 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe * Room Syringe * *
Room Bag * Room Bag * *
Room Vial Room Vial * * *
Fridge Syringe Fridge Syringe *
Fridge Bag * Fridge Bag * *
Fridge Vial * * * Fridge Vial * * * *
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Figure 3.36 Triglyceride loss after 7 days of storage of Intralipid® in syringes, PN bags and glass vials. 
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3.8.2 HNE production 
 
HNE production was observed within syringes stored at both fridge and room 
temperatures and minimally in room temperature PN bags. Room temperature 
syringes created a maximum of 10.209 µM HNE whilst fridge temperature storage 
yielded 8.38 µM HNE however this result was under the LOQ for the method. Both 
fridge PN bags and all glass vials showed no detectable HNE creation despite a 
level of TAG loss in PN bags similar to that within syringes. This result is interesting 
as it is apparent that peroxidation is still occurring within PN bags due to the TAG 
losses seen and the production of other peroxidation products (discussed in section 
3.8.3). It can be postulated that potentially the products being created through the 
peroxidation process are either different within PN bags to syringes, or the rate of 
terminal peroxidation is different, i.e. less of the secondary product HNE is being 
made and greater amounts of primary peroxidation products are present. The 
presence of water within the emulsion could also permit hydrolysis reactions to 
occur, cleaving fatty acids from the glycerol backbone and causing TAG losses to 
be observed. Whilst the method was developed to specifically look for HNE present 
within samples, other peroxidation products were seen within the UV chromatogram 
and identified as discussed in 3.8.3. The method is limited however to UV detection 
at 222 nm wavelength and therefore other peroxidation products that would be 
detected with different wavelengths may be present within samples but 
undetectable due to the fixed wavelength of the equipment used.  
The amount of HNE present within syringes is however of clinical significance, 
particularly with regards to the delivery of lipids to neonatal patients. As discussed in 
section 1.7 HNE at a concentration of less than 1 µM is shown to be genotoxic to 
cells (Esterbauer 1993). Delivery of lipids to paediatric patients is currently given 
through storage in 50 ml syringes and as such the production of HNE in both room 
and fridge temperatures is important. With respect to HNE alone, the move of lipids 
from syringes to PN bags for light protected Intralipid® would be beneficial to 
eliminate HNE production.  
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3.8.3 Degradation products ‘A’ and ‘B’ 
 
The production of further degradation products as shown in figures 3.16 and 3.25 
(UV chromatograms of PN bags and syringes at room temperature above in results 
section) labelled A and B are of interest and whilst the assay is not validated enable 
a concentration of these products to be calculated, their presence is important and 
as such investigated further. As discussed above, the UV chromatograms produced 
were from a wavelength of 222 nm as the detector used was at a fixed wavelength 
only. Both Intralipid® in room temperature syringes and PN bags formed a new peak 
through the course of testing labelled peak ‘B’ on chromatograms. Syringes stored 
at room temperature produced a further peak ‘A’ product.  
Peak ‘A’ elutes early in the chromatogram of syringes at room temperature, near the 
HNE peak and therefore it was predicted that this peak was a secondary aldehydic 
product of peroxidation similar to HNE. Peak B elutes later in the chromatogram and 
was predicted to be the triglyceride ‘remnant’ i.e. the shorter TAG left after cleavage 
of secondary peroxidation products from the fatty acids present. To confirm these 
predictions eluate from the HPLC was collected at each of the time peaks 
corresponding to peaks A and B from multiple runs of the day 84 room temperature 
syringes and peak B from the day 84 room temperature PN bags. These fragments 
were then subjected to mass spectrometry analysis as per section 2.11.2. Peak B 
was detected in positive mode as per method, whilst peak ‘A’ was only detectable in 
negative mode, however all other parameters remained as defined in section 2.11.2. 
Figures 3.37 and 3.38 show the mass spectrum obtained for each peak. Table 3.2 
Summarises the results from each peak.  
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Figure 3.37 Mass spectrum for Peak ‘A’ in room temperature Intralipid® light protected syringes at day 84. 
 
Figure 3.38 Mass spectrum for peak ‘B’ in Intralipid® light protected syringes. PN bags peak ‘B’ gave the same 
m/z data. 
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Table 3.2 Mass spectrometry results for peak A and B in Intralipid® syringes and PN bags at room temperature. 
Peak 
reference 
Storage 
container 
Storage 
Temperature 
Average 
m/z data 
(n=3) 
A Syringe Room 366.34 (-ve 
mode)  
B Syringe Room 496.40 
(+ve mode) 
B PN bag Room 496.34 
(+ve mode) 
 
3.8.3.1 Peak A 
 
Mass spectrometry data showed peak A to have a m/z ratio of 366.34 in negative 
mode. With respect to its elution position in the chromatogram of Intralipid® syringes 
at room temperature, peak A elutes close to HNE. Whilst HNE was selected as the 
secondary peroxidation product to be monitored due to its known toxicity, it was 
predicted that many other primary and secondary peroxidation products would also 
be produced. The presence of multiple fatty acids with multiple levels of 
unsaturation within Intralipid® chemically predicts the production of several 
secondary products of differing carbon chain length. Table 3.2 Shows the calculated 
theoretical m/z for secondary aldehydic products of increasing chain length. The 
table includes only products that can be formed form linoleic, linolenic or oleic acids 
as these are the only fatty acids present within the TAGs in Intralipid® that are liable 
to peroxidation.  
As shown in table 3.3 the mass spectrometry data for peak A in room temperature 
syringes gave an average m/z of 366.30 which matches the theoretical data for 4-
hydroxyundec-2-enal (HUE). HUE is a secondary aldehyde formed from the 
peroxidation of oleic acid (Loidl-Stahlhofen et al. 1995). Whilst little studied in 
comparison to HNE, HUE confers a level of toxicity greater than that of the smaller 
C6 aldehyde Hydroxyhexenal (HHE) formed from linolenic acid (18:3) when 
considering DNA damage (Eckl et al. 1993) and therefore is of clinical significance. 
Whilst the concentration of HUE produced in the 84 days syringes cannot be 
quantified by the assay, the peak area observed approximately 3 times greater than 
the quantified peak of HNE (figure 3.16), indicating that the HUE present is at a 
concentration higher than that of HNE, however each of these aldehydes will have a 
different absorption level at 222 nm and therefore the concentration of HUE cannot 
accurately be gauged from comparison with HNE alone.  
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Looking into the rate of production of peak A/HUE within Intralipid® room 
temperature syringes, peak area was monitored through the 84 days of testing. 
Figure 3.39 represents the formation of this peak within room temperature syringes. 
The data shows a relatively steady rate of HUE (peak A) production across the 84-
day testing period indicating a steady rate of oleic acid peroxidation occurring. Of 
the triglycerides identified and monitored peaks 2,3,5 and 6 contain at least one 
oleic acid within its corresponding triglyceride and all show a substantial loss over 
storage, theoretically allowing a production of HUE to occur through peroxidation.  
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Table 3.3 Potential secondary peroxidation products from linoleic (18:2), linolenic (18:3) and oleic acids (18:1). 
Name Carbon 
number 
Structure Mass spectrometry predicted data 
m/z [M-H]- [2M-H]- 
4-hydroxyhex-2-enal 
(HHE) 
C6 
 
114.07 113.07 227.14 
4-hydroxynon-2-enal 
(HNE) 
C9 
 
156.12 155.12 311.24 
4-hydroxydec-2-enal 
(HDE) 
C10 
 
170.13 169.13 339.26 
4-hydroxyundec-2-enal 
(HUE) 
C11 
 
185.15 184.15 366.30 
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Figure 3.39 Formation of HUE (Peak A) in 50 ml Intralipid® syringes at room (red) and fridge (blue) temperatures.   
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3.8.3.2 Peak B 
 
As shown in table 3.2 and figure 3.38 the mass spectrometry data from peak B in 
both room temperature syringes and PN bags show the production of a peak with a 
m/z of 496.35. The prediction for this peak was that it could potentially be the 
remains of a triglyceride after the fatty acids within the TAG had peroxidised and 
cleaved, leaving a smaller chained TAG ‘remnant’. When considering the peaks 
monitored, peak 3, (C18:1/18:1/18:2) contains two oleic acid fatty acids and one 
linoleic acid. At the end of 84 days of storage in syringes this TAG lost over 30 % at 
room temperature and over 20 % at fridge temperature. Chemically, the 
peroxidation of this TAG as shown schematically in figure 3.40 could theoretically 
peroxidise to form 2 molecules of HUE and 1 molecule of HNE per TAG. This 
peroxidation pathway would leave the TAG ‘remnant’ as shown in figure 3.40 which 
has a molecular weight of 495.35 and a predicted [M+H]+ of 496. This matches the 
results seen from peak B and as such confirms the likelihood that B is a remnant of 
Peak 3 triglyceride and its peroxidation. 
The rate of TAG remnant production, whilst not quantifiable through the assay, was 
plotted as shown in figure 3.41 for room temperature syringes and room 
temperature bags. Both show a production of this TAG remnant, suggesting 
peroxidation of peak 3, however room temperature bags did not show an apparent 
production of HUE. This suggests therefore, that peak B may not only be attributed 
to a TAG remnant from peak 3 but potentially from more than one compound with 
the same m/z, caused through the peroxidation and cleavage of other fatty acids 
present within the numerous TAGs present. For the purposes of this work, further 
identification was not achieved due to the limited fractionation capacity of the mass 
spectrometry and that the main aims of the project were to monitor the TAG loss 
and HNE production as validated in the method, within PN lipids. The clinical 
relevance of the peak B is important as it indicates peroxidation and TAG 
breakdown is occurring in the Intralipid® bag and syringe samples tested at room 
temperature.  
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Figure 3.40 Predicted chemical schematic of the production of HUE and HNE and Tag remnant from Peak 3 TAG 
in Intralipid® 
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Figure 3.41 HPLC-UV results of TAG remnant/peak B formation in Intralipid® room temperature syringes and bags. 
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Intralipid® Non-light Protected 
Syringes, Bags and Vials
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4.1. Introduction to non-light protected testing 
 
Light induced lipid peroxidation or photo-oxidation as discussed in section 1.5.1 
(introduction section 1.5) provides a secondary pathway for the initiation of 
peroxidation within lipid emulsions. As discussed in chapter 3 in light protected 
testing, the level of oxygen present within the storage system is critical to the 
peroxidation process. This is equally true for non-light protected lipid emulsions as 
the propagation of the peroxidation process is oxygen dependant (Halliwell and 
Chirico 1993). 
4.1.1. Light radical formation 
 
The formation of a reactive oxygen species (ROS), commonly a peroxyl radical, due 
to light exposure provides the radical required for the initiation of peroxidation 
(Mühlebach and Steger 1998; Hardy and Puzovic 2009). Light exposure in the 
presence of oxygen can further lead to the creation of singlet oxygen (1O2). Whilst 
not a ‘true radical’, the formation of two negatively charged electrons within the 
same orbital creates an unstable species with high reactivity. Singlet oxygen is 
commonly formed in the presence of a photo-sensitizer such as riboflavin in the 
case of milk peroxidation, however evidence postulates that its production may 
result as a degradation product of lipid peroxides (Van Dyck 2010; Leray 2016). 
Therefore, this chapter looks at non-light protected Intralipid® in the same containers 
and conditions as outlined in testing protocol in section 3.4 minus the light protective 
foil. The work aimed to create a dataset that acts as a comparator to light protected 
data, giving an indication on whether photooxidation could occur and if the rate and 
extent of peroxidation seen differed from light protected containers.  
4.2. Light control 
 
To create a set of comparative data to that collected in chapter 3, the same testing 
protocol was carried out for non-light protected lipid syringes, ML bags and glass 
vials. Intralipid® samples were prepared as per section 3.4 and held at both fridge 
and room temperature. The variable factor tested was light exposure and therefore 
light exposure was controlled throughout storage. For fridge temperatures light 
exposure was limited due to the nature of the storage within a refrigerator, however 
containers were exposed to ambient light during testing and placed on separate 
fridge shelves to maximise available light exposure. The lack of a light control 
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mechanism for fridge storage temperatures was a factor that could not be altered 
within this testing however introduction of a light source within a refrigerator would 
enable light exposure to be further controlled.  
4.2.1. Stability chamber light and temperature control 
 
For room temperature, storage containers were placed in a stability chamber 
(Sanyo/Weiss Gallenkamp model PSC062). This enabled control over temperature, 
humidity and light exposure. Temperature was set at 22 oC throughout storage to 
match the average temperature of the room data in chapter 3. Humidity was 
controlled at 60 % throughout storage to match the testing protocols used for 
physical stability within the laboratory. The primary purpose of the stability chamber 
was to enable control over the type and extent of light exposure samples would be 
subject to. Cool white visible strip lights are used within the chamber to emit a light 
that falls within the ICH Q1B guidelines for pharma-light sources for stability testing 
(Harmonisation 1996). As per the chamber’s manual, light emission was validated 
and monitored using lux sensors to ensure uniformity of emitted light. Intensity of 
light was set to level 5/10 as per manual to mimic exposure to natural daylight (with 
UV exposure) (Weiss Gallenkamp 2006). Samples were placed on shelves within 
the stability chamber ensuring that equal distances between placement of samples 
was achieved.  
4.3. Testing schedule 
 
An identical testing protocol was followed as per section 3.4. To summarise, 50 ml 
of Intralipid® was placed in 50 ml syringes, 50 ml ML PN bags and 50 ml glass vials, 
the latter being purged with nitrogen after formulation. Six samples of each lipid in 
each container were produced, 3 held at room temperature as discussed above and 
3 at fridge temperature. All samples were tested in triplicate using the HPLC method 
set out in chapter 2 at days 0, 1, 2, 7, 14, 28, 56 and 84. The following results 
sections detail the data collected from all samples that were exposed to light 
throughout storage. The control sample used for each day of testing was a lipid in 
its original container that was light protected with foil to prevent possible 
peroxidation and ensure a control set of data.  
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4.4. Intralipid® non-light protected syringe results 
 
As discussed in section 3.5 all data was analysed using Chromeleon software 
(Thermo Scientific) with each six TAG peaks monitored through CAD detection as a 
% loss in peak area. HNE production is presented in figure 4.7 ± standard deviation, 
however as shown in the 84-day chromatograms in figure 4.11 HNE detection was 
minimal and below the validated limit of quantification.  All RSD’s were monitored for 
all peaks and controls throughout testing to ensure data was precise and 
reproducible. As shown in appendix 2 all RSD’s were <12 which were acceptable 
(as discussed in section 3.4).  
TAG loss exceeded 40 % for peaks 3 to 6 at both fridge and room temperatures as 
shown in figures 4.1 to 4.6. Raw data for all results is shown in appendix 2.  Peaks 1 
and 2 showed a maximal loss of 35 and 30 % respectively. As shown in figures 4.1 
and 4.2 temperature had a statistically significant effect on TAG loss for peaks 1 
(C18:2/18:2/18:2) and 2 (C18:2/18:2/18:1), but little effect on the level of TAG loss 
for all other peaks monitored. TAG results are discussed further in section 4.7. 
As postulated in section 3.8.3 two degradation products were visualised and 
identified in the light protected testing results. Peak ‘A’ being identified potentially 
was HUE and peak ‘B’ as a triglyceride remnant due to the peroxidation of peak 3. 
In the non-light protected results as shown in figures 4.8 and 4.9 both products are 
identified. HUE (peak ‘A’) was detected in both fridge and room temperatures. The 
triglyceride remnant (peak ‘B’) was produced and detected in room temperature 
Intralipid® syringes but undetectable in fridge storage. Both products are discussed 
further in section 4.7. 
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Figure 4.1 HPLC-CAD results for peak 1 (C18:2/18:2/18:2) triglyceride of Intralipid® 20 % stored in non-light 
protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points 
 
 
Figure 4.2 HPLC-CAD results for peak 2 (C18:2/18:2/18:1) triglyceride of Intralipid® 20 % stored in non-light 
protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. 
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Figure 4.3 HPLC-CAD results for peak 3 (C18:2/18:1/18:1) triglyceride of Intralipid® 20 % stored in non-light 
protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. 
 
 
Figure 4.4 HPLC-CAD results for peak 4 (C18:2/18:2/16:0) triglyceride of Intralipid® 20 % stored in non-light 
protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. 
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Figure 4.5 HPLC-CAD results for peak 5 (C18:2/18:1/18:0) triglyceride of Intralipid® 20 % stored in non-light 
protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. 
 
 
Figure 4.6 HPLC-CAD results for peak 6 (C18:2/18:1/16:0) triglyceride of Intralipid® 20 % stored in non-light 
protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points 
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Figure 4.7 HPLC-UV data showing the production of 4-Hydroxynonenal in Intralipid® 20 % over 84-day storage 
and both room (red) and fridge (blue) temperatures in 50 ml syringes. 
 
 
Figure 4.8 HPLC-UV data showing the formation of HUE (Peak A) in non-light protected 50 ml Intralipid® syringes 
at room (red) and fridge (blue) temperatures. 
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Figure 4.9 HPLC-UV data showing the production of the TAG remnant/peak B in non-light protected 50 ml 
Intralipid® syringes at room temperature. 
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Figure 4.10 HPLC-CAD chromatograms of Intralipid® 20% stored in non-light protected 50 ml syringes. Day 0 control (black), day 84 fridge temperature (blue trace) and day 84 room 
temperature (red trace). The y-axis of each chromatogram gives an indication of peak height and the corresponding drop in peak area seen in the 84 day chromatograms. Overlaid 
chromatogram shows changes in peaks in comparison to control. 
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Figure 4.11 HPLC-UV chromatograms of Intralipid® 20% stored in 50 ml syringes. Day 0 chromatogram (black trace), day 84 fridge temperature syringes (blue trace) and day 84 room 
temperature syringes (red trace). The production of HNE, HUE and the TAG remnant can be seen in room temperature syringes as indicated on the chromatogram. 
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Figure 4.12 Overlaid HPLC-UV chromatograms of day 0 (black trace) and day 84 room temperature (red trace) Intralipid® 20 % stored in non-light protected 50 ml syringes. Peaks on the 84 day 
chromatogram highlighted in red show HUE and the TAG remnant formation. 
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4.5.  Intralipid® non-light protected bag results 
 
As per testing protocol 250 ml Baxa EVA multi-layer PN bags were filled with 50 ml 
Intralipid® 20 % and stored at room and fridge temperature with exposure to light. 
Room temperature samples were held in the stability chamber as described in 
section 4.2.1 to control light exposure levels and temperature. At each point of 
testing 1 ml of lipid was removed and tested. All possible air was removed from 
each PN bag at all testing points. A control sample in its original packaging was 
tested at each time point to ensure method precision. All results were performed in 
triplicate and standard deviations and relative standard deviations calculated for 
each point. Raw data is shown in appendix 2 and the following figures 4.13 to 4.18 
show the data for all six TAGs monitored as a % loss from their day 0 amount. 
The data collected when analysed showed RSD’s of the day 84 control samples to 
be >12 which, as detailed in chapter 2 was considered an unacceptable level of 
variation for the CAD detector. Therefore, whilst the following figures show the 
plotted day 84 results, all day 84 results were marked as outliers and excluded from 
the analysis in section 4.7. The high RSD’s in the samples occurred across all day 
84 samples tested for the ML PN bags and was attributed to an increased ambient 
temperature within the testing laboratory (hottest day of the year). The HPLC 
system was cleaned using a standard organic protocol and testing of subsequent 
samples was carried out only when the ambient temperature within the laboratory 
had reduced. All RSD’s for the next set of samples run fell within acceptable levels.  
At day 56, all TAGs monitored showed a maximal loss of ~20 %. All TAGs other 
than peak 3 (C18:2/18:1/18:1) showed a significantly higher level of loss at room 
temperatures than at fridge temperatures.  
No quantifiable levels of HNE were observed throughout both fridge and room 
temperature storage. HUE as identified in section 3.8.3 was detected as shown in 
figure 4.19 in PN bags stored at room temperature. Fridge storage inhibited the 
production of HUE.  
The TAG remnant/ peak B as discussed in section 3.8.3 was identified in room 
temperature PN bags as shown in figure 4.20. Fridge storage inhibited its formation, 
suggesting that the peroxidation processes monitored were minimal in PN bags 
stored at fridge temperatures. Results are discussed further in context with all 
results within the chapter in section 4.7. 
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Figure 4.13 HPLC-CAD results for peak 1 (C18:2/18:2/18:2) triglyceride of 50 ml Intralipid® 20 % stored in 250ml 
non-light protected PN bags. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Orange points denotes day 84 results 
identified as anomalous. 
 
 
Figure 4.14 HPLC-CAD results for peak 2 (C18:2/18:2/18:1) triglyceride of 50ml Intralipid® 20 % stored in light 
protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Orange points denotes day 84 results 
identified as anomalous. 
0
5
10
15
20
25
30
35
40
45
0 10 20 30 40 50 60 70 80 90
%
 lo
ss
Day of testing
Peak 1 (C18:2/18:2/18:2) % loss
Intralipid® Room temperature % loss Intralipid® Fridge temperature % loss
0
10
20
30
40
50
60
70
0 10 20 30 40 50 60 70 80 90
%
 lo
ss
Day of testing
Peak 2 (C18:2/18:2/18:1) % loss
Intralipid® Room temperature % loss Intralipid® Fridge temperature % loss
186 
 
 
Figure 4.15 HPLC-CAD results for peak 3 (C18:2/18:1/18:1) triglyceride of 50 ml Intralipid® 20 % stored in light 
protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Orange points denotes day 84 results 
identified as anomalous. 
 
 
Figure 4.16 HPLC-CAD results for peak 4 (C18:2/18:2/16:0) triglyceride of 50 ml Intralipid® 20 % stored in light 
protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Orange points denotes day 84 results 
identified as anomalous. 
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Figure 4.17 HPLC-CAD results for peak 5 (C18:2/18:1/18:0) triglyceride of 50 ml Intralipid® 20 % stored in light 
protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Orange points denotes day 84 results 
identified as anomalous. 
 
 
Figure 4.18 HPLC-CAD results for peak 6 (C18:2/18:1/16:0) triglyceride of 50 ml Intralipid® 20 % stored in light 
protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Orange points denotes day 84 results 
identified as anomalous. 
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Figure 4.19 HPLC-UV results for 250ml ML PN bags exposed to light. Red indicates formation of HUE in Room 
temperature bags, blue indicates lack of HUE in fridge temperature bags over 84 days. 
 
 
Figure 4.20 HPLC-UV result showing the production in peak area of the TAG remnant/peak B in PN bags at room 
temperature.
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Figure 4.21 HPLC-CAD chromatograms of 50 ml Intralipid® 20% stored in 250 ml PN bags. Day 0 control (black), day 84 fridge temperature chromatogram (blue trace) and day 84 room 
temperature (red trace). The y-axis of each chromatogram gives an indication of peak height and the corresponding drop in peak area seen in the 84 day chromatograms. Overlaid 
chromatogram shows changes in peaks in comparison to control. 
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Figure 4.22 HPLC-UV chromatograms of 50 ml Intralipid® 20% stored in 250 ml light exposed PN bags. Day 0 chromatogram (black trace), day 84 fridge temperature bags (blue trace) and day 
84 room temperature syringes (red trace). The production of HUE and the TAG remnant in room temperature bags can be seen and is indicated on the chromatogram. 
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Figure 4.23 Overlaid HPLC-UV chromatograms of day 0 (black trace) and day 84 room temperature (red trace) Intralipid® 20 % stored in 250 ml light exposed PN bags. Peaks on the 84 day 
chromatogram highlighted in red show HUE and TAG remnant production. 
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4.6. Intralipid® non-light protected vial results 
 
As per protocol, glass vials were filled with 50 ml Intralipid® and sealed with metal 
crimps. Oxygen was removed from the lipid and headspace using nitrogen as 
described in section 3.2.3. At each testing point 1 ml of lipid was removed from the 
vial and placed into autosampler vials for testing. All vials were left exposed to light 
with room temperature samples placed in a stability chamber to control light 
intensity and temperature.  
All peaks/TAGs monitored showed minimal (less than 15 %) loss over 84-day 
storage at both temperatures except peak 2 (TAG C18:2/18:2/18:1) which showed 
~40% loss at day 84 in both fridge and room temperatures. The RSD’s of the control 
sample used each day fell above acceptable levels for all peaks at day 84 of testing 
which was attributed to high laboratory temperatures on day 84. When considering 
up to day 56 results, all peaks/TAGs showed a less than 15% loss. TAG loss was 
inhibited in all samples until day 28. Figures 4.24 to 4.29 show the HPLC-CAD 
results for each peak expressed as a % loss of peak area from day 0. All raw data is 
recorded in appendix 2.   
No HNE, HUE or TAG remnant was recorded in any of the samples across the 84- 
day testing period (figures 4.30 to 4.32). This indicates a lack of peroxidation 
occurring within all samples. The lack of TAG loss until day 56 in all samples 
indicates that the method of oxygen replacement with nitrogen at all testing points 
was successful until this point in preventing identifiable peroxidation from occurring. 
The increase in TAG loss at day 84 could be due to an ingress of oxygen into the 
system and the initiation of peroxidation occurring after day 56, however the 
increased values and RSD’s of the control samples at day 84 correspond to the 
increased % loss seen in all samples. This indicates that the day 84 results may not 
be precise and as such are excluded from further analysis. The high laboratory 
temperatures on day 84 testing could have contributed to the increased RSD’s and 
TAG loss rather than oxygen ingress.  
The lack of identifiable peroxidation products within Intralipid® vials exposed to light 
suggests that effective removal of oxygen inhibits the initiation of peroxidation. This 
indicates that the peroxidation processes occurring within Intralipid® samples are 
oxygen dependant as shown in chapter 1 (section 1.5). Results are further 
discussed in comparison with PN bags and syringes in section 4.7.  
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Figure 4.24 HPLC-CAD results for peak 1 (C18:2/18:2/18:2) triglyceride of Intralipid® 20 % stored in 50ml non-
light protected glass vials. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Day 84 results highlighted in orange and 
excluded from further analysis due to high RSD’s. 
 
 
Figure 4.25 HPLC-CAD results for peak 2 (C18:2/18:2/18:1) triglyceride of Intralipid® 20 % stored in non-light 
protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Day 84 results highlighted in orange and 
excluded from further analysis due to high RSD’s. 
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Figure 4.26 HPLC-CAD results for peak 3 (C18:2/18:1/18:1) triglyceride of Intralipid® 20 % stored in non-light 
protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Day 84 results highlighted in orange and 
excluded from further analysis due to high RSD’s. 
 
Figure 4.27 HPLC-CAD results for peak 4 (C18:2/18:2/16:0) triglyceride of Intralipid® 20 % stored in non-light 
protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Day 84 results highlighted in orange and 
excluded from further analysis due to high RSD’s. 
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Figure 4.28 HPLC-CAD results for peak 5 (C18:2/18:1/18:0) triglyceride of Intralipid® 20 % stored in non-light 
protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Day 84 results highlighted in orange and 
excluded from further analysis due to high RSD’s. 
 
 
Figure 4.29 HPLC-CAD results for peak 6 (C18:2/18:1/16:0) triglyceride of Intralipid® 20 % stored in non-light 
protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room (Red) and Fridge 
(Blue) results shown with standard deviation error bars on all points. Day 84 results highlighted in orange and 
excluded from further analysis due to high RSD’s. 
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Figure 4.30 HPLC-CAD chromatograms of Intralipid® 20% stored in 50 ml glass vials. Day 0 control (black), day 84 fridge temperature chromatogram (blue trace) and day 84 room temperature 
(red trace). Overlaid chromatogram shows changes in peaks in comparison to control. 
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Figure 4.31 HPLC-UV chromatograms of Intralipid® 20% stored in 50 ml glass vials. Day 0 chromatogram (black trace), day 84 fridge temperature syringes (blue trace) and day 84 room 
temperature syringes (red trace). The lack of production of new peaks indicates a lack of degradation products. 
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Figure 4.32 Overlaid HPLC-UV chromatograms. Day 0 (back trace) and day 84 room temperature (red trace) Intralipid® stored in 50 ml glass vials. The presence of no new peaks indicates a lack 
of degradation/peroxidation products seen at this specific wavelength (222 nm). 
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4.7.  Discussion of Intralipid® non-light protected results.  
 
4.7.1. Triglyceride loss 
 
Both syringes and PN bags under all temperatures showed significant TAG losses. 
Table 4.1 indicates the statistically significant results between different container 
types at different temperatures as tested by ANOVA analysis using SPSS (appendix 
3). Syringe results were analysed up to 84 days, however both PN bag and glass 
vial results were only analysed up to 56 days due to increased RSD’s of the control 
sample tested on day 84. Therefore, when considering all container types 
collectively, only the results up to and including day 56 are analysed. 
Figure 4.34 shows the % loss of each monitored TAG after 56 days of storage. All 
results gave a maximal loss of under 30 %. When considering the level of 
peroxidation occurring in each TAG monitored, a higher level of unsaturation should 
be predictive of an increased level of peroxidation. However, for the non-light 
protected results at day 56, the highest level of TAG loss observed was for peak 4 
(C18:2/18:2/16:0) in syringes at room temperature. If analysed collectively across all 
containers Peak 3 (C18:2/18:1/18:1) as shown in figure 4.34 creates the most 
consistent % loss of around 20 %. Both peaks contain multiple levels of 
unsaturation.  
With regards to the initiation of peroxidation, the higher the level of unsaturation 
present, the greater the likelihood of a lipid free radical being created. The presence 
of multiple double bonds within a fatty acid enables the stabilisation of a free radical 
via electron delocalisation through the double bonds, increasing the probability of 
extraction of a hydrogen by a ROS or photo-oxidation and the initiation of 
peroxidation. Peroxidation is therefore initiated easier in polyunsaturated than 
mono-saturated fatty acids (Porter et al. 1995). It can be predicted because of this 
that the TAGs monitored with higher levels unsaturated fatty acids should have an 
increased rate of peroxidation.  
Figure 4.33 shows the results of all containers at 7 days of storage. The highest 
levels of % loss occur in Peak 3 (C18:1/18:1/18:2) and 4 (C18:2/18:2/16:0) in PN 
bags at both temperatures. Both TAGs contain multiple linoleic acids which would 
be predicted to peroxidise first due to its higher level of unsaturation.  Following 
Portor et al’s (1995) finding of lower bond dissociation energy requirements for the 
initiation of peroxidation within linoleic acid vs, oleic acid, it could be predicted that 
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peak 1 (C18:2/18:2/18:2) should have the highest rate of peroxidation. However as 
shown in figure 4.33 peaks 3 and 4 have higher initial rate of peroxidation observed 
by % loss at 7 days. It is of note that when considering the oxidation of fatty acids 
within emulsions as opposed to pure oils, work by Khanum, R and Thevanayagam, 
H (Khanum and Thevanayagam 2017) suggests that the presence of oleic acid 
within an emulsion increases the amount of lipid hydroperoxides (transient primary 
peroxidation products) produced by over 5 % vs polyunsaturated emulsions alone. 
The rate of peroxidation within the emulsion was unaffected suggesting that fatty 
acid composition of TAGs within an emulsion was a minor influence on the rate of 
peroxidation and other factors such as temperature were predicted to be rate 
limiting. When considering the total level of peroxidation as indicated by % TAG loss 
across all containers at 56 days, peak 3 shows the highest average % loss. Peak 3 
(C18:2/18:1/18:1) contains linoleic acid, predicted to peroxidise first due to its 
multiple double bonds, and oleic acid, a mono-saturate which requires more energy 
to extract a hydrogen and form a lipid radical. If we consider Khanum and 
Thevanayaham’s (Khanum and Thevanayagam 2017) work and extrapolate it as a 
predictor to the level of peroxidation occurrence in Intralipid®, peak 3 
(C18:2/18:1/18:1) would be indicated to peroxidise to the highest degree as shown 
in figures 4.33 and 4.34.  
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Figure 4.33 Triglyceride loss after 7 days of storage of Intralipid® in syringes, PN bags and glass vials 
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Figure 4.34 Triglyceride loss at 56 days storage for Intralipid® stored in syringes, PN bags and glass vials. 
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Table 4.1 Non-light protected Intralipid® in all containers at all temperatures for each of the six peaks monitored. * indicates significant differences between results as calculated through 
ANOVA analysis with post hock Tukey analysis between each container type. (significant defined as P<0.05). 
 
  
Peak 1 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 4 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe * * Room Syringe * *
Room Bag * * * Room Bag * * * *
Room Vial * * Room Vial * *
Fridge Syringe * * * Fridge Syringe * *
Fridge Bag * * Fridge Bag * *
Fridge Vial * * * * Fridge Vial * * * *
Peak 2 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 5 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe * * Room Syringe * * *
Room Bag * Room Bag * * * *
Room Vial * * Room Vial * * *
Fridge Syringe * * * Fridge Syringe * *
Fridge Bag * * * * Fridge Bag * *
Fridge Vial * * Fridge Vial * * * *
Peak 3 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 6 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe * * Room Syringe * * *
Room Bag * * * Room Bag * * * *
Room Vial * * Room Vial * *
Fridge Syringe * * Fridge Syringe * * * *
Fridge Bag * Fridge Bag * * *
Fridge Vial * * * * Fridge Vial * * * *
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4.7.1.1. Oxygen availability 
 
The presence of oxygen is a key factor in the initiation of peroxidation as discussed 
in section 1.5.1 (chapter 1). When considering the level of TAG loss shown in the 
day 7 results (figure 4.33) multi-layer PN bags which are oxygen impermeable show 
significantly greater TAG loss than syringes. As discussed in section 3.8.1 with light 
protected Intralipid® testing whilst PN bags are impermeable to oxygen and syringes 
permit a level of oxygen ingress, initial presence of atmospheric oxygen will be 
higher in PN bags. This is due to the manufacturing process which leaves a small 
amount of air in the PN bag after formulation. All air is initially removed from 
syringes, with air ingress occurring over a prolonged period of storage. BD syringes 
are formed of propylene barrels and plungers and latex free elastomer stoppers (BD 
Medical 2015). Whilst the materials themselves are impermeable to oxygen, the 
movable nature of the barrel and plunger permits a level of oxygen ingress during 
storage. As such whilst initial 7-day results (figure 4.33) show low levels of TAG loss 
in syringes, loss at 56 days is maximal in syringes compared to PN bags. It is 
postulated that peroxidation in PN bags is therefore initially rapid due to the 
presence of a limited volume of atmospheric air but limited by the impermeable 
nature of the multi-layer bags, hence when oxygen supplies are exhausted, 
peroxidation rate reduces. Conversely in syringes little air is present within the 
syringe initially, causing a reduced rate of peroxidation, however over the storage 
time, air ingress initiates peroxidation and ultimately results in a higher % TAG loss 
occurring. The importance of oxygen is further substantiated by the relatively 
minimal % TAG loss observed in the non-light protected glass vials filled under 
nitrogen.  
4.7.1.2. Temperature effect on TAG loss 
 
Temperature had a significant effect on the level of TAG loss in syringes, but little 
effect on loss in PN bags or glass vials. There was a statistically significant 
difference between temperature of storage (P<0.05 ANOVA with post hoc Tukey 
HSD analysis) in the level of TAG loss and therefore peroxidation within peak 1 in 
vials, peak 2 in syringes and bags, peak 3 in vials, peak 4 in bags and vials, peak 5 
in bags and vials and peak 6 in all containers. Table 4.1 Summaries these results 
indicating statistical significance. The results indicate that in non-light protected 
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containers, temperature has a significant effect on TAG loss and the level of 
peroxidation occurring after prolonged storage periods (56 days). It is hypothesised 
that room temperature storage would cause a higher level of peroxidation or TAG 
loss as increased temperatures increase the number of collisions occurring between 
molecules thereby increasing the rate at which peroxidation occurs (Seppanen and 
Saari Csallany 2002; Yuan et al. 2018). To investigate this day 7 TAG loss results 
for all non-light protected containers were analysed and shown in figure 4.33 
Peroxidation levels indicated by % TAG loss for non-light protected syringes at day 
7 were significantly greater in fridge temperatures than room temperature storage 
(10-20% vs 0 to 10% TAG loss). Therefore, a raised temperature of storage with 
regards to the initiation of peroxidation in syringes has little effect. When considering 
PN bag results at 7 days, room temperature bags did have a greater % TAG loss for 
peaks 1 to 4 and peak 6, suggesting that the rate of initial peroxidation in PN bags 
may be affected by raised temperatures. Glass vials with oxygen excluded through 
nitrogen addition provided an interesting comparator between temperatures. 
Oxygen removed vials were designed as a control to provide a comparator to the 
level of oxygen dependant mechanisms of peroxidation occurring vs other lipid 
breakdown. Whilst the % TAG loss in the glass vials was minimal throughout 
storage, at 7 days temperature influenced TAG loss with all peaks showing a 
greater loss at room temperature than fridge temperature.  
From the results above with regards to oxygen presence and temperature of 
storage, the presence of oxygen is shown to be a vital factor in the initiation and rate 
of peroxidation occurring, with PN bags with oxygen present at day 0 having a 
greater rate of TAG loss than syringes and vials. When considering temperature, 
the results indicate that lipid stored at room temperature in the presence of oxygen 
show the highest level of TAG loss and therefore indicates the highest level of 
peroxidation.  
4.7.1.3. Light exposure and TAG loss 
 
The data within this chapter as discussed in section 4.1 is designed to create a 
comparative data set for Intralipid® stored in syringes, bags and vials between light 
exposed and light protected containers discussed in chapter 3. As such, results 
between chapters and the analysis of the effect of light on the levels of TAG loss 
and peroxidation occurring can be found in chapter 7.  
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4.7.2. Peroxidation products formation 
 
4.7.2.1. HNE formation 
 
As shown by figure 4.11 and 4.12 HNE was only detected in room temperature non-
light protected syringes. Whilst figure 4.12 shows the production of a HNE peak 
under HPLC-UV conditions, the amount of HNE present is below the limit of 
quantification. Therefore, whilst the data was recorded and plotted in figure 4.7 the 
levels cannot be deemed reliable. All other containers at all temperatures shown no 
detectable HNE production throughout storage. This suggests that the peroxidation 
occurring in the lipid (indicated by significant TAG losses) is not forming HNE as a 
secondary product. The peroxidation pathways as described in chapter 1 (section 
1.5.1) shows the formation of many primary and secondary peroxidation products 
from TAG breakdown. The products formed as indicated by TAG losses could be 
other secondary products (see HUE and TAG remnant formation below) or primary 
hydroperoxides. 
The secondary aldehyde produced is dependent on the position of the double bonds 
within a TAGs fatty acids and the positional isomers created. Extensive work has 
been undertaken by multiple researchers into the primary hydroperoxides created 
through the different positional isomers formed upon hydrogen extraction and initial 
lipid radical formation (Porter et al. 1980; Schneider et al. 2001; Porter 2013). From 
this work we can postulate that the peroxidation processes occurring in light 
exposed Intralipid® could theoretically be creating secondary products other than 
HNE. The TAG losses within specific peaks as discussed above indicate the 
greatest levels of peroxidation occurred in peak 3 (C18:2/18:1/18:1). Theoretically 
this TAG could only make HNE from the linoleic acid fatty acid chain with potentially 
different aldehydes being produced dependant on which double bond is targeted 
during peroxidation. Light exposure and therefore the potential for photo-oxidation 
processes to occur could also lead to the production of different secondary products 
other than HNE. As shown below, both HUE and the TAG remnant from peak 3 
(C18:2/18:1/18:1) are identified in all containers that show significant TAG losses 
(PN bags and syringes). As the UV detector used throughout the studies was set at 
222nm, there is potential that other peroxidation products may be being formed and 
simply not detected at this specific wavelength. Such small products would also be 
volatile in nature and therefore not detected by the CAD detector.  
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4.7.2.2. HUE formation 
 
HUE was detected in room temperature PN bags, room temperature syringes and to 
a lesser extent fridge temperature syringes as shown in figures 4.8 and 4.19. All 
peak areas detected were relatively small (~2 Pa). This peak was not validated with 
the assay due to its unexpected formation upon testing and therefore a limit of 
detection in terms of a concentration of HUE present cannot be established. With 
regards to peak height however a LOD can be established using the signal to noise 
ratio of the chromatogram. A signal to noise ratio >3 is sufficient as a LOD (Synder 
et al. 1997). As such, the level of HUE detected in syringes and PN bags produced 
a signal to noise ratio >3 for all chromatograms, therefore establishing that HUE is 
detectable through UV. The concentration of HUE present cannot be calculated 
however due to the lack of a HUE standard for validation. The comparison between 
light and non-light exposed containers with regards to HUE production is discussed 
further in chapter 7. Room temperature syringes within this non-light protected 
dataset produced the highest level of HUE. Temperature of storage influenced the 
production of HUE, thought to be produced from the peroxidation of oleic acid as 
discussed in chapter 3. The greatest level of TAG loss seen in room temperature 
syringes was peak 5 (C18:2/18:1/18:0) and peak 3 (C18:2/18:1/18:1) (figure 4.34), 
both containing oleic acid and therefore predicted to create HUE through the 
peroxidation process.  
4.7.2.3. TAG remnant formation 
 
Peak ‘B’ or the triglyceride remnant identified in chapter 3 through mass 
spectrometry was detected in room temperature syringes and room temperature PN 
bags exposed to light throughout storage (figures 4.9 and 4.20). Whilst again 
unquantifiable in terms of concentration due to the lack of validation of the peak, all 
peaks observed at all time points were above a LOD established from a signal to 
noise ratio of >3. Room temperature syringes produced the highest recorded levels 
of this TAG remnant which as discussed in chapter 3 could be formed from the 
peroxidation of the peak 3 TAG. The presence of this TAG remnant, the production 
of HUE and the % TAG losses seen can be used to confirm the occurrence of lipid 
peroxidation in syringes and PN bags. Further analysis of the TAG remnant 
formation in light exposed and light protected containers of Intralipid® is discussed in 
chapter 
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Syringes, Bags and Vials 
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5.1. Introduction to stability testing SMOFlipid® 
 
Both the chapters 5 and 6 utilise the method developed in chapter 2 to test the 
newer intravenous lipid emulsion SMOFlipid® under a variety of storage containers 
and conditions. As per previous chapters containers tested were 50 ml syringes, 
250 ml multilayer (ML) PN bags and 50 ml glass vials as described in detail in 
section 3.2. Assay validation is described in chapter 2 enables 10 TAGs to be 
monitored in SMOFlipid® and the occurrence of HNE. These TAGs as identified 
through mass spectrometry (section 2.12 chapter 2) are summarised in table 5.1 
and shown in figure 5.1 in a standard SMOFlipid® chromatogram.  
Table 5.1 TAG Peaks identified, validated and monitored during the stability testing of SMOFlipid® 
Peak number TAG identified 
1 C8:0/8:0/8:0 
2 C8:0/8:0/10:0 
3 C8:0/10:0/10:0 
4 C10:0/10:0/10:0 
5 C18:2/18:2/18:2 
6 C18:2/18:2/18:1 
7 C18:1/18:1/18:2 
8 C18:2/18:2/16:0 
9 C18:1/18:1/18:1 
10 C18:2/18:1/16:0 
 
The initial 4 peaks monitored in SMOFlipid® contain relatively short chain saturated 
fatty acids which when considered as individual fatty acids are resistant to 
peroxidation (Manuel-y-Keenoy et al. 2016; Khanum and Thevanayagam 2017). 
Therefore, they will be used as a comparator to the TAG losses observed in peaks 5 
to 10 where levels of unsaturation are present.  
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Figure 5.1 HPLC-CAD chromatogram of SMOFlipid® showing the 10 peaks monitored during the following stability testing. 
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5.2.  SMOFlipid® components vs. Intralipid® 
  
The fatty acid composition of SMOFlipid® is governed by the oils which make up the 
emulsion formulation as shown in table 5.2 Unlike Intralipid® where soybean oil is 
the singular component oil of the emulsion, SMOFlipid® contains a mixture of oils 
(discussed in detail in chapter 1, section 1.2). The combination of oils (soybean, 
olive, fish and synthesised saturated medium chain triglycerides (MCT’s)) produces 
the increased numbers of TAGs visualised in the SMOFlipid® chromatogram (figure 
5.1). The 10 TAGs monitored for SMOFlipid® are formed from the soybean oil, olive 
oil and MCT components of the emulsion. Olive oil contains the same fatty acids as 
soybean oil but in different proportions. Oleic acid (C18:1) is the prominent fatty acid 
in olive oil. This is reflected in the proportions of fatty acids seen in each lipid 
emulsion as shown in table 5.2 As such, the proportions of TAGs/ peaks 5 to 10 in 
SMOFlipid® will be different to Intralipid®.  
Table 5.2 Fatty acid composition and proportions within SMOFlipid® and Intralipid®. Data extracted 
from SmPCs for each lipid. 
Fatty acid Carbon number: 
double bond 
SMOFlipid®® 20 % Intralipid® 20 % 
Oleic acid C18:1 23-35% 19-30% 
Linoleic acid C18:2 14-25% 44-62% 
Caprylic acid C8:0 13-24% - 
Palmitic acid C16:0 7-12% 7-14% 
Capric acid C10:0 5-15% - 
Stearic acid C18:0 1.5-4% 1.4-5.5% 
α-linolenic acid C18:3 1.5-3.5% 4-11% 
EPA C20:5 1-3.5% - 
DHA C22:6 1-3.5% - 
 
Figure 5.2 shows the chromatograms of the same volumes of SMOFlipid® and 
Intralipid® overlaid indicating the differences in peak size and therefore proportions 
of TAGs 5 to 10 in each emulsion. 
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Figure 5.2 HPLC-CAD chromatograms of Intralipid® (white peaks) and SMOFlipid® (red peaks) showing the differences in TAG proportions for peaks 5 to 10. 
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As predicted by the components of each lipid, peak 9 (C18:1/18:1/18:1) is larger in 
SMOFlipid® than in Intralipid® as oleic acid is the prominent fatty acid in olive oil. 
Through comparing the differences in TAG amounts in SMOFlipid® vs. Intralipid® we 
can predict that the levels of potential peroxidation and therefore TAG losses will be 
different in each lipid. When considering the olive oil and soybean oil proportions 
alone, the extent of peroxidation would be postulated to be less in SMOFlipid® than 
Intralipid® due to the increased levels of saturated and monounsaturated fatty acids 
present, reducing the ease of peroxidation.  
It is of note however that whilst not monitored through the assay due to the small 
quantities present, SMOFlipid® also contains two fatty acids from fish oil (EPA and 
DHA), both long chain and highly unsaturated. These are therefore particularly 
prone to peroxidation and have the potential to initiate the process, creating highly 
reactive lipid radicals which could subsequently abstract hydrogens from TAGs with 
lower levels of unsaturation (those found within the olive oil and soybean oil portions 
of the emulsion), leading hypothetically to higher levels of peroxidation in 
SMOFlipid® than would be expected in olive oil and soybean oil alone.  
5.2.1. Vitamin E  
 
To counteract the potentially pro-oxidant nature of the introduction of fish oils into 
the emulsion and to reduce the level of peroxidation occurring, SMOFlipid® 
emulsion contains added α-tocopherol (vitamin E) at a concentration of between 
16.3 to 22.5 mg per 100 ml (Kabi 2018). The effectiveness of vitamin E as an anti-
oxidant and free-radical scavenger has been questioned in recent research and 
many contradictory papers exist. With specific regards to vitamin E supplementation 
in lipid emulsions, recent work has focused on the levels of vitamin E within blood 
samples of patient receiving PN, concluding that vitamin E addition positively 
increased level within blood, thus reducing in vivo oxidation (Wu et al. 1999; 
Nonneman et al. 2002). It is worth noting however that supplementation with high 
levels of vitamin E  when considering the use of vitamin E as an anti-oxidant in vitro 
has been shown to increase overall mortality rates (Miller et al. 2005).  
Conversely to the multiple works that deal with the in vivo effects of vitamin E 
supplementation, less work has considered the in vitro anti-oxidant nature of 
tocopherols with relation to the extent of lipid peroxidation during storage. 
Skouroliakou et al. (2012) monitored the levels of peroxidation and vitamin E 
content in all-in-one PN containing SMOFlipid®. Whilst the determination of 
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peroxidation was completed via the FOX assay which as discussed in chapter 1 
(section 1.6.3) can overestimate the level of peroxides present, they concluded that 
whilst vitamin E levels remained chemically stable over 24 hours lipid peroxidation 
was the limiting factor on chemical stability. When considering the anti-oxidant 
capacity of vitamin E on reducing lipid peroxidation, its mechanism of action 
involves its conjugation with a lipid radical, eliminating the radical and creating a 
tocopherol-lipid complex. Yamauchi (1997) provides a detailed description of this 
process as shown in figure 5.3 When applied to the lipid peroxidation occurring in 
SMOFlipid® as seen in the Skouroliakou et al study, it can be postulated that if the 
vitamin E present is working as an anti-oxidant, its measured levels should 
decrease through storage. However, levels remained static over >24hours, 
suggesting that potentially the level of effectiveness of the addition of vitamin E 
should be questioned. It is worth noting however when considering this study in 
relation to the work presented here, 24 hours is a short storage time compared to 
the 84 days studied in this work.  Hoff and Michaelson’s review (2009) also found 
studies where the levels of primary hydroperoxides were unaffected by the 
presence of vitamin E in lipid emulsions stored in light-protected syringes, again 
postulating that vitamin E may not be effective in preventing in vitro peroxidation 
occurring.  
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Figure 5.3 Adapted from Yamauchi, R (1997), the proposed mechanism of tocopherol (vitamin E) anti-oxidant capacity. LH, polyunsaturated lip radical; LOOH, Iipid 
hydroperoxide; LOO• Iipid-peroxyl radical; TO•, α-tocopheroxyl. 
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5.3. Testing protocol and schedule. 
 
To facilitate comparisons to be made between SMOFlipid® stability testing and the 
Intralipid® testing seen in chapters 3 and 4, the same testing protocols and schedule 
as laid out in chapter 3 (section 3.4) will be used for SMOFlipid® testing.  
To summarise, 10 identified TAG peaks were monitored for SMOFlipid® emulsion. 
50 ml of lipid was placed in 50 ml syringes, 250 ml ML PN bags and 50 ml glass 
vials (with nitrogen replacement or air). All containers were light protected using 
aluminium foil throughout storage. 6 of each container type were formulated, 3 
stored at fridge temperature (2-8oC) and 3 stored at room temperature (22oC). 
Testing was carried out at days 0, 1, 2, 5, 7, 14, 28, 56 and 84 as per lab protocols 
for physical stability testing. At each testing point, 1ml of lipid was removed under 
aseptic conditions and placed in an amber HPLC vial for testing. For glass vials, at 
each testing time point nitrogen was flowed through the lipid and headspace after 
removal of lipid for testing to maintain the oxygen free environment.  
Each sample was subjected to HPLC as per chapter 2 with the 10 validated TAGs 
monitored during storage through CAD detection, the production of HNE through UV 
detection and the production of HUE and the TAG remnant products found and 
identified during the testing of Intralipid® (section 3.8.3). Control samples of new 
SMOFlipid® held in its original container were tested at each time point and RSD’s 
of all control samples monitored. Data was excluded if RSD’s fell above the 
acceptable range of <12 (section 3.4). Results for each container type are shown in 
the following sections. 
5.4. SMOFlipid® light protected syringe results 
 
Chromatogram results for each day of testing were integrated using Chromeleon 
(Thermo Scientific) and peak area reported (raw data for all results within chapter 
shown in appendix 2). For HPLC-CAD results for each of the 10 monitored 
triglycerides data is presented as a % loss from day 0 with room and fridge 
temperature results indicated on each graph. Standard deviation error bars are 
present on all results.  
As shown in figures 5.4 to 5.13 maximal % TAG loss was recorded in peak 6, 9 and 
10 at 25 % over 84 days. All TAG peaks monitored showed little loss (< 20 %) up to 
56 days of testing with a rapid rise in loss detected from day 56 onwards. 
Temperature had little effect on stability, with fridge temperature samples showing 
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greater loss than room temperature samples across all TAGs but the difference not 
being statistically significant (section 5.7). Results for all monitored TAGs are 
discussed further in section 5.7. 
Minimal HNE was produced throughout 84 days of storage at both temperatures. 
Figure 5.14 shows HNE results with standard error bars. The amount of HNE 
produced a maximal peak area of 3.41 (AU). This area using the calibration 
equation shown in figure 3.6 (section3.5) (y = 0.2476x + 1.0452) equates to a 
concentration of 1.889 µM. As discussed in chapter 2, the limit of quantification for 
the assay of HNE is 8.974 µM. As such the levels of HNE recorded are so minimal 
that they are not reliably quantifiable through the assay.  
Despite little HNE being recorded, room temperature syringes showed the 
production of HUE from day 14 onwards which positively correlated to the 
production of the TAG remnant from day 28 onwards as shown in figures 5.15 and 
5.16. Fridge temperature syringes showed no TAG remnant but a small amount of 
HUE from day 56 onwards. All light protected syringe results are discussed further 
in section 5.7. 
  
218 
 
 
Figure 5.4 HPLC-CAD results for peak 1 (C8:0/8:0/8:0) triglyceride of SMOFlipid® 20 % stored in light 
protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) and 
Fridge (Blue) results shown with standard deviation error bars on all points. 
 
Figure 5.5 HPLC-CAD results for peak 2 (C8:0/8:0/10:0) triglyceride of SMOFlipid® 20 % stored in light 
protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) and 
Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 5.6 HPLC-CAD results for peak 3 (C8:0/10:0/10:0) triglyceride of SMOFlipid® 20 % stored in 
light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) 
and Fridge (Blue) results shown with standard deviation error bars on all points. 
 
 
Figure 5.7 HPLC-CAD results for peak 4 (C10:0/10:0/10:0) triglyceride of SMOFlipid® 20 % stored in 
light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) 
and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 5.8 HPLC-CAD results for peak 5 (C18:2/18:2/18:2) triglyceride of SMOFlipid® 20 % stored in 
light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) 
and Fridge (Blue) results shown with standard deviation error bars on all points. 
 
 
Figure 5.9 HPLC-CAD results for peak 6 (C18:2/18:2/18:1) triglyceride of SMOFlipid® 20 % stored in 
light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) 
and Fridge (Blue) results shown with standard deviation error bars on all points. 
0
5
10
15
20
25
30
35
0 10 20 30 40 50 60 70 80 90
%
 lo
ss
Day of testing
Peak 5 (C18:2/18:2/18:2) % loss
SMOFlipid® room temperature % loss SMOFlipid® Fridge temperature % loss
0
5
10
15
20
25
30
35
0 10 20 30 40 50 60 70 80 90
%
 lo
ss
Day of testing
Peak 6 (C18:2/18:2/18:1) % loss
SMOFlipid® room temperature % loss SMOFlipid® Fridge temperature % loss
221 
 
 
Figure 5.10 HPLC-CAD results for peak 7 (C18:2/18:1/18:1) triglyceride of SMOFlipid® 20 % stored in 
light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) 
and Fridge (Blue) results shown with standard deviation error bars on all points. 
 
 
Figure 5.11 HPLC-CAD results for peak 8 (C18:2/18:2/16:0) triglyceride of SMOFlipid® 20 % stored in 
light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) 
and Fridge (Blue) results shown with standard deviation error bars on all points. 
0
5
10
15
20
25
30
0 10 20 30 40 50 60 70 80 90
%
 lo
ss
Day of testing
Peak 7 (C18:2/18:1/18:1) % loss
SMOFlipid® room temperature % loss SMOFlipid® Fridge temperature % loss
0
5
10
15
20
25
30
35
0 10 20 30 40 50 60 70 80 90
%
 lo
ss
Day of testing
Peak 8 (C18:2/18:2/16:0) % loss
SMOFlipid® room temperature % loss SMOFlipid® Fridge temperature % loss
222 
 
 
Figure 5.12 HPLC-CAD results for peak 9 (C18:2/18:1/18:0) triglyceride of SMOFlipid® 20 % stored in 
light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) 
and Fridge (Blue) results shown with standard deviation error bars on all points. 
 
 
 
Figure 5.13 HPLC-CAD results for peak 10 (C18:2/18:1/16:0) triglyceride of SMOFlipid® 20 % stored in 
light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) 
and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 5.14 HPLC-UV data showing the minimal production of 4-Hydroxynonenal in SMOFlipid® 20 % 
over 84-day storage and both room (red) and fridge (blue) temperatures in 50 ml syringes. 
 
 
 
Figure 5.15 HUE production in 50 ml SMOFlipid® light protected syringes over 84 days of storage. 
Room temperature (red trace) and fridge temperature (blue trace). 
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Figure 5.16 HPLC-UV of TAG remnant production in 50 ml SMOFlipid® light protected syringes over 84 
days storage. Room temperature (red trace) showing production from day 28, no fridge temperature 
production (blue trace). 
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Figure 5.17 HPLC-CAD chromatograms of SMOFlipid® 20% stored in 50 ml syringes. Day 0 control (black), day 84 fridge temperature (blue trace) and day 84 room 
temperature (red trace). Overlaid chromatogram shows changes in peaks in comparison to control. 
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Figure 5.18 HPLC-UV chromatograms of SMOFlipid® 20% stored in 50 ml syringes. Day 0 chromatogram (black trace), day 84 fridge temperature syringes (blue trace) and day 
84 room temperature syringes (red trace). The production of HNE, HUE and TAG remnant in room temperature syringes can be seen and is indicated on the chromatogram. 
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Figure 5.19 Overlaid HPLC-UV chromatograms of day 0 (black trace) and day 84 room temperature (red trace) SMOFlipid® 20 % stored in 50 ml syringes. Peaks on the 84 day 
chromatogram highlighted in red show HNE, HUE and TAG remnant.
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5.5. SMOFlipid® light-protected PN bag results 
 
Following the testing protocol laid out in section 3.4, 250ml Baxa multi-layer PN 
bags were filled with 50 ml SMOFlipid® and all possible air removed. All containers 
were covered with aluminium foil to protect from light. At each testing point 1ml of 
lipid was removed and all air removed from the PN bag. A control sample of 
SMOFlipid® in its original packaging was testing at each time point to ensure 
precision was maintained. All results were performed in triplicate and standard 
deviation and relative standard deviation calculated. Any result with a control 
sample RSD of >12 was excluded from further analysis as per method precision 
limits set out in section 3.5. 
Figures 5.20 to 5.29 show the % losses recorded for each of the 10 TAGs 
monitored. Raw data is recorded in appendix 2.  All data is recorded and shown 
graphically up to day 84, however the control samples RSD’s fell outside the 
acceptable range (>12) on day 84. Therefore, day 84 results are indicated on 
graphs in orange and excluded from further analysis in section 5.7. Day 84 testing 
was performed with raised laboratory temperatures which could have accounted for 
the variation in precision observed in the results. Figure 5.31 shows the stacked 
chromatograms of day 56 SMOFlipid® in PN bags stored and room and fridge 
temperature and a control sample, indicating the % loss in peak area observed 
through a change in peak area and height.  
PN bags produced a maximal % loss of over 40 % in both room and fridge 
temperature samples. Greatest loss was observed in peaks 8, 9 and 10 
corresponding to TAGs containing largely C18:2 (linoleic) and C18:1 (oleic) fatty 
acids with minimal C18:0 (stearic) and C16:0 (palmitic) fatty acids. Room 
temperature losses were greater than fridge temperature for all peaks, but 
statistically significant differences were observed in peaks 1, 6 and 9 (see section 
5.7 for further analysis).  
No detectable HNE or HUE was recorded in any PN bags over 84 days of storage 
at either temperature, however TAG remnant production was observed in room 
temperature PN bags from day 14 onwards as shown in figure 5.30. This suggests 
that the apparent peroxidation observed through significant TAG losses could be 
through processes different to those observed previously in this work. As such 
potentially different secondary peroxidation products could be created which are 
undetectable by the UV assay as it has a fixed wavelength of 222 nm. Potential 
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pathways of peroxidation and the TAG losses observed are discussed further in 
section 5.7. 
 
Figure 5.20 HPLC-CAD results for peak 1 (C8:0/8:0/8:0) triglyceride of SMOFlipid® 20 % stored in light 
protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. Room (Red) 
and Fridge (Blue) results shown with standard deviation error bars on all points. Orange data from day 
84 excluded from further analysis due to high RSD. 
 
Figure 5.21 HPLC-CAD results for peak 2 (C8:0/8:0/10:0) triglyceride of SMOFlipid® 20 % stored in 
light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Orange data 
from day 84 excluded from further analysis due to high RSD. 
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Figure 5.22 HPLC-CAD results for peak 3 (C8:0/10:0/10:0) triglyceride of SMOFlipid® 20 % stored in 
light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Orange data 
from day 84 excluded from further analysis due to high RSD. 
 
 
 
Figure 5.23 HPLC-CAD results for peak 4 (C10:0/10:0/10:0) triglyceride of 50 ml SMOFlipid® 20 % 
stored in light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. 
Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Orange 
data from day 84 excluded from further analysis due to high RSD. 
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Figure 5.24 HPLC-CAD results for peak 5 (C18:2/18:2/18:2) triglyceride of 50 ml SMOFlipid® 20 % 
stored in 250ml light protected PN bags. Percentage loss of peak shown calculated from day 0 data. 
Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Orange 
data from day 84 excluded from further analysis due to high RSD. 
 
 
 
Figure 5.25 HPLC-CAD results for peak 6 (C18:2/18:2/18:1) triglyceride of 50ml SMOFlipid® 20 % 
stored in light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. 
Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 5.26 HPLC-CAD results for peak 7 (C18:2/18:1/18:1) triglyceride of 50 ml SMOFlipid® 20 % 
stored in light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. 
Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Orange 
data from day 84 excluded from further analysis due to high RSD. 
 
 
 
Figure 5.27 HPLC-CAD results for peak 8 (C18:2/18:2/16:0) triglyceride of 50 ml SMOFlipid® 20 % 
stored in light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. 
Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Orange 
data from day 84 excluded from further analysis due to high RSD. 
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Figure 5.28 HPLC-CAD results for peak 9 (C18:2/18:1/18:0) triglyceride of 50 ml SMOFlipid® 20 % 
stored in light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. 
Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Orange 
data from day 84 excluded from further analysis due to high RSD. 
 
 
 
Figure 5.29 HPLC-CAD results for peak 10 (C18:2/18:1/16:0) triglyceride of 50 ml SMOFlipid® 20 % 
stored in light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. 
Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 5.30 HPLC-UV of TAG remnant production in 50 ml SMOFlipid® light protected 250 ml PN bags 
over 84 days storage. Room temperature (red trace) showing production from day 28, no fridge 
temperature production (blue trace). 
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Figure 5.31 HPLC-CAD chromatograms of 50 ml SMOFlipid® 20% stored in 250 ml PN bags. Day 0 control (black), day 84 fridge temperature chromatogram (blue trace) and 
day 84 room temperature (red trace). Overlaid chromatogram with signal time offset shows changes in peaks in comparison to control. 
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Figure 5.32 HPLC-UV chromatograms of 50 ml SMOFlipid® 20% stored in 250 ml PN bags. Day 0 chromatogram (black trace), day 84 fridge temperature bags (blue trace) and 
day 84 room temperature syringes (red trace). TAG remnant production is indicated in room temperature PN bags. 
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Figure 5.33 Overlaid HPLC-UV chromatograms of day 0 (black trace) and day 84 room temperature (red trace) SMOFlipid® 20 % stored in 250 ml PN bags. Peak on the 84-
day chromatogram highlighted in red shows the TAG remnant produced. 
TAG Remnant 
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5.6. SMOFlipid® light protected glass vial results 
 
50 ml of SMOFlipid® was sealed in 50 ml glass vials as per testing protocol in 
section 3.4. Atmospheric air was removed through nitrogen purging as discussed in 
chapter 3.2.3. Air was purged again with nitrogen at each testing point after removal 
of lipid. All vials were protected from light with aluminium foil wraps. All results are 
recorded in triplicate and standard deviations and relative standard deviation 
calculated. All chromatograms were integrated, and peak areas calculated and 
recorded. TAG losses are shown as % loss from a day 0 standard. At each time 
point to ensure method precision a control sample of new SMOFlipid® was tested 
and its RSD monitored for acceptability (<12) (Fox et al. 2013; Márquez-Sillero et al. 
2013). 
Figures 5.34 to 5.43 show the TAG losses for all monitored peaks. Chromatograms 
seen in figures 5.44 and 5.45 indicate the day 84 TAG losses observed and the lack 
of secondary peroxidation products. All vials indicated minimal TAG losses through 
the initial 28 days of testing. However, beyond this time point TAG losses increased 
to a maximum of 35 % in room temperature vials and ~ 20 % at fridge temperature. 
Temperature had a significant effect on TAG loss (statistically different for peaks 
4,6,8,9 and 10, see section 5.7). Peroxidation and therefore TAG loss was 
minimised until day 28 which can be explained by the successful removal of air and 
therefore oxygen from the system by nitrogen purging. This prevents the initiation of 
oxygen-dependant peroxidation from occurring. Light protection also inhibits photo-
oxidation from initiating the peroxidation process. The rise in TAG loss at day 28 
could be due to oxygen ingress through repeated sampling through the rubber vial 
tops, creating a passage for air to leak into the system during prolonged storage.  
No HNE, HUE or TAG remnant were detected throughout the 84-day storage period 
at both temperatures, suggesting that minimal peroxidation was occurring. Whilst 
TAG losses were observed from day 28 onwards, the lack of detectable secondary 
peroxidation products could suggest that peroxidation is still within the initiation and 
propagation phases, that the products formed from day 28 onwards are the initial 
primary lipid hydroperoxides not detected through the assay, or that different 
secondary products are formed and not detected. Both the lack of products and the 
TAG losses are discussed further in section 5.7. 
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Figure 5.34 HPLC-CAD results for peak 1 (C8:0/8:0/8:0) triglyceride of SMOFlipid® 20 % stored in 
50ml light protected glass vials. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
 
 
 
Figure 5.35 HPLC-CAD results for peak 2 (C8:0/8:0/10:0) triglyceride of SMOFlipid® 20 % stored in 
light protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 5.36 HPLC-CAD results for peak 3 (C8:0/10:0/10:0) triglyceride of SMOFlipid® 20 % stored in 
50ml light protected glass vials. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
 
 
 
Figure 5.37 HPLC-CAD results for peak 4 (C10:0/10:0/10:0) triglyceride of SMOFlipid® 20 % stored in 
50ml light protected glass vials. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 5.38 HPLC-CAD results for peak 5 (C18:2/18:2/18:2) triglyceride of SMOFlipid® 20 % stored in 
50ml light protected glass vials. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
 
 
 
Figure 5.39 HPLC-CAD results for peak 6 (C18:2/18:2/18:1) triglyceride of SMOFlipid® 20 % stored in 
light protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 5.40 HPLC-CAD results for peak 7 (C18:2/18:1/18:1) triglyceride of SMOFlipid® 20 % stored in 
light protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
 
 
 
Figure 5.41 HPLC-CAD results for peak 8 (C18:2/18:2/16:0) triglyceride of SMOFlipid® 20 % stored in 
light protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 5.42 HPLC-CAD results for peak 9 (C18:2/18:1/18:0) triglyceride of SMOFlipid® 20 % stored in 
light protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
 
 
 
Figure 5.43 HPLC-CAD results for peak 10 (C18:2/18:1/16:0) triglyceride of SMOFlipid® 20 % stored in 
light protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 5.44 HPLC-CAD chromatograms of SMOFlipid® 20% stored in 50 ml glass vials. Day 0 control (black), day 84 fridge temperature chromatogram (blue trace) and day 84 
room temperature (red trace). Overlaid chromatogram with signal time offset shows changes in peaks in comparison to control. 
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Figure 5.45 HPLC-UV chromatograms of SMOFlipid® 20% stored in 50 ml glass vials. Day 0 chromatogram (black trace), day 84 fridge temperature syringes (blue trace) and 
day 84 room temperature syringes (red trace). The lack of production of new peaks indicates a lack of degradation products. 
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Figure 5.46 Overlaid HPLC-UV chromatograms. Day 0 (back trace) and day 84 room temperature (red trace) SMOFlipid® stored in 50 ml glass vials. The presence of no new 
peaks indicates a lack of degradation/peroxidation products seen at 222 nm wavelength. 
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5.7. Discussion of SMOFlipid® light protected results 
 
5.7.1. Triglyceride loss 
 
TAG losses occurred in all containers at fridge and room temperatures over 84 days 
of storage. Table 5.3 shows the statistical significance in the differences between 
containers and temperatures. All data was analysed by ANOVA using SPSS (IBM 
version 25) with Tukey post-hoc analysis (appendix 3 shows data). Statistical 
significance was achieved with a P<0.05. Room temperature PN bags showed the 
greatest level of TAG loss for all peaks at day 56. Temperature had a significant 
effect on PN bag results but little effect on syringes or glass vials. Figure 5.49 
shows the level of TAG losses seen for all containers at both temperatures at 56 
days. Day 84 data is excluded from the comparison between containers as PN bag 
data showed high control RSD’s on day 84.  
PN bags showed maximal losses of >40 % at room temperature with fridge 
temperature reducing the level of TAG loss observed. During the formulation of PN 
bags lipid is removed from its original container (flexible infusion bag) using a 50 ml 
BD Plastipak syringe and needle. The lipid is then injected into the 250 ml PN bag 
and as much air as possible removed. During this production process, the act of 
pulling lipid into a syringe could introduce air and therefore oxygen into the lipid in 
the form of dissolved oxygen that cannot be removed. Once in the PN bag, whilst all 
possible air is removed, small amounts remain. In clinical practise an amount less 
than the area of a 50 pence piece is deemed acceptable upon formulation. The 
oxygen present in the PN bags tested could initiate the peroxidation process, 
accounting for the large TAG losses observed. Fridge temperature storage will 
inhibit the peroxidation process occurring as temperature acts to reduce the number 
of collisions occurring between molecules, thus physically reducing the ability of lipid 
radicals to interact with another lipid molecule and propagate the peroxidation cycle 
(Steger and Mühlebach 1997; Seppanen and Saari Csallany 2002). When 
considering each TAG monitored, PN bags showed greatest losses in peaks 5,8,9 
and 10, TAGs containing polyunsaturated and monounsaturated fatty acids prone to 
peroxidation. There were however significant losses in peaks 1 to 4 which is of note 
as these peaks contain only saturated fatty acids, discussed further in section 5.7.2.  
When considering the syringe results, TAG losses were greatest in peaks 5 to 10 
(<20 %) at day 56, with minimal losses in TAGs 1 to 4. This is suggestive of 
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peroxidation, as expected, occurring primarily in polyunsaturated and 
monounsaturated fatty acids. No significant difference was shown between fridge 
and room temperatures. Both the rate and extent of peroxidation was significantly 
lower in all syringes than PN bags. Figure 5.47 shows the day 7 data for all 
containers and allows a comparison into the rate of peroxidation. Syringes when 
formulated have all visible air removed and at each testing time point all air again is 
expelled before storage. This minimises oxygen presence, though as discussed in 
chapter 4.7.1.1, oxygen can leech into syringes bypassing the rubber seals on the 
plunger and barrel over time.  This is reflected when looking at the figures shown in 
section 5.4 for each TAG where the greatest losses occur over the last 28 days of 
storage, indicating the initiation of peroxidation as oxygen becomes present in the 
system.  
As predicted, all glass vials showed little (<10 %) losses during the first 28 days of 
storage with exception of peak 1 at room temperature where oxygen is minimised 
within the system due to the presence of nitrogen. However, as the data at day 56 
shows (figure 5.49) TAG losses increased after day 28 up to 30 %. All peaks 1 to 10 
suffered similar amounts of loss over 56 days. The loss of TAGs from day 28 
onwards suggests ingress of oxygen into the system and the initiation of 
peroxidation. Whilst every effort was made to prevent the presence of oxygen, the 
repetitive piercing of the rubber vial septum could have weakened the seal to the 
point where oxygen could leech into the system. To try and prevent this in future 
testing at every testing point a different section of the rubber bung was pierced to try 
and prevent a weak area occurring. It is again worth noting that TAG losses were 
recorded in peaks 1 to 4, TAGs made of saturated fatty acids which should not be 
susceptible to peroxidation however the TAG losses suggest the breakdown of 
these TAGs (discussed further in section 5.7.2). 
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Figure 5.47 Triglyceride loss at 7 days storage for SMOFlipid® stored in syringes, PN bags and glass vials. 
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Figure 5.48 Triglyceride loss at 28 days storage for SMOFlipid® stored in syringes, PN bags and glass vials. 
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Figure 5.49 Triglyceride loss at 56 days storage for SMOFlipid® stored in syringes, PN bags and glass vials. 
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Table 5.3 Light protected SMOFlipid® in all containers at all temperatures for each of the ten peaks monitored. * indicates significant differences between results as calculated 
through ANOVA analysis with post hock Tukey analysis between each container type. (significant defined as P<0.05). 
 
Peak 1 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 5 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe * * Room Syringe *
Room Bag * * * Room Bag *
Room Vial Room Vial *
Fridge Syringe Fridge Syringe
Fridge Bag * Fridge Bag *
Fridge Vial * Fridge Vial * *
Peak 2 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 6 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 9 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe * Room Syringe * Room Syringe * * *
Room Bag * * * Room Bag * Room Bag * * * * *
Room Vial Room Vial * * Room Vial * *
Fridge Syringe * * Fridge Syringe * Fridge Syringe * *
Fridge Bag * Fridge Bag * * * * Fridge Bag * *
Fridge Vial * Fridge Vial * Fridge Vial * * * * *
Peak 3 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 7 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 10 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe Room Syringe * Room Syringe * *
Room Bag Room Bag * Room Bag * * *
Room Vial Room Vial * * * Room Vial * * *
Fridge Syringe Fridge Syringe * Fridge Syringe * *
Fridge Bag Fridge Bag Fridge Bag *
Fridge Vial Fridge Vial Fridge Vial * * *
Peak 4 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 8 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe * Room Syringe * * *
Room Bag * * * * Room Bag * * * *
Room Vial * * Room Vial * * *
Fridge Syringe * Fridge Syringe * *
Fridge Bag * Fridge Bag * * * *
Fridge Vial * * * Fridge Vial * * * *
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5.7.2. Saturated TAG losses 
 
As figure 5.49 shows apart from SMOFlipid® stored in 50 ml syringes, PN bags and 
to a lesser extent glass vials showed significant losses in peaks 1 to 4 over 56 days 
of storage at all temperatures. As shown in chapter 2 through mass spectrometry 
peaks 1 to 4 were identified as TAGs with saturated fatty acids. Each TAG (1 to 4) is 
formed from medium chain (8 to 10 carbons) caprylic and capric fatty acids 
chemically synthesised from coconut oil. As discussed in section 5.2 these 
saturated TAGs were chosen to be monitored due to their expected lack of 
susceptibility to peroxidation and therefore loss. Therefore, the results showing a 
drop in these TAGs are not predicted. To ensure the results were precise, as for all 
testing control samples of SMOFlipid® in its original container was tested at all time 
points. As discussed through the results in this chapter all RSDs were monitored 
and found to be within acceptable limits (<12). As such the results obtained were 
deemed reliable and therefore the loss of saturated TAGs indicates that processes 
other than peroxidation of unsaturated lipids may have occurred. When considering 
the overall levels of TAG losses occurring the loss in saturated TAGs only occurs 
when overall TAG losses are high. From this it can be postulated that saturated 
TAG loss only appears when high levels of peroxidation is present.  
Considering other research, little work can be found on the potential breakdown of 
saturated TAGs within emulsions. Endres and Kummerow’s (1962) research 
showed the breakdown of saturated TAGs occurring with thermal oxidation at high 
temperatures through hydrolysis of the ester linkage between the fatty acid and the 
glycerol backbone. Applying this breakdown process to the saturated TAGs in 
SMOFlipid® the expected results would show a loss of each TAG peak (1 to 4) as 
fatty acids were cleaved from each TAG resulting in free fatty acids, mono and 
diacylglycerides. Whilst SMOFlipid® testing was not carried out under high 
temperatures (room and fridge only), the saturated TAG losses occurred only in 
lipids where excess peroxidation was seen and as such in lipids where high levels 
of reactive oxygen species, lipid radicals and highly reactive lipid hydroperoxides 
will be present. The presence of water and oxygen within these emulsions also 
would theoretically permit hydrolysis to occur. The CAD detector used would be 
unable to detect the free fatty acids formed due to their relative volatility. As the 
assay is monitoring only the 10 TAGs identified, the breakdown of these saturated 
TAGs into mono and diacylglycerides would be indicated by peak loss as seen. 
Whilst this process acts as a hypothesis for the saturated TAG losses seen, further 
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work beyond the scope of this thesis could confirm the processes occurring. The 
lipid could be subjected to HPLC-UV designed to specifically look for the free fatty 
acids present from the TAG breakdown, or mass spectrometry could be employed 
to identify the fatty acid methyl esters, mono and diacylglycerides formed.  
 
5.7.3. HNE, HUE and TAG remnant production 
 
Contrary to TAG losses which were greatest in PN bags, the only recorded 
occurrences of HNE and HUE were found in syringes. Whilst the level of HNE 
recorded was under the level of quantitation (LOQ), significant HUE was seen in 
room temperature syringes at day 14 onwards and in fridge temperature syringes 
from day 56. Considering HUE production, looking at the TAG losses in PN bags at 
day 56 all peaks monitored showed significant losses except for peak 7 
(C18:2/18:1/18:1) which showed minimal (~ 10 % room and <5 % fridge) loss. As 
discussed in chapter 3 (section 3.8.3) figure 5.50 shows the potential pathway for 
the production of HUE from the peak 7 triglyceride. The lack of HUE seen in PN 
bags would be predicted if the lack of loss of peak 7 was used as a predictor for its 
formation. This pathway of HUE production is supported when considering the 
production of HUE in room temperature syringes. Figure 5.49 shows the 56-day 
results for all peaks. The greatest TAG losses observed for syringes were seen for 
peaks 6,7 and 10 corresponding to TAGs C18:2/18:2/18:1, C18:2/18:1/18:1 and 
C18:2/18:1/16:0). It would be expected that both HUE and HNE would be formed 
from the peroxidation of these TAGs, only HUE is shown in the data (HNE present 
but below LOQ). The results do however substantiate the production of HUE from 
TAGs containing oleic acid (C18:1).  
TAG remnant production was observed in syringes from day 28 onwards and in PN 
bags from day 14 onwards at room temperatures only. The proposed schematic for 
the production of the TAG remnant from peak 7 is suggested in chapter 3 and 
summarised again below in figure 5.50. 
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Figure 5.50 As shown in chapter 3 schematic of the potential chemical breakdown of peak 7 TAG with 
the production of HUE and HNE. 
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TAG remnant production is temperature dependant as shown by the data recorded. 
Both syringes and bags as discussed above have HUE present at day 56 but not 
HNE. This questions the validity of the schematic shown in figure 5.50 due to the 
lack of HNE from the proposed pathway of peroxidation. One possible explanation 
however is the peroxidation of the linoleic acid is occurring at either the other double 
bond or at the same bond as the schematic indicates but at the other end, leading to 
a different positional isomer being creating. This would create a different positional 
hydroperoxide as a primary product and ultimately a secondary peroxidation 
product, potentially not visualised through the UV chromatogram at the wavelength 
of 222 nm. Figure 5.51 Shows the potential peroxidation of linoleic acid, the 
positional isomers and products created. Of interest within this schematic is the 
production of a possible 11-hydroperoxide only found in peroxidation in the 
presence of an antioxidant. SMOFlipid® unlike Intralipid® contains tocopherols with 
the ambition to quench free radicals and inhibit peroxidation. Its effectiveness 
however is questioned as discussed in section 5.2.1. Schneider’s (2009) work that 
shows the occurrence of an 11-hydroperoxide in the presence of tocopherols 
provides a potential pathway where other peroxidation products (not HNE/HUE) 
would be formed and subsequently not identified through this assay.  
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Figure 5.51 Potential products of Linoleic acid peroxidation. *bis-allylic 11-Hydroperoxide, formed only in the presence of an antioxidant such as vitamin E (tocopherols) 
(Schneider 2009).
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6.1. Introduction to non-light protected SMOFlipid® testing 
 
As discussed for Intralipid® non-light protected testing in chapter 4 (section 4.1), 
light induced peroxidation (photo-oxidation) is an alternative pathway for lipid radical 
formation and breakdown to occur. This chapter of testing subjects SMOFlipid® to 
controlled light exposure with the aim to provide an insight into the importance of 
light protection of PN. Light radical formation is discussed in section 4.1.1. 
6.2.  Light control 
 
To enable a comparative set of data to be established an identical testing protocol 
to all previous chapters was employed. In summary, 50 ml syringes, 250ml ML PN 
bags and 50 ml glass vials (vials filled with nitrogen) were filled with 50 ml 
SMOFlipid® and all possible air removed. Fridge temperature samples were held in 
a refrigerator and as such light exposure was limited. Room temperature containers 
were exposed to controlled light through storage in a stability chamber as discussed 
in section 4.2.1. Light intensity was set as 5/10 as per the manufacturer’s 
recommendations providing a mimic for natural light (Weiss Gallenkamp, 2006). 
Humidity was controlled to 60 % and temperature to 22oC, reflecting light protected 
room temperature storage.  
6.3. Testing schedule 
 
As all previous chapters 6 samples of each container were formulated, 3 
refrigerated and 3 stored at room temperature, all exposed to light as discussed 
above. 1 ml of lipid was removed at each timepoint and placed into amber HPLC 
vials for testing. All possible air was removed from each container at each timepoint 
and nitrogen replaced in glass vials as per protocol in section 3.8. Samples were 
tested at days 0, 1, 2, 7, 14, 28, 56 and 84. All samples were subjected to the HPLC 
method as described in chapter 2. A control sample of SMOFlipid® in its original 
packaging was tested at all timepoints, its RSD monitored for method precision. 
Between each sample a blank of 30 minutes was run as described in chapter 2 to 
ensure column cleaning and effective re-equilibration. For each of the 10 peaks 
monitored for SMOFlipid® TAG loss was recorded as peak area and presented as a 
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% loss from day 0. The production of secondary peroxidation products HNE, HUE 
and the TAG remnant were monitored through UV detection and presented as peak 
area. All chromatograms were integrated using Chromeleon software (Thermo 
Scientific) and all samples tested in triplicate. Standard deviations and RSD’s were 
calculated for all results. 
6.4. SMOFlipid® non-light protected syringe results. 
 
Figures 6.1 to 6.10 show the TAG loss results for non-light protected syringes 
through 84 days. However, the RSD’s of the control samples for peaks 1, 2, 3, 4, 5, 
9 and 10 at days 56 and 84 fell out of the acceptable range of <12. As shown on 
each of the peaks graphs, presented as % TAG loss from day 0, day 56 and 84 
results are marked in orange to indicate the high RSD’s. Maximal peak loss at 84 
days was observed for peak 9 at room temperature of 50 %. However, when 
considering only up to the day 28 results due to the RSD drift in control samples 
(discussed in section 6.7.2), minimal TAG loss was seen across all peaks with peak 
10 at room temperature showing the highest level of ~12 %. As shown in the figures 
for the syringe results, the majority of TAG losses visualised occurred during later 
storage times (56 to 84 days). The high RSD’s of the control samples at these 
timepoints do however make the results questionable and are discussed further in 
section 6.7. The peak areas recorded for the control samples were ~ 50 % greater 
than all other control readings. As an approximation if adjusted for this within the 
day 84 results of the affected peaks, maximal TAG loss would be estimated to be 
around 25 %. Temperature had little effect on early storage, however at 84 days 
(when considering adjusted values) there was a statistically significant (ANOVA 
one-way with Tukey post-hoc) difference in room and fridge temperature recordings 
for peaks 1 to 5, 9 and 10 as summarised in table 6.1 (section 6.7) with room 
temperature syringes showing greater % TAG losses.  
Figure 6.11 shows the production of minimal levels of HNE detected through the UV 
assay. The maximum peak area observed was 4.423 (AU) for room temperature 
syringes and 3.584 for fridge temperature samples. Using the calibration equation 
from the validation of HNE (y = 0.2476x + 1.0452) the recorded areas equate to 
13.642 µM and 10.253 µM of HNE which is above the limit of quantification (LOQ) 
for the assay. The results are however significant in terms of concentrations at day 
84. Levels of HNE recorded are only quantifiable from day 14 onwards when they 
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exceed the LOQ for the assay. As shown temperature effects the production of HNE 
but both temperatures tested produced quantifiable levels over 84 days.  
When considering the production of the other peroxidation products identified in 
chapter 3 and monitored, HUE was observed in SMOFlipid® non-light protected 
syringes at room temperature from day 14 onwards and in fridge temperature 
syringes from day 56 as shown in figure 6.12 The amounts observed cannot be 
quantified as discussed in previous chapters due to the lack of validation of the 
assay for HUE detection. The differences in peak areas observed between 
containers and lipids is however comparable and discussed in chapter 7.  
Figure 6.13 shows the production of the TAG remnant peroxidation product 
monitored through UV detection. This peak was present in room temperature 
syringes only from day 14 onwards. Again, whilst not quantifiable due to a lack of a 
standard for validation, the comparison between lipids and containers can be 
undertaken and is discussed in chapter 7. The production of this TAG remnant 
between non-light protected containers of SMOFlipid® is compared in section 6.7. 
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Figure 6.1 HPLC-CAD results for peak 1 (C8:0/8:0/8:0) triglyceride of SMOFlipid® 20 % stored in non-
light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) 
and Fridge (Blue) results shown with standard deviation error bars on all points. Orange points indicate 
readings where RSD of control samples exceeded acceptable levels.   
 
 
Figure 6.2 HPLC-CAD results for peak 2 (C8:0/8:0/10:0) triglyceride of SMOFlipid® 20 % stored in non-
light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room (Red) 
and Fridge (Blue) results shown with standard deviation error bars on all points. Orange points indicate 
readings where RSD of control samples exceeded acceptable levels. 
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Figure 6.3 HPLC-CAD results for peak 3 (C8:0/10:0/10:0) triglyceride of SMOFlipid® 20 % stored in 
non-light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Orange points 
indicate readings where RSD of control samples exceeded acceptable levels. 
 
 
 
Figure 6.4 HPLC-CAD results for peak 4 (C10:0/10:0/10:0) triglyceride of SMOFlipid® 20 % stored in 
non-light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Orange points 
indicate readings where RSD of control samples exceeded acceptable levels. 
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Figure 6.5 HPLC-CAD results for peak 5 (C18:2/18:2/18:2) triglyceride of SMOFlipid® 20 % stored in 
non-light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Orange points 
indicate readings where RSD of control samples exceeded acceptable levels. 
 
 
 
Figure 6.6 HPLC-CAD results for peak 6 (C18:2/18:2/18:1) triglyceride of SMOFlipid® 20 % stored in 
non-light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 6.7 HPLC-CAD results for peak 7 (C18:2/18:1/18:1) triglyceride of SMOFlipid® 20 % stored in 
non-light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
 
 
Figure 6.8 HPLC-CAD results for peak 8 (C18:2/18:2/16:0) triglyceride of SMOFlipid® 20 % stored in 
non-light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
0
5
10
15
20
25
30
35
0 10 20 30 40 50 60 70 80 90
%
 lo
ss
Day of testing
Peak 7 (C18:2/18:1/18:1) % loss
SMOFlipid® Room temperature % loss SMOFlipid® Fridge temperature % loss
0
5
10
15
20
25
0 10 20 30 40 50 60 70 80 90
%
 lo
ss
Day of testing
Peak 8 (C18:2/18:2/16:0) % loss
SMOFlipid® Room temperature % loss SMOFlipid® Fridge temperature % loss
266 
 
 
Figure 6.9 HPLC-CAD results for peak 9 (C18:2/18:1/18:0) triglyceride of SMOFlipid® 20 % stored in 
non-light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Orange points 
indicate readings where RSD of control samples exceeded acceptable levels. 
 
 
Figure 6.10 HPLC-CAD results for peak 10 (C18:2/18:1/16:0) triglyceride of SMOFlipid® 20 % stored in 
non-light protected 50 ml syringes. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Orange points 
indicate readings where RSD of control samples exceeded acceptable levels. 
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Figure 6.11 HPLC-UV data showing the minimal production of 4-Hydroxynonenal in SMOFlipid® 20 % 
over 84-day storage and both room (red) and fridge (blue) temperatures in 50 ml non-light protected 
syringes. 
 
 
 
Figure 6.12 HUE production in 50 ml SMOFlipid® non-light protected syringes over 84 days of storage. 
Room temperature (red trace) and fridge temperature (blue trace). 
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Figure 6.13 HPLC-UV of TAG remnant production in 50 ml SMOFlipid® non-light protected syringes 
over 84 days storage. Room temperature (red trace) showing production from day 28, no fridge 
temperature production (blue trace). 
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Figure 6.14 HPLC-CAD chromatograms of SMOFlipid® 20% stored in non-light protected 50 ml syringes. Day 0 control (black), day 84 fridge temperature (blue trace) and day 
84 room temperature (red trace). Overlaid chromatogram with signal time offset shows changes in peaks in comparison to control. 
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Figure 6.15 HPLC-UV chromatograms of SMOFlipid® 20% stored in non-light protected 50 ml syringes. Day 0 chromatogram (black trace), day 84 fridge temperature syringes 
(blue trace) and day 84 room temperature syringes (red trace). The production of HNE, HUE and TAG remnant in room and fridge temperature syringes can be seen and is 
indicated on the chromatogram. 
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Figure 6.16 Overlaid HPLC-UV chromatograms of day 0 (black trace) and day 84 room temperature (red trace) SMOFlipid® 20 % stored in non-light protected 50 ml syringes. 
Peaks on the 84-day chromatogram highlighted in red show HNE, HUE and TAG remnant. 
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6.5. SMOFlipid® non-light protected PN bag results.  
 
Formulation of each PN bag sample was done according to testing protocols 
(section 6.2.3) with 1ml of lipid removed at each testing timepoint and all possible 
air removed. As discussed previously small volumes of air remain within each bag 
as reflected in clinical practise. Control samples of lipid were tested at all timepoints 
and RSD’s monitored for method precision. All chromatograms were integrated, and 
peak areas recorded. 
Figures 6.17 to 6.26 show the % TAG losses recorded for all 10 peaks compared to 
day 0. RSD’s for peaks 1, 2, 3, 5, 8 and 9 were above the acceptable levels at day 
28 testing. Therefore, for these peaks day 28 results were identified as outliers as 
shown on each figure and excluded from analysis. For peaks 6, 7 and 8 day-84 
control RSD’s fell out of acceptable ranges. As such results are identified on each 
figure in orange and excluded from analysis. Although the RSD’s of the control 
samples above fell outside the acceptable level of 12, maximal RSD’s recorded 
were 16 and as such consideration is given to these results when comparing 
containers (section 6.7). At day 56 where all RSD’s were within acceptable limits 
maximal TAG losses recorded were ~20 % for peak 7 (C18:2/18:1/18:1) and peak 5 
(C18:2/18:2/18:2) both at fridge temperatures. Both TAGs were predicted to be the 
most liable to peroxidation and breakdown due to the high levels of unsaturation 
present. No statistical difference was seen between temperatures of storage (table 
6.1 section 6.7).  TAG losses were observed in peaks 1 to 4 though minimal at day 
56 (less than 10 %) levels rise significantly at day 84 (~ 25 %). All four saturated 
peaks have acceptable control RSD’s for day 84 samples, so the results can be 
considered accurate. The loss of saturated TAGs is discussed further with all results 
in section 6.7. 
No detectable levels of HNE were observed in all PN bags across 84 days of 
storage. With regards to HUE production, only a very small peak area was recorded 
in fridge temperature bags at day 84 (figure 6.27), however the amount present is 
not quantifiable due to the lack of assay validation for HUE as discussed in chapter 
7. The production of the TAG remnant is seen in significant quantities from day 7 
onwards in room temperature PN bags (figures 6.28, 6.29, 6.30). Comparison 
between containers is shown in section 6.7.  
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Figure 6.17 HPLC-CAD results for peak 1 (C8:0/8:0/8:0) triglyceride of 50 ml SMOFlipid® 20 % stored 
in non-light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. 
Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Day 28 
outliers excluded from analysis. 
 
 
Figure 6.18 HPLC-CAD results for peak 2 (C8:0/8:0/10:0) triglyceride of 50 ml SMOFlipid® 20 % stored 
in non-light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 data. 
Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Day 28 
outliers excluded from analysis. 
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Figure 6.19 HPLC-CAD results for peak 3 (C8:0/10:0/10:0) triglyceride of 50 ml SMOFlipid® 20 % 
stored in non-light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 
data. Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Day 
28 outliers excluded from analysis. 
 
 
 
Figure 6.20 HPLC-CAD results for peak 4 (C10:0/10:0/10:0) triglyceride of 50 ml SMOFlipid® 20 % 
stored in non-light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 
data. Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 6.21 HPLC-CAD results for peak 5 (C18:2/18:2/18:2) triglyceride of 50 ml SMOFlipid® 20 % 
stored in 250ml non-light protected PN bags. Percentage loss of peak shown calculated from day 0 
data. Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Day 
28 outliers excluded from analysis. 
 
 
 
Figure 6.22 HPLC-CAD results for peak 6 (C18:2/18:2/18:1) triglyceride of 50ml SMOFlipid® 20 % 
stored in non-light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 
data. Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
Orange data from day 84 excluded from further analysis due to high RSD. 
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Figure 6.23 HPLC-CAD results for peak 7 (C18:2/18:1/18:1) triglyceride of 50 ml SMOFlipid® 20 % 
stored in non-light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 
data. Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
Orange data from day 84 excluded from further analysis due to high RSD. 
 
 
 
Figure 6.24 HPLC-CAD results for peak 8 (C18:2/18:2/16:0) triglyceride of 50 ml SMOFlipid® 20 % 
stored in non-light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 
data. Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
Orange data from day 84 excluded from further analysis due to high RSD. 
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Figure 6.25 HPLC-CAD results for peak 9 (C18:2/18:1/18:0) triglyceride of 50 ml SMOFlipid® 20 % 
stored in non-light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 
data. Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. Day 
28 outlier excluded from analysis. 
 
 
 
Figure 6.26 HPLC-CAD results for peak 10 (C18:2/18:1/16:0) triglyceride of 50 ml SMOFlipid® 20 % 
stored in non-light protected 250 ml PN bags. Percentage loss of peak shown calculated from day 0 
data. Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points 
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Figure 6.27 HUE production in 50 ml SMOFlipid® stored in non-light protected 250 ml PN bags over 84 
days of storage. Room temperature (red trace) and fridge temperature (blue trace). 
 
 
 
Figure 6.28 HPLC-UV of TAG remnant production in 50 ml SMOFlipid® non-light protected 250 ml PN 
bags over 84 days storage. Room temperature (red trace) showing production from day 7, no fridge 
temperature production (blue trace). 
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Figure 6.29 HPLC-CAD chromatograms of 50 ml SMOFlipid® 20% stored in 250 ml non-light protected PN bags. Day 0 control (black), day 84 fridge temperature 
chromatogram (blue trace) and day 84 room temperature (red trace). Overlaid chromatogram with signal time offset shows changes in peaks in comparison to control. 
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Figure 6.30 HPLC-UV chromatograms of 50 ml SMOFlipid® 20% stored in non-light protected 250 ml PN bags. Day 0 chromatogram (black trace), day 84 fridge temperature 
bags (blue trace) and day 84 room temperature syringes (red trace). TAG remnant production is indicated in room temperature PN bags. 
281 
 
 
Figure 6.31 Overlaid HPLC-UV chromatograms of day 0 (black trace) and day 84 room temperature (red trace) SMOFlipid® 20 % stored in non-light protected 250 ml PN bags. 
Peak on the 84 day chromatogram highlighted in red shows the TAG remnant produced.
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6.6. SMOFlipid® non-light protected vials results.  
 
All 50 ml glass vials were filled as per protocol in section 3.4 and all possible 
atmospheric air removed through purging with nitrogen bubbled through the lipid 
and headspace. Air was further purged with nitrogen at all testing points to maintain 
an oxygen free environment through storage. Removal of lipid for testing was 
performed with a needle and syringe and at each timepoint the rubber septum was 
pierced in a different place to try and minimise air seeping into the vial. The purpose 
of the inclusion of glass vials within the study was to create a data set that indicated 
the importance of oxygen within the system with regards to TAG loss and 
peroxidation. All samples were tested in triplicate with standard deviations and 
relative standard deviations calculated. A control sample of lipid in its original 
container was tested at each timepoint and RSD’s monitored for method precision. 
All chromatograms were integrated using Chromeleon software and peak areas 
recorded.  
TAG results are presented as % loss from day 0 testing. All ten TAGs monitored 
showed minimal TAG losses over 84 days of storage. This is significant, as shown 
in previous chapters all lipids within vials had shown TAG losses later during 
storage due to hypothesised air leakage into the vial thereby initiating peroxidation. 
The method of vial testing (moving testing sites at each sampling time, re-purging 
with nitrogen) was modified after each set of testing, thereby ultimately creating a 
testing protocol where minimal TAG losses were shown, creating a positive set for 
comparison of lipid stored in an air-free testing environment. The results in this data 
set as presented in figures 6.32 to 6.41 show the very minimal TAG losses 
(maximum of ~ 7 %) over 84 days, with the majority of TAGs showing no loss. With 
respect to the control sample RSD’s over 84 days the set of samples taken at day 2 
exceeded the acceptable RSD level of 12 for peaks 2, 5, 6, 7,8 and 10 and as such 
results for day 2 were excluded from analysis (all results at this time point were 0).  
Reinforcing the results shown in the TAG loss figured discussed above no 
detectable HNE, HUE or TAG remnant were seen throughout storage at either 
temperature of storage as shown in figured 6.42, 6.43 and 6.44. The results when 
considered collectively indicate a lack of peroxidation and TAG breakdown 
occurring, suggesting that a lack of oxygen within a storage system inhibits loss 
occurring. These results compound the evidence that oxygen presence is vital for 
the occurrence of peroxidation within SMOFlipid® and indicated that peroxidation is 
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the mechanism resulting in the observed TAG losses in other containers. Results 
are discussed further in section 6.7.  
 
Figure 6.32 HPLC-CAD results for peak 1 (C8:0/8:0/8:0) triglyceride of SMOFlipid® 20 % stored in 
50ml non-light protected glass vials. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
 
Figure 6.33 HPLC-CAD results for peak 2 (C8:0/8:0/10:0) triglyceride of SMOFlipid® 20 % stored in 
non-light protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. 
Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 6.34 HPLC-CAD results for peak 3 (C8:0/10:0/10:0) triglyceride of SMOFlipid® 20 % stored in 
50ml non-light protected glass vials. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
 
 
 
Figure 6.35 HPLC-CAD results for peak 4 (C10:0/10:0/10:0) triglyceride of SMOFlipid® 20 % stored in 
50ml non-light protected glass vials. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 6.36 HPLC-CAD results for peak 5 (C18:2/18:2/18:2) triglyceride of SMOFlipid® 20 % stored in 
50ml non-light protected glass vials. Percentage loss of peak shown calculated from day 0 data. Room 
(Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
 
 
 
Figure 6.37 HPLC-CAD results for peak 6 (C18:2/18:2/18:1) triglyceride of SMOFlipid® 20 % stored in 
non-light protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. 
Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 6.38 HPLC-CAD results for peak 7 (C18:2/18:1/18:1) triglyceride of SMOFlipid® 20 % stored in 
non-light protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. 
Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
 
 
 
Figure 6.39 HPLC-CAD results for peak 8 (C18:2/18:2/16:0) triglyceride of SMOFlipid® 20 % stored in 
non-light protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. 
Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 6.40 HPLC-CAD results for peak 9 (C18:2/18:1/18:0) triglyceride of SMOFlipid® 20 % stored in  
non-light protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. 
Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
 
 
 
Figure 6.41HPLC-CAD results for peak 10 (C18:2/18:1/16:0) triglyceride of SMOFlipid® 20 % stored in 
non-light protected 50 ml glass vials. Percentage loss of peak shown calculated from day 0 data. 
Room (Red) and Fridge (Blue) results shown with standard deviation error bars on all points. 
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Figure 6.42 HPLC-CAD chromatograms of SMOFlipid® 20% stored in 50 ml non-light protected glass vials. Day 0 control (black), day 84 fridge temperature chromatogram 
(blue trace) and day 84 room temperature (red trace). Right hand axis (peak area) gives an indication of the lack of loss in peak area across 84 days compared to control. 
Overlaid chromatogram with signal time offset shows changes in peaks in comparison to control. 
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Figure 6.43 HPLC-UV chromatograms of SMOFlipid® 20% stored in 50 ml non-light protected glass vials. Day 0 chromatogram (black trace), day 84 fridge temperature 
syringes (blue trace) and day 84 room temperature syringes (red trace). The lack of production of new peaks indicates a lack of degradation products. 
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Figure 6.44 Overlaid HPLC-UV chromatograms. Day 0 (back trace) and day 84 room temperature (red trace) and fridge temperature (blue) SMOFlipid® stored in non-light 
protected 50 ml glass vials. The presence of no new peaks indicates a lack of degradation/peroxidation products seen at 222 nm wavelength. 
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6.7. Discussion of SMOFlipid® non-light protected results.  
 
6.7.1. Triglyceride loss 
 
When considering the TAG losses between different containers of SMOFlipid® when 
not-light protected, the RSD drift observed in day 56 and 84 syringes and day 28 PN 
bag results make comparison difficult. However, figures 6.46 and 6.45 show the 
TAG losses at day 7 and day 84 for all containers with standard deviation. The day 
84 results for syringes were recorded as markedly higher however the RSD of the 
control samples at this timepoint (~ 22) was nearly double that of the acceptable 
variation in precision. Whilst not considered precise due to the variation in control 
samples the TAG losses in syringes for day 84 as shown in 6.45 have been 
corrected by the same amount as the variation in the control sample. This enables 
the day 84 results to be broadly compared between containers. PN bags showed 
maximal losses at all peaks except peak 7 (C18:2/18:1/18:1) where minimal losses 
(>5 %) were recorded across all containers. Unsaturated peaks (5, 8, 9 and 10) 
showed significant losses in PN bags at all temperatures. These peaks correspond 
to TAGs containing C18:2 and 18:1 fatty acids and present TAG losses of between 
20 to 25 % as discussed in previous results sections. The smallest levels of TAG 
losses through all containers was observed in peak 6 (C18:2/18:2/18:1) and peak 7 
(C18:2/18:1/18:1) which is markedly different to the results observed in other 
chapters and discussed further in chapter 7.  
When considering the effect of temperature on the level of TAG losses observed, 
table 6.1 shows results that are statistically significant (P<0.05) between containers 
at fridge and room temperatures as tested by ANOVA one-way analysis with Tukey 
post hoc testing. Significant differences are recorded between temperatures in 
syringes for peaks 1, 2, 3, 4, 5, 9 and 10, corresponding to the four saturated TAGs 
monitored (peaks 1 to 4), peak 5 (C18:2/18:2/18:2), peak 9 (C18:2/18:1/18:0) and 
peak 10 (C18:2/18:1/16:0). No statistically significant differences were observed in 
PN bags at different temperatures and glass vials showed a single significant result 
for peak 3 (C8:0/10:0/10:0). Results indicate that temperature has the largest effect 
on TAG loss in syringes. One can postulate that a raised temperature acts by 
increasing the collisions between TAG molecules thus increasing TAG loss both 
through peroxidation and hydrolysis. Whilst table 6.1 shows statistical significance 
between non-light protected containers at two temperatures, trends exist between 
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the data created in all previous chapters and as such all are discussed further in 
chapter 7. 
Loss of saturated TAGs occurred both in PN bags (up to ~30 %) and in syringes 
(~17 %). In both containers, loss occurred at 84 days when there was significant 
unsaturated peroxidation (peaks 5 (C18:2/18:2/18:2), 8 (C18:2/18:2/16:0), 9 
(C18:2/18:1/18:0) and 10 (C18:2/18:1/16:0). This, as discussed in chapter 5 (section 
5.7.2) indicates saturated TAG losses occurring at high energy levels through 
processes other than peroxidation. It is postulated that hydrolysis reactions leading 
to cleavage of fatty acids from the saturated TAG backbone result in the TAG losses 
observed. When looking at figure 6.45 showing the TAG losses occurring at day 7, 
saturated TAG losses are observed in all containers up to ~15 % (room temperature 
PN bags). Levels of losses in unsaturated TAGs at this timepoint are only raised in 
room temperature syringes and glass vials whilst PN bag unsaturated losses are < 
5 %. This is of interest as previous data only show saturated TAG losses occurring 
when high levels of unsaturated TAG loss and perceived peroxidation is recorded. 
The data suggests the breakdown of saturated TAGs through hydrolysis occurred in 
relatively low energy systems where little other peroxidation was observed. As such 
the postulated hydrolysis reactions and the availability of water within the emulsion 
must be considered and is discussed further in chapter 7. 
6.7.2. RSD variation 
 
As indicated throughout the testing in this chapter, both syringe and PN bags at 
days 56 and 84 and day 28 respectively recorded control sample results that 
resulted in RSD values above an acceptable level, up to a maximum of ~22. All 
testing was undertaken over a tight testing schedule and as such was carried out 
over a period of around 4.5 weeks where raised temperatures within the laboratory 
were experienced. This was due to the unusually hot weather at the time and was 
unavoidable. Whilst every effort was made to reduce temperatures within the 
laboratory environment, the raised temperatures resulted in the RSD and result 
variations seen within this time period. This affected results at different timepoints 
across all lipids and containers tested and is discussed further in chapter 7.   
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Figure 6.45 Triglyceride loss at 84 days storage for SMOFlipid® stored in non-light protected syringes, PN bags and glass vials. * Denotes syringe results adjusted according to 
level of RSD drift of control sample as discussed in section 6.7.1. 
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Figure 6.46 Triglyceride loss at 7 days storage for SMOFlipid® stored in non-light protected syringes, PN bags and glass vials. 
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Table 6.1 Non-light protected SMOFlipid® in all containers at all temperatures for each of the ten peaks monitored. * indicates significant differences between results as 
calculated through ANOVA analysis with post hock Tukey analysis between each container type. (significant defined as P<0.05). 
 
Peak 1 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 5 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe * * * * * Room Syringe * * *
Room Bag * * * Room Bag * * *
Room Vial * * * * Room Vial * *
Fridge Syringe * * * Fridge Syringe * *
Fridge Bag * * * Fridge Bag * *
Fridge Vial * * * * Fridge Vial * * *
Peak 2 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 6 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 9 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe * * * * * Room Syringe Room Syringe * * * * *
Room Bag * * * Room Bag Room Bag * *
Room Vial * * * * Room Vial * Room Vial * * *
Fridge Syringe * * * Fridge Syringe * Fridge Syringe * * * *
Fridge Bag * * * Fridge Bag * * Fridge Bag * * *
Fridge Vial * * * * Fridge Vial Fridge Vial * * *
Peak 3 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 7 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 10 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe * * * * * Room Syringe Room Syringe * * * *
Room Bag * * * Room Bag Room Bag * *
Room Vial * * * * * Room Vial Room Vial * *
Fridge Syringe * * * Fridge Syringe Fridge Syringe * *
Fridge Bag * * * Fridge Bag Fridge Bag *
Fridge Vial * * * * * Fridge Vial Fridge Vial *
Peak 4 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 8 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe * * * Room Syringe
Room Bag * * Room Bag
Room Vial * * Room Vial *
Fridge Syringe * * * Fridge Syringe *
Fridge Bag * Fridge Bag * *
Fridge Vial * Fridge Vial
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6.7.3. HNE, HUE and TAG remnant production. 
 
As discussed in section 6.4, HNE was only detected in non-light protected syringes 
(13.6 µM at room temperature and 10.2 µM at fridge temperature). The formation of 
HNE as one of the secondary products of the peroxidation of linoleic acid was 
predicted to occur where TAGs with C18:2 fatty acids underwent large losses. As 
figure 6.45 shows, peaks 5 (C18:2/18:2/18:2), 6 (C18:2/18:2/18:1), 7 
(C18:2/18:1/18:1), 8 (C18:2/18:2/16:0) and 9 (C18:2/18:1/18:0) all showed maximal 
losses in PN bags as opposed to syringes. Room temperature syringes where HNE 
was maximal experienced TAG losses of peak 5, 8 and 9 however all were less 
than PN bags. As such it can be postulated that peroxidation occurring in syringes 
resulted in different products being formed vs PN bags. As previously discussed in 
chapter 5 there are multiple potential sites for the peroxidation of linoleic acid, 
resulting in four potential hydroperoxides. From these primary products HNE is only 
one of multiple secondary products that can be formed. The lack of HNE in PN bags 
indicates a lack of peroxidation occurring at the 9’ position of the linoleic acid 
backbone. The relatively large TAG losses occurring in such bags indicate 
peroxidation or breakdown of TAGs is occurring. Therefore, the peroxidation of 
linoleic acid containing TAGs within PN bags is resulting either in other secondary 
peroxidation products being formed or the loss of whole fatty acids from the glycerol 
backbone of the triglyceride through hydrolysis. The presence of a large proportion 
of water within the SMOFlipid® emulsion needs to be considered in the losses of all 
TAGs both saturated and unsaturated that are observed. Whilst this is discussed in 
detail in chapter 7, it is important to note that hydrolysis alone cannot be attributed 
to the TAG losses observed in all containers. This is substantiated by the detection 
of the secondary peroxidation product HUE in room temperature syringes and room 
temperature PN bags.  Figure 6.47 shows the production of HUE in both bags and 
syringes. As indicated maximal HUE is formed within room temperature syringes. 
Whilst as previously discussed the concentration of HUE present cannot be 
calculated due to a lack of available standard for validation, both the peak heights 
observed for room temperature syringes and PN bags give a signal to noise ratio of 
>3 and are therefore detectable. Temperature has an effect on HUE formation with 
fridge storage inhibiting its formation (discussed further in chapter 7).  
Figure 6.48 shows the TAG remnant formation in both room temperature syringes 
and PN bags. Maximal amounts were recorded in PN bags, corresponding to the 
higher levels of TAG losses observed. As previously postulated the TAG remnant 
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m/z corresponds to the breakdown of peak 7 (C18:2/18:1/18:1). The results shown 
in figure 6.45 indicate minimal losses to this peak 7 and therefore the production of 
relatively large quantities of TAG remnant (see chapter 7 for comparisons) is of 
interest. The m/z of the TAG remnant as identified through mass spectrometry was 
495.40 (496.4 [M-H]+) and postulated to be from the peroxidation of peak 7 creating 
HNE and HUE and the TAG remnant. The lack of apparent peak 7 peroxidation and 
the presence of water within the emulsions results in the conclusion that the TAG 
remnant could also be due to a different peak/TAG breakdown. A combination of 
peroxidation and hydrolysis of different TAG peaks resulting in a TAG remnant with 
the same m/z ratio as identified, offers a potential explanation for the presence of 
the TAG remnant and lack of HUE and HNE seen in PN bags. The specific TAGs 
liable to breakdown and the chemical processes resulting in the TAG remnant 
formation are discussed further in chapter 7.  
  
298 
 
 
Figure 6.47 Production of HUE in non-light protected syringes and PN bags with 50 ml of SMOFlipid® 
over 84 days storage. 
 
 
Figure 6.48 TAG remnant production in non-light protected SMOFlipid® room temperature syringes and 
PN bags over 84 days storage. 
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Lipid Formulation Comparisons, 
Discussion and Conclusions 
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The following chapter is divided into two main sections, initially the comparison of 
SMOFLipid® and Intralipid® results in the four previous chapters followed by 
discussion of the results and conclusions from this thesis.  
7.1. Introduction to SMOFlipid® and Intralipid® comparisons 
 
Due to the large amount of data presented in the previous chapters, comparisons 
between each of the two lipid formulations tested is presented in the following text 
by dividing results into the following sections;  
• Peroxidation products monitored (HNE, HUE and TAG remnant). 
• Unsaturated TAGs monitored (peaks 5 to 10) are compared considering light 
protected and non-light protected results and differences between 
temperatures of storage 
• Saturated TAG losses only seen in SMOFlipid® are discussed with 
comparisons between light and non-light protection and temperature.  
• All of the monitored TAGs (1 to 10) comparisons are presented split into 
each container type followed by comparison between containers for each 
lipid.  
 
7.2. Peroxidation product comparisons 
 
7.2.1. 4-Hydroxynonenal (HNE)  
HNE was detected in syringes of both lipid formulations at both temperatures (room 
22oC and fridge, 4oC). Figure 7.1 presents this data showing Intralipid® and 
SMOFlipid® in light protected and non-light protected syringes at room and fridge 
temperatures. Maximal HNE was found in non-light protected SMOFlipid® room 
temperature syringes at a concentration of 13.65 µM. As previously discussed in the 
method validation section for HNE (chapter 2), the limit of quantification (LOQ) was 
established as 8.974 µM and is shown on the graph. As indicated, results at day 84 
for all syringes except SMOFlipid® and Intralipid® fridge temperature (2 to 8oC) fall 
above the LOQ and can therefore be considered accurate. The maximal 
concentrations at day 84 for each syringe are shown in table 7.1. Temperature has 
a minimal effect on the amount of HNE produced for all lipids, producing an average 
of 1.76 µM difference between temperatures.   
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Figure 7.1 HNE production in SMOFlipid® and Intralipid® syringes. 
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Table 7.1 Maximal concentrations of HNE produced in lipid syringes. 
Lipid type Room or Fridge 
Temperature 
Light (LP) or Non-
light (NLP) 
protection 
Concentration at 
day 84 (µM) 
SMOFlipid® Room NLP 13.655 
SMOFlipid® Fridge NLP 10.20 
SMOFlipid® Room LP 9.57 
SMOFlipid® Fridge LP 8.47 (under LOQ) 
Intralipid® Room NLP 10.18 
Intralipid® Fridge NLP 9.36 
Intralipid® Room LP 10.07 
Intralipid® Fridge LP 8.39 (under LOQ) 
 
Light protection for SMOFlipid® syringes had a positive effect in reducing the level of 
HNE produced by 4.08 µM (approximately a third). It was predicted that non-light 
protected syringes would produce more HNE than light protected syringes due to 
the potential for light-initiated peroxidation (photo-oxidation) to occur in addition to 
‘standard’ peroxidation and TAG breakdown. This is as shown in SMOFlipid®, 
however little difference (<1 µM) is observed in Intralipid® syringes indicating that 
minimal HNE is produced by photo-oxidation.  
HNE as discussed in chapter 1 is produced through the peroxidation and 
breakdown of linoleic acid (C18:2) through production of a primary hydroperoxide at 
the 9’ position (denoted from the free methyl end) of the fatty acid as shown in figure 
5.51 (chapter 5) and subsequent cleavage producing HNE and a fatty acid remnant 
attached to the TAG backbone. Linoleic acid is found in relatively high 
concentrations in SMOFlipid® (14 to 25%) but in significantly greater amounts in 
Intralipid® (44 to 62%) (Eriksson 2001; Kabi 2018) and as such it would be predicted 
that under the same conditions, Intralipid® should create more HNE than 
SMOFlipid®. Results contradict this however, with SMOFlipid® NLP room 
temperature syringes producing ~4 µM more HNE than Intralipid® under the same 
conditions. One explanation for the results observed is that more overall 
peroxidation (and thus many different oxidation products) is occurring in SMOFlipid® 
than Intralipid® due to the presence of multiple poly-unsaturated TAGs in 
SMOFlipid® from both soybean (C18:3, C18:2 and C18:1) and fish oil (C20:5, 
C22:6). Whilst minimal and as such not monitored with the assay used in this work, 
the multiple double bonds in fish oil are liable to peroxidation, creating more lipid 
radicals than found in Intralipid®. As discussed in chapter 1, lipid peroxidation and 
breakdown is a self-propagating cyclical reaction and therefore the greater number 
of lipid radicals present, the greater the rate and amount of peroxidative breakdown, 
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ultimately leading to the largest amounts of secondary products created. Thus, this 
breakdown does not necessarily resulting in a single product formation, i.e. HNE.  
As discussed in previous results chapters and shown in figure 5.51 (chapter 5) the 
peroxidation of linoleic acid can lead to multiple secondary peroxidation products, 
HNE being only one of them. The assay developed and used only detects HNE, 
HUE and a TAG remnant. All syringes tested in both lipids undergo significant TAG 
losses as shown in subsequent sections except NLP SMOFlipid® room temperature 
syringes which conversely show the highest levels of HNE. Whilst the multiple levels 
of unsaturation present in fish oils when in combination with other oils within an 
emulsion could increase the levels of peroxidation present in vitro, when considering 
the important fact that this work deals with IVLE’s for infusion to patients, in vivo fish 
oils have been shown to reduce the levels of HNE formed within cells (Ishikado et 
al. 2013).  
When considering the relevance of the detection of HNE within syringes, all 
produced a concentration of ~ 10 µM or above upon storage. Esterbauer, Schaur 
and Zollner’s work (1991) on the toxicity of HNE provides an extensive review on 
the in vivo toxicity of HNE. The review states “HNE concentrations in the range of 1 
to 20 µM can inhibit DNA and protein synthesis, stimulate phospholipase A2 and 
inhibit c-myc expression.” All the syringes tested other than the light protected fridge 
samples produced HNE at concentrations within this range and as such can be 
considered to be within toxic levels. It is noteworthy however that whilst this 
concentration of HNE is present within the lipids tested and therefore have the 
potential to be infused into the patient, this level of lipid would then be dispersed 
throughout a patient’s blood volume, reducing the systemic concentration of HNE 
compared to that found within the syringes. The levels produced however are 
significant and important in the clinical development of future lipid emulsions and 
storage containers.  
As discussed in chapter 1, many recent works exist implicating HNE in multiple 
disease pathologies including cancer, colorectal inflammation, metabolic and 
neurological disorders (Esterbauer et al. 1991; Chen et al. 2006; Castro et al. 2016; 
Rossin et al. 2016; Zarkovic et al. 2016). With specific regards to PN patients, 
plasma adducts of protein-HNE was shown to be raised in long term home PN 
patients albeit in a small sample population (41) indicating the delivery of HNE 
within PN correlates to an increase in plasma levels (Massorenti et al. 2004). The 
results obtained are therefore clinically relevant and of importance when considering 
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the delivery of lipids to neonatal patients. The work within this thesis was designed 
to test lipid emulsions in 50 ml quantities replicating the amount and storage of lipids 
administered to neonatal patients. The detection of HNE within syringes is important 
as current clinical practise involves the storage and delivery of neonatal PN lipids in 
50 ml syringes. Recent clinical safety concerns have been raised over the 
inappropriateness of syringes as storage devices due to the permeability of oxygen 
and the potential for leachables to enter stored components. As such there is a 
drive to move small volume lipids from syringes to small volume PN bags. With 
regards to the HNE data acquired during this work, the results substantiate this 
recommendation as HNE was only detected in syringes and not in PN bags.  
7.2.2. Hydroxy-undecanal (HUE) 
 
HUE was identified through mass spectrometry as shown in chapter 3 section 
3.8.3.1 and formed from the peroxidation of omega-9 TAGs containing oleic acid 
(C18:1). Oleic acid peroxidation requires much greater bond dissociation energy 
(approx. 10kcal/mol) to abstract a hydrogen than in the case of linoleic or linolenic 
acids (C18:2 & C18:3) due to the singular double bond and therefore relatively 
‘stable’ electron pairs. As such the identification of HUE within lipids confers high 
levels of energy within a system and therefore the potential for extensive 
peroxidation to be present. As the assay was developed to detect HNE and 
validated accordingly and due to the lack of an available standard of HUE for 
validation purposes, results are presented as peak area rather than concentration. 
Limits of detection and quantification cannot be established in terms of 
concentration again due to a lack of validation, however a signal to noise ratio for 
the HUE peak could be established. From this a LOD and LOQ using a signal to 
noise ratio of >3 and >10 respectively (Synder et al. 1997) could be used to monitor 
each HUE peak recorded to ensure some precision within the results presented. All 
results had a signal to noise ratio above 10. Both SMOFlipid® and Intralipid® created 
HUE through storage in syringes and in PN bags. Results were significantly higher 
in syringes than PN bags for both lipids. Room temperature Intralipid® and 
SMOFlipid® light protected syringes produced maximum levels of HUE over 84 
days. All light protected containers for both lipids produced significantly more HUE 
than non-light protected containers. This is of interest as non-light protected 
containers were predicted to produce more HUE due to light exposure and photo-
oxidation potential. Results indicate a lack of photo-oxidation processes occurring 
with both lipids tested. The light protection employed aluminium foil wraps and it can 
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be postulated that this could cause an insulation effect on the container, increasing 
temperature of the lipid leading to the results observed. It is again worth noting that 
the assay developed and used was designed to detect HNE and as such monitors a 
specific wavelength of 222 nm. Therefore, results shown cannot conclusively 
determine if other secondary peroxidation products other than HNE and HUE are 
being created and not visualised at this specific wavelength. Further work beyond 
the scope of this thesis using a variable wavelength or diode array detector could 
determine the presence of further peroxidation products and establish an overall 
picture on the levels of secondary or end products of peroxidation present within 
samples.  
Figures 7.2, 7.3 and 7.4 graphically show the data recorded for each container 
where HUE was detected. As shown, all light protected syringes produced 
significantly more HUE than non-light protected containers as discussed above. 
Temperature of storage influenced HUE production as predicted with room 
temperature syringes and PN bags producing more HUE than fridge storage. PN 
storage within a clinical setting is always within fridge temperatures and results 
substantiate the necessity for this to continue. With regards to the rate of HUE 
production, all room temperature syringes created HUE at a relatively steady rate as 
shown within the graphical figures from within the first week of storage. This is 
significant as current practise limits small volume lipids for neonatal patients to less 
than 7 days storage. The presence of HUE within the initial days of testing is of 
clinical importance when considering the infusion of such lipids into neonatal 
premature patients who will already be under high levels of oxidative stress. Whilst 
HUE confers less toxicity than HNE (Eckl et al. 1993) its presence in infused lipids 
could potentially cause harm to a patient if there innate antioxidant systems are 
already stressed. The results for PN bags differ from syringes in their capacity to 
limit HUE formation during initial storage. Only room temperature PN bags produced 
detectable levels of HUE and only from day 14 onwards, indicating that with respect 
to secondary peroxidation products PN bag storage is superior to syringe storage of 
lipids. A caveat to this however is that the assay and work is detecting secondary 
peroxidation products, i.e. end stage peroxidation products. Whilst the results 
indicate greater levels of peroxidation in syringes than PN bags, consideration must 
be given to the primary products of peroxidation, namely lipid hydroperoxides. 
Whilst results above indicate PN bag storage is superior to syringe storage, TAG 
losses occurring the PN bags is far higher than within syringe indicating higher 
levels of peroxidation or TAG breakdown in bags. One explanation for these results 
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that seem to contradict each other is the possibility of peroxidation within PN bags is 
occurring but at testing products present are primary products namely lipid 
hydroperoxides. As such this would be indicated by TAG losses with an apparent 
lack of secondary peroxidation products as shown in the data. PN bags are 
impermeable to oxygen whereas syringes permit oxygen to leak into the storage 
system over time. One can postulate that this increase in oxygen is catalysing the 
cleavage of short chain aldehydes from lipid hydroperoxides resulting in the raised 
levels of secondary products seen within syringes. The limited supply of oxygen 
within impermeable PN bags however is being used for initiation and propagation of 
peroxidation and resulting in the formation of hydroperoxides that are then held in 
‘stasis’ and therefore a lack of secondary products is recorded. Beyond the scope of 
this work, further studies detecting the presence and levels of hydroperoxides, 
whilst complicated and often not accurate, would prove the presence of 
hydroperoxides within PN bags.  
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Figure 7.2 HUE production in SMOFlipid® containers Standard deviation error bars indicated on results. 
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Figure 7.3 HUE production in Intralipid® containers. Standard deviation error bars indicated on results. 
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Figure 7.4 HUE production across all containers of SMOFlipid® and Intralipid® both light and non-light protected at fridge and room temperatures. 
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As predicted, removal of oxygen from the storage system results in an apparent lack 
of peroxidation when considering the detection of secondary peroxidation products. 
No HUE or HNE was detected in any of the glass vials tested that were purged with 
nitrogen to remove atmospheric air. The results substantiate the necessity of 
oxygen in the production of secondary products within the lipid emulsions tested. 
7.2.3. TAG remnant 
 
The TAG ‘remnant’ was identified through mass spectrometry in chapter 3 section 
3.8.3.2. The proposed production of this remnant at the stage of initial identification 
was from the cleavage of HUE (x2) and HNE (x1) from peak 7 TAG 
(C18:1/18:1/18:2). As shown schematically in figure 7.5 the TAG remnant with a m/z 
of 495.4 could also be from the breakdown of peak 5 (c18:2/18:2/18:2) or peak 10 
(18:2/18:1/16:0) as well as peak 7 (C18:1/18:1/18:2). The level of TAG loss of each 
of these peaks is discussed section 7.4, but broadly all undergo TAG loss during 
storage in both lipid formulations. As shown the production of a remnant with the 
m/z of 495 from peak 5 (C18:2/18:2/18:2) involves a loss of one HNE molecule and 
a process different than the typical peroxidative cleavage of an aldehyde from the 
end of one of the other linoleic acid chains. Hydrolysis of the ester bond between 
the fatty acid and the glycerol backbone of the TAG is instead the process that 
leads to the production of a diacylglyceride remnant that has a m/z ratio of 495. 
Whist considered unlikely within an oil, the presence of extensive water within a lipid 
emulsion and therefore the interaction between water and TAGs at the oil-to-water 
interface makes hydrolysis of TAGs within emulsions a possibility. The extensive 
losses of the saturated TAGs found in SMOFlipid® and discussed in section 7.3 
substantiate this. The production of the remnant from peak 10 (C18:2/18:1/16:0) 
also involves the hydrolytic cleavage of the saturated palmitic acid chain from the 
glycerol backbone. Whilst the work cannot definitively ascertain which peak’s 
breakdown is responsible for the production of the TAG remnant seen, peroxidation 
is more likely than hydrolysis. This is due to the limited amounts of appropriate 
TAGs that would be at the oil-water interface to undergo hydrolysis and the 
presence of both HNE and relatively high levels of HUE within the results as 
discussed above and as such the production of the remnant from Peak 7 
(C18:1/18:1/18:2) is probable.  
As discussed above in HUE results an analytical standard for the TAG remnant 
molecule was not obtainable and therefore results cannot be validated. LOD’s and 
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LOQ’s were calculated as signal to noise ratios as with HUE and all results were 
above 10 conferring a level of reliability. Results are therefore presented as peak 
area rather than concentration.  
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Figure 7.5 Chemical reaction schematic of hydrolysis of fatty acid from TAG backbone and cleavage of HNE from TAG 5 (C18:2/18:2/18:2) producing TAG remnant. 
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Both lipid formulations results show the formation of the TAG remnant only at room 
temperature storage. All non-light protected containers produce substantially more 
remnant than light protected for both lipids. Differences are apparent between 
Intralipid® and SMOFlipid® when looking at the highest levels of remnant formation 
in each container type. All TAG remnant results are shown in figures 7.6, 7.7 and 
7.8. In SMOFlipid® maximal results were recorded in non-light protected PN bags. 
This is similar to the extensive TAG losses observed in PN. The Intralipid® results 
were highest in non-light protected syringes which also produced maximal levels of 
TAG losses for each of the six peaks monitored. This indicates that the highest 
levels of peroxidation are occurring in room temperature PN bags and syringes for 
SMOFlipid® and Intralipid® respectively.  
It was predicted that non-light protected containers would result in the highest levels 
of peroxidation as discussed in chapter 1 due to the potential for photo-oxidation to 
occur as well as the ‘standard’ initiation pathways for peroxidation. Results 
substantiate this in respect to levels of TAG remnant seen. HUE production as 
discussed above is higher in light protected containers, however significant amounts 
are also produced in non-light protected lipids, whilst conversely HNE is higher in 
non-light protected SMOFlipid® syringes. When considering which pathways of 
peroxidation are responsible for the products detected, from the results obtained it is 
not possible to definitively ascertain the level of photo-oxidation occurring in any 
containers. The TAG remnant and HNE results indicate a definite increase in 
peroxidation occurring in non-light protected containers and as such it can be 
postulated that light exposure is a catalyst for peroxidation suggesting the presence 
of a level of photo-oxidation within SMOFlipid® PN bags and Intralipid syringes.  
 The lack of TAG remnant seen in fridge temperature containers is of interest, 
though it is noteworthy that whilst non-light protection was employed, when placed 
within a refrigerator, containers are stored in the dark and as such only experience 
limited light exposure upon their removal for sampling. This is a definite limitation to 
the fridge temperature work with respect to non-light protection, however within a 
clinical setting all containers are refrigerated and as such the results between light 
and non-light protected containers held at such temperatures is relevant and 
discussed in subsequent sections. 
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Figure 7.6 TAG remnant production within SMOFlipid® room temperature containers. Standard deviation error bars indicated on results.  
0
2
4
6
8
10
12
14
16
18
20
0 10 20 30 40 50 60 70 80 90
P
ea
k 
ar
ea
 (
A
U
)
Day of testing
SMOFlipid® TAG Remnant production
SMOFlipid® Light protected room temperature syringes SMOFlipid® Non-light protected room temperature syringes
SMOFlipid® Light protected room temperature PN bags SMOFlipid® Non-light protceted room temperature PN bags
315 
 
 
Figure 7.7 TAG remnant production in Intralipid® room temperature containers. Standard deviation error bars indicated on results.  
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Figure 7.8 TAG remnant production in all containers of SMOFlipid® and Intralipid®.  
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Collectively the terminal products detected and monitored within this work (HNE, 
HUE, TAG remnant) show the presence of peroxidation within all PN bags and 
syringes. Whilst a lack of TAG remnant was seen in all fridge temperature 
containers, and results show a significant reduction in terminal products within 
refrigerated containers, quantifiable levels were still detected and whilst only HNE 
concentrations can be definitively determined, even at fridge temperatures up to 
~10 µM concentrations were detected within both SMOFlipid® and Intralipid® 
syringes. This is critically important as this work was designed to give an initial set 
of data that explored the potential for chemical breakdown of lipids to occur during 
storage as per common clinical practise before delivery to the patient. The 
identification of secondary peroxidation products from as little as two days onwards 
in fridge temperature containers is clinically relevant and suggests that an update to 
clinical protocols may be required. This is discussed further in section 7.8. 
7.3. Saturated TAG losses in SMOFlipid® 
 
The following sections deal with the comparison between containers, non-light and 
light protection and temperatures of storage of SMOFlipid®. Saturated peaks 1 to 4 
(C8:0/8:0/8:0, C8:0/8:0/10:0, C8:0/10:0/10:0 and C10:0/10:0/10:0) are present only 
within SMOFlipid® from chemically synthesised fatty acids derived from coconut oil. 
Each peaks’ results are presented in the following subsections. As previously 
discussed in chapters 5 and 6, such saturated TAGs should be resistant to 
peroxidative breakdown due to the lack of unsaturation. The losses observed are 
therefore due to a different chemical degeneration postulated to be hydrolysis and 
cleavage of fatty acids from the TAG glycerol backbone. The presence of relatively 
high levels of water within SMOFlipid® emulsions and the potential for an lipid 
hydroperoxides to be present (R-COO/R-COOH) from peroxidation of unsaturated 
TAGs create conditions where hydrolytic cleavage at the ester linkage of the fatty 
acid can occur, creating the results discussed below.  
7.3.1. Peak 1 (C8:0/8:0/8:0) 
 
Figure 7.9 shows the % losses of peak 1 observed in all SMOFlipid® containers. As 
shown, light protected PN bags both room and fridge showed maximal losses of 
over 40 % and ~ 27 % respectively at day 56. Data within the graph for each 
container is only included up to the point where RSD’s for control samples were 
within acceptable limits (<12). The light protected glass vials recorded the second 
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highest TAG losses seen. As discussed in chapter 5, the high levels of TAG losses 
observed in glass vials from day 28 onwards for all peaks was potentially due to 
ingress of oxygen within the system during sampling resulting in the initiation of 
peroxidation. The lack of secondary products within these vials suggests that 
peroxidation may be in the propagation phase and be in the form of hydroperoxides. 
Such lipid primary products would result in a lowering of pH favouring hydrolytic 
reactions and producing the cleavage of fatty acids from the TAG as shown in the 
graph for peak 1.  
Whilst light protected results showed significant losses for all containers, non-light 
protected also produced losses, particularly within PN bags suggesting that light 
protection was not a dependant factor in limiting peroxidative hydrolysis from 
occurring. Both syringe results are of interest as little TAG 1 losses are observed in 
non-light protected samples but up to ~ 25 % of loss in light protected syringes. As 
discussed in subsequent unsaturated sections non-light protected syringes showed 
minimal losses throughout all peaks monitored whereas light protected syringes 
produced significant loss again substantiating the lack of importance of light 
protection of syringes when considering this pathway of degradation.   
Temperature of storage does have a significant effect on light protected storage with 
greater losses observed in room temperature syringes, PN bags and vials. Non-light 
protected results for this peak across all containers are not affected by temperature 
of storage. Higher temperatures of storage would be predicted to catalyse 
hydrolysis reactions occurring and result in higher TAG losses. This whilst observed 
in light protected results is contradicted by the non-light protected containers. The 
results when considered separately suggest that temperature of storage influences 
PN bags to a greater extent than syringes, a trend that is seen across all 
peaks/TAGs monitored in SMOFlipid®. The oxygen availability within each container 
must be considered as an overarching factor limiting the occurrence of peroxidation 
and subsequent hydrolysis and can explain the losses observed in different 
containers. This is discussed in detail in section 7.8. 
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Figure 7.9 Peak 1 (C8:0/8:0/8:0) losses in SMOFlipid® containers at room and fridge temperatures.  
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7.3.2. Peak 2 (C8:0/8:0/10:0) 
 
Results for peak 2 as shown in figure 7.10 show similar trends as for the peak 1 
results discussed above. Light protected results for all containers show significantly 
more loss than non-light protected results. PN bags give maximal losses of 35 % at 
room temperature at 56 days. Light protected glass vials also show significant loss 
suggesting oxygen ingress as discussed above. Within syringes, minimal loss is 
observed in non-light protected samples however light protected syringes do show 
significant loss of ~ 20 % over 84 days. This substantiates the results seen in peak 
1 and suggest that non-light protection and as such photo-oxidation is not present in 
significant quantities within SMOFlipid® containers.  
The initial rate of saturated loss observed is greater in PN bags than within syringes. 
Light protected syringes only show evidence of hydrolysis and peak 2 loss from day 
28 and significant loss (more than ~ 5 %) from day 56 onwards. Conversely PN 
bags show significant TAG loss by day 14. The availability of oxygen within syringes 
and bags must be considered when looking at the levels of TAG loss observed. PN 
bags are formulated with a small but finite volume of air left in them and as such 
oxygen is present both within this air bubble and dissolved within the lipid from the 
manufacturing process which utilises a syringe to draw lipid from its raw material 
container, a process which can result in dissolved oxygen forming within the lipid. It 
is postulated that this available oxygen from day 0 of storage within PN bags results 
in the rapid onset of peroxidation and hydrolysis seen and therefore the higher initial 
TAG losses observed. Syringes however have minimal levels of air and oxygen 
present initially as all non-dissolved air is completely removed at manufacturing. 
Therefore, peroxidation, hydrolysis and TAG losses are only observed upon air 
ingress into the syringe due to leakage into the system over time between the barrel 
of the syringe and the rubber plunger resulting in the slower rates of saturated TAG 
losses observed. As discussed in pervious sections, hydrolysis and subsequent 
TAG loss appeared to only occur when significant unsaturated peroxidation was 
detected, i.e. when high levels of radicals, hydroperoxides and secondary products 
are present (high levels of energy).  
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Figure 7.10 Peak 2 (C8:0/8:0/10:0) TAG loss observed in SMOFlipid® in all containers at room and fridge temperatures. 
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Temperature has a similar effect to peak 1 results and is implicated in the level of 
hydrolysis occurring within PN bags and glass vials. To a lesser extent, light 
protected syringes only show a ~2 % variation between temperatures. When 
considering peak 1 and 2 collectively it was predicted that levels of loss should be 
similar between peaks due to the lack of selectiveness of hydrolytic cleavage of 
saturated fatty acids. This is substantiated in the results with less than a 5 % 
difference observed between peaks for each container subset of results.  
7.3.3. Peak 3 (C8:0/10:0/10:0) 
 
As figure 7.11 displays, the results for peak 3 follow the same trends as recorded for 
peaks 1 and 2. Temperature had a much larger effect in light protected containers 
than non-light protected ones particularly for PN bags and glass vials. Syringes 
again show less of a difference than with non-light protected results showing 
minimal (< 5 %) TAG losses for both temperatures and ~3 % difference between 
light protected syringes. It can be postulated that the combination of oxygen 
availability and temperature are limiting factors on the rate and extent of 
peroxidation and hydrolysis. PN bags where oxygen is available from day 0 suffer 
greater losses which are limited by fridge temperature storage. Syringes where 
oxygen in only available over prolonged storage times show less TAG loss and as 
such temperature has less of an effect on loss occurring.  
The results for all saturated peaks as shown in figures 7.9 to 7.12 show the TAG 
losses occurring in all SMOFlipid® containers over up to 84 days. Of interest is the 
fluctuations observed in results over time. It was predicted that losses occurring 
should increase over time and whist this is the case in the majority of results and 
represents an overall trend, results appear to reduce in % loss at certain data points 
(e.g. Day 56 Non-light protected PN bag results). Whilst no definitive explanation 
can be formed from this work and the results obtained, several potential reasons for 
the fluctuation in results can be postulated. For minor deviations from the above 
trend, variation in control samples below the acceptable RSD level of 12 will create 
minor deviations in the results obtained for the tested samples including the 
reduction in results observed. The large deviations in results as shown in the PN 
bag day 56 results show the potential for condensation reactions to occur between 
cleaved and therefore ‘free’ fatty acids and the OH of the glycerol backbone, 
reforming saturated TAGs and resulting in the reductions observed in TAG loss. It 
can be postulated that the availability of water within the emulsion and the presence 
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of TAGs at the water-oil interface will govern the losses or reformations of TAGs 
observed.  
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Figure 7.11 Peak 3 (C8:0/10:0/10:0) TAG losses in all containers at room and fridge temperatures. 
0
5
10
15
20
25
30
35
40
0 10 20 30 40 50 60 70 80 90
%
 lo
ss
Day of testing
Peak 3 % loss to 84 days
SMOFlipid® light protected room temperature syringes SMOFlipid® Non-light protected room temperature syringes
SMOFlipid® light protected fridge temperature syringes SMOFlipid® Non-light protected fridge temperature syringes
SMOFlipid® Light protected room temperature PN bags SMOFlipid® Non-light protected room temperature PN bags
SMOFlipid® Light protected fridge temperature PN bags SMOFlipid® Non-light protected fridge temperature PN bags
SMOFlipid® Light protected room temperature vials SMOFlipid® Non-light protected room temperature vials
SMOFlipid® Light protected fridge temperature vials SMOFlipid® Non-light protected fridge temperature vials
325 
 
7.3.4. Peak 4 (C10:0/10:0/10:0) 
 
Figure 7.12 shows the results for all SMOFlipid® containers and follows similar 
trends in loss to those discussed in all the previous peaks (1 to 3). Peak 4 light 
protected PN bags held at room temperature produced the maximum loss observed 
(37%). Lower temperature had a significant effect on light protected containers, 
reducing % loss in each by up to 15 % (light protected glass vials). Within syringes 
minimal loss was observed throughout 84 days in non-light protected results and up 
to 56 days in light protected samples, suggesting the initiation of peroxidation only 
upon oxygen ingress during extended storage times. The conclusions drawn above 
for the previous 3 peaks and all saturated TAGs (C8:0/8:0/8:0, C8:0/8:0/10:0, 
C8:0/10:0/10:0, C10:0/10:0/10:0) are applicable to all peaks 1 to 4 and show that 
when considering saturated TAG loss and hydrolysis occurring chain length (C8 to 
C10) does not affect levels of cleavage and loss.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
326 
 
 
Figure 7.12 Peak 4 (C10:0/10:0/10:0) % losses in all SMOFlipid® containers at room and fridge temperatures. 
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7.4. Unsaturated TAG losses in Intralipid® and SMOFlipid® 
 
The following comparisons between each lipid, container and mode of storage are 
presented in graphical form. Each lipid is compared in each container both light 
protected and non-light protected. The large amount of data present prevents 
graphical representation of all results together and therefore they are split as 
described above (section 7.1) to enable comparisons to be drawn. Each peak (5 to 
10) are discussed in the following subsections. All results displayed are those where 
control sample RSD’s were below 12 and therefore considered reliable. Therefore, 
whilst all available data is plotted (up to day 84), day 28 results for syringes and day 
56 results for PN bags and vials serve as the points at which main comparisons are 
drawn as this timepoint is the latest at which all tested containers have reliable 
results. 
As discussed within the assay validation section in chapter 2, limits of detection 
(LOD) and limits of quantification (LOQ) for TAG losses were unable to be 
calculated from the validation protocols due to the lack of available standards for 
calibration. Using a signal to noise ratio for each peak, an LOD and LOQ were 
however established as a minimum % TAG remaining. All of the following results for 
peaks 5 to 10 show results that were recorded to be well below the maximum loss 
that would result in being under the LOQ for each peak. Therefore, all results 
displayed in the following sections were deemed quantifiable.  
 
7.4.1. Peak 5 (C18:2/18:2/18:2) 
7.4.1.1. Syringes 
 
Figure 7.13 shows peak 5 results for both lipids in each container in light protected 
and non-light protected samples. In syringes Intralipid® both light and non-light 
protected show larger losses than SMOFlipid® syringes. Room temperature non-
light protected Intralipid® syringes show maximal losses of 25 % at 28 days storage. 
Light protected Intralipid® results were ~10 % lower than non-light protected 
samples and indicate that within Intralipid®, light exposure had an effect on 
peroxidation and TAG loss occurring. Peak 5 contains three linoleic fatty acids 
(C18:2) which were predicted to be highly susceptible to peroxidation due to their 
level of unsaturation. The TAG losses observed substantiate this as does this TAG 
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loss when HUE and TAG remnant productions are also collectively considered. Both 
HUE production and TAG remnant formation were high in Intralipid® room 
temperature non-light protected results, however HUE formation was increased in 
light protected syringes. The results with the TAG losses observed for Intralipid® 
indicate high levels of peroxidation, and it can be postulated that a level of photo-
oxidation is occurring within syringes. The process of photo-oxidation favours the 
formation of different hydro-peroxides (Porter et al. 1995). As discussed in section 
5.7.3 (chapter 5), four potential hydroperoxides are formed from the peroxidation of 
linoleic acid, however auto-oxidation (‘standard’ peroxidation) favours the formation 
of two hydroperoxides at the 9’ and 13’ positions. Photo-oxidation has the ability to 
form all four hydroperoxides and whilst beyond the scope of this work, detection of 
these four hydroperoxides within the lipids tested would provide confirmation of the 
occurrence of photo-oxidation of linoleic acid.  
SMOFlipid® syringes showed markedly less peroxidation and % loss of peak 5 in 
both light and non-light protected samples except for fridge temperature light 
protected results that gave a maximum of ~15 % loss at 28 days. All other 
SMOFlipid® syringes gave no detectable levels of loss at 28 days suggesting a lack 
of peroxidation. It is postulated that the lack of initial available oxygen within the 
syringe system inhibits the initiation of peroxidation. The extensive loss seen in 
Intralipid® at the same timepoint however contradicts this and as such the large 
difference in loss between the two lipids tested needs to be further considered. The 
addition of vitamin E within SMOFlipid® and its absence in Intralipid® provides a 
possible explanation for the lack of peroxidation shown however when considering 
loss of the same peak in PN bags, SMOFlipid® showed the greatest losses. 
Therefore, the anti-oxidant activity of the added tocopherols does not provide an 
adequate explanation for the syringe losses observed. 
It can be postulated that the vulnerability of each lipid emulsion to photo-oxidation 
may be different due to the higher numbers of different TAGs observed within 
SMOFlipid® and the lower concentration of linoleic acid containing TAGs compared 
to Intralipid®. The light exposure and surface area of exposure in all syringes tested 
was constant, however when considering the TAGs present at the edge of each oil 
globule within an emulsion, i.e. the TAGs that would have physical exposure to light, 
the increase in TAGs present within SMOFlipid® of which four do not contain linoleic 
acid, would lead to less numbers of peak 5 (C18:2/18:2/18:2) physically exposed to 
light and could explain the apparent lack of TAG loss observed. When considering 
the result within SMOFlipid® and the HNE, HUE and TAG remnant production 
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collectively, positive production of all the secondary products suggests peroxidation 
is occurring within syringes. The lack of losses observed at day 28 for both light 
protected and non-light protected samples suggests a delay in peroxidation. Beyond 
28 days, the RSD’s of control samples for days 56 and 84 for non-light protected 
SMOFlipid® syringes fell outside of acceptable levels and were therefore excluded 
from analysis. The day 56 and 84 results for light protected SMOFlipid® syringes are 
however recorded and deemed precise and show peak 5 TAG loss occurring up to 
~ 20 % at both temperatures. As such it is postulated that TAG losses and 
subsequent production of secondary products is delayed but present in all 
SMOFlipid® syringes.  
Temperature had a significant effect (~ 15 %) in Intralipid® non-light protected 
syringes, however little difference is observed in light protected results in both lipids. 
As such this suggests that the potential for photo-oxidation is inhibited by fridge 
temperature storage.  
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Figure 7.13 Peak 5 (C18:2/18:2/18:2) TAG losses occurring in 50 ml syringes of SMOFlipid® (blue traces) and Intralipid® (pink/purple traces). 
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7.4.1.2. PN bags 
 
RSD’s of control samples for both lipids for PN bag results were within acceptable 
levels for all results up to and including day 56. As such, day 56 is considered as a 
point of comparison between PN bags, however day 28 results are also considered 
to enable comparison between syringes and bags.  
As shown in figure 7.14 within PN bags light protected results for both lipids gave 
maximal losses of 40 % for SMOFlipid® and ~28 % for Intralipid® both at room 
temperature, in contrast to syringe results where non-light protected results were 
maximal. Total losses observed for PN bags were similar to syringes at day 28, with 
extensive losses occurring in later storage periods (55 and 84).  Within PN bags all 
light protected samples suffered greater losses than non-light protected results 
suggesting that photo-oxidation within PN bags is not an extensive mechanism of 
peroxidation.  
Temperature of storage had a significant (7 to ~15 %) effect on limiting peak 5 
(C18:2/18:2/18:2) TAG loss in SMOFlipid® containers both light and non-light 
protected, however results show little effect in inhibition of loss within all Intralipid® 
bags at day 84. As discussed above with syringes, both temperature and oxygen 
availability were predicted to be limiting factors on the occurrence of peroxidation 
and subsequent TAG loss. 
Within PN bags of both lipids a limited finite amount of atmospheric air is left within 
each container upon manufacturing. The presence of such oxygen from day 0 and 
raised temperatures are postulated to cause the initiation of and catalyse 
peroxidation creating TAG losses observed.  When considering the peak 5 TAG 
loss within PN bags collectively with the secondary peroxidation products discussed 
in previous sections, only the TAG remnant was detected within PN bags of 
SMOFlipid®, whilst the TAG remnant and minimal levels of HUE were shown within 
Intralipid®. These results when considered collectively with the greater TAG losses 
in SMOFlipid® with lower levels of secondary products suggest that within 
SMOFlipid® the stage of peroxidation may differ to that within Intralipid® at each 
time-point of testing. The initial primary peroxidation products of lipid 
hydroperoxides are as previously discussed not detected through this assay. As 
such, it is postulated that within PN bags SMOFlipid® peroxidation when tested 
through 84 days produced primary hydroperoxides, with lower amounts of 
secondary cleavages occurring than within Intralipid®. Whilst this explains the 
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apparent TAG loss in SMOFlipid® PN bags observed with the lack of HUE or HNE, 
the substantial production of the TAG remnant as shown in figure 7.6 is of interest. 
As previously postulated, the TAG remnant within Intralipid® and until now within 
SMOFlipid® was formed from the cleavage of secondary peroxidation products from 
peak 7 (C18:2/18:1/18:1). The results within PN bags however contradict this due to 
the presence of large amounts of the TAG remnant within SMOFlipid® but an 
absence of HUE or HNE. As such, it can be postulated that within such PN bags, 
which as shown in the saturated TAG loss figures 7.9 to 7.12 show the largest 
levels of hydrolysis, that the TAG remnant seen within these containers may be 
resultant from the cleavage of a fatty acid from peak 10 (C18:2/18:1/16:0) through 
hydrolysis. As discussed within the TAG remnant section above (7.2.3) further 
identification of the chemical structure of the TAG remnant beyond that carried out 
was not possible within this work, however future studies using a sensitive mass 
spectrometer and fragmentation analysis of this remnant would give a definitive 
answer to the TAG remnant composition. 
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Figure 7.14 Peak 5 (C18:2/18:2/18:2) TAG loss in SMOFlipid® and Intralipid® PN 250 ml PN bags filled with 50 ml of lipid. 
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7.4.1.3. Glass Vials 
 
RSD’s of control samples for all glass vials were acceptable up to and including day 
56 results and therefore are used for comparisons. As discussed through previous 
chapters glass vial results were designed to provide a comparative set of data to PN 
bags and syringes. Each vial was purged with nitrogen during production to remove 
atmospheric air and therefore exclude oxygen from the system during storage. This 
was designed to indicate the vital nature of oxygen within the peroxidation pathway 
and TAG losses observed within each lipid. As established previously, oxygen 
ingress at sampling times was observed within these vials and extensive TAG 
losses were therefore observed in both Intralipid® and SMOFlipid® light protected 
results. Light protected testing occurred prior to initiation of non-light protected 
testing and as such modification of the method occurred with nitrogen being passed 
through all vials at each sampling point. In response, a minimal level of peak 5 TAG 
loss is observed in all non-light protected results. Figure 7.15 shows the TAG losses 
for peak 5 (C18:2/18:2/18:2) in both lipids. As shown, SMOFlipid® light protected 
vials and Intralipid® light protected vials recorded maximal losses. Whilst due to the 
ingress of oxygen, the higher levels of loss in SMOFlipid® is postulated to be caused 
by a level of hydrolysis occurring as previously discussed. Such hydrolysis appears 
to be lacking within Intralipid® where peroxidation is the driving lipid breakdown 
pathway.  
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Figure 7.15 Peak 5 (C18:2/18:2/18:2) TAG loss occurring in SMOFlipid® and Intralipid® 50 ml glass vials. 
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7.4.1.4. Peak 5 (C18:2/18:2/18:2) conclusions 
 
Maximal TAG loss was observed in light protected SMOFlipid® PN bags (> 40 %) 
followed by Intralipid® non-light protected syringes (< 35 %). Temperature 
influenced non-light protected syringes, non-light and light protected PN bags of 
both lipids and fridge storage effectively reduced TAG loss occurring. Peak 5 TAG 
loss occurred in all containers at all temperatures of storage except non-light 
protected SMOFlipid® syringes although these results are only shown up to day 28 
due to control sample RSD drift. Hydrolysis reactions within peak 5 appear to occur 
within SMOFlipid® but not within Intralipid® and explain the large losses observed 
within SMOFlipid® PN bags and glass vials with the absence of recorded secondary 
peroxidation products other than the TAG remnant. It is postulated that the stage of 
peroxidation occurring within 84-day storage of SMOFlipid® is different 
(hydroperoxides) to that within Intralipid® where terminal peroxidation products are 
detected.  
7.4.2. Peak 6 (C18:2/18:2/18:1) 
7.4.2.1. Syringes  
 
As discussed in peak 5 comparisons RSD’s were acceptable within syringes until 
day 28 and as such this day of testing was used for comparisons. All light protected 
results within both lipids showed maximal losses recorded, suggesting a lack of 
photo-oxidation occurring within this TAG. Figure 7.16 shows the TAG loss 
observed within both lipids in syringes. At day 28, all syringes tested recorded a 
level of TAG loss, with temperature having a significant effect on loss observed, 
fridge temperatures inhibiting loss and therefore peroxidation occurring. 
Peroxidation and therefore TAG losses increase in all results except light protected 
SMOFlipid® fridge samples from day 14 onwards, substantiating previous 
conclusions that oxygen presence is vital in the initiation and propagation of 
peroxidation. As such syringe losses are limited initially as oxygen ingress is at a 
minimal rate due to leaking between the syringe barrel and plunger. Peroxidation of 
peak 6 (C18:2/18:2/18:1) is predicted to cleave each of the fatty acid chains, 
resulting in one molecule of HUE from oleic acid and the formation of secondary 
aldehydic products from linoleic acid, one of which being HNE. When considering 
the peak 6 syringe results collectively with the HNE and HUE, formation of HUE was 
highest in light protected Intralipid® and SMOFlipid® room temperature syringes, 
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which recorded ~35 % and ~20 % of peak 6 TAG loss, showing as predicted the 
peroxidation of oleic acid from peak 6. The production of HNE was however highest 
in SMOFlipid® non-light protected syringes, which showed little loss within peak 6 
and suggests that HNE production is from another TAG within the lipid.  
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Figure 7.16 Peak 6 (C18:2/18:2/18:1) TAG losses in SMOFlipid® and Intralipid® 50 ml syringes at room and fridge temperatures. 
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7.4.2.2. PN bags 
 
Within PN bags SMOFlipid® light protected results showed maximal peak 6 loss of 
>30 %. All light protected results for both lipids produced larger losses than non-
light protected results as shown in figure 7.17, suggesting a lack of photo-oxidation 
occurring. Rates of TAG loss and peroxidation unlike syringes was rapid initially and 
reduced over prolonged storage which, as postulated in peak 5 results, was due to 
the oxygen availability within the PN bags. The finite amount of air present within 
PN bags at the point of manufacturing leads to initial rapid peroxidation and TAG 
loss, with a tapering of the rate as oxygen is exhausted and the termination of 
peroxidation occurs.  
Whilst SMOFlipid® showed maximal loss, Intralipid® PN bags also showed extensive 
losses of >25 %. The breakdown of Peak 6 TAG (C18:2/18:2/18:1) would be 
predicted to formulate HUE and potentially HNE as discussed within syringe results. 
However, results obtained for PN bags showed no HNE formation within PN bags 
and minimal HUE production over 84 days, suggesting that losses observed within 
PN bags could be resultant from the peroxidation of the linoleic acid chains within 
the TAG at a position where the secondary product produced is not HNE but 
another secondary aldehyde and as such not detected through the assay. This 
explains the extensive losses observed with little HNE or HUE detected. 
7.4.2.3. Glass vials 
 
Glass vial results for peak 6 (C18:2/18:2/18:1) follow identical trends to peak 5 
losses. SMOFlipid® light protected vials show maximal losses followed by Intralipid® 
light protected vials which as discussed previously were tested first and as such the 
method of sampling used left the potential for ingress of oxygen within the vial, 
resulting in peroxidation and the TAG losses observed. All vials where nitrogen was 
used to purge air at all testing points showed minimal TAG loss over 84 days. As 
with peak 5 the higher TAG loss in SMOFlipid® was postulated to be due to an 
element of hydrolysis and peroxidation occurring. Figure 7.18 shows all peak 6 
(C18:2/18:2/18:1) TAG losses in glass vial samples tested.  
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Figure 7.17 Peak 6 (C18:2/18:2/18:1) TAG loss in SMOFlipid® and Intralipid® PN bags at room and fridge temperatures. 
0
5
10
15
20
25
30
35
0 10 20 30 40 50 60 70 80 90
%
 lo
ss
Day of testing
Peak 6 PN bags % losses
SMOFlipid® Light protected room temperature PN bags Intralipid® Light protected room temperature PN bags
SMOFlipid® Light protected fridge temperature PN bags Intralipid® Light protected fridge temperature PN bags
SMOFlipid® Non-light protected room temperature PN bags Intralipid® Non-light protected room temperature PN bags
SMOFlipid® Non-light protected fridge temperature PN bags Intralipid® Non-light protected fridge temperature PN bags
341 
 
 
Figure 7.18 Peak 6 (C18:2/18:2/18:1) TAG losses in SMOFlipid® and Intralipid® 50 ml glass vials at room and fridge temperatures. 
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7.4.2.4. Peak 6 conclusions 
 
Following similar trends as seen with peak 5 TAG losses, peak 6 loss was maximal 
in light protected SMOFlipid® PN bags followed by light protected Intralipid® syringes 
both at room temperatures. HUE formation within syringes suggests peak 6 TAG 
loss through oleic acid peroxidation. The lack of HNE and minimal HUE within 
SMOFlipid® PN bags suggests a level of hydrolysis is responsible for the TAG 
losses observed. Maximal losses observed within peak 6 are similar to the levels of 
loss observed in peak 5 across all containers tested. Light protected results in all 
containers showed maximal peak 6 (C18:2/18:2/18:1) TAG losses and a lack of 
photo-oxidation is concluded from these results.  
7.4.3. Peak 7 (C18:2/18:1/18:1) 
 
Peak 7 results are of particular interest as it is postulated that the TAG remnant 
formed is from the peroxidation of this TAG and the loss of HNE and HUE. As with 
all previous peaks container results are shown with comparisons between lipid 
formulations and levels of light protection drawn. 
7.4.3.1. Syringes 
 
As shown in figure 7.19 syringe results for peak 7 show maximal TAG losses 
occurring in non-light protected Intralipid® (~ 38 %) and light protected Intralipid® (~ 
34 %) syringes at room temperature, though fridge temperature also showed 
significant losses greater than all SMOFlipid® syringes tested. At day 28, 
SMOFlipid® light protected syringes showed peak 7 loss however non-light 
protected syringes showed no losses. This indicates the potential for the presence 
of a level of photo-oxidation to be present within Intralipid® and an apparent lack 
within SMOFlipid® syringes. Both lipids showed a significant effect when 
temperature of storage is considered, with fridge storage prohibiting loss occurring 
within Intralipid®. Within SMOFlipid® light protected results however recorded fridge 
temperature losses significantly greater than room temperature syringes. This 
indicates within these samples’ peroxidation was not inhibited by refrigeration.   
When considering the results collectively with secondary peroxidation product 
results, Intralipid® light protected syringes show high levels of HUE as does light 
protected SMOFlipid® syringes which, whilst smaller also show peak 7 TAG loss (15 
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– 20 %). The peroxidative breakdown of peak 7 to create the TAG remnant 
observed requires the cleavage of two molecules of HUE and one molecule of HNE. 
TAG remnant results show highest levels of production in Intralipid® non-light 
protected syringes (room temperature) which show the largest levels of peak 7 loss. 
HNE production of ~ 10 µM was also observed within these syringes which when 
considered collectively indicate the peroxidation of TAG 7, the cleavage of HNE and 
HUE and the formation of the TAG remnant within Intralipid® as previously 
predicted. Within SMOFlipid syringes, HNE production is maximal (non-light 
protected), a level of HUE production is observed (light protected) and TAG remnant 
production is present but minimal. The TAG losses observed within these syringes 
for peak 7 is minimal in light protected syringes and very low (< 1%) in non-light 
protected results suggesting that the production of the secondary products seen is 
due to minimal peak 7 peroxidation and due to other TAG breakdown. 
7.4.3.2. PN Bags 
 
PN bag results for peak 7 (C18:2/18:1/18:1) show markedly different trends to those 
observed in previous peaks (5 & 6).  At day 56 Intralipid® light protected and non-
light protected bags showed maximal loss (25 %) with no significant difference 
between temperatures of storage. SMOFlipid® PN bags in comparison to previous 
peaks discussed show significantly less loss for peak 7. Light protected results of (3 
– 12 %) for SMOFlipid® and (~3 to 20 %) for non-light protected PN bags at day 56 
show significant differences between temperatures of storage. All results for peak 7 
PN bags are presented in figure 7.20. 
When considered with the secondary product results discussed above, within PN 
bags the lack of HNE and minimal HUE detected suggests that the peroxidation 
within this TAG is unlikely to be due to cleavage of HNE and HUE as shown 
previously in syringes. There is however a level of TAG remnant produced within 
both SMOFlipid® and Intralipid® PN bags. This is of interest and suggests that the 
TAG remnant structure within these bags may be different to that observed within 
syringes and potentially be formed from the breakdown of a different TAG. The 
presence of significant losses within Intralipid® and the lack of HNE or HUE 
observed provides evidence for the presence of hydrolysis occurring within PN 
bags. Cleavage of one or more of the fatty acids from the TAG backbone of peak 7 
would result in the loss observed within PN bags and correspond to the lack of 
presence of secondary products.  
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Figure 7.1 Peak 7 (C18:2/18:1/18:1) TAG losses in 50 ml syringes of SMOFlipid® and Intralipid® at room and fridge temperatures. 
0
5
10
15
20
25
30
35
40
45
0 10 20 30 40 50 60 70 80 90
%
 lo
ss
Day of testing
Peak 7 syringes % losses
SMOFlipid® Light protected room temperature syringes Intralipid® Light protected room temperature syringes
SMOFlipid® Light protected fridge temperature syringes Intralipid® Light protected fridge temperature syringes
SMOFlipid® Non-light protected room temperature syringes Intralipid® Non-light protected room temperature syringes
SMOFlipid® Non-light protected fridge temperature syringes Intralipid® Non-light protected fridge temperature syringes
345 
 
 
Figure 1.2 Peak 7 (C18:2/18:1/18:1) TAG losses in PN bags of SMOFlipid® and Intralipid® at room and fridge temperatures. 
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7.4.3.3. Glass vials 
 
As with previous peaks 5 and 6, peak 7 (C18:2/18:1/18:1) show similar trends in 
losses observed. Both lipids light protected results show maximal losses as 
postulated due to oxygen ingress into the system. The lack of all secondary 
products indicates that the losses seen are due either to hydrolysis of fatty acids 
from the TAG backbone, peroxidation resulting in different secondary products not 
detected or that peroxidation present is limited and as such primary products (lipid 
hydroperoxides) are present and not detected. Confirmation of the type of losses 
observed could be carried out in future studies through detection and identification 
of free fatty acids as methyl esters through mass spectrometry. Figure 7.21 shows 
all glass vial results recorded for all temperatures. As indicated in non-light 
protected results when vials were purged with nitrogen at each sampling point 
peroxidation was minimal to zero again substantiating the vital nature of oxygen 
presence for peroxidation and TAG loss.  
7.4.3.4. Peak 7 conclusions 
 
Results within syringes show the positive peroxidation of peak 7 with the production 
of HNE and HUE and indicate that the TAG remnant observed is resultant from 
peak 7 breakdown within syringes. PN bag results differ from syringes and indicate 
a minimal loss of peak 7 through production of the TAG remnant and it is postulated 
that either hydrolysis or cleavage of different secondary products from linoleic acid 
is the cause of the TAG loss observed. Intralipid® results for both PN bags and 
syringes are significantly higher than SMOFlipid® though TAG loss occurs in both 
lipids. Light protection had a positive effect in syringes but less in PN bags 
suggesting that temperature has an effect on the initial trends of TAG loss observed 
when oxygen presence is minimal (syringes). It can be postulated that within 
syringes high temperatures creates plastic and rubber weakening which increases 
the leakage of oxygen into the system leading to the superior levels of TAG loss 
observed at room temperatures.  
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Figure 1.3 Peak 7 (C18:2/18:1/18:1) TAG losses in 50 ml glass vials of SMOFlipid® and Intralipid® at room and fridge temperatures. 
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7.4.4. Peak 8 (C18:2/18:2/16:0) 
7.4.4.1. Syringes 
 
Peak 8 syringes follow similar to trends in results to peaks 5 and 6 with all Intralipid® 
results surpassing SMOFlipid® losses. Non-light protected results are maximal in 
Intralipid® (~ 30 % at day 28) with zero levels recorded in SMOFlipid® at the same 
time point. Temperature has a negative effect in all results where loss was recorded 
suggesting an inhibition of TAG loss at fridge temperatures. When considering 
results for peak 8 in combination with HNE, HUE and TAG remnant production, 
HNE would be the only secondary product potentially detected due to the TAGs 
chemical structure. Losses within Intralipid® syringes are substantial and could 
therefore contribute to the HNE detected within these containers. Figure 7.22 shows 
the peak 8 TAG losses observed in both lipids in syringes.  
7.4.4.2. PN bags 
 
PN bag results follow the same trends as peaks 5 and 6 with SMOFlipid® light 
protected bags creating maximal losses of > 45 %. This is the highest loss observed 
in all unsaturated peaks (5 to 10) and suggests extensive TAG breakdown is 
occurring. Light protected Intralipid® results also show extensive loss (~ 30%). A 
lack of HNE is observed within PN bags of both lipids suggesting that the 
peroxidation occurring within this TAG is either at a different site within the linoleic 
acid chain or through a different degradation process.  Figure 7.23 shows the PN 
bag results for peak 8 TAG in both lipids at room and fridge temperatures.  
As previously discussed in chapter 5, linoleic acid is predicted to peroxidise readily 
where available oxygen is present. The products created however are dependent on 
the double bond targeted and the positional hydroperoxide created. It can therefore 
be postulated that peroxidation occurring is resulting in a different aldehydic 
product, one that is not detected at 222nm through UV detection. It is also of note 
however that as shown in peaks 1 to 4 in SMOFlipid®, hydrolytic reactions appear to 
occur within the emulsions. Peak 8 contains a palmitic acid chain which can be 
postulated to also be prone to hydrolysis.  
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Figure 1.4 Peak 8 (C18:2/18:2/16:0) TAG losses in 50 ml syringes of SMOFlipid® and Intralipid® at room and fridge temperatures. 
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Figure 1.5 Peak 8 (C18:2/18:2/16:0) TAG losses in PN bags of SMOFlipid® and Intralipid® at room and fridge temperatures. 
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7.4.4.3. Glass vials 
 
Glass vials show under 25 % loss in all containers with light protected results 
maximal for both SMOFlipid® and Intralipid® in line with previous peaks results and 
due to ingress of oxygen into the vial. Non-light protected results where nitrogen 
was purged at all testing points showed minimal (near zero) losses and suggest that 
the lack of oxygen within the system prohibits peroxidation occurring. The lack of 
TAG losses within glass vials also indicates a lack of hydrolysis occurring. Whilst 
hydrolysis of the ester bonds between the fatty acid chain and the glycerol 
backbone does not require oxygen, it is postulated that the hydrolysis reactions only 
occur where the emulsion system is under a state of high energy, i.e. where high 
levels of peroxidation and reactive oxygen/radicals are present. Figure 7.24 shows 
the peak 8 TAG losses recorded in all glass vials.  
7.4.4.4. Peak 8 conclusions 
 
Peak 8 losses were similar to those shown in peaks 5 and 6 and indicate maximal 
losses in Intralipid® within syringes and SMOFlipid® in PN bags. Peak 8 
(C18:2/18:2/16:0) results showed evidence of hydrolysis of fatty acids from the TAG 
backbone contributing to the losses observed and the postulated presence of 
secondary peroxidation products other than HNE that were therefore not detected 
through the assay.  
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Figure 1.6 Peak 8 (C18:2/18:2/16:0) TAG losses in 50 ml glass vials of SMOFlipid® and Intralipid® at room and fridge temperatures. 
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7.4.5. Peak 9 (C18:1/18:1/18:1) 
 
It is postulated that within each lipid, higher peak 9 TAG losses would be observed 
within SMOFlipid® than Intralipid® due to increased quantities of oleic acid present 
within SMOFlipid® as previously discussed in chapter 5 (section 5.1). Oleic acid 
peroxidation is predicted to create HUE as a secondary aldehydic product and as 
such SMOFlipid® was postulated to make higher levels of loss.  
7.4.5.1. Syringes 
 
Intralipid® non-light protected syringes created maximal losses of > 45% followed by 
SMOFlipid® light protected results of >25 %. SMOFlipid® non-light protected 
syringes at day 28 showed no TAG loss, however RSD’s of control samples beyond 
28 days of testing exclude further results from analysis so later TAG loss in these 
syringes cannot be excluded. When considering HUE production collectively with 
C18:1/18:1/18:1 TAG loss observed Intralipid® and SMOFlipid® light protected and 
non-light protected results all show a level of production of HUE within syringes and 
when considered with the peak 9 TAG losses indicates peroxidation of oleic acid 
chains resulting in HUE production and losses observed.  
Figure 7.25 shows the peak 9 TAG losses recorded in all syringes tested. As with 
pervious peaks 5, 6 and 8 temperature had a significant effect on all results except 
non-light protected SMOFlipid® with Intralipid® loss being inhibited as predicted by 
fridge storage. SMOFlipid® light protected results as with previous peaks are of 
interest as fridge temperature results recorded higher losses than those stored at 
room temperature. This result when considered with the zero losses recorded in 
non-light protected SMOFlipid® syringes at day 28 show little peroxidation within 
room temperature syringes. The presence of vitamin E within this emulsion offers a 
potential explanation for this when considering the syringe results alone, however 
as previously seen extensive TAG losses are observed in PN bags and as such 
vitamin E appears ineffective as an antioxidant. Hydrolysis of a fatty acid from peak 
9 TAG within SMOFlipid® is postulated to be unaffected by temperature and could 
therefore create the greater loss observed within fridge temperature results.  
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Figure 1.7. Peak 9 (C18:1/18:1/18:1) TAG losses within 50 ml syringes of SMOFlipid® and Intralipid® at room and fridge temperatures. 
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7.4.5.2. PN bags 
 
As with syringe results above, PN bag data for peak 9 (C18:1/18:1/18:1) follow the 
same trends as peaks 5,6 and 8 with SMOFlipid® light protected PN bags recording 
maximal losses of 45 % at room temperature. All light protected bags showed 
greater losses than non-light protected samples indicating a lack of photooxidation 
occurring. The minimal HUE detected within PN bags suggests that the extensive 
losses observed within this TAG are due to hydrolysis and cleavage of fatty acid(s) 
from the TAG backbone. This TAG (C18:1/18:1/18:1) is particularly important when 
considering the large loss observed within SMOFlipid® as it substantiates the 
evidence of hydrolytic TAG breakdown occurring. The only two secondary aldehydic 
products formed from oleic acid due to its single double bond is that of HUE (C11) 
and hydroxydecenal (HDE C10) as discussed in chapter 3 (peak B identification). 
Therefore, the minimal HUE observed and the lack of other unknown new peaks 
within the UV chromatogram seen from SMOFlipid® PN bags suggests that 
hydrolysis is the only breakdown occurring.  
Within all PN bag results for peak 9 temperature had a predicted effect on storage 
where fridge temperatures reduced TAG losses. Figure 7.26 shows peak 9 losses 
within both lipids.  
7.4.5.3. Glass vials 
 
As shown in figure 7.27 both peak 9 SMOFlipid® and Intralipid® light protected glass 
vials recorded similar losses and trends of results to previous peaks where oxygen 
ingress into the testing system occurred at sampling. Intralipid® non-light protected 
results were higher than in previous peaks, but under 20 % at day 56 (day 84 result 
excluded due to high control RSDs). The level of control of oxygen within all 
samples appeared to directly relate to the levels of TAG loss observed.  
7.4.5.4. Peak 9 conclusions 
 
The peak 9 results are of interest as significant losses are observed in both lipid 
formulations in different storage containers. SMOFlipid® PN bags and Intralipid® 
syringes, both light protected showed maximal losses with the formation of HUE in 
Intralipid® syringes indicating peroxidation of this TAG into terminal secondary 
products. Large PN bag SMOFlipid® losses with minimal detection of secondary 
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peroxidation products suggest extensive hydrolysis occurring or peroxidation in 
early stages (lipid hydroperoxides).  
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Figure 1.8  Peak 9 (C18:1/18:1/18:1) TAG losses in PN bags of SMOFlipid® and Intralipid® at room and fridge temperatures. 
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Figure 1.9 Peak 9 (C18:1/18:1/18:1) TAG losses in 50 ml glass vials of SMOFlipid® and Intralipid® at room and fridge temperatures. 
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7.4.6. Peak 10 (C18:2/18:1/16:0) 
 
Peak 10 losses follow trends as discussed above for peaks 5, 6, 8 and 9. The 
breakdown of peak 10 was previously postulated to form a TAG remnant matching 
the m/z of the TAG remnant monitored. This would be formulated from a hydrolysis 
of the C16:0 fatty acid from the glycerol backbone of the TAG. Results indicating 
this would be expected to show a large % TAG loss and a lack of apparent HNE or 
HUE formation.  
7.4.6.1. Syringes 
 
Intralipid® syringes both light and non-light protected show maximal losses of peak 
10 of >40 % and >30 % respectively at room temperatures. At day 28 SMOFlipid® 
syringes show losses in all conditions except in fridge temperature non-light 
protected samples. The presence of non-light protected room temperature 
peroxidation at day 28 is of interest as this TAG is the only result at 28 days for 
SMOFlipid® that shows any TAG loss in non-light protected syringes. This result 
when coupled with the finding of the highest (>13 µM) concentration of HNE in all 
syringes suggests that peak 10 peroxidation within syringes is responsible for the 
HNE formation within SMOFlipid®. 
Figure 7.28 shows the peak 10 TAG loss occurring in all syringes of both lipids. 
Whilst previous results showed a large effect on loss by temperature of storage, 
only non-light protected SMOFlipid® syringes showed a large variation of results 
between temperatures. As such for this particular TAG, temperature of storage has 
little effect on the peroxidation and TAG losses occurring within syringes.  
7.4.6.2. PN bags  
 
SMOFlipid® light protected PN bags showed maximal losses of ~ 40 % at day 56 
followed by light protected and non-light protected Intralipid® PN bags. All of these 
PN bags show minimal levels of HUE production and a lack of HNE production 
indicating a lack of terminal peroxidation product formation. When considering the 
TAG remnant formation seen in PN bags both Intralipid® and SMOFlipid® non-light 
protected samples show significant TAG remnant production. This finding however 
when compared to the minimal peak 10 TAG losses observed in these PN bags 
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indicates that peak 10 peroxidation within PN bags is not responsible for the TAG 
remnant formation observed.  
Figure 7.29 shows the peak 10 TAG losses for both lipids within PN bags. As 
predicted for all results within PN bags temperature of storage had an effect on TAG 
loss seen with fridge temperatures inhibiting TAG loss observed.  
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Figure 1.10. Peak 10 (C18:2/18:1/16:0) TAG losses in 50 ml syringes of SMOFlipid® and Intralipid® at room and fridge temperatures. 
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Figure 1.11 Peak 10 (C18:2/18:1/16:0) TAG losses in PN bags of SMOFlipid® and Intralipid® at room and fridge temperatures. 
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7.4.6.3. Glass vials 
 
As shown in figure 7.30 glass vial results follow the same trends as peaks 5,6 and 8 
with SMOFlipid® and Intralipid® light protected vials showing maximal losses due to 
early testing without nitrogen purging and subsequent oxygen ingress into the 
system leading to TAG breakdown. Both lipid non-light protected sample sets 
showed minimal to no loss of peak 10 throughout storage and confirm the lack of 
TAG breakdown when oxygen is removed from the storage system. Temperature of 
storage for light protected results where losses were observed affected TAG 
breakdown significantly. The lack of any secondary peroxidation products or TAG 
remnant within these vials however suggest either peroxidative breakdown is 
resulting in secondary products not detected through the assay, that peroxidation is 
in an earlier stage (propagation) or that hydrolysis is responsible for the TAG losses 
observed.  
7.4.6.4. Peak 10 conclusions 
 
When considered collectively peak 10 results indicate extensive losses are 
occurring within PN bags and syringes of both lipids. Syringe results indicate that 
peak 10 is responsible for the production of HNE within SMOFlipid® non-light 
protected syringes through cleavage of the C18:2 chain. In contrast to this 
SMOFlipid® and Intralipid® within PN bags shows extensive peak 10 loss but a lack 
of detected secondary products suggesting PN peak 10 breakdown could be 
creating undetected secondary products. The lack of loss in non-light protected 
SMOFlipid® PN bags indicates that peak 10 is not undergoing hydrolysis of the 
C16:0 chain and production of the TAG remnant observed.  
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Figure 1.12 Peak 10 (C18:2/18:1/16:0) TAG loss in 50 ml glass vials of SMOFlipid® and Intralipid® at room and fridge temperatures. 
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7.5. Statistical trends between chapters 
 
As shown in table 7.2 combination of the statistical analysis done in each result 
chapter for each lipid by ANOVA one-way analysis with Tukey post-hoc testing 
indicates the statistical significance for each peak between lipid formulations. 
Peaks 1 to 4 only occur within SMOFlipid® and whilst multiple significant results are 
indicated, there is a lack of trends observed. Peaks 5 to 10 occur within both 
SMOFlipid® and Intralipid® and multiple significant results occur within both lipids in 
light and non-light protected results. The highlighted results indicate where results 
were significant across both lipids in either light protected, or non-light protected 
containers. Only 5 results were significant across all samples in both light states, 
however multiple results were significant between each light state as highlighted 
within the table. This is significant as the highlighted peaks indicate a trend within 
either light protected or non-light protected results and these specific results (peak, 
container and temperature) could be used to monitor further lipids tested depending 
on the light state used.  
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Table 7.2 Statistical significance between SMOFlipid® and Intralipid® both non-light and light protected. Yellow highlights non-light protected results of both lipids. Orange 
highlights light protected results of both lipids. Analysis by ANOVA one-way analysis and Tukey post hoc testing. Significance set as p<0.05.  
 
Peak 1 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 5 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial * SMOFlipid® NLP
Room Syringe ** * * ** * Room Syringe ** *** * ** * SMOFlipid® LP LP both lipids
Room Bag ** * * ** Room Bag ** *** * *** * Intralipid® LP NLP both lipids
Room Vial * * * * Room Vial *** *** * * * * Intralipid® NLP
Fridge Syringe * * * Fridge Syringe * * * ** **
Fridge Bag * * * * Fridge Bag * * * ***
Fridge Vial * ** * * Fridge Vial *** *** ** ** ****
Peak 2 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 6 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 9 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe ** * * * * Room Syringe * * * Room Syringe *** ** * ** ****
Room Bag ** * * ** Room Bag ** * Room Bag *** *** ** ** ***
Room Vial * * * * Room Vial ** * *** * Room Vial ** *** * * ***
Fridge Syringe * * * * * Fridge Syringe * * *** ** Fridge Syringe * ** * * ****
Fridge Bag * * * * Fridge Bag * ** *** *** ** Fridge Bag ** * * * ***
Fridge Vial * ** * * Fridge Vial * * * ** ** Fridge Vial **** *** *** **** ***
Peak 3 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 7 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 10 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe * * * * * Room Syringe * * ** Room Syringe ** *** ** * ***
Room Bag * * * Room Bag * ** * * Room Bag ** *** *** * **
Room Vial * * * * * Room Vial * ** * * Room Vial *** *** * * **
Fridge Syringe * * * Fridge Syringe * * * Fridge Syringe ** *** * * **
Fridge Bag * * * Fridge Bag ** Fridge Bag * * * * ***
Fridge Vial * * * * * Fridge Vial ** * * * ** Fridge Vial *** ** ** ** ***
Peak 4 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial Peak 8 Room syringe Room Bag Room Vial Fridge Syringe Fridge Bag Fridge Vial
Room Syringe * * * * Room Syringe ** ** * * ***
Room Bag * ** ** * Room Bag ** ** *** * **
Room Vial * ** * Room Vial * ** ** ***
Fridge Syringe * ** * Fridge Syringe * ** *** *
Fridge Bag * * Fridge Bag * * ** ** ***
Fridge Vial * * * * Fridge Vial *** ** *** * ***
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7.6. RSD variation in control samples 
 
Within each chapter and each graph plotted, results were highlighted as outliers 
where the RSD of the control sample run at that testing timepoint exceeded an 
acceptable level (>12% as previously discussed). The drift in RSD beyond this level 
was an indication of a loss of reliability of the assay and as such the results were 
excluded from comparisons between chapters. The results where the RSD’s were 
excessive for control samples were either days 28, 56 or 84 of testing. Due to the 
testing schedule and the method used, each sample set tested (one sample set was 
one lipid in one container at both temperatures either light or non-light protected) 
took a total of 22 hours to complete and therefore only one set was tested on each 
day. The large amount of data collected and the testing time for each set meant a 
tight schedule over 10+ months was used to enable all results to be obtained. When 
considering the dates when the containers were tested that resulted in excessive 
RSD’s of control samples, these were over a period of ~ 8 weeks during the 
summer months. During this time the laboratory where the HPLC equipment was 
placed regularly exceeded 30oC ambient temperature. The rise in room temperature 
was linked to the high RSD’s observed and whilst the column temperature was 
maintained at 5oC and the autosampler at 8oC, no temperature control was possible 
over the solvents used until they were drawn into the system from the HPLC bottle. 
The HPLC system whilst managing to maintain the column and autosampler 
settings did struggle to maintain these temperatures at times and as such the 
ambient temperature was concluded to be responsible for the high RSD’s observed. 
This was substantiated by the return of control RSDs to within acceptable levels 
when the ambient temperature of the laboratory returned to normal. Future studies 
ideally would be within a laboratory with ambient temperature control to exclude the 
problem reoccurring.  
7.7. Conclusions between lipids.  
 
As shown within the comparisons between chapters made in section 7.4 the TAG 
losses observed and the extent of peroxidation recorded varies between lipids and 
different containers. Intralipid® showed maximal peroxidation, TAG loss and the 
production of HNE and HUE within both light protected and non-light protected 
syringes at room and fridge temperatures. SMOFlipid® conversely showed maximal 
TAG losses and TAG remnant production in light protected PN bags at both 
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temperatures, however the production of the secondary peroxidation products HNE 
and HUE were only observed in syringes. Considering each lipid formulation 
individually Intralipid® results within syringes indicate the presence of peroxidation 
through ‘standard’ mechanisms (radical initiation, propagation and termination) over 
extensive testing time. Rate of production of products and TAG losses was slow 
initially and increased during storage, suggesting oxygen availability is a crucial 
factor in peroxidation occurring. The leach of air into syringes during storage is the 
initiating factor in the extensive peroxidation occurring. The presence of HNE, HUE 
and TAG remnant show peroxidation progressing through to the termination phase 
and the production of toxic secondary aldehydes. Whilst smaller in percentage, 
significant (>25 %) losses were also observed in Intralipid® PN bags however only 
the TAG remnant and minimal HUE were recorded suggesting a lower amount of 
terminal peroxidation occurring. The TAG losses observed however indicated 
initiation of peroxidation is occurring and as such it is postulated that within these 
PN bags peroxidation is either maintained in an earlier stage (hydroperoxides rather 
than terminal secondary aldehydes) or that hydrolysis reactions are occurring at the 
water-oil interface of the emulsion and cleaving fatty acids from the glycerol 
backbone of the TAG. Rates of TAG losses within Intralipid® PN bags are initially 
higher than within syringes, with a slowing of loss occurring during extended 
storage. It is concluded that again oxygen availability is a key control in the rate of 
loss observed. The finite oxygen available within PN bags results in initial rapid TAG 
loss occurring however as this oxygen supply is exhausted loss rates reduce. This 
apparent reliance on oxygen within these sets of results indicates the likelihood that 
the loss within Intralipid® bags is as a result of peroxidation rather than hydrolysis.  
When considering the SMOFlipid® results obtained, the stark difference to Intralipid® 
within both syringes and PN bags is of interest. SMOFlipid® experienced maximal 
loss in PN bags for all peaks both saturated and unsaturated. All light protected 
results for SMOFlipid® were worse than non-light protected results. The extensive 
saturated losses observed within PN bags indicates the presence of hydrolysis 
within the emulsion. The positive presence of the TAG remnant within these PN 
bags and the lack of HNE and HUE substantiates the occurrence of hydrolysis both 
within saturated and unsaturated peaks. Conversely within syringes the presence of 
HNE and TAG remnant within SMOFlipid® syringes indicates peroxidation is also 
occurring within unsaturated peaks. The results suggest that a combination of 
hydrolysis and peroxidation is possible within SMOFlipid® which, when considering 
its formulation with highly unsaturated fish oils, suggests that the reactive energy 
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within the system, i.e. the level of peroxidation/radicals likely to be present is higher 
compared to soybean oil alone as in Intralipid®. 
When considering the results in the context of light protection, the highest results in 
both lipids were observed in light protected samples which is particularly interesting 
as PN and lipids are always protected from light. Whilst previous work testing the 
effects of light protection on PN as discussed in chapter 3 showed a positive 
correlation between light protection and a reduction in mortality of patients receiving 
PN (Chessex et al. 2007), when considering lipids alone results within this work 
suggests light protection is less important. The results also indicate a lack of photo-
oxidation within lipid emulsions alone. A caveat to these results when applied to PN 
mixtures however is that light induced peroxidation is proven to be more prominent 
in the presence of riboflavin and trace elements which are within all-in one mixtures 
of PN (Allwood and Kearney 1998). As such whilst light protection is not proven to 
be beneficial within this study it should be continued in PN mixtures used within 
clinical practise.  
Conversely to light protection results, temperature of storage testing gave results as 
were predicted with fridge temperatures (with the exception of SMOFlipid® light 
protected syringes) inhibiting or reducing TAG losses and peroxidation products 
occurring.  
When considering SMOFlipid® previous contradicting works has shown the addition 
of tocopherols to the lipid emulsion to be beneficial in reducing the level of 
peroxidation occurring (Pironi et al. 2003) and that high concentrations of 
tocopherols were shown to have a pro-oxidative effect (Steger and Mühlebach 
1998). The Pironi et al. (2003) study however used a colorimetric kit to measure the 
occurrence of lipid peroxides and HPLC of TBA adducts to measure MDA content. 
Both methods as discussed in chapter 1 can potentially over and under estimate the 
occurrence of peroxidation. Whilst the data produced within this thesis was testing 
lipids alone (i.e. not in all-in-one mixtures) the presence of added tocopherols within 
SMOFlipid® is of interest as the results indicate extensive TAG loss occurring within 
this lipid. As discussed above, the levels of proven peroxidation within this lipid were 
however lower than Intralipid® when considering the formation of TAG remnants and 
HUE. HNE however was highest within SMOFlipid® syringes indicating the presence 
of lipid peroxidation occurring. The extensive TAG losses seen in PN bags is 
postulated to be a combination of peroxidation and hydrolysis and as such the 
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positive presence of HNE within SMOFlipid® syringes suggests that the ability of 
tocopherols to act as an anti-oxidant within a high energy system is questionable.  
When considering how tocopherols quench radicals, the structure of tocopherols are 
as shown in figure 7.31 These act as chain-breaking anti-oxidants where the radical 
is transferred from the lipid radical to the tocopherol structure creating a phenoxyl 
radical which is resonance stabilised and therefore ‘contains’ the radical until a 
termination reaction occurs (Burton and Ingold 1986; Niki 1987). For this to occur as 
described the physical position of the tocopherol molecule needs to be very close to 
the radical attached to the complex TAG molecule. Whilst theoretically possible due 
to the lipid soluble nature of tocopherols, the relatively large size of each TAG 
molecule is postulated to cause physical hindrance to the anti-oxidant ability of 
tocopherols. As such, the extensive peroxidation and lack of inhibition by addition of 
tocopherols within SMOFlipid® is explained.  
 
 
 
 
Figure 1.13 Chemical structure of tocopherols (vitamin E). R 
groups denotes differences in structure dependant on form as shown in table. 
 
7.8. Clinical relevance of study 
 
As presented in the objectives and introduction this study was designed to create an 
initial set of data looking into the TAG loss and peroxidation occurrence within two 
lipid emulsions. Its aim was to develop and employ an assay that was reliable and 
repeatable and enable the chemical stability of an established lipid emulsion and a 
newer lipid emulsion to be tested. As discussed above the results for both lipid 
formulations show extensive TAG losses throughout storage over 84 days at both 
fridge and room temperatures and the production of HNE, HUE and a TAG remnant 
that serve as confirmation of the occurrence of peroxidation.  
When considering current clinical practise adult PN is often delivered in an all-in-one 
mixture of aqueous and lipid components, making chemical testing difficult due to 
Tocopherol R5 R7 
α CH3 CH3 
β CH3 H 
 H CH3 
 H H 
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the inherent complexities of the formulation. Common physical stability testing done 
for such regimes are carried out over 84 days and used to provide storage limits 
and conditions. Whilst the data within the studies carried out in this work is with lipid 
alone, the combination of lipid with aqueous components, vitamins and trace 
elements has been proven to enhance instability within the formulation when 
considering physical stability (Allwood and Kearney 1998; Driscoll et al. 2007b; 
Ferguson et al. 2014). When considering chemical stability, the presence of trace 
elements and vitamins are known to catalyse the rate of peroxidation occurring 
within all-in-one PN. Work by Grand et al. (2011) measured the levels of MDA 
present within all-in-one PN mixtures with vitamins, iron and trace elements and 
concluded that all additions resulted in higher levels of MDA observed. Therefore, in 
relation to the work compiled within this thesis it can be postulated that the 
peroxidation and TAG loss observed within all-in-one mixtures would be greater 
than the results and extensive losses observed within lipid emulsions alone. As 
such, the data produced is of great clinical significance to both lipid only PN 
(neonatal) and adult all-in-one PN.  
Current storage of neonatal PN lipids is within 50 ml syringes, stored light protected 
and at fridge temperature. Typical delivery is over 24 hours via syringe driver at 
temperatures up to 300C and as such the room temperature data collected is 
relevant. The presence of HNE and HUE within both room and fridge temperature 
syringes is important as delivery of any concentration of these toxic peroxidation 
products to a neonatal patient whose innate anti-oxidant system is already stressed 
is potentially catastrophic. The data suggests that limiting the storage of this 
neonatal lipid PN to a maximum of 24 hours and maintaining fridge storage 
throughout would limit the peroxidation occurring, however the storage device 
should be reviewed for future delivery. Whilst 250 ml PN bags were tested within 
this study due to a lack of availability of 50 ml bags, ideally 50 ml PN bags would be 
employed as a substitute for 50 ml syringes for neonatal lipids. The data produced 
showed extensive TAG losses within these bags, but a lack of HNE and minimal 
HUE suggesting the occurrence of hydrolytic TAG breakdown as opposed to 
peroxidation. Whilst not optimal for delivery to the neonate, the lack of peroxidation 
products would be favourable when compared to lipids stored within syringes. 
Further in-depth testing of 50 ml PN bags over an initial 48-hour period would 
confirm the safety of this device with respect to lipid peroxidation and chemical 
stability.  
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When considering the two lipids together, SMOFlipid® showed greater levels of TAG 
losses within PN bags and showed maximal HNE production in syringes, however 
Intralipid® produced more consistent TAG losses and HNE, HUE and TAG remnant 
production within all containers. As such it can be concluded that with regards to 
lipid peroxidation alone, SMOFlipid® is superior to Intralipid® though both lipid 
formulations are not optimal when considering the actual lipid amount delivered to a 
patient vs the amount of lipid prescribed. Future research and development into a 
lipid emulsion formulated to optimise chemical stability is a recommendation made 
from the conclusions within this work. Whilst lipids are typically formulated to match 
research into optimal patient nutrition this body of work suggests that patients may 
not be receiving the prescribed amount or chemical composition of lipid as 
previously thought. As such, the development of a chemically stable lipid emulsion 
that provides a finite amount of lipid to the patient in un-peroxidised form would lead 
to optimal safe delivery of nutrition to the patient.  
Clinical recommendations from the work within this study include moving small 
volume lipid PN from syringes to PN bags, light protecting all containers and 
delivery lines (though only relevant in limiting TAG remnant production and HNE 
formation), limiting storage of lipids to 24 hours prior to delivery to the neonatal 
patient and storing all lipids at fridge temperatures. With respect to adult all-in-one 
PN the work suggests that the extensive storage limits placed on home PN (limits 
formed from physical stability testing) may not be appropriate in delivering a lipid 
containing PN that is stable to the patient. As such storage limits should be 
reviewed on lipid containing PN.  
7.9. Study limitations and future work 
 
As discussed in section 7.8 PN bags tested were as small as possible but in 
practise ideally 50 ml bags would be used for the storage of lipid portions of PN. 
Therefore, whilst the data collected is relevant as it is the first chemical stability data 
collected with respect to TAG loss and peroxidation, ideally the study should be 
repeated using 50 ml PN bags to provide an accurate overview.  
With regards to SMOFlipid® and the perceived relatively high levels of hydrolysis 
observed and with respect to further identification of the TAG remnant structure 
detected, identification of fatty acids methyl esters through mass spectrometry could 
be employed to provided confirmation on the presence and type of free fatty acids 
and as such the position of hydrolysis occurring within TAGs monitored.  The 
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presence of earlier stages of peroxidation ie. the presence of primary peroxidation 
products (hydroperoxides) is also postulated to be responsible for some of the data 
observed and as such, whilst hydroperoxide testing is often not accurate (see 
introduction chapter), detection of hydroperoxides in combination with the assay 
used within this work or the addition of reducing agents would confirm their 
presence or lack of within each lipid formulation tested.  
The presence of oxygen within the storage system was proven through the studies 
to be of vital importance in the extent of peroxidation and TAG losses observed. The 
testing protocol within glass vials where oxygen was replaced with nitrogen was 
designed to act as a control to show the removal of oxygen led to the inhibition of 
TAG losses and peroxidation occurring. Whilst the protocol was updated through 
the testing to try and ensure a lack of oxygen ingress into the container at each 
testing point, TAG losses were still observed which were postulated to be from 
either oxygen ingress into the system (though a lack of peroxidation products were 
detected) or through hydrolysis. As such glass vial results whilst still of interest did 
not act as controls per se. Future work to confirm hydrolysis as the cause of the 
TAG loss observed would aid to substantiate the data collected that shows the vital 
presence of oxygen for peroxidation to occur.  
This study was designed to look at lipid emulsions alone, with no other additives 
present. Within a clinical setting this work is directly relevant to lipid delivery to 
neonatal patients however adults commonly have all-in-one PN. The additions of 
other required elements to lipids for all-in-one PN is postulated to have a further 
destabilising effect on lipids and catalyse peroxidation occurring. Whilst the study 
results reported stand alone as a vitally important piece of research that should 
influence PN storage, future work testing lipids within all-in-one mixtures would be 
ideal to formulate stability data that is directly transferable to the clinic. There are 
however inherent challenges when considering lipid testing within all-in-one PN. For 
example, HNE is known to readily bond with amino acids, particularly cysteine 
residues as supplied within the amino acid portion of all-in-one PN. As such the 
detection of free HNE as presented within the assay developed would not be 
appropriate for all-in-one PN and further assay modifications would be required to 
detect such bound HNE. It is postulated that a lipid extraction stage would be 
required prior to lipid analysis with this assay for all-in-one PN, enabling the lipid 
portion to be analysed without the HPLC chromatograms being altered by other 
non-lipid components. The non-aqueous nature of the HPLC assay would also be 
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incompatible with aqueous portions of a PN mixture making lipid extraction 
necessary.  
At the time of writing to my knowledge this is the first chemical stability study 
undertaken on the two lipid emulsions using the assay developed and presented 
within this work looking at both TAG losses and peroxidation products occurring. 
Future work as discussed above would act to extend the stability testing carried out 
to include all-in-one PN mixtures. The testing of other lipid emulsions could also be 
possible using the same assay if it was validated for each lipid used. Whilst the data 
and conclusions drawn from this work show the occurrence of extensive TAG loss 
and peroxidation within both lipids that are currently used within PN delivery it is 
important to recognise that PN delivery to a patient is only undertaken in critical 
illness. As such, PN provides life sustaining nutrition and thus this work should 
serve to limit the storage time placed on current PN and drive research into the 
development of more stable lipids and not prohibit the delivery of currently available 
lipids in clinical practise.  
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Appendix 2: Statistical Analysis Data 
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For all statistical analysis: 
Group 1 = Room temperature syringes 
Group 2 = Room temperature PN bags 
Group 3 = Room temperature vials 
Group 4 = Fridge temperature syringes 
Group 5 = Fridge temperature PN bags 
Group 6 = Fridge temperature vials 
 
 
Intralipid® light protected containers. Peak 1 (C18:2/18:2/18:20) 
 
ANOVA 
data 
 Sum of Squares df Mean Square F Sig. 
Between Groups 1581.723 5 316.345 45.340 .000 
Within Groups 83.726 12 6.977   
Total 1665.449 17    
 
 
Dependent Variable:   data   
 
(I) group (J) group 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Tukey HSD 1.00 2.00 -2.61947 2.15672 .822 -9.8637 4.6248 
3.00 15.99782* 2.15672 .000 8.7536 23.2421 
4.00 .64976 2.15672 1.000 -6.5945 7.8940 
5.00 .14625 2.15672 1.000 -7.0980 7.3905 
6.00 21.94051* 2.15672 .000 14.6962 29.1848 
2.00 1.00 2.61947 2.15672 .822 -4.6248 9.8637 
3.00 18.61730* 2.15672 .000 11.3730 25.8616 
4.00 3.26923 2.15672 .662 -3.9750 10.5135 
5.00 2.76572 2.15672 .789 -4.4785 10.0100 
6.00 24.55998* 2.15672 .000 17.3157 31.8043 
3.00 1.00 -15.99782* 2.15672 .000 -23.2421 -8.7536 
2.00 -18.61730* 2.15672 .000 -25.8616 -11.3730 
4.00 -15.34807* 2.15672 .000 -22.5923 -8.1038 
5.00 -15.85158* 2.15672 .000 -23.0958 -8.6073 
6.00 5.94269 2.15672 .134 -1.3016 13.1870 
4.00 1.00 -.64976 2.15672 1.000 -7.8940 6.5945 
2.00 -3.26923 2.15672 .662 -10.5135 3.9750 
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3.00 15.34807* 2.15672 .000 8.1038 22.5923 
5.00 -.50351 2.15672 1.000 -7.7478 6.7408 
6.00 21.29076* 2.15672 .000 14.0465 28.5350 
5.00 1.00 -.14625 2.15672 1.000 -7.3905 7.0980 
2.00 -2.76572 2.15672 .789 -10.0100 4.4785 
3.00 15.85158* 2.15672 .000 8.6073 23.0958 
4.00 .50351 2.15672 1.000 -6.7408 7.7478 
6.00 21.79427* 2.15672 .000 14.5500 29.0385 
6.00 1.00 -21.94051* 2.15672 .000 -29.1848 -14.6962 
2.00 -24.55998* 2.15672 .000 -31.8043 -17.3157 
3.00 -5.94269 2.15672 .134 -13.1870 1.3016 
4.00 -21.29076* 2.15672 .000 -28.5350 -14.0465 
5.00 -21.79427* 2.15672 .000 -29.0385 -14.5500 
 
 
Peak 2 
 
ANOVA 
   
 Sum of Squares df Mean Square F Sig. 
Between Groups 2024.317 5 404.863 29.936 .000 
Within Groups 162.293 12 13.524   
Total 2186.610 17    
 
 
 
Post Hoc Tests 
 
Dependent Variable:      
Tukey HSD   
(I) Peak 2 (J) Peak 2 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 11.96103* 3.00271 .017 1.8752 22.0469 
3.00 23.75384* 3.00271 .000 13.6680 33.8397 
4.00 4.73452 3.00271 .627 -5.3514 14.8204 
5.00 12.84170* 3.00271 .011 2.7558 22.9276 
6.00 31.09713* 3.00271 .000 21.0113 41.1830 
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2.00 1.00 -11.96103* 3.00271 .017 -22.0469 -1.8752 
3.00 11.79280* 3.00271 .019 1.7069 21.8787 
4.00 -7.22651 3.00271 .228 -17.3124 2.8594 
5.00 .88067 3.00271 1.000 -9.2052 10.9665 
6.00 19.13610* 3.00271 .000 9.0502 29.2220 
3.00 1.00 -23.75384* 3.00271 .000 -33.8397 -13.6680 
2.00 -11.79280* 3.00271 .019 -21.8787 -1.7069 
4.00 -19.01931* 3.00271 .000 -29.1052 -8.9334 
5.00 -10.91213* 3.00271 .031 -20.9980 -.8263 
6.00 7.34330 3.00271 .215 -2.7426 17.4292 
4.00 1.00 -4.73452 3.00271 .627 -14.8204 5.3514 
2.00 7.22651 3.00271 .228 -2.8594 17.3124 
3.00 19.01931* 3.00271 .000 8.9334 29.1052 
5.00 8.10718 3.00271 .146 -1.9787 18.1931 
6.00 26.36261* 3.00271 .000 16.2767 36.4485 
5.00 1.00 -12.84170* 3.00271 .011 -22.9276 -2.7558 
2.00 -.88067 3.00271 1.000 -10.9665 9.2052 
3.00 10.91213* 3.00271 .031 .8263 20.9980 
4.00 -8.10718 3.00271 .146 -18.1931 1.9787 
6.00 18.25543* 3.00271 .001 8.1696 28.3413 
6.00 1.00 -31.09713* 3.00271 .000 -41.1830 -21.0113 
2.00 -19.13610* 3.00271 .000 -29.2220 -9.0502 
3.00 -7.34330 3.00271 .215 -17.4292 2.7426 
4.00 -26.36261* 3.00271 .000 -36.4485 -16.2767 
5.00 -18.25543* 3.00271 .001 -28.3413 -8.1696 
 
*. The mean difference is significant at the 0.05 level. 
 
Peak 3 
 
ANOVA 
 
 Sum of Squares df Mean Square F Sig. 
Between Groups 808.313 5 161.663 7.888 .002 
Within Groups 245.944 12 20.495   
 
Total 
1054.257 17 
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Post Hoc Tests 
 
Dependent Variable:      
Tukey HSD   
(I) Peak 3 (J) Peak 3 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 5.26978 3.69642 .713 -7.1462 17.6858 
3.00 11.05002 3.69642 .092 -1.3660 23.4660 
4.00 10.10323 3.69642 .139 -2.3128 22.5192 
5.00 4.89331 3.69642 .768 -7.5227 17.3093 
6.00 21.35050* 3.69642 .001 8.9345 33.7665 
2.00 1.00 -5.26978 3.69642 .713 -17.6858 7.1462 
3.00 5.78024 3.69642 .634 -6.6358 18.1962 
4.00 4.83345 3.69642 .776 -7.5825 17.2494 
5.00 -.37648 3.69642 1.000 -12.7925 12.0395 
6.00 16.08072* 3.69642 .009 3.6647 28.4967 
3.00 1.00 -11.05002 3.69642 .092 -23.4660 1.3660 
2.00 -5.78024 3.69642 .634 -18.1962 6.6358 
4.00 -.94679 3.69642 1.000 -13.3628 11.4692 
5.00 -6.15672 3.69642 .576 -18.5727 6.2593 
6.00 10.30048 3.69642 .128 -2.1155 22.7165 
4.00 1.00 -10.10323 3.69642 .139 -22.5192 2.3128 
2.00 -4.83345 3.69642 .776 -17.2494 7.5825 
3.00 .94679 3.69642 1.000 -11.4692 13.3628 
5.00 -5.20992 3.69642 .722 -17.6259 7.2061 
6.00 11.24727 3.69642 .084 -1.1687 23.6633 
5.00 1.00 -4.89331 3.69642 .768 -17.3093 7.5227 
2.00 .37648 3.69642 1.000 -12.0395 12.7925 
3.00 6.15672 3.69642 .576 -6.2593 18.5727 
4.00 5.20992 3.69642 .722 -7.2061 17.6259 
6.00 16.45719* 3.69642 .008 4.0412 28.8732 
6.00 1.00 -21.35050* 3.69642 .001 -33.7665 -8.9345 
2.00 -16.08072* 3.69642 .009 -28.4967 -3.6647 
3.00 -10.30048 3.69642 .128 -22.7165 2.1155 
4.00 -11.24727 3.69642 .084 -23.6633 1.1687 
5.00 -16.45719* 3.69642 .008 -28.8732 -4.0412 
 
*. The mean difference is significant at the 0.05 level. 
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Peak 4 
ANOVA 
   
 Sum of Squares df Mean Square F Sig. 
Between Groups 1563.901 5 312.780 11.875 .000 
Within Groups 316.074 12 26.339   
Total 1879.974 17    
 
Post Hoc Tests 
 
Dependent Variable:      
Tukey HSD   
(I) Peak 4 (J) Peak 4 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 6.28486 4.19042 .671 -7.7904 20.3602 
3.00 15.29437* 4.19042 .031 1.2191 29.3697 
4.00 15.19651* 4.19042 .032 1.1212 29.2718 
5.00 1.88766 4.19042 .997 -12.1876 15.9630 
6.00 27.09318* 4.19042 .000 13.0179 41.1685 
2.00 1.00 -6.28486 4.19042 .671 -20.3602 7.7904 
3.00 9.00951 4.19042 .326 -5.0658 23.0848 
4.00 8.91166 4.19042 .336 -5.1636 22.9870 
5.00 -4.39720 4.19042 .892 -18.4725 9.6781 
6.00 20.80832* 4.19042 .003 6.7330 34.8836 
3.00 1.00 -15.29437* 4.19042 .031 -29.3697 -1.2191 
2.00 -9.00951 4.19042 .326 -23.0848 5.0658 
4.00 -.09786 4.19042 1.000 -14.1732 13.9774 
5.00 -13.40671 4.19042 .065 -27.4820 .6686 
6.00 11.79881 4.19042 .122 -2.2765 25.8741 
4.00 1.00 -15.19651* 4.19042 .032 -29.2718 -1.1212 
2.00 -8.91166 4.19042 .336 -22.9870 5.1636 
3.00 .09786 4.19042 1.000 -13.9774 14.1732 
5.00 -13.30886 4.19042 .068 -27.3842 .7664 
6.00 11.89667 4.19042 .117 -2.1786 25.9720 
5.00 1.00 -1.88766 4.19042 .997 -15.9630 12.1876 
2.00 4.39720 4.19042 .892 -9.6781 18.4725 
3.00 13.40671 4.19042 .065 -.6686 27.4820 
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4.00 13.30886 4.19042 .068 -.7664 27.3842 
6.00 25.20552* 4.19042 .001 11.1302 39.2808 
6.00 1.00 -27.09318* 4.19042 .000 -41.1685 -13.0179 
2.00 -20.80832* 4.19042 .003 -34.8836 -6.7330 
3.00 -11.79881 4.19042 .122 -25.8741 2.2765 
4.00 -11.89667 4.19042 .117 -25.9720 2.1786 
5.00 -25.20552* 4.19042 .001 -39.2808 -11.1302 
401 
 
The mean difference is significant at the 0.05 level. 
 
Peak 5 
ANOVA 
   
 Sum of Squares df Mean Square F Sig. 
Between Groups 842.524 5 168.505 7.651 .003 
Within Groups 242.268 11 22.024   
Total 1084.792 16    
 
Post Hoc Tests 
Dependent Variable:      
Tukey HSD   
(I) Peak 5 (J) Peak 5 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -6.16841 4.28412 .705 -20.7788 8.4420 
3.00 3.89072 4.28412 .936 -10.7196 18.5011 
4.00 -2.24418 4.28412 .994 -16.8545 12.3662 
5.00 -3.67204 4.28412 .949 -18.2824 10.9383 
6.00 14.71895* 4.28412 .048 .1086 29.3293 
2.00 1.00 6.16841 4.28412 .705 -8.4420 20.7788 
3.00 10.05913 3.83183 .170 -3.0088 23.1270 
4.00 3.92424 3.83183 .900 -9.1437 16.9921 
5.00 2.49638 3.83183 .984 -10.5715 15.5643 
6.00 20.88737* 3.83183 .002 7.8195 33.9553 
3.00 1.00 -3.89072 4.28412 .936 -18.5011 10.7196 
2.00 -10.05913 3.83183 .170 -23.1270 3.0088 
4.00 -6.13490 3.83183 .614 -19.2028 6.9330 
5.00 -7.56276 3.83183 .412 -20.6307 5.5052 
6.00 10.82823 3.83183 .126 -2.2397 23.8961 
4.00 1.00 2.24418 4.28412 .994 -12.3662 16.8545 
2.00 -3.92424 3.83183 .900 -16.9921 9.1437 
3.00 6.13490 3.83183 .614 -6.9330 19.2028 
5.00 -1.42786 3.83183 .999 -14.4958 11.6400 
6.00 16.96313* 3.83183 .010 3.8952 30.0310 
5.00 1.00 3.67204 4.28412 .949 -10.9383 18.2824 
2.00 -2.49638 3.83183 .984 -15.5643 10.5715 
3.00 7.56276 3.83183 .412 -5.5052 20.6307 
4.00 1.42786 3.83183 .999 -11.6400 14.4958 
6.00 18.39099* 3.83 83 .006 5.3231 31.4589 
6.00 1.00 -14.71895* 4.28412 .048 -29.3293 -.1086 
2.00 -20.88737* 3.83183 .002 -33.9553 -7.8195 
3.00 -10.82823 3.83183 .126 -23.8961 2.2397 
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Peak 6 
ANOVA 
   
 Sum of Squares df Mean Square F Sig. 
Between Groups 2064.022 5 412.804 15.261 .000 
Within Groups 324.593 12 27.049   
Total 2388.615 17    
 
Post Hoc Tests 
Dependent Variable:      
Tukey HSD   
(I) Peak 6 (J) Peak 6 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .97716 4.24652 1.000 -13.2866 15.2409 
3.00 20.27470* 4.24652 .005 6.0110 34.5384 
4.00 9.91372 4.24652 .253 -4.3500 24.1775 
5.00 5.58095 4.24652 .773 -8.6828 19.8447 
6.00 29.70878* 4.24652 .000 15.4451 43.9725 
2.00 1.00 -.97716 4.24652 1.000 -15.2409 13.2866 
3.00 19.29753* 4.24652 .007 5.0338 33.5613 
4.00 8.93656 4.24652 .346 -5.3272 23.2003 
5.00 4.60379 4.24652 .879 -9.6599 18.8675 
6.00 28.73162* 4.24652 .000 14.4679 42.9954 
3.00 1.00 -20.27470* 4.24652 .005 -34.5384 -6.0110 
2.00 -19.29753* 4.24652 .007 -33.5613 -5.0338 
4.00 -10.36098 4.24652 .217 -24.6247 3.9028 
5.00 -14.69375* 4.24652 .042 -28.9575 -.4300 
6.00 9.43409 4.24652 .296 -4.8296 23.6978 
4.00 1.00 -9.91372 4.24652 .253 -24.1775 4.3500 
2.00 -8.93656 4.24652 .346 -23.2003 5.3272 
3.00 10.36098 4.24652 .217 -3.9028 24.6247 
5.00 -4.33277 4.24652 .902 -18.5965 9.9310 
6.00 19.79506* 4.24652 .006 5.5313 34.0588 
5.00 1.00 -5.58095 4.24652 .773 -19.8447 8.6828 
2.00 -4.60379 4.24652 .879 -18.8675 9.6599 
3.00 14.69375* 4.24652 .042 .4300 28.9575 
4.00 4.33277 4.24652 .902 -9.9310 18.5965 
6.00 24.12784* 4.24652 .001 9.8641 38.3916 
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6.00 1.00 -29.70878* 4.24652 .000 -43.9725 -15.4451 
2.00 -28.73162* 4.24652 .000 -42.9954 -14.4679 
3.00 -9.43409 4.24652 .296 -23.6978 4.8296 
4.00 -19.79506* 4.24652 .006 -34.0588 -5.5313 
5.00 -24.12784* 4.24652 .001 -38.3916 -9.8641 
 
*. The mean difference is significant at the 0.05 level. 
 
 
 
 
Intralipid® light protected containers. 
 Peak 1 (C18:2/18:2/18:2) 
 
ANOVA 
data 
 Sum of Squares df Mean Square F Sig. 
Between Groups 1581.723 5 316.345 45.340 .000 
Within Groups 83.726 12 6.977   
Total 1665.449 17    
 
 
Dependent Variable:   data   
 
(I) group (J) group 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Tukey HSD 1.00 2.00 -2.61947 2.15672 .822 -9.8637 4.6248 
3.00 15.99782* 2.15672 .000 8.7536 23.2421 
4.00 .64976 2.15672 1.000 -6.5945 7.8940 
5.00 .14625 2.15672 1.000 -7.0980 7.3905 
6.00 21.94051* 2.15672 .000 14.6962 29.1848 
2.00 1.00 2.61947 2.15672 .822 -4.6248 9.8637 
3.00 18.61730* 2.15672 .000 11.3730 25.8616 
4.00 3.26923 2.15672 .662 -3.9750 10.5135 
5.00 2.76572 2.15672 .789 -4.4785 10.0100 
6.00 24.55998* 2.15672 .000 17.3157 31.8043 
3.00 1.00 -15.99782* 2.15672 .000 -23.2421 -8.7536 
2.00 -18.61730* 2.15672 .000 -25.8616 -11.3730 
4.00 -15.34807* 2.15672 .000 -22.5923 -8.1038 
5.00 -15.85158* 2.15672 .000 -23.0958 -8.6073 
404 
 
6.00 5.94269 2.15672 .134 -1.3016 13.1870 
4.00 1.00 -.64976 2.15672 1.000 -7.8940 6.5945 
2.00 -3.26923 2.15672 .662 -10.5135 3.9750 
3.00 15.34807* 2.15672 .000 8.1038 22.5923 
5.00 -.50351 2.15672 1.000 -7.7478 6.7408 
6.00 21.29076* 2.15672 .000 14.0465 28.5350 
5.00 1.00 -.14625 2.15672 1.000 -7.3905 7.0980 
2.00 -2.76572 2.15672 .789 -10.0100 4.4785 
3.00 15.85158* 2.15672 .000 8.6073 23.0958 
4.00 .50351 2.15672 1.000 -6.7408 7.7478 
6.00 21.79427* 2.15672 .000 14.5500 29.0385 
6.00 1.00 -21.94051* 2.15672 .000 -29.1848 -14.6962 
2.00 -24.55998* 2.15672 .000 -31.8043 -17.3157 
3.00 -5.94269 2.15672 .134 -13.1870 1.3016 
4.00 -21.29076* 2.15672 .000 -28.5350 -14.0465 
5.00 -21.79427* 2.15672 .000 -29.0385 -14.5500 
 
 
Peak 2 
 
ANOVA 
   
 Sum of Squares df Mean Square F Sig. 
Between Groups 2024.317 5 404.863 29.936 .000 
Within Groups 162.293 12 13.524   
Total 2186.610 17    
 
 
 
Post Hoc Tests 
 
Dependent Variable:      
Tukey HSD   
(I) Peak 2 (J) Peak 2 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 11.96103* 3.00271 .017 1.8752 22.0469 
3.00 23.75384* 3.00271 .000 13.6680 33.8397 
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4.00 4.73452 3.00271 .627 -5.3514 14.8204 
5.00 12.84170* 3.00271 .011 2.7558 22.9276 
6.00 31.09713* 3.00271 .000 21.0113 41.1830 
2.00 1.00 -11.96103* 3.00271 .017 -22.0469 -1.8752 
3.00 11.79280* 3.00271 .019 1.7069 21.8787 
4.00 -7.22651 3.00271 .228 -17.3124 2.8594 
5.00 .88067 3.00271 1.000 -9.2052 10.9665 
6.00 19.13610* 3.00271 .000 9.0502 29.2220 
3.00 1.00 -23.75384* 3.00271 .000 -33.8397 -13.6680 
2.00 -11.79280* 3.00271 .019 -21.8787 -1.7069 
4.00 -19.01931* 3.00271 .000 -29.1052 -8.9334 
5.00 -10.91213* 3.00271 .031 -20.9980 -.8263 
6.00 7.34330 3.00271 .215 -2.7426 17.4292 
4.00 1.00 -4.73452 3.00271 .627 -14.8204 5.3514 
2.00 7.22651 3.00271 .228 -2.8594 17.3124 
3.00 19.01931* 3.00271 .000 8.9334 29.1052 
5.00 8.10718 3.00271 .146 -1.9787 18.1931 
6.00 26.36261* 3.00271 .000 16.2767 36.4485 
5.00 1.00 -12.84170* 3.00271 .011 -22.9276 -2.7558 
2.00 -.88067 3.00271 1.000 -10.9665 9.2052 
3.00 10.91213* 3.00271 .031 .8263 20.9980 
4.00 -8.10718 3.00271 .146 -18.1931 1.9787 
6.00 18.25543* 3.00271 .001 8.1696 28.3413 
6.00 1.00 -31.09713* 3.00271 .000 -41.1830 -21.0113 
2.00 -19.13610* 3.00271 .000 -29.2220 -9.0502 
3.00 -7.34330 3.00271 .215 -17.4292 2.7426 
4.00 -26.36261* 3.00271 .000 -36.4485 -16.2767 
5.00 -18.25543* 3.00271 .001 -28.3413 -8.1696 
 
*. The mean difference is significant at the 0.05 level. 
 
Peak 3 
 
ANOVA 
 
 Sum of Squares df Mean Square F Sig. 
Between Groups 808.313 5 161.663 7.888 .002 
Within Groups 245.944 12 20.495   
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Total 
1054.257 17 
   
 
Post Hoc Tests 
 
Dependent Variable:      
Tukey HSD   
(I) Peak 3 (J) Peak 3 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 5.26978 3.69642 .713 -7.1462 17.6858 
3.00 11.05002 3.69642 .092 -1.3660 23.4660 
4.00 10.10323 3.69642 .139 -2.3128 22.5192 
5.00 4.89331 3.69642 .768 -7.5227 17.3093 
6.00 21.35050* 3.69642 .001 8.9345 33.7665 
2.00 1.00 -5.26978 3.69642 .713 -17.6858 7.1462 
3.00 5.78024 3.69642 .634 -6.6358 18.1962 
4.00 4.83345 3.69642 .776 -7.5825 17.2494 
5.00 -.37648 3.69642 1.000 -12.7925 12.0395 
6.00 16.08072* 3.69642 .009 3.6647 28.4967 
3.00 1.00 -11.05002 3.69642 .092 -23.4660 1.3660 
2.00 -5.78024 3.69642 .634 -18.1962 6.6358 
4.00 -.94679 3.69642 1.000 -13.3628 11.4692 
5.00 -6.15672 3.69642 .576 -18.5727 6.2593 
6.00 10.30048 3.69642 .128 -2.1155 22.7165 
4.00 1.00 -10.10323 3.69642 .139 -22.5192 2.3128 
2.00 -4.83345 3.69642 .776 -17.2494 7.5825 
3.00 .94679 3.69642 1.000 -11.4692 13.3628 
5.00 -5.20992 3.69642 .722 -17.6259 7.2061 
6.00 11.24727 3.69642 .084 -1.1687 23.6633 
5.00 1.00 -4.89331 3.69642 .768 -17.3093 7.5227 
2.00 .37648 3.69642 1.000 -12.0395 12.7925 
3.00 6.15672 3.69642 .576 -6.2593 18.5727 
4.00 5.20992 3.69642 .722 -7.2061 17.6259 
6.00 16.45719* 3.69642 .008 4.0412 28.8732 
6.00 1.00 -21.35050* 3.69642 .001 -33.7665 -8.9345 
2.00 -16.08072* 3.69642 .009 -28.4967 -3.6647 
3.00 -10.30048 3.69642 .128 -22.7165 2.1155 
4.00 -11.24727 3.69642 .084 -23.6633 1.1687 
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5.00 -16.45719* 3.69642 .008 -28.8732 -4.0412 
 
*. The mean difference is significant at the 0.05 level. 
 
Peak 4 
ANOVA 
   
 Sum of Squares df Mean Square F Sig. 
Between Groups 1563.901 5 312.780 11.875 .000 
Within Groups 316.074 12 26.339   
Total 1879.974 17    
 
Post Hoc Tests 
 
Dependent Variable:      
Tukey HSD   
(I) Peak 4 (J) Peak 4 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 6.28486 4.19042 .671 -7.7904 20.3602 
3.00 15.29437* 4.19042 .031 1.2191 29.3697 
4.00 15.19651* 4.19042 .032 1.1212 29.2718 
5.00 1.88766 4.19042 .997 -12.1876 15.9630 
6.00 27.09318* 4.19042 .000 13.0179 41.1685 
2.00 1.00 -6.28486 4.19042 .671 -20.3602 7.7904 
3.00 9.00951 4.19042 .326 -5.0658 23.0848 
4.00 8.91166 4.19042 .336 -5.1636 22.9870 
5.00 -4.39720 4.19042 .892 -18.4725 9.6781 
6.00 20.80832* 4.19042 .003 6.7330 34.8836 
3.00 1.00 -15.29437* 4.19042 .031 -29.3697 -1.2191 
2.00 -9.00951 4.19042 .326 -23.0848 5.0658 
4.00 -.09786 4.19042 1.000 -14.1732 13.9774 
5.00 -13.40671 4.19042 .065 -27.4820 .6686 
6.00 11.79881 4.19042 .122 -2.2765 25.8741 
4.00 1.00 -15.19651* 4.19042 .032 -29.2718 -1.1212 
2.00 -8.91166 4.19042 .336 -22.9870 5.1636 
3.00 .09786 4.19042 1.000 -13.9774 14.1732 
5.00 -13.30886 4.19042 .068 -27.3842 .7664 
6.00 11.89667 4.19042 .117 -2.1786 25.9720 
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5.00 1.00 -1.88766 4.19042 .997 -15.9630 12.1876 
2.00 4.39720 4.19042 .892 -9.6781 18.4725 
3.00 13.40671 4.19042 .065 -.6686 27.4820 
4.00 13.30886 4.19042 .068 -.7664 27.3842 
6.00 25.20552* 4.19042 .001 11.1302 39.2808 
6.00 1.00 -27.09318* 4.19042 .000 -41.1685 -13.0179 
2.00 -20.80832* 4.19042 .003 -34.8836 -6.7330 
3.00 -11.79881 4.19042 .122 -25.8741 2.2765 
4.00 -11.89667 4.19042 .117 -25.9720 2.1786 
5.00 -25.20552* 4.19042 .001 -39.2808 -11.1302 
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. The mean difference is significant at the 0.05 level. 
 
Peak 5 
ANOVA 
   
 Sum of Squares df Mean Square F Sig. 
Between Groups 842.524 5 168.505 7.651 .003 
Within Groups 242.268 11 22.024   
Total 1084.792 16    
 
Post Hoc Tests 
Dependent Variable:      
Tukey HSD   
(I) Peak 5 (J) Peak 5 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -6.16841 4.28412 .705 -20.7788 8.4420 
3.00 3.89072 4.28412 .936 -10.7196 18.5011 
4.00 -2.24418 4.28412 .994 -16.8545 12.3662 
5.00 -3.67204 4.28412 .949 -18.2824 10.9383 
6.00 14.71895* 4.28412 .048 .1086 29.3293 
2.00 1.00 6.16841 4.28412 .705 -8.4420 20.7788 
3.00 10.05913 3.83183 .170 -3.0088 23.1270 
4.00 3.92424 3.83183 .900 -9.1437 16.9921 
5.00 2.49638 3.83183 .984 -10.5715 15.5643 
6.00 20.88737* 3.83183 .002 7.8195 33.9553 
3.00 1.00 -3.89072 4.28412 .936 -18.5011 10.7196 
2.00 -10.05913 3.83183 .170 -23.1270 3.0088 
4.00 -6.13490 3.83183 .614 -19.2028 6.9330 
5.00 -7.56276 3.83183 .412 -20.6307 5.5052 
6.00 10.82823 3.83183 .126 -2.2397 23.8961 
4.00 1.00 2.24418 4.28412 .994 -12.3662 16.8545 
2.00 -3.92424 3.83183 .900 -16.9921 9.1437 
3.00 6.13490 3.83183 .614 -6.9330 19.2028 
5.00 -1.42786 3.83183 .999 -14.4958 11.6400 
6.00 16.96313* 3.83183 .010 3.8952 30.0310 
5.00 1.00 3.67204 4.28412 .949 -10.9383 18.2824 
2.00 -2.49638 3.83183 .984 -15.5643 10.5715 
3.00 7.56276 3.83183 .412 -5.5052 20.6307 
4.00 1.42786 3.83183 .999 -11.6400 14.4958 
6.00 18.39099* 3.83183 .006 5.3231 31.4589 
6.00 1.00 -14.71895* 4.28412 .048 -29.3293 -.1086 
2.00 -20.88737* 3.83183 .002 -33.9553 -7.8195 
3.00 -10.82823 3.83183 .126 -23.8961 2.2397 
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Peak 6 
ANOVA 
   
 Sum of Squares df Mean Square F Sig. 
Between Groups 2064.022 5 412.804 15.261 .000 
Within Groups 324.593 12 27.049   
Total 2388.615 17    
 
Post Hoc Tests 
Dependent Variable:      
Tukey HSD   
(I) Peak 6 (J) Peak 6 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .97716 4.24652 1.000 -13.2866 15.2409 
3.00 20.27470* 4.24652 .005 6.0110 34.5384 
4.00 9.91372 4.24652 .253 -4.3500 24.1775 
5.00 5.58095 4.24652 .773 -8.6828 19.8447 
6.00 29.70878* 4.24652 .000 15.4451 43.9725 
2.00 1.00 -.97716 4.24652 1.000 -15.2409 13.2866 
3.00 19.29753* 4.24652 .007 5.0338 33.5613 
4.00 8.93656 4.24652 .346 -5.3272 23.2003 
5.00 4.60379 4.24652 .879 -9.6599 18.8675 
6.00 28.73162* 4.24652 .000 14.4679 42.9954 
3.00 1.00 -20.27470* 4.24652 .005 -34.5384 -6.0110 
2.00 -19.29753* 4.24652 .007 -33.5613 -5.0338 
4.00 -10.36098 4.24652 .217 -24.6247 3.9028 
5.00 -14.69375* 4.24652 .042 -28.9575 -.4300 
6.00 9.43409 4.24652 .296 -4.8296 23.6978 
4.00 1.00 -9.91372 4.24652 .253 -24.1775 4.3500 
2.00 -8.93656 4.24652 .346 -23.2003 5.3272 
3.00 10.36098 4.24652 .217 -3.9028 24.6247 
5.00 -4.33277 4.24652 .902 -18.5965 9.9310 
6.00 19.79506* 4.24652 .006 5.5313 34.0588 
5.00 1.00 -5.58095 4.24652 .773 -19.8447 8.6828 
2.00 -4.60379 4.24652 .879 -18.8675 9.6599 
3.00 14.69375* 4.24652 .042 .4300 28.9575 
4.00 4.33277 4.24652 .902 -9.9310 18.5965 
6.00 24.12784* 4.24652 .001 9.8641 38.3916 
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6.00 1.00 -29.70878* 4.24652 .000 -43.9725 -15.4451 
2.00 -28.73162* 4.24652 .000 -42.9954 -14.4679 
3.00 -9.43409 4.24652 .296 -23.6978 4.8296 
4.00 -19.79506* 4.24652 .006 -34.0588 -5.5313 
5.00 -24.12784* 4.24652 .001 -38.3916 -9.8641 
 
*. The mean difference is significant at the 0.05 level. 
 
 
 
 
 
SMOFlipid Light Protected stats day 84 
Peak 1 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 808.974 5 161.795 5.338 .008 
Within Groups 363.723 12 30.310   
Total 1172.697 17    
 
 
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) factor (J) factor 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -16.54606* 4.49520 .029 -31.6451 -1.4470 
3.00 -6.22767 4.49520 .735 -21.3267 8.8714 
4.00 -3.38638 4.49520 .970 -18.4854 11.7126 
5.00 .33040 4.49520 1.000 -14.7686 15.4294 
6.00 4.56813 4.49520 .904 -10.5309 19.6672 
2.00 1.00 16.54606* 4.49520 .029 1.4470 31.6451 
3.00 10.31839 4.49520 .267 -4.7806 25.4174 
4.00 13.15968 4.49520 .102 -1.9393 28.2587 
5.00 16.87646* 4.49520 .026 1.7774 31.9755 
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6.00 21.11419* 4.49520 .005 6.0152 36.2132 
3.00 1.00 6.22767 4.49520 .735 -8.8714 21.3267 
2.00 -10.31839 4.49520 .267 -25.4174 4.7806 
4.00 2.84130 4.49520 .986 -12.2577 17.9403 
5.00 6.55808 4.49520 .694 -8.5409 21.6571 
6.00 10.79580 4.49520 .229 -4.3032 25.8948 
4.00 1.00 3.38638 4.49520 .970 -11.7126 18.4854 
2.00 -13.15968 4.49520 .102 -28.2587 1.9393 
3.00 -2.84130 4.49520 .986 -17.9403 12.2577 
5.00 3.71678 4.49520 .957 -11.3822 18.8158 
6.00 7.95451 4.49520 .517 -7.1445 23.0535 
5.00 1.00 -.33040 4.49520 1.000 -15.4294 14.7686 
2.00 -16.87646* 4.49520 .026 -31.9755 -1.7774 
3.00 -6.55808 4.49520 .694 -21.6571 8.5409 
4.00 -3.71678 4.49520 .957 -18.8158 11.3822 
6.00 4.23773 4.49520 .927 -10.8613 19.3368 
6.00 1.00 -4.56813 4.49520 .904 -19.6672 10.5309 
2.00 -21.11419* 4.49520 .005 -36.2132 -6.0152 
3.00 -10.79580 4.49520 .229 -25.8948 4.3032 
4.00 -7.95451 4.49520 .517 -23.0535 7.1445 
5.00 -4.23773 4.49520 .927 -19.3368 10.8613 
*. The mean difference is significant at the 0.05 level. 
 
 
Peak 2 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 530.356 5 106.071 2.284 .112 
Within Groups 557.177 12 46.431   
Total 1087.533 17    
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Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) factor (J) factor 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -9.60232 5.56366 .541 -28.2902 9.0856 
3.00 -5.02127 5.56366 .939 -23.7092 13.6666 
4.00 1.31459 5.56366 1.000 -17.3733 20.0025 
5.00 5.18139 5.56366 .931 -13.5065 23.8693 
6.00 5.64119 5.56366 .905 -13.0467 24.3291 
2.00 1.00 9.60232 5.56366 .541 -9.0856 28.2902 
3.00 4.58105 5.56366 .957 -14.1068 23.2689 
4.00 10.91691 5.56366 .414 -7.7710 29.6048 
5.00 14.78371 5.56366 .156 -3.9042 33.4716 
6.00 15.24351 5.56366 .137 -3.4444 33.9314 
3.00 1.00 5.02127 5.56366 .939 -13.6666 23.7092 
2.00 -4.58105 5.56366 .957 -23.2689 14.1068 
4.00 6.33587 5.56366 .856 -12.3520 25.0237 
5.00 10.20266 5.56366 .482 -8.4852 28.8905 
6.00 10.66246 5.56366 .438 -8.0254 29.3503 
4.00 1.00 -1.31459 5.56366 1.000 -20.0025 17.3733 
2.00 -10.91691 5.56366 .414 -29.6048 7.7710 
3.00 -6.33587 5.56366 .856 -25.0237 12.3520 
5.00 3.86680 5.56366 .979 -14.8211 22.5547 
6.00 4.32659 5.56366 .966 -14.3613 23.0145 
5.00 1.00 -5.18139 5.56366 .931 -23.8693 13.5065 
2.00 -14.78371 5.56366 .156 -33.4716 3.9042 
3.00 -10.20266 5.56366 .482 -28.8905 8.4852 
4.00 -3.86680 5.56366 .979 -22.5547 14.8211 
6.00 .45980 5.56366 1.000 -18.2281 19.1477 
6.00 1.00 -5.64119 5.56366 .905 -24.3291 13.0467 
2.00 -15.24351 5.56366 .137 -33.9314 3.4444 
3.00 -10.66246 5.56366 .438 -29.3503 8.0254 
4.00 -4.32659 5.56366 .966 -23.0145 14.3613 
5.00 -.45980 5.56366 1.000 -19.1477 18.2281 
 
 
414 
 
 
Peak 3 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 521.890 5 104.378 2.002 .151 
Within Groups 625.725 12 52.144   
Total 1147.615 17    
 
 
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) factor (J) factor 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -8.59684 5.89597 .694 -28.4009 11.2073 
3.00 -1.80353 5.89597 1.000 -21.6076 18.0006 
4.00 -1.35164 5.89597 1.000 -21.1557 18.4525 
5.00 6.63823 5.89597 .862 -13.1659 26.4423 
6.00 7.18519 5.89597 .820 -12.6189 26.9893 
2.00 1.00 8.59684 5.89597 .694 -11.2073 28.4009 
3.00 6.79331 5.89597 .850 -13.0108 26.5974 
4.00 7.24521 5.89597 .815 -12.5589 27.0493 
5.00 15.23508 5.89597 .175 -4.5690 35.0392 
6.00 15.78203 5.89597 .152 -4.0221 35.5861 
3.00 1.00 1.80353 5.89597 1.000 -18.0006 21.6076 
2.00 -6.79331 5.89597 .850 -26.5974 13.0108 
4.00 .45190 5.89597 1.000 -19.3522 20.2560 
5.00 8.44176 5.89597 .709 -11.3623 28.2459 
6.00 8.98872 5.89597 .657 -10.8154 28.7928 
4.00 1.00 1.35164 5.89597 1.000 -18.4525 21.1557 
2.00 -7.24521 5.89597 .815 -27.0493 12.5589 
3.00 -.45190 5.89597 1.000 -20.2560 19.3522 
5.00 7.98987 5.89597 .751 -11.8142 27.7940 
6.00 8.53682 5.89597 .700 -11.2673 28.3409 
5.00 1.00 -6.63823 5.89597 .862 -26.4423 13.1659 
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2.00 -15.23508 5.89597 .175 -35.0392 4.5690 
3.00 -8.44176 5.89597 .709 -28.2459 11.3623 
4.00 -7.98987 5.89597 .751 -27.7940 11.8142 
6.00 .54696 5.89597 1.000 -19.2571 20.3511 
6.00 1.00 -7.18519 5.89597 .820 -26.9893 12.6189 
2.00 -15.78203 5.89597 .152 -35.5861 4.0221 
3.00 -8.98872 5.89597 .657 -28.7928 10.8154 
4.00 -8.53682 5.89597 .700 -28.3409 11.2673 
5.00 -.54696 5.89597 1.000 -20.3511 19.2571 
 
 
Peak 4 
 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 1856.172 5 371.234 10.120 .001 
Within Groups 440.220 12 36.685   
Total 2296.392 17    
 
 
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) factor (J) factor 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -24.53633* 4.94537 .003 -41.1474 -7.9252 
3.00 -8.65009 4.94537 .528 -25.2612 7.9610 
4.00 1.59302 4.94537 .999 -15.0181 18.2041 
5.00 -11.18614 4.94537 .280 -27.7972 5.4250 
6.00 6.14996 4.94537 .808 -10.4611 22.7611 
2.00 1.00 24.53633* 4.94537 .003 7.9252 41.1474 
3.00 15.88624 4.94537 .064 -.7249 32.4973 
4.00 26.12935* 4.94537 .002 9.5182 42.7405 
5.00 13.35019 4.94537 .146 -3.2609 29.9613 
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6.00 30.68629* 4.94537 .001 14.0752 47.2974 
3.00 1.00 8.65009 4.94537 .528 -7.9610 25.2612 
2.00 -15.88624 4.94537 .064 -32.4973 .7249 
4.00 10.24311 4.94537 .361 -6.3680 26.8542 
5.00 -2.53605 4.94537 .995 -19.1472 14.0751 
6.00 14.80005 4.94537 .092 -1.8111 31.4112 
4.00 1.00 -1.59302 4.94537 .999 -18.2041 15.0181 
2.00 -26.12935* 4.94537 .002 -42.7405 -9.5182 
3.00 -10.24311 4.94537 .361 -26.8542 6.3680 
5.00 -12.77916 4.94537 .175 -29.3903 3.8319 
6.00 4.55694 4.94537 .933 -12.0542 21.1680 
5.00 1.00 11.18614 4.94537 .280 -5.4250 27.7972 
2.00 -13.35019 4.94537 .146 -29.9613 3.2609 
3.00 2.53605 4.94537 .995 -14.0751 19.1472 
4.00 12.77916 4.94537 .175 -3.8319 29.3903 
6.00 17.33610* 4.94537 .039 .7250 33.9472 
6.00 1.00 -6.14996 4.94537 .808 -22.7611 10.4611 
2.00 -30.68629* 4.94537 .001 -47.2974 -14.0752 
3.00 -14.80005 4.94537 .092 -31.4112 1.8111 
4.00 -4.55694 4.94537 .933 -21.1680 12.0542 
5.00 -17.33610* 4.94537 .039 -33.9472 -.7250 
*. The mean difference is significant at the 0.05 level. 
 
Peak 5 
 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 802.503 5 160.501 5.053 .010 
Within Groups 381.192 12 31.766   
Total 1183.694 17    
 
 
 
 
 
417 
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) factor (J) factor 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -13.31572 4.60188 .108 -28.7731 2.1416 
3.00 -5.08835 4.60188 .870 -20.5457 10.3690 
4.00 -3.32274 4.60188 .975 -18.7801 12.1346 
5.00 1.58196 4.60188 .999 -13.8754 17.0393 
6.00 8.55297 4.60188 .468 -6.9044 24.0103 
2.00 1.00 13.31572 4.60188 .108 -2.1416 28.7731 
3.00 8.22737 4.60188 .507 -7.2300 23.6847 
4.00 9.99298 4.60188 .317 -5.4644 25.4503 
5.00 14.89768 4.60188 .061 -.5597 30.3550 
6.00 21.86869* 4.60188 .005 6.4113 37.3260 
3.00 1.00 5.08835 4.60188 .870 -10.3690 20.5457 
2.00 -8.22737 4.60188 .507 -23.6847 7.2300 
4.00 1.76561 4.60188 .999 -13.6917 17.2230 
5.00 6.67031 4.60188 .699 -8.7870 22.1277 
6.00 13.64131 4.60188 .096 -1.8160 29.0987 
4.00 1.00 3.32274 4.60188 .975 -12.1346 18.7801 
2.00 -9.99298 4.60188 .317 -25.4503 5.4644 
3.00 -1.76561 4.60188 .999 -17.2230 13.6917 
5.00 4.90470 4.60188 .886 -10.5527 20.3621 
6.00 11.87571 4.60188 .176 -3.5816 27.3331 
5.00 1.00 -1.58196 4.60188 .999 -17.0393 13.8754 
2.00 -14.89768 4.60188 .061 -30.3550 .5597 
3.00 -6.67031 4.60188 .699 -22.1277 8.7870 
4.00 -4.90470 4.60188 .886 -20.3621 10.5527 
6.00 6.97101 4.60188 .662 -8.4863 22.4284 
6.00 1.00 -8.55297 4.60188 .468 -24.0103 6.9044 
2.00 -21.86869* 4.60188 .005 -37.3260 -6.4113 
3.00 -13.64131 4.60188 .096 -29.0987 1.8160 
4.00 -11.87571 4.60188 .176 -27.3331 3.5816 
5.00 -6.97101 4.60188 .662 -22.4284 8.4863 
*. The mean difference is significant at the 0.05 level. 
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Peak 6 
 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 1042.843 5 208.569 7.407 .002 
Within Groups 337.878 12 28.157   
Total 1380.722 17    
 
 
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) factor (J) factor 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .91972 4.33255 1.000 -13.6330 15.4724 
3.00 -3.83048 4.33255 .943 -18.3832 10.7222 
4.00 .52397 4.33255 1.000 -14.0287 15.0767 
5.00 17.73514* 4.33255 .014 3.1824 32.2878 
6.00 11.86061 4.33255 .138 -2.6921 26.4133 
2.00 1.00 -.91972 4.33255 1.000 -15.4724 13.6330 
3.00 -4.75020 4.33255 .874 -19.3029 9.8025 
4.00 -.39575 4.33255 1.000 -14.9485 14.1570 
5.00 16.81542* 4.33255 .021 2.2627 31.3681 
6.00 10.94089 4.33255 .191 -3.6118 25.4936 
3.00 1.00 3.83048 4.33255 .943 -10.7222 18.3832 
2.00 4.75020 4.33255 .874 -9.8025 19.3029 
4.00 4.35445 4.33255 .908 -10.1983 18.9072 
5.00 21.56563* 4.33255 .003 7.0129 36.1183 
6.00 15.69110* 4.33255 .032 1.1384 30.2438 
4.00 1.00 -.52397 4.33255 1.000 -15.0767 14.0287 
2.00 .39575 4.33255 1.000 -14.1570 14.9485 
3.00 -4.35445 4.33255 .908 -18.9072 10.1983 
5.00 17.21117* 4.33255 .018 2.6585 31.7639 
6.00 11.33664 4.33255 .166 -3.2161 25.8893 
5.00 1.00 -17.73514* 4.33255 .014 -32.2878 -3.1824 
419 
 
2.00 -16.81542* 4.33255 .021 -31.3681 -2.2627 
3.00 -21.56563* 4.33255 .003 -36.1183 -7.0129 
4.00 -17.21117* 4.33255 .018 -31.7639 -2.6585 
6.00 -5.87453 4.33255 .751 -20.4272 8.6782 
6.00 1.00 -11.86061 4.33255 .138 -26.4133 2.6921 
2.00 -10.94089 4.33255 .191 -25.4936 3.6118 
3.00 -15.69110* 4.33255 .032 -30.2438 -1.1384 
4.00 -11.33664 4.33255 .166 -25.8893 3.2161 
5.00 5.87453 4.33255 .751 -8.6782 20.4272 
*. The mean difference is significant at the 0.05 level. 
 
Peak 7 
 
ANOVA 
data   
 Sum of Squares Df Mean Square F Sig. 
Between Groups 1768.098 5 353.620 6.612 .004 
Within Groups 641.760 12 53.480   
Total 2409.857 17    
 
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) factor (J) factor 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 2.71994 5.97104 .997 -17.3363 22.7762 
3.00 -20.66453* 5.97104 .042 -40.7208 -.6083 
4.00 -6.53251 5.97104 .875 -26.5888 13.5237 
5.00 11.90738 5.97104 .398 -8.1489 31.9636 
6.00 -4.09578 5.97104 .980 -24.1520 15.9605 
2.00 1.00 -2.71994 5.97104 .997 -22.7762 17.3363 
3.00 -23.38447* 5.97104 .020 -43.4407 -3.3282 
4.00 -9.25245 5.97104 .642 -29.3087 10.8038 
5.00 9.18744 5.97104 .649 -10.8688 29.2437 
6.00 -6.81572 5.97104 .855 -26.8720 13.2405 
3.00 1.00 20.66453* 5.97104 .042 .6083 40.7208 
2.00 23.38447* 5.97104 .020 3.3282 43.4407 
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4.00 14.13202 5.97104 .241 -5.9242 34.1883 
5.00 32.57191* 5.97104 .002 12.5157 52.6282 
6.00 16.56875 5.97104 .130 -3.4875 36.6250 
4.00 1.00 6.53251 5.97104 .875 -13.5237 26.5888 
2.00 9.25245 5.97104 .642 -10.8038 29.3087 
3.00 -14.13202 5.97104 .241 -34.1883 5.9242 
5.00 18.43989 5.97104 .078 -1.6164 38.4961 
6.00 2.43673 5.97104 .998 -17.6195 22.4930 
5.00 1.00 -11.90738 5.97104 .398 -31.9636 8.1489 
2.00 -9.18744 5.97104 .649 -29.2437 10.8688 
3.00 -32.57191* 5.97104 .002 -52.6282 -12.5157 
4.00 -18.43989 5.97104 .078 -38.4961 1.6164 
6.00 -16.00317 5.97104 .151 -36.0594 4.0531 
6.00 1.00 4.09578 5.97104 .980 -15.9605 24.1520 
2.00 6.81572 5.97104 .855 -13.2405 26.8720 
3.00 -16.56875 5.97104 .130 -36.6250 3.4875 
4.00 -2.43673 5.97104 .998 -22.4930 17.6195 
5.00 16.00317 5.97104 .151 -4.0531 36.0594 
*. The mean difference is significant at the 0.05 level. 
 
Peak 8 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 6556.672 5 1311.334 67.623 .000 
Within Groups 232.703 12 19.392   
Total 6789.375 17    
 
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) factor (J) factor 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -38.09953* 3.59555 .000 -50.1767 -26.0224 
3.00 -.02888 3.59555 1.000 -12.1060 12.0483 
4.00 3.61324 3.59555 .908 -8.4639 15.6904 
421 
 
5.00 -30.76121* 3.59555 .000 -42.8384 -18.6841 
6.00 14.37192* 3.59555 .017 2.2948 26.4491 
2.00 1.00 38.09953* 3.59555 .000 26.0224 50.1767 
3.00 38.07065* 3.59555 .000 25.9935 50.1478 
4.00 41.71277* 3.59555 .000 29.6356 53.7899 
5.00 7.33832 3.59555 .376 -4.7388 19.4155 
6.00 52.47145* 3.59555 .000 40.3943 64.5486 
3.00 1.00 .02888 3.59555 1.000 -12.0483 12.1060 
2.00 -38.07065* 3.59555 .000 -50.1478 -25.9935 
4.00 3.64212 3.59555 .905 -8.4350 15.7193 
5.00 -30.73233* 3.59555 .000 -42.8095 -18.6552 
6.00 14.40080* 3.59555 .017 2.3236 26.4780 
4.00 1.00 -3.61324 3.59555 .908 -15.6904 8.4639 
2.00 -41.71277* 3.59555 .000 -53.7899 -29.6356 
3.00 -3.64212 3.59555 .905 -15.7193 8.4350 
5.00 -34.37445* 3.59555 .000 -46.4516 -22.2973 
6.00 10.75868 3.59555 .092 -1.3185 22.8358 
5.00 1.00 30.76121* 3.59555 .000 18.6841 42.8384 
2.00 -7.33832 3.59555 .376 -19.4155 4.7388 
3.00 30.73233* 3.59555 .000 18.6552 42.8095 
4.00 34.37445* 3.59555 .000 22.2973 46.4516 
6.00 45.13313* 3.59555 .000 33.0560 57.2103 
6.00 1.00 -14.37192* 3.59555 .017 -26.4491 -2.2948 
2.00 -52.47145* 3.59555 .000 -64.5486 -40.3943 
3.00 -14.40080* 3.59555 .017 -26.4780 -2.3236 
4.00 -10.75868 3.59555 .092 -22.8358 1.3185 
5.00 -45.13313* 3.59555 .000 -57.2103 -33.0560 
*. The mean difference is significant at the 0.05 level. 
 
Peak 9 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 2144.027 5 428.805 45.584 .000 
Within Groups 112.884 12 9.407   
Total 2256.910 17    
422 
 
 
 
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) factor (J) factor 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -21.11967* 2.50426 .000 -29.5313 -12.7081 
3.00 -2.86925 2.50426 .853 -11.2809 5.5424 
4.00 -3.21955 2.50426 .787 -11.6312 5.1921 
5.00 -10.04204* 2.50426 .017 -18.4537 -1.6304 
6.00 15.17858* 2.50426 .001 6.7670 23.5902 
2.00 1.00 21.11967* 2.50426 .000 12.7081 29.5313 
3.00 18.25042* 2.50426 .000 9.8388 26.6620 
4.00 17.90012* 2.50426 .000 9.4885 26.3117 
5.00 11.07763* 2.50426 .008 2.6660 19.4892 
6.00 36.29825* 2.50426 .000 27.8866 44.7099 
3.00 1.00 2.86925 2.50426 .853 -5.5424 11.2809 
2.00 -18.25042* 2.50426 .000 -26.6620 -9.8388 
4.00 -.35030 2.50426 1.000 -8.7619 8.0613 
5.00 -7.17279 2.50426 .113 -15.5844 1.2388 
6.00 18.04783* 2.50426 .000 9.6362 26.4594 
4.00 1.00 3.21955 2.50426 .787 -5.1921 11.6312 
2.00 -17.90012* 2.50426 .000 -26.3117 -9.4885 
3.00 .35030 2.50426 1.000 -8.0613 8.7619 
5.00 -6.82249 2.50426 .141 -15.2341 1.5891 
6.00 18.39813* 2.50426 .000 9.9865 26.8097 
5.00 1.00 10.04204* 2.50426 .017 1.6304 18.4537 
2.00 -11.07763* 2.50426 .008 -19.4892 -2.6660 
3.00 7.17279 2.50426 .113 -1.2388 15.5844 
4.00 6.82249 2.50426 .141 -1.5891 15.2341 
6.00 25.22063* 2.50426 .000 16.8090 33.6322 
6.00 1.00 -15.17858* 2.50426 .001 -23.5902 -6.7670 
2.00 -36.29825* 2.50426 .000 -44.7099 -27.8866 
3.00 -18.04783* 2.50426 .000 -26.4594 -9.6362 
4.00 -18.39813* 2.50426 .000 -26.8097 -9.9865 
5.00 -25.22063* 2.50426 .000 -33.6322 -16.8090 
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*. The mean difference is significant at the 0.05 level. 
 
 
 
Peak 10 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 867.569 5 173.514 11.064 .000 
Within Groups 188.196 12 15.683   
Total 1055.765 17    
 
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) factor (J) factor 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -13.89003* 3.23347 .010 -24.7510 -3.0291 
3.00 -14.49756* 3.23347 .008 -25.3585 -3.6366 
4.00 -.69651 3.23347 1.000 -11.5575 10.1645 
5.00 -9.36269 3.23347 .107 -20.2237 1.4983 
6.00 2.90669 3.23347 .939 -7.9543 13.7677 
2.00 1.00 13.89003* 3.23347 .010 3.0291 24.7510 
3.00 -.60752 3.23347 1.000 -11.4685 10.2534 
4.00 13.19352* 3.23347 .015 2.3326 24.0545 
5.00 4.52734 3.23347 .727 -6.3336 15.3883 
6.00 16.79673* 3.23347 .002 5.9358 27.6577 
3.00 1.00 14.49756* 3.23347 .008 3.6366 25.3585 
2.00 .60752 3.23347 1.000 -10.2534 11.4685 
4.00 13.80105* 3.23347 .011 2.9401 24.6620 
5.00 5.13486 3.23347 .620 -5.7261 15.9958 
6.00 17.40425* 3.23347 .002 6.5433 28.2652 
4.00 1.00 .69651 3.23347 1.000 -10.1645 11.5575 
2.00 -13.19352* 3.23347 .015 -24.0545 -2.3326 
3.00 -13.80105* 3.23347 .011 -24.6620 -2.9401 
5.00 -8.66618 3.23347 .151 -19.5271 2.1948 
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6.00 3.60320 3.23347 .866 -7.2578 14.4642 
5.00 1.00 9.36269 3.23347 .107 -1.4983 20.2237 
2.00 -4.52734 3.23347 .727 -15.3883 6.3336 
3.00 -5.13486 3.23347 .620 -15.9958 5.7261 
4.00 8.66618 3.23347 .151 -2.1948 19.5271 
6.00 12.26939* 3.23347 .024 1.4084 23.1304 
6.00 1.00 -2.90669 3.23347 .939 -13.7677 7.9543 
2.00 -16.79673* 3.23347 .002 -27.6577 -5.9358 
3.00 -17.40425* 3.23347 .002 -28.2652 -6.5433 
4.00 -3.60320 3.23347 .866 -14.4642 7.2578 
5.00 -12.26939* 3.23347 .024 -23.1304 -1.4084 
*. The mean difference is significant at the 0.05 level. 
 
 
SMOFlipid® Non-light Protected Stats 
Peak 1 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 3060.438 5 612.088 49.414 .000 
Within Groups 136.256 11 12.387   
Total 3196.693 16    
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) group (J) group 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 17.24114* 2.87366 .001 7.4409 27.0413 
3.00 43.09015* 3.21285 .000 32.1332 54.0471 
4.00 15.52526* 2.87366 .002 5.7251 25.3255 
5.00 19.11033* 2.87366 .000 9.3101 28.9105 
6.00 35.41277* 2.87366 .000 25.6126 45.2130 
2.00 1.00 -17.24114* 2.87366 .001 -27.0413 -7.4409 
3.00 25.84901* 3.21285 .000 14.8920 36.8060 
4.00 -1.71588 2.87366 .989 -11.5161 8.0843 
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5.00 1.86920 2.87366 .984 -7.9310 11.6694 
6.00 18.17163* 2.87366 .001 8.3714 27.9718 
3.00 1.00 -43.09015* 3.21285 .000 -54.0471 -32.1332 
2.00 -25.84901* 3.21285 .000 -36.8060 -14.8920 
4.00 -27.56489* 3.21285 .000 -38.5219 -16.6079 
5.00 -23.97982* 3.21285 .000 -34.9368 -13.0228 
6.00 -7.67738 3.21285 .239 -18.6343 3.2796 
4.00 1.00 -15.52526* 2.87366 .002 -25.3255 -5.7251 
2.00 1.71588 2.87366 .989 -8.0843 11.5161 
3.00 27.56489* 3.21285 .000 16.6079 38.5219 
5.00 3.58507 2.87366 .806 -6.2151 13.3853 
6.00 19.88751* 2.87366 .000 10.0873 29.6877 
5.00 1.00 -19.11033* 2.87366 .000 -28.9105 -9.3101 
2.00 -1.86920 2.87366 .984 -11.6694 7.9310 
3.00 23.97982* 3.21285 .000 13.0228 34.9368 
4.00 -3.58507 2.87366 .806 -13.3853 6.2151 
6.00 16.30244* 2.87366 .002 6.5022 26.1026 
6.00 1.00 -35.41277* 2.87366 .000 -45.2130 -25.6126 
2.00 -18.17163* 2.87366 .001 -27.9718 -8.3714 
3.00 7.67738 3.21285 .239 -3.2796 18.6343 
4.00 -19.88751* 2.87366 .000 -29.6877 -10.0873 
5.00 -16.30244* 2.87366 .002 -26.1026 -6.5022 
*. The mean difference is significant at the 0.05 level. 
 
Peak 2 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 2137.546 5 427.509 52.318 .000 
Within Groups 98.057 12 8.171   
Total 2235.603 17    
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) group (J) group 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
426 
 
1.00 2.00 8.23816* 2.33401 .038 .3984 16.0779 
3.00 32.80617* 2.33401 .000 24.9664 40.6459 
4.00 15.73291* 2.33401 .000 7.8931 23.5727 
5.00 11.59816* 2.33401 .003 3.7584 19.4379 
6.00 25.74490* 2.33401 .000 17.9051 33.5847 
2.00 1.00 -8.23816* 2.33401 .038 -16.0779 -.3984 
3.00 24.56801* 2.33401 .000 16.7282 32.4078 
4.00 7.49474 2.33401 .064 -.3450 15.3345 
5.00 3.36000 2.33401 .705 -4.4798 11.1998 
6.00 17.50673* 2.33401 .000 9.6670 25.3465 
3.00 1.00 -32.80617* 2.33401 .000 -40.6459 -24.9664 
2.00 -24.56801* 2.33401 .000 -32.4078 -16.7282 
4.00 -17.07327* 2.33401 .000 -24.9130 -9.2335 
5.00 -21.20801* 2.33401 .000 -29.0478 -13.3682 
6.00 -7.06128 2.33401 .087 -14.9010 .7785 
4.00 1.00 -15.73291* 2.33401 .000 -23.5727 -7.8931 
2.00 -7.49474 2.33401 .064 -15.3345 .3450 
3.00 17.07327* 2.33401 .000 9.2335 24.9130 
5.00 -4.13475 2.33401 .516 -11.9745 3.7050 
6.00 10.01199* 2.33401 .010 2.1722 17.8518 
5.00 1.00 -11.59816* 2.33401 .003 -19.4379 -3.7584 
2.00 -3.36000 2.33401 .705 -11.1998 4.4798 
3.00 21.20801* 2.33401 .000 13.3682 29.0478 
4.00 4.13475 2.33401 .516 -3.7050 11.9745 
6.00 14.14674* 2.33401 .001 6.3070 21.9865 
6.00 1.00 -25.74490* 2.33401 .000 -33.5847 -17.9051 
2.00 -17.50673* 2.33401 .000 -25.3465 -9.6670 
3.00 7.06128 2.33401 .087 -.7785 14.9010 
4.00 -10.01199* 2.33401 .010 -17.8518 -2.1722 
5.00 -14.14674* 2.33401 .001 -21.9865 -6.3070 
*. The mean difference is significant at the 0.05 level. 
 
Peak 3 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 3642.549 5 728.510 86.193 .000 
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Within Groups 101.425 12 8.452   
Total 3743.975 17    
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) group (J) group 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 11.81551* 2.37376 .003 3.8422 19.7888 
3.00 42.26333* 2.37376 .000 34.2900 50.2366 
4.00 14.37392* 2.37376 .001 6.4006 22.3472 
5.00 14.34605* 2.37376 .001 6.3728 22.3193 
6.00 33.77944* 2.37376 .000 25.8062 41.7527 
2.00 1.00 -11.81551* 2.37376 .003 -19.7888 -3.8422 
3.00 30.44781* 2.37376 .000 22.4745 38.4211 
4.00 2.55840 2.37376 .881 -5.4149 10.5317 
5.00 2.53054 2.37376 .886 -5.4427 10.5038 
6.00 21.96393* 2.37376 .000 13.9907 29.9372 
3.00 1.00 -42.26333* 2.37376 .000 -50.2366 -34.2900 
2.00 -30.44781* 2.37376 .000 -38.4211 -22.4745 
4.00 -27.88941* 2.37376 .000 -35.8627 -19.9161 
5.00 -27.91727* 2.37376 .000 -35.8906 -19.9440 
6.00 -8.48388* 2.37376 .035 -16.4572 -.5106 
4.00 1.00 -14.37392* 2.37376 .001 -22.3472 -6.4006 
2.00 -2.55840 2.37376 .881 -10.5317 5.4149 
3.00 27.88941* 2.37376 .000 19.9161 35.8627 
5.00 -.02787 2.37376 1.000 -8.0011 7.9454 
6.00 19.40553* 2.37376 .000 11.4322 27.3788 
5.00 1.00 -14.34605* 2.37376 .001 -22.3193 -6.3728 
2.00 -2.53054 2.37376 .886 -10.5038 5.4427 
3.00 27.91727* 2.37376 .000 19.9440 35.8906 
4.00 .02787 2.37376 1.000 -7.9454 8.0011 
6.00 19.43339* 2.37376 .000 11.4601 27.4067 
6.00 1.00 -33.77944* 2.37376 .000 -41.7527 -25.8062 
2.00 -21.96393* 2.37376 .000 -29.9372 -13.9907 
3.00 8.48388* 2.37376 .035 .5106 16.4572 
4.00 -19.40553* 2.37376 .000 -27.3788 -11.4322 
5.00 -19.43339* 2.37376 .000 -27.4067 -11.4601 
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*. The mean difference is significant at the 0.05 level. 
 
Peak 4 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 1160.618 5 232.124 11.454 .000 
Within Groups 243.189 12 20.266   
Total 1403.807 17    
 
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) group (J) group 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 5.85486 3.67566 .618 -6.4914 18.2011 
3.00 20.46599* 3.67566 .001 8.1197 32.8122 
4.00 22.87239* 3.67566 .000 10.5261 35.2186 
5.00 9.14353 3.67566 .202 -3.2027 21.4898 
6.00 14.69164* 3.67566 .017 2.3454 27.0379 
2.00 1.00 -5.85486 3.67566 .618 -18.2011 6.4914 
3.00 14.61113* 3.67566 .018 2.2649 26.9574 
4.00 17.01753* 3.67566 .006 4.6713 29.3638 
5.00 3.28867 3.67566 .941 -9.0576 15.6349 
6.00 8.83678 3.67566 .229 -3.5095 21.1830 
3.00 1.00 -20.46599* 3.67566 .001 -32.8122 -8.1197 
2.00 -14.61113* 3.67566 .018 -26.9574 -2.2649 
4.00 2.40641 3.67566 .984 -9.9398 14.7527 
5.00 -11.32246 3.67566 .079 -23.6687 1.0238 
6.00 -5.77435 3.67566 .630 -18.1206 6.5719 
4.00 1.00 -22.87239* 3.67566 .000 -35.2186 -10.5261 
2.00 -17.01753* 3.67566 .006 -29.3638 -4.6713 
3.00 -2.40641 3.67566 .984 -14.7527 9.9398 
5.00 -13.72887* 3.67566 .027 -26.0751 -1.3826 
6.00 -8.18075 3.67566 .294 -20.5270 4.1655 
5.00 1.00 -9.14353 3.67566 .202 -21.4898 3.2027 
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2.00 -3.28867 3.67566 .941 -15.6349 9.0576 
3.00 11.32246 3.67566 .079 -1.0238 23.6687 
4.00 13.72887* 3.67566 .027 1.3826 26.0751 
6.00 5.54811 3.67566 .665 -6.7981 17.8944 
6.00 1.00 -14.69164* 3.67566 .017 -27.0379 -2.3454 
2.00 -8.83678 3.67566 .229 -21.1830 3.5095 
3.00 5.77435 3.67566 .630 -6.5719 18.1206 
4.00 8.18075 3.67566 .294 -4.1655 20.5270 
5.00 -5.54811 3.67566 .665 -17.8944 6.7981 
*. The mean difference is significant at the 0.05 level. 
 
Peak 5 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 2250.812 5 450.162 29.273 .000 
Within Groups 184.538 12 15.378   
Total 2435.351 17    
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) group (J) group 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 15.49333* 3.20190 .004 4.7384 26.2482 
3.00 35.07140* 3.20190 .000 24.3165 45.8263 
4.00 26.08252* 3.20190 .000 15.3276 36.8374 
5.00 22.99089* 3.20190 .000 12.2360 33.7458 
6.00 28.19060* 3.20190 .000 17.4357 38.9455 
2.00 1.00 -15.49333* 3.20190 .004 -26.2482 -4.7384 
3.00 19.57806* 3.20190 .001 8.8231 30.3330 
4.00 10.58919 3.20190 .055 -.1657 21.3441 
5.00 7.49756 3.20190 .250 -3.2574 18.2525 
6.00 12.69727* 3.20190 .018 1.9424 23.4522 
3.00 1.00 -35.07140* 3.20190 .000 -45.8263 -24.3165 
2.00 -19.57806* 3.20190 .001 -30.3330 -8.8231 
4.00 -8.98887 3.20190 .123 -19.7438 1.7660 
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5.00 -12.08051* 3.20190 .025 -22.8354 -1.3256 
6.00 -6.88079 3.20190 .326 -17.6357 3.8741 
4.00 1.00 -26.08252* 3.20190 .000 -36.8374 -15.3276 
2.00 -10.58919 3.20190 .055 -21.3441 .1657 
3.00 8.98887 3.20190 .123 -1.7660 19.7438 
5.00 -3.09164 3.20190 .920 -13.8466 7.6633 
6.00 2.10808 3.20190 .983 -8.6468 12.8630 
5.00 1.00 -22.99089* 3.20190 .000 -33.7458 -12.2360 
2.00 -7.49756 3.20190 .250 -18.2525 3.2574 
3.00 12.08051* 3.20190 .025 1.3256 22.8354 
4.00 3.09164 3.20190 .920 -7.6633 13.8466 
6.00 5.19972 3.20190 .600 -5.5552 15.9546 
6.00 1.00 -28.19060* 3.20190 .000 -38.9455 -17.4357 
2.00 -12.69727* 3.20190 .018 -23.4522 -1.9424 
3.00 6.88079 3.20190 .326 -3.8741 17.6357 
4.00 -2.10808 3.20190 .983 -12.8630 8.6468 
5.00 -5.19972 3.20190 .600 -15.9546 5.5552 
*. The mean difference is significant at the 0.05 level. 
 
 
 
 
 
Peak 6 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 317.391 5 63.478 3.492 .035 
Within Groups 218.157 12 18.180   
Total 535.548 17    
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Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) group (J) group 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -4.75567 3.48136 .745 -16.4493 6.9379 
3.00 1.29015 3.48136 .999 -10.4034 12.9837 
4.00 1.29015 3.48136 .999 -10.4034 12.9837 
5.00 -10.59906 3.48136 .084 -22.2927 1.0945 
6.00 -2.97735 3.48136 .950 -14.6710 8.7162 
2.00 1.00 4.75567 3.48136 .745 -6.9379 16.4493 
3.00 6.04582 3.48136 .535 -5.6478 17.7394 
4.00 6.04582 3.48136 .535 -5.6478 17.7394 
5.00 -5.84339 3.48136 .568 -17.5370 5.8502 
6.00 1.77831 3.48136 .995 -9.9153 13.4719 
3.00 1.00 -1.29015 3.48136 .999 -12.9837 10.4034 
2.00 -6.04582 3.48136 .535 -17.7394 5.6478 
4.00 .00000 3.48136 1.000 -11.6936 11.6936 
5.00 -11.88921* 3.48136 .046 -23.5828 -.1956 
6.00 -4.26751 3.48136 .817 -15.9611 7.4261 
4.00 1.00 -1.29015 3.48136 .999 -12.9837 10.4034 
2.00 -6.04582 3.48136 .535 -17.7394 5.6478 
3.00 .00000 3.48136 1.000 -11.6936 11.6936 
5.00 -11.88921* 3.48136 .046 -23.5828 -.1956 
6.00 -4.26751 3.48136 .817 -15.9611 7.4261 
5.00 1.00 10.59906 3.48136 .084 -1.0945 22.2927 
2.00 5.84339 3.48136 .568 -5.8502 17.5370 
3.00 11.88921* 3.48136 .046 .1956 23.5828 
4.00 11.88921* 3.48136 .046 .1956 23.5828 
6.00 7.62170 3.48136 .309 -4.0719 19.3153 
6.00 1.00 2.97735 3.48136 .950 -8.7162 14.6710 
2.00 -1.77831 3.48136 .995 -13.4719 9.9153 
3.00 4.26751 3.48136 .817 -7.4261 15.9611 
4.00 4.26751 3.48136 .817 -7.4261 15.9611 
5.00 -7.62170 3.48136 .309 -19.3153 4.0719 
*. The mean difference is significant at the 0.05 level. 
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Peak 7 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 65.062 5 13.012 1.180 .374 
Within Groups 132.342 12 11.029   
Total 197.404 17    
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) group (J) group 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 4.84717 2.71152 .507 -4.2606 13.9550 
3.00 4.97836 2.71152 .480 -4.1294 14.0861 
4.00 4.97836 2.71152 .480 -4.1294 14.0861 
5.00 2.36611 2.71152 .946 -6.7417 11.4739 
6.00 4.97836 2.71152 .480 -4.1294 14.0861 
2.00 1.00 -4.84717 2.71152 .507 -13.9550 4.2606 
3.00 .13119 2.71152 1.000 -8.9766 9.2390 
4.00 .13119 2.71152 1.000 -8.9766 9.2390 
5.00 -2.48105 2.71152 .935 -11.5888 6.6267 
6.00 .13119 2.71152 1.000 -8.9766 9.2390 
3.00 1.00 -4.97836 2.71152 .480 -14.0861 4.1294 
2.00 -.13119 2.71152 1.000 -9.2390 8.9766 
4.00 .00000 2.71152 1.000 -9.1078 9.1078 
5.00 -2.61224 2.71152 .921 -11.7200 6.4955 
6.00 .00000 2.71152 1.000 -9.1078 9.1078 
4.00 1.00 -4.97836 2.71152 .480 -14.0861 4.1294 
2.00 -.13119 2.71152 1.000 -9.2390 8.9766 
3.00 .00000 2.71152 1.000 -9.1078 9.1078 
5.00 -2.61224 2.71152 .921 -11.7200 6.4955 
6.00 .00000 2.71152 1.000 -9.1078 9.1078 
5.00 1.00 -2.36611 2.71152 .946 -11.4739 6.7417 
2.00 2.48105 2.71152 .935 -6.6267 11.5888 
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3.00 2.61224 2.71152 .921 -6.4955 11.7200 
4.00 2.61224 2.71152 .921 -6.4955 11.7200 
6.00 2.61224 2.71152 .921 -6.4955 11.7200 
6.00 1.00 -4.97836 2.71152 .480 -14.0861 4.1294 
2.00 -.13119 2.71152 1.000 -9.2390 8.9766 
3.00 .00000 2.71152 1.000 -9.1078 9.1078 
4.00 .00000 2.71152 1.000 -9.1078 9.1078 
5.00 -2.61224 2.71152 .921 -11.7200 6.4955 
 
Peak 8 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 1312.543 5 262.509 5.259 .009 
Within Groups 599.050 12 49.921   
Total 1911.593 17    
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) group (J) group 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -9.25770 5.76893 .611 -28.6351 10.1197 
3.00 9.72563 5.76893 .564 -9.6518 29.1030 
4.00 9.72563 5.76893 .564 -9.6518 29.1030 
5.00 -11.01537 5.76893 .441 -30.3927 8.3620 
6.00 6.88664 5.76893 .832 -12.4907 26.2640 
2.00 1.00 9.25770 5.76893 .611 -10.1197 28.6351 
3.00 18.98332 5.76893 .056 -.3941 38.3607 
4.00 18.98332 5.76893 .056 -.3941 38.3607 
5.00 -1.75767 5.76893 1.000 -21.1351 17.6197 
6.00 16.14433 5.76893 .125 -3.2330 35.5217 
3.00 1.00 -9.72563 5.76893 .564 -29.1030 9.6518 
2.00 -18.98332 5.76893 .056 -38.3607 .3941 
4.00 .00000 5.76893 1.000 -19.3774 19.3774 
5.00 -20.74100* 5.76893 .034 -40.1184 -1.3636 
6.00 -2.83899 5.76893 .996 -22.2164 16.5384 
434 
 
4.00 1.00 -9.72563 5.76893 .564 -29.1030 9.6518 
2.00 -18.98332 5.76893 .056 -38.3607 .3941 
3.00 .00000 5.76893 1.000 -19.3774 19.3774 
5.00 -20.74100* 5.76893 .034 -40.1184 -1.3636 
6.00 -2.83899 5.76893 .996 -22.2164 16.5384 
5.00 1.00 11.01537 5.76893 .441 -8.3620 30.3927 
2.00 1.75767 5.76893 1.000 -17.6197 21.1351 
3.00 20.74100* 5.76893 .034 1.3636 40.1184 
4.00 20.74100* 5.76893 .034 1.3636 40.1184 
6.00 17.90201 5.76893 .076 -1.4754 37.2794 
6.00 1.00 -6.88664 5.76893 .832 -26.2640 12.4907 
2.00 -16.14433 5.76893 .125 -35.5217 3.2330 
3.00 2.83899 5.76893 .996 -16.5384 22.2164 
4.00 2.83899 5.76893 .996 -16.5384 22.2164 
5.00 -17.90201 5.76893 .076 -37.2794 1.4754 
*. The mean difference is significant at the 0.05 level. 
 
Peak 9 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 5143.157 5 1028.631 43.631 .000 
Within Groups 282.910 12 23.576   
Total 5426.067 17    
 
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
(I) group (J) group 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 26.16098* 3.96450 .000 12.8446 39.4774 
3.00 51.93696* 3.96450 .000 38.6205 65.2534 
4.00 15.59392* 3.96450 .019 2.2775 28.9104 
5.00 31.12492* 3.96450 .000 17.8085 44.4414 
6.00 41.80813* 3.96450 .000 28.4917 55.1246 
2.00 1.00 -26.16098* 3.96450 .000 -39.4774 -12.8446 
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3.00 25.77598* 3.96450 .000 12.4596 39.0924 
4.00 -10.56706 3.96450 .154 -23.8835 2.7494 
5.00 4.96394 3.96450 .804 -8.3525 18.2804 
6.00 15.64715* 3.96450 .019 2.3307 28.9636 
3.00 1.00 -51.93696* 3.96450 .000 -65.2534 -38.6205 
2.00 -25.77598* 3.96450 .000 -39.0924 -12.4596 
4.00 -36.34304* 3.96450 .000 -49.6595 -23.0266 
5.00 -20.81204* 3.96450 .002 -34.1285 -7.4956 
6.00 -10.12883 3.96450 .183 -23.4453 3.1876 
4.00 1.00 -15.59392* 3.96450 .019 -28.9104 -2.2775 
2.00 10.56706 3.96450 .154 -2.7494 23.8835 
3.00 36.34304* 3.96450 .000 23.0266 49.6595 
5.00 15.53100* 3.96450 .019 2.2146 28.8474 
6.00 26.21421* 3.96450 .000 12.8978 39.5306 
5.00 1.00 -31.12492* 3.96450 .000 -44.4414 -17.8085 
2.00 -4.96394 3.96450 .804 -18.2804 8.3525 
3.00 20.81204* 3.96450 .002 7.4956 34.1285 
4.00 -15.53100* 3.96450 .019 -28.8474 -2.2146 
6.00 10.68321 3.96450 .147 -2.6332 23.9996 
6.00 1.00 -41.80813* 3.96450 .000 -55.1246 -28.4917 
2.00 -15.64715* 3.96450 .019 -28.9636 -2.3307 
3.00 10.12883 3.96450 .183 -3.1876 23.4453 
4.00 -26.21421* 3.96450 .000 -39.5306 -12.8978 
5.00 -10.68321 3.96450 .147 -23.9996 2.6332 
*. The mean difference is significant at the 0.05 level. 
 
Peak 10 
 
ANOVA 
data   
 Sum of Squares df Mean Square F Sig. 
Between Groups 2090.489 5 418.098 13.451 .000 
Within Groups 372.986 12 31.082   
Total 2463.476 17    
 
Multiple Comparisons 
Dependent Variable:   data   
Tukey HSD   
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(I) group (J) group 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 7.64932 4.55208 .567 -7.6408 22.9394 
3.00 30.34354* 4.55208 .000 15.0535 45.6336 
4.00 27.26062* 4.55208 .001 11.9705 42.5507 
5.00 19.87551* 4.55208 .009 4.5854 35.1656 
6.00 22.90446* 4.55208 .003 7.6144 38.1945 
2.00 1.00 -7.64932 4.55208 .567 -22.9394 7.6408 
3.00 22.69422* 4.55208 .003 7.4041 37.9843 
4.00 19.61130* 4.55208 .010 4.3212 34.9014 
5.00 12.22619 4.55208 .149 -3.0639 27.5163 
6.00 15.25514 4.55208 .051 -.0349 30.5452 
3.00 1.00 -30.34354* 4.55208 .000 -45.6336 -15.0535 
2.00 -22.69422* 4.55208 .003 -37.9843 -7.4041 
4.00 -3.08292 4.55208 .981 -18.3730 12.2072 
5.00 -10.46803 4.55208 .266 -25.7581 4.8221 
6.00 -7.43908 4.55208 .594 -22.7292 7.8510 
4.00 1.00 -27.26062* 4.55208 .001 -42.5507 -11.9705 
2.00 -19.61130* 4.55208 .010 -34.9014 -4.3212 
3.00 3.08292 4.55208 .981 -12.2072 18.3730 
5.00 -7.38511 4.55208 .601 -22.6752 7.9050 
6.00 -4.35616 4.55208 .923 -19.6462 10.9339 
5.00 1.00 -19.87551* 4.55208 .009 -35.1656 -4.5854 
2.00 -12.22619 4.55208 .149 -27.5163 3.0639 
3.00 10.46803 4.55208 .266 -4.8221 25.7581 
4.00 7.38511 4.55208 .601 -7.9050 22.6752 
6.00 3.02895 4.55208 .983 -12.2611 18.3190 
6.00 1.00 -22.90446* 4.55208 .003 -38.1945 -7.6144 
2.00 -15.25514 4.55208 .051 -30.5452 .0349 
3.00 7.43908 4.55208 .594 -7.8510 22.7292 
4.00 4.35616 4.55208 .923 -10.9339 19.6462 
5.00 -3.02895 4.55208 .983 -18.3190 12.2611 
*. The mean difference is significant at the 0.05 level. 
 
 
 
